<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:7d5f2313-da7e-4c21-ae64-20c312577ca6,g:96c7eedb-222e-4ce1-8711-4aa0ad24c488,d:dfe6e72973fb4e83b28a5bb34d34299f--><html xml:lang="en-US" xmlns="http://www.w3.org/1999/xhtml" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pfe="http://www.pfizer.com/20230402" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><head><meta content="text/html" http-equiv="Content-Type"/>
<title>pfe-20230402</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xMy9mcmFnOjg5ZjM0NjkwYzhkODRlOWQ5ZWZjYTBlMjcyYTYyOTI5L3RhYmxlOmQ4ZmU0MWM4ZWJkNjQ4OWRiN2Q3YzM1NjNlNjMzZmU5L3RhYmxlcmFuZ2U6ZDhmZTQxYzhlYmQ2NDg5ZGI3ZDdjMzU2M2U2MzNmZTlfMy0xLTEtMS02MTQ4NjE_560de0ec-fe6a-474c-bd9c-b6a3a56e27dd" name="dei:EntityCentralIndexKey">0000078003</ix:nonnumeric><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xMy9mcmFnOjg5ZjM0NjkwYzhkODRlOWQ5ZWZjYTBlMjcyYTYyOTI5L3RhYmxlOmQ4ZmU0MWM4ZWJkNjQ4OWRiN2Q3YzM1NjNlNjMzZmU5L3RhYmxlcmFuZ2U6ZDhmZTQxYzhlYmQ2NDg5ZGI3ZDdjMzU2M2U2MzNmZTlfNC0xLTEtMS02MTQ4NjE_bb0a9403-5641-408f-90ad-13f3b170dc0c" name="dei:CurrentFiscalYearEndDate">12/31</ix:nonnumeric><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xMy9mcmFnOjg5ZjM0NjkwYzhkODRlOWQ5ZWZjYTBlMjcyYTYyOTI5L3RhYmxlOmQ4ZmU0MWM4ZWJkNjQ4OWRiN2Q3YzM1NjNlNjMzZmU5L3RhYmxlcmFuZ2U6ZDhmZTQxYzhlYmQ2NDg5ZGI3ZDdjMzU2M2U2MzNmZTlfNS0xLTEtMS02MTQ4NjE_c773e81a-28ef-42d4-97e0-a19e1c562d3c" name="dei:DocumentFiscalYearFocus">2023</ix:nonnumeric><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xMy9mcmFnOjg5ZjM0NjkwYzhkODRlOWQ5ZWZjYTBlMjcyYTYyOTI5L3RhYmxlOmQ4ZmU0MWM4ZWJkNjQ4OWRiN2Q3YzM1NjNlNjMzZmU5L3RhYmxlcmFuZ2U6ZDhmZTQxYzhlYmQ2NDg5ZGI3ZDdjMzU2M2U2MzNmZTlfNi0xLTEtMS02MTQ4NjE_2d828e30-a578-45ca-8a13-046351b4fcb2" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonnumeric><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xMy9mcmFnOjg5ZjM0NjkwYzhkODRlOWQ5ZWZjYTBlMjcyYTYyOTI5L3RhYmxlOmQ4ZmU0MWM4ZWJkNjQ4OWRiN2Q3YzM1NjNlNjMzZmU5L3RhYmxlcmFuZ2U6ZDhmZTQxYzhlYmQ2NDg5ZGI3ZDdjMzU2M2U2MzNmZTlfNy0xLTEtMS02MTQ4NjE_2b0cc164-7dea-451e-9511-d24bad117836" name="dei:AmendmentFlag">false</ix:nonnumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaref xlink:href="pfe-20230402.xsd" xlink:type="simple"></link:schemaref></ix:references><ix:resources><xbrli:context id="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibcd151dd3f214701babfebf86e922d7a_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0603609d3bec4a6a87253aad5ea4b471_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i98345eeda59b40e1bf683199e6621b70_I20230505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitnumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitnumerator><xbrli:unitdenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitdenominator></xbrli:divide></xbrli:unit><xbrli:context id="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70d6d5a20e1d40cba199341b3b73b075_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5bdebedec26437f8cbbbdce5b21d21c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f03522ae364485796d05257a1b6db08_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i261e12058ffe48059a8a12445930d2a2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8190f97254a4b67b0ea33cef0e90617_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbabb6e3c4954e1f8070b22d9961be09_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida9c1b5f32d74a9096e75c2c6f0ac461_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bf219d82ee94bca8aef5121ea78402f_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idc96417637d64170bd5c537156fa67a4_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3b2a02412cfa42b99a1c0fca37814fa6_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic1dc28ef83404ef286e672b1e3544189_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie3ad02e451334330b79a341af46dec8e_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i55e5b495c0304bf2a27da7ded92c9d0b_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i559872c075ee4a26bea2162cc9c64559_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibd06635aa84f4f1eafbd6daa01d1ec5f_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i595d0c9b83914c939b87b9422a11c0bc_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id80c77441aa04de88b6f4fcfa3924b16_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b3f31bb3146428db3b31dd357e1038b_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id86c995eba51451eaa0b5251fe10bb38_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id66ed0a340cd4e61a832ab5f54048d3b_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b028541801148348adb94e8c78bfe72_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b2ec5ba17d244748a7c2878368847c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6fcde9afeff496597110980c3bf762b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id90e1b0cb0ff4c459c9a846fb1d1cadf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb46cde3f7da4c84ab951adfaee1d495_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4031987465804d71afb53f1719495e8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64827359d1254cb5a23ef4ab99e9b4a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1474ecbf5b04969be2c6f95d35ad5c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42818567227049ae86716dcfa81be15a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie36984cd4c2542f287d6333783d3c9bb_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i212875c91a504755b1b31552f587a1f5_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if6c09adb5a184b1f817106477f3ac00d_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icfaef4cce36c4acaab6465881acc8595_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6a440eee62b846e980ce6a650594b2e5_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i20bc9c7efd6c45008d4b8416a5e76092_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2f1e593a96da49818806f331d10248b6_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i74b3d0f2769e476e90a954e83a028866_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aac7e1c9e764ff797561f2e43bd3b76_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b8ab74deec64ca3b90f9ad6f6ffeacb_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8760b8f797fe46f2b2d41e752a5dc5b8_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4501537c703041ef8eddb2b307f0d45a_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5af5a3ee4e64e8288837d331207a533_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9db1fa85f21540c69fc0f8788087f2e0_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1264e68793a244719dccb7ff8c8de271_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="operatingsegment"><xbrli:measure>pfe:operatingSegment</xbrli:measure></xbrli:unit><xbrli:context id="i53ef084cb9aa479f93fde209ac7953c7_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ac95719c6e9404daf6bf462bd06569d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74bb48599a6f4bc3801d3f73331a259b_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if49206e13d134dfda6216a41c3b8a6ff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d8c414e5fef44a6b7c25acd4bac30ba_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaedb0f64969b481c84e4f6fbd2d4bb46_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id14e153b5d344b928f40eaf62587c627_D20221005-20221005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:GBTMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-10-05</xbrli:startdate><xbrli:enddate>2022-10-05</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i15d9a21578c64a228860f837d5cf557a_I20221005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:GBTMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bccc70dd1fe4389b244d15026f2c2b3_I20221005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:GBTMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d4579612b1043cd9649f54d1edcacb1_I20221005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:GBTMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1ee0785cf9247fdb4e3d1a937467cd7_D20221005-20221005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:GBTMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-10-05</xbrli:startdate><xbrli:enddate>2022-10-05</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i20f51dc72dd747ce86bcf503d86ac0a3_D20221003-20221003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BiohavenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-10-03</xbrli:startdate><xbrli:enddate>2022-10-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia96ebcfc61a44fa19d17aefdb43b29dc_I20221003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BiohavenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e7bf15e610e44fa8e9437efe4f62103_I20221003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BiohavenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6390c994a17b4a5b8ce8821c9fc82f12_D20221003-20221003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BiohavenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-10-03</xbrli:startdate><xbrli:enddate>2022-10-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i83509965137c436db600b7c5a56f2bdf_I20221003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:BiohavenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19befe23ac00436590104096f9c04d08_D20220311-20220311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-03-11</xbrli:startdate><xbrli:enddate>2022-03-11</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4f56fd894373416d8484b87702511be5_I20220311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73849b5e38fe445886e1403af608d42f_I20220311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b047b35887f49b2bd8f996ea23ae6f4_I20220311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9606172460e446fa94e858e88d105ceb_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f718193e68c40368f374983948b0629_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40ac168f544d411b8d314f2a8adb5220_I20220718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="icdd92e027b2b41b8a762d6449cf3f5a0_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i543e6671e5af4fbea60527c817946d61_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie50e162a989c436485c1ce071b9178aa_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia51c01f32fe149eea64c684e5bc3f164_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7a0f02fad816440ea104abcf9ee938e4_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-10-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibd5559567aed4bc6b3cdc90bfb24932f_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ConsumerHealthcareJVHaleonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-10-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8db9385fd11b4f34a9a00ad99b96ee74_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06738249302c478d802b2593c91103fd_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e058f03345d43f689a94b97da6cd9c9_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if0451d8a803648f78c3f5b829fb2b882_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4425b4566be44b0c82ea48bffac35b0b_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1c0346762e1e4d89ae68f7c0434a757b_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i91a85b0bab2a4a25a80b150460d4175b_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie15edb16dff343adb61bbb6cf1f06a67_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if3137b642ecd48d3ac8fbc6639f747f7_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i48f5884165aa44be8f684791c8a08fbb_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2c138911a1d04f5d8ed218c8b37ed1d2_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9c1193f1a4714912a5d71e60826acdac_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib27bcc9d493049d8abe864e62fb64d25_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:RestructuringChargesAndAcquisitionRelatedCostsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArenaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaef57a77f73c40c2a69a601492af0dd1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i153f75c15e9942659dc27e0ad196f97b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48c28c40ac824eeb9ac2a1816c6a9a52_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i368e6697c57a4f37beb8d7b70ff5899b_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i11d465c2222f44d9a33767557caa2a0d_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic2161e17146141d2aa15a69116852f3f_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i856c15cefad24430994db47f81fce0c6_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d4fa6526f2e42cca30abe7b32f896e2_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i706a5dc562734084a9a495cb02b91211_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a4b74c508194edd9e71424cfe35e881_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechAndCerevelTherapeuticsLLCMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if4108bffa817457b9f4f93f3df5b3b5a_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iece3f81689ed43ed8131977e5397a8b5_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic5128331c6f7443784a0eceb48c89a99_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i26a1855fa83845c58c5e96adbae43a8a_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:NimbusMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i50b8a990e8d945a991c47c03ad000ded_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3a9c8665ecc2474ca39f0f97addda98f_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d9efa631eb349daafaf29d270f1c7ff_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib15c5b5368114b4fa2a9617c1936084c_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11e8ce6ff1b04567943de7da6408d022_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5961b2a105b04fa99c374113d2d3b409_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7b15c009527b405a90632ab077451178_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd26ebcbc96b4b52b9bb151e168773bb_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa4e5719a8f74b069fef9b1b80758cdd_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44bfc66b5faa4451b77492ea0cf703d1_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i481af342fa644071b566691370861280_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie6e2d5620afa435e8c12a808e5a20a45_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2de7039d729496a9d132d5ed4b7a2df_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib951119d7c294b8e943132d574990796_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec0c75cf014d48c6b822f51540a69197_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib120fd43f21647ddb9c5494438dfb27e_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5f655837df224047b8fb5f3b4ad5b104_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i716dec095fa343959adf62bbbcc3ce7a_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ed5041454dc4cf5aad5955d010fc8a9_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70be0839ad7e48599085d6446707c05a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73e5d62d81bc499da2aca918e59eb08a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73d6c2bb40234687bf1e772888a62827_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc11023bbf49477c9abadf68c2fdafad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28aec41f275d40739620a1ffc1732fbe_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i097ebc813b09417eb7b6094a4e02d882_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i61abe8ecaa42466ebb9062a884933adf_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7fcb2dc9e0dc462baa886c47dacaed5d_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9b8f808c40014053974afeae95dcc5fc_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe58268f6d3743d78ce8f6aaef3189cc_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51efada37c9e4f8a869567aaff2988a6_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b50745be4b54f9497e8f094b4dd8f76_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d606c945f7549d5bc3f5f1f8665adf9_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia46504589b004d6fa2609cecc9012836_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58b21a4b85f4482795c2771776ba8633_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie46b930976e249fdaea796d4fa2b7b8c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i565b6fcf9ae64ce39bcbab011f8dd7d1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i192980577b0c4f0981555fd501a1d150_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecc885f49b7d45a9b934afd40fe3006d_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5904d7defc84b3084a0fd70092bdb4f_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f92a9a413b644978ffcd1ae87c971b8_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9972d1eb40ed45b9821d96a0b8ba5241_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90b766324f684d5baf778cb5ab2d8410_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92b39d6ab4e5439792f6377a57331e5a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3ff63be924144e7ac9fd6beaf47befa_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39cc63e230cf425a936cad5d0717822e_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ec58cfb00e34e75a2f3d433e6cdfb11_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c65e147ec6e4bc69f19a1a7d0e3a7d0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i781190e221ff4ddca6902a13f2b4dd90_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3432d9c7ecea4b49864e9e66b1baf99b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5c5c9c817834a0caeb2a147527ed138_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b21e5b5246d46ad974f05d903d8b4dd_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0a87850f2aa405a9345270e91d26958_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b9719f9edd849cdab5ecc23dd4e7c9f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i769dc7c8abe042c3a951e960a1ddac25_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idce6ccc9da564c1992278f6a300ad0d7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc2ce490fbee48ea9689f31c8a73d04d_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e8357c0f19e454599d090ded0557281_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife57ae03c0fe4843ac1b83037b5ff4ac_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i864fc4705f944124b1eba4d1de555e08_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f55508de5fb4336952f9147cbc6c137_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2132291dc8354e1499b96bcef2a202d9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8d699dfc3fa4866b42a913ae8c98024_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22b956d13b1545e08061dca9e2ca06fc_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29046713fe024bafabb44075d5d8584e_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fa43fc6fd3944da9bb513aabe0ab04a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10f14a77c0704f2b947c0c286d7b7d6a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i401894b5618f4f6ab973ca8531f20c67_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf663226f0a44897b1344e21006095e5_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic908d1a89ce64f1b861fa9f902325473_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99f5dba2972b401f92b964ce16601abf_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cb751f97e434348994191a1a74967f5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9855a29ecb747f19d2f9ab60bade6d4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7062657ec9f48e7bdf45c670efa169a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee604dbe45724d1db52a74f05df5081a_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f8561ec5412432c9b16babf091d4a61_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1753a6ccbf134ef8a340a2a0b5cfc10a_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic733693e0d044ad1803f32b2cb02dc78_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02e9eee4872f4799a567067b60388073_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc606e152567469cbd54e263cb16cb8a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff5c651c676441a88c310767e186683b_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i250d6371ddb146ebb7dbbf6cf6cf8160_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd249c12adde4a8aaa7404e5f28b3010_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if44d68b42d9b45c382f432e3bf32a000_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecee9657c34c499c965713cb427a1768_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7b5afc63cf549c9b1c787dcac9721bd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e49e53cba5241169d36b0f20e4d6aae_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5dffd587e3f4f62bc262afbb7d2d350_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bf89d5536d346ca9712c32543b25fda_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae0be8ee2cae44f2889e654da82c15af_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09cab9a4f13d4d5aae7fba72a9f1b74a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63d5f34336a2433fbae846b80449195e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie99ba1cb8cad4c95aba0f37d9954899c_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1257fd1c5a9a4af5a4cefa2e7aeff2de_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i368fb3b063904d93ac238f87f334805f_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib881931063d349bd8f09ed1011114106_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1e7f5ee536f4910b00145c02b95b137_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5935b162be79465ab3653c973b48c873_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie24fac8d934c453db027f78b65a6fae1_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd0cba878a1d480aa706fed19765b8b2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c67bdd88afa47bc9af801dd825ae9f3_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21bbff20f21e4991bc76884f8ea69d2c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i210c72d001c34f5b95af4b5c4d917483_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92ce9efcdfc14d63ab7f16c619432fba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7344a643d1c4c50b2b6819ae77eff62_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i574c50d8ce5d41ce9c8bb578961580ff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd1041c914fb4bf08a322e2bb1d57c54_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50eb5b5f439a4f408e8814dcd78406eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0276ef4a58a49189a96eb0b86e12f67_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia718855a6cad4e90a5c1afdd2d69bcb3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b7e1cceac144343ab580a8feeb62b10_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbaea048f6dd4b4c9f2628db0fcd2ff2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55a99842f0f54e7d90dda5512ae6cda5_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0b68a7a1360743aea85f2e90df318303_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8e08a3bcc664863a2de2d5d8e095957_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7047fc651abb407b95b0e414a4b1ff86_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie11fd9ae0e5d4b23917b2737bdb19811_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i575da8208e1845289afd26828dfb95e7_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1dff75245484d3bba5fe84c1d63611a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00f38c7951e44b5cae17839d79ede5d7_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4adceb36e10947acbfe50e66edfdb800_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25ba3cba6fef459a8d23cd8dd88e4951_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcdc45ae25474e52a9cc689f7943751a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79a4a6c5b5914f978e0161dc14967489_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4ec559a8febf4df6bd2f3a91b0d559a0_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6e0b3cd23cfa4e079a148202064f19eb_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib6b75c023f5540e9bb79fc95baf2a51c_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3b5cd220c52b4bceaf2a3ede95ee4b2d_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1a47d1927ce14e11905195dcc3ed843c_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i43a56508200245189b6559561d72937e_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iefbfac3f7c3a46b2a71f1cb0891912bc_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9297ef5cd28e4bbaaf1e772677fa3c64_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i20a3bf5204674c29af71b88494db6878_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i923c886a6e4a409b802615f6993c34f3_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic68930364f6e421db82430af61554cea_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9319a48dddf84917a4e0e8d99676ff46_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i64a45a7d126f4c59946c1cfaac8a62f1_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id4bb66f56f034240be2d396bdb5a0da2_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8986081e6afe4d859ff9981809c0c41b_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie25436cb1a6a4ccda5d54fd7d841e316_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36fdcd53aa6d43d3b8ba420de4367710_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaa1f325078f494ab39c94ab1fbf0b75_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib23edf5b9ef34621a697cfcb5d13aad6_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23778ed383104e048f685a44a2a2b78c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if63149af93f943bc81c8955590d63913_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31716fa685b44d31ba4d09a270e648f1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i022ceb0775f9487f99fe2d259639c88c_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e867f30236a439d9cc3fde888440520_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia175e99147dc4e84b88faf8958e1ac2a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5137093847654fc0948b33ea6b027e43_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77f1db46087441bf8d0f1e7bcbdabcbc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i759bc7d5791e4fa3abf61f7f5b948b7b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6b24b3a07954187b5bc84a075e08bd6_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia67f90e9ee984736a03c42fa2d0f4190_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80a72b9fde2247d08e63d5c5f5b199ba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70f5a45c59f348ff999efa622517e19c_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8023deb5656547f9b7dbeffe9ba29540_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3358f7116d834cc8a5b54b93d6b96097_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic4f2b470c8b84d51984bbd3c4208ad1c_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic7bd2b9d3b8e4dfe94ccb01ef6c06931_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9b360f41c3eb45d099b9841bdd9aec3d_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i40492025ce5649019eeb09c5d59d13d9_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i30711953403d465aae1ade1a854b3060_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9a76066cd27341e78cef591f9df5cd40_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="pfe:ExpirationPeriodAxis">pfe:Expiring2030Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:PfizerAndVersusSeveralGenericManufacturersMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-08-01</xbrli:startdate><xbrli:enddate>2022-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>pfe:patent</xbrli:measure></xbrli:unit><xbrli:context id="i53b5aacd2ce84cfdab19c4d92d5faf64_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="pfe:ExpirationPeriodAxis">pfe:Expiring2033Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:PfizerAndVersusSeveralGenericManufacturersMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-08-01</xbrli:startdate><xbrli:enddate>2022-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5a7b5f1bd4354a74babd4ae2171ed072_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:PfizerAndVersusSeveralGenericManufacturersMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-08-01</xbrli:startdate><xbrli:enddate>2022-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idf5ccc1825fd445ebe4560e83a1930f9_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:ModernaTXUSPatentInfringementCaseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-08-01</xbrli:startdate><xbrli:enddate>2022-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8541a2634e9345ae81ecd804da5ad468_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:ModernaTXEuropeanPatentInfringementCaseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-08-01</xbrli:startdate><xbrli:enddate>2022-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i893e8816ebcd4b80b04f031849309ef5_D20220901-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:ModernaTXEuropeanPatentInfringementCaseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-09-01</xbrli:startdate><xbrli:enddate>2022-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4acda04ccc0f418c9766a62f03abaa29_D20230401-20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:ArbutusAndGenevantUSPatentInfringementCaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-04-01</xbrli:startdate><xbrli:enddate>2023-04-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i81fa44c335a441e69bcbe5b0b0c2522e_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-07-01</xbrli:startdate><xbrli:enddate>2022-07-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1b2ba49765614b829a5d721ca534a4b9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:DocetaxelMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-01-01</xbrli:startdate><xbrli:enddate>2018-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="manufacturer"><xbrli:measure>pfe:manufacturer</xbrli:measure></xbrli:unit><xbrli:context id="ia3666e86c68743e3a070924a59c2de42_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i670e31781cda409696a800a888c74490_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i95b1e226cff5434ebc93d3df2d02c3b1_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i53eaca2641034b1593e2e403207d78ec_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i99fbc7d71a0c4e2483ac04c3d705e295_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i57e0e00856144b72a6c3eb80e5849d80_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id61874b1d7274f79a89e4ee0f9f2ec19_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iec11a909a8d84154be6b2d58180cdaa7_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i44167f056c7642e196f616282f12a2f1_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0c22bde603be40fea38a68ae24c32c3f_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if1300e53c4724633b3821ae11a7bb3e6_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iab8e06a5f2fa4ac48e34ffcde10456cb_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iefc2254b125b4cd985bd107f8811ff60_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i645b5c8c0a5f4681997ad0138410ccc3_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if89b9f6fcf2841de8dc20b376d962713_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6573754ecd3e42e48b06ddd54186fc24_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i128c9b41016b43909793ad8f216aff4e_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if33ff7f5e9bf48d69ab7816d9ffc54c2_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i49db5cab1bca4cfcbb1d67e745703c3b_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifc98eadee0884b35b8dc6599365211c7_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i348f1631a68a49bc9a4cff950a2314d3_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1638235866704d47ac70fa86e8afcecc_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id2781bcedc0f4e15b4ff9b8d9f8dae32_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibeb4bdf50c6e409a9ad2229d39abf845_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2c8e95d2a03b4063b88ba80bda3c7da8_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5712dec49ad742cd98de702a6f1dde5b_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1127cf0ab5b34ebaa36393ad7d4a552f_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i24695e5ff7f840c3ae48b9f34c74134a_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5957d758659a4ec690ea56b1618242a1_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id13997e0e5a24763b549edc0dc3fe91a_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie9e3a66284cf45b2a09e34da580d1d29_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4ba0b7fb374645928603ba9b7cebec94_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i389f1083a03043e88aad44b112f7be8c_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5f26f31de52b4e9a879e3308e11dd9f1_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibe1ea6419acf41f5b07a3b8f5b3896a7_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:NurtecODTVyduraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i354de13a0bb042a2ba38dd91459c360e_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:NurtecODTVyduraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i869f2f8a64ec4b6fa54fb3db4169e876_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ida60af953e4241d1ac923e8d2658c098_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9c30c20ce164455da8c51e84339aa211_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3402db239e4a4405af9cab6cc9574fd2_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i528c3830f3fc42ceb033c6c1a1451076_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i27d9bb242ddf4a63b385ead1fb0ad10b_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id43bedcbb0d94ae2bb2c0aaca155cc6d_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i638b0cb14b2847fa86615a6c07ac2772_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia9e86d694fc34637aaf65a9a734f7750_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherPrimaryCareProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i49a9a121621742a1b69ef002bb6bce77_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherPrimaryCareProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:PrimaryCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia0eeb27c12964aeabe04ba88c950ede5_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i11d969a73e8b4e06915d2a823bed0f3a_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib93771c7f62b468a8faa5b28f2297553_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic9904c6f00ef4e679f41f043cba7d258_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie52e1b074ef64b888816b016a9f45c24_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9e64a745e7bf42e4acad26d2c6ca8d2a_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i59479af84e0e4b7bbc1814201d2f7f9b_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id0540ed5c04548468fa93495ce9fd793_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i845f22da610444929d12887bb6ca9d0a_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i817106f80d7d4d05a69740b45ab017da_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if9ca52bb68fb48ae82c1c403c9766d06_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic94de054c1a6436c90321135c2724744_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if7733cbdaedd4915a78e847a76a493c1_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i39f9e687c6b34b0990a6b0df9ad3f40a_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie8dac551f64e41a2b1a77890b84d2c12_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i289af8f0768d4b2e889aad3b1f3e0f4f_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia2a584308c6e4451a4eabaa8926603f3_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:IgPortfolioProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i135c45cb011440ef98a64d2a8d5e52f2_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:IgPortfolioProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if9f84c3c3f2848b38eb5462ea7a160be_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i232cf2079c584aef90ec2a67007659d3_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i291744920e9c4e36afa7e5168f89e573_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8fc7c3a0298d4a1088dcee3e23ef45f2_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id85c2181d493450b9b95eda9c86146ce_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifd027ccaec6546e49e8f34d03003159e_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifb9366ece85d408b982207fd148b4d3e_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OxbrytaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6174ff5489684e17b545dde750a70ec4_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OxbrytaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib0a8aeea6a18419ba89076878429f31b_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i92ab0a5cba3041f6a4221763f0bb94fe_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i344c5d90f5fa4164bdc545bc4b074dfe_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5daf065159f2420b8e6c1f4fc071b36e_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ied077209200a435bb4dc6eec71ad489b_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id9a772ff20444822bb098d41d5ae65c3_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i467a8ce1ecd1470ca834426c38899777_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0e528f7f630d4567ab67dea4ae44c136_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i727d7cc39ca54a6893b055d5d266fe85_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if103824a352d4d4eaac336d1bc831a7f_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icc3b9ed64d3a4863b154b3e5f3987914_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherSpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9c4b53c6463f4588b027b8d451e90e59_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherSpecialtyCareMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:SpecialtyCareMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8d25b2a0fd034a989b55ded7b0193ce9_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id2121803a98d4b488ac1667823fadfc9_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i58a82c91e2c4486289e3a6b7f4ce62ff_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1ba3ef91c841475493a8aa4230556125_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i33f4247a54c64ffabe79f8106533d31c_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id8c77f5483ef4835beb4b08df03fa0bd_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4f591dc7d7d744189dc874ec5f23ea2d_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i86bfd321371a40f9b7a0bd06a3e42775_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id60fd44f86a44a55bb3f3ae03ee4667e_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i75c216a7df064cf1811aaa96db8ac4d1_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i50fcac2e1cd54ced9a7c3b2c5dc7190f_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idebd875adcc54aa3b2628429cfa3dbc4_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4b19ccfe6bde4624bcbd202b0b8ff414_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibd6f431718c945a9a8d867fa6c6d5197_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i08c908e71c64421f80a1cb282d21aa4c_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib93da2cd973e4a3fbcc6fdb3f57f7cd4_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i659a9e5c96f84ae0804790b9ead07065_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibb4395a058f347c8a45174512ae0fce3_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia2403811901c4d05b23627f50a0526c2_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if5e834c200804fd3afe076765c81956a_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i69b4d270e9f04278b1dca58a4c63cf14_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BavencioAllianceRevenuesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie6aa532d58f948b6a980c1e20035d1df_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BavencioAllianceRevenuesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i114d6cba7a08402eaaf457696bb70d89_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i15d91f7557bc4fef8ff7c65f4d65a84c_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i16cd9778c4214c2eaf51fee4d3eb3c73_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5a546d464a89465492912faeee75695e_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i03abea77b6c14d6098cae50d18daa406_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6da2c4e45428414b954bbf0b9fc2a247_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2e6002d9f1d941eaa32b3f311c3b2992_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic56f4b14084c4b61b7991d596bc14c49_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id1fd922b4a1641a7bde85069306fa0ec_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i530d999411e245438a38cdfd15184aaa_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i10b264208d264c8792dfbb8cbee54cf6_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TrazimeraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idf1c7a65121d4f9e9c2e78bb9af9a121_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TrazimeraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3b2f4dbfa6f441489c5facdb83064e9a_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9b4a607655f34d0a8173005638136eaf_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib421ce6581a645469a2501d06a96db02_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BusinessInnovationSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7c676d1f835648639f85e5de4f5c0f13_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BusinessInnovationSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7da57388d26a42a2985af1ba64f42d98_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BusinessInnovationSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie4030d39e6184e02b450995611e3f6f6_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BusinessInnovationSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i226e3f0a94274f62b0553d0c910082d1_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BusinessInnovationSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PfizerIgniteMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i30d715ba3f5a4b8d9e0155525508aba3_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BusinessInnovationSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PfizerIgniteMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iecfbe8c1d41349cdb14a026a4c5eae76_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i683dc90f3a6c40adb8a077cd9efbef56_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie4d12f048f8447f69be50e2fcdfa49fc_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BusinessInnovationSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if266e8cb9f4f47798aaf8f321af14bae_D20220101-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BusinessInnovationSegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-04-03</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if92711a6b5604c1db4ab5d516cfc9a54_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i476e4b3305dd4520810b579696f19d35_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb698020b89848d9b13f1f0a818f53b4_D20230101-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2023-01-01</xbrli:startdate><xbrli:enddate>2023-04-02</xbrli:enddate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNi04LTEtMS02MTQ4NjE_781d0c49-a3d1-4c56-9334-7e69baf03b0c" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNi04LTEtMS02MTQ4NjE_781d0c49-a3d1-4c56-9334-7e69baf03b0c" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzA0OQ_c59437bc-4d74-4876-923a-2226bf670027"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNi0xMi0xLTEtNjE0ODYx_c0607e67-192d-46b3-b23f-97a720d97216" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNi0xMi0xLTEtNjE0ODYx_c0607e67-192d-46b3-b23f-97a720d97216" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzA0OQ_c59437bc-4d74-4876-923a-2226bf670027"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC0yLTEtMS02NzY4OTg_eac3406b-7c62-4a1c-a47a-ac568294b241" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NQ_efff7e59-fd15-468f-9e0e-11694d4c9ef9"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC0yLTEtMS02NzY4OTg_eac3406b-7c62-4a1c-a47a-ac568294b241" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NA_034f4111-ff43-4e4b-9029-668d23b72473"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfMy00LTEtMS02MTQ4NjE_f1c04cbe-9d08-4c7e-84b5-451c58dfdf2e" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NA_034f4111-ff43-4e4b-9029-668d23b72473"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfMy00LTEtMS02MTQ4NjE_f1c04cbe-9d08-4c7e-84b5-451c58dfdf2e" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NQ_efff7e59-fd15-468f-9e0e-11694d4c9ef9"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNS0xMi0xLTEtNjE0ODYx_db51b44c-b1e2-4a3e-b872-0515039bbae3" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNS0xMi0xLTEtNjE0ODYx_db51b44c-b1e2-4a3e-b872-0515039bbae3" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMA_c38ff664-eb9f-410a-b981-1c377989408f"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTQtMTAtMS0xLTYxNDg2MQ_d25f5005-224e-46d2-8fc3-de775e2cf00f" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzA0OQ_c59437bc-4d74-4876-923a-2226bf670027"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTQtMTAtMS0xLTYxNDg2MQ_d25f5005-224e-46d2-8fc3-de775e2cf00f" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC02LTEtMS02NzY4OTg_3c57a6b5-58bc-4ddc-9529-9d4e9f92d6cf" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NQ_efff7e59-fd15-468f-9e0e-11694d4c9ef9"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC02LTEtMS02NzY4OTg_3c57a6b5-58bc-4ddc-9529-9d4e9f92d6cf" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NA_034f4111-ff43-4e4b-9029-668d23b72473"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNS02LTEtMS02MTQ4NjE_5d3f59f6-19f2-431f-a145-30c49029025d" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMA_c38ff664-eb9f-410a-b981-1c377989408f"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNS02LTEtMS02MTQ4NjE_5d3f59f6-19f2-431f-a145-30c49029025d" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTYtMTAtMS0xLTYxNDg2MQ_430a09ad-89f6-4ffc-a095-ab6aa372a865" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTYtMTAtMS0xLTYxNDg2MQ_430a09ad-89f6-4ffc-a095-ab6aa372a865" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAxNg_24be5b54-e8b8-4b6d-87b0-bd16bc053216"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfMTAtNi0xLTEtNjE0ODYx_6eb334de-0315-4c65-8513-29007f538528" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyNTI_10bc6fed-0d8b-4984-a671-75af585d806a"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfMTAtNi0xLTEtNjE0ODYx_6eb334de-0315-4c65-8513-29007f538528" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyNzQ_d25d3c78-63a3-4649-b67f-65616f3a9753"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfMy04LTEtMS02MTQ4NjE_4182e2a2-e178-4538-a4cd-51b56db152cc" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NQ_efff7e59-fd15-468f-9e0e-11694d4c9ef9"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfMy04LTEtMS02MTQ4NjE_4182e2a2-e178-4538-a4cd-51b56db152cc" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NA_034f4111-ff43-4e4b-9029-668d23b72473"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTctMTAtMS0xLTYxNDg2MQ_4918adf1-1453-48db-a246-f2c979955522" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAxNg_24be5b54-e8b8-4b6d-87b0-bd16bc053216"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTctMTAtMS0xLTYxNDg2MQ_4918adf1-1453-48db-a246-f2c979955522" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC00LTEtMS02NzY4OTg_72a8ea85-8438-4687-9db8-750c7ad23bb7" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NA_034f4111-ff43-4e4b-9029-668d23b72473"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC00LTEtMS02NzY4OTg_72a8ea85-8438-4687-9db8-750c7ad23bb7" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NQ_efff7e59-fd15-468f-9e0e-11694d4c9ef9"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTQtNi0xLTEtNjE0ODYx_8c2722db-45c9-4662-933d-76cc62b2769d" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTQtNi0xLTEtNjE0ODYx_8c2722db-45c9-4662-933d-76cc62b2769d" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzA0OQ_c59437bc-4d74-4876-923a-2226bf670027"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfMy0yLTEtMS02MTQ4NjE_501fa62c-f7e0-4fc5-9c8d-f09114c9b4a1" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NQ_efff7e59-fd15-468f-9e0e-11694d4c9ef9"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfMy0yLTEtMS02MTQ4NjE_501fa62c-f7e0-4fc5-9c8d-f09114c9b4a1" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NA_034f4111-ff43-4e4b-9029-668d23b72473"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC04LTEtMS02MTQ4NjE_2ea0291b-2feb-4fea-bec8-ae8dc8d5752b" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NA_034f4111-ff43-4e4b-9029-668d23b72473"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC04LTEtMS02MTQ4NjE_2ea0291b-2feb-4fea-bec8-ae8dc8d5752b" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NQ_efff7e59-fd15-468f-9e0e-11694d4c9ef9"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTctNi0xLTEtNjE0ODYx_74d16b25-d672-4f34-89dd-f27042213fab" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTctNi0xLTEtNjE0ODYx_74d16b25-d672-4f34-89dd-f27042213fab" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAxNg_24be5b54-e8b8-4b6d-87b0-bd16bc053216"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfMTAtOC0xLTEtNjE0ODYx_cecc7199-4473-417f-9bed-9b56e6512d2d" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyNzQ_d25d3c78-63a3-4649-b67f-65616f3a9753"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfMTAtOC0xLTEtNjE0ODYx_cecc7199-4473-417f-9bed-9b56e6512d2d" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyNTI_10bc6fed-0d8b-4984-a671-75af585d806a"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTYtOC0xLTEtNjE0ODYx_e52db2d8-e913-44e2-b91e-f34c3ed5bb22" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTYtOC0xLTEtNjE0ODYx_e52db2d8-e913-44e2-b91e-f34c3ed5bb22" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAxNg_24be5b54-e8b8-4b6d-87b0-bd16bc053216"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfNi04LTEtMS02MTQ4NjE_6877f3a8-36d3-4228-ba11-1c3bf278a5f9" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyNzQ_d25d3c78-63a3-4649-b67f-65616f3a9753"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfNi04LTEtMS02MTQ4NjE_6877f3a8-36d3-4228-ba11-1c3bf278a5f9" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEzMDE_0446c25b-b600-4f12-9ddc-ff2fd399b19d"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTQtMTItMS0xLTYxNDg2MQ_3cd81b17-e1be-4ccf-a7c4-1bb942febebe" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzA0OQ_c59437bc-4d74-4876-923a-2226bf670027"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTQtMTItMS0xLTYxNDg2MQ_3cd81b17-e1be-4ccf-a7c4-1bb942febebe" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC02LTEtMS02MTQ4NjE_2a55468a-a3ea-4b85-82a4-d3bbf9200372" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NQ_efff7e59-fd15-468f-9e0e-11694d4c9ef9"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC02LTEtMS02MTQ4NjE_2a55468a-a3ea-4b85-82a4-d3bbf9200372" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NA_034f4111-ff43-4e4b-9029-668d23b72473"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC04LTEtMS02NzY4OTg_bbbe0dd3-d5d0-4aa3-ac49-56a2a6861357" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NA_034f4111-ff43-4e4b-9029-668d23b72473"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC04LTEtMS02NzY4OTg_bbbe0dd3-d5d0-4aa3-ac49-56a2a6861357" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NQ_efff7e59-fd15-468f-9e0e-11694d4c9ef9"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTctOC0xLTEtNjE0ODYx_8c8e06fa-c087-4632-84c9-fbad1e9cdd7d" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAxNg_24be5b54-e8b8-4b6d-87b0-bd16bc053216"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTctOC0xLTEtNjE0ODYx_8c8e06fa-c087-4632-84c9-fbad1e9cdd7d" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNS0xMC0xLTEtNjE0ODYx_e6e3c342-f3b9-4d85-aa17-6afc54d73d5f" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMA_c38ff664-eb9f-410a-b981-1c377989408f"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNS0xMC0xLTEtNjE0ODYx_e6e3c342-f3b9-4d85-aa17-6afc54d73d5f" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC00LTEtMS02MTQ4NjE_d0ecd745-d37e-4c83-81a4-6de71427014b" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NA_034f4111-ff43-4e4b-9029-668d23b72473"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC00LTEtMS02MTQ4NjE_d0ecd745-d37e-4c83-81a4-6de71427014b" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NQ_efff7e59-fd15-468f-9e0e-11694d4c9ef9"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfMy02LTEtMS02MTQ4NjE_ea804fd2-c4dc-4227-8e9d-7888c58b77fe" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NA_034f4111-ff43-4e4b-9029-668d23b72473"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfMy02LTEtMS02MTQ4NjE_ea804fd2-c4dc-4227-8e9d-7888c58b77fe" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NQ_efff7e59-fd15-468f-9e0e-11694d4c9ef9"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC0yLTEtMS02MTQ4NjE_297343f3-8f5f-4d18-8d9a-fe06e4029965" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NQ_efff7e59-fd15-468f-9e0e-11694d4c9ef9"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC0yLTEtMS02MTQ4NjE_297343f3-8f5f-4d18-8d9a-fe06e4029965" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NA_034f4111-ff43-4e4b-9029-668d23b72473"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfNC0yLTEtMS02MTQ4NjE_cd7e06a4-c039-4529-8caf-f0b15e806506" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RleHRyZWdpb246MWQwYWUyNjBlYWMwNDRkMTk2NDJjM2RmMTg5OWY2NzlfMzQ4_8e2f8f71-e075-40d2-8b3c-63da28965877"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfNC0yLTEtMS02MTQ4NjE_cd7e06a4-c039-4529-8caf-f0b15e806506" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RleHRyZWdpb246MWQwYWUyNjBlYWMwNDRkMTk2NDJjM2RmMTg5OWY2NzlfMTQ4NDM0MDY5NzUzOTc_35caf586-a2e2-4584-a335-b5dfe8fb6772"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTYtMTItMS0xLTYxNDg2MQ_9cf69fae-dc11-4bbc-932b-94bf2d1c1527" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTYtMTItMS0xLTYxNDg2MQ_9cf69fae-dc11-4bbc-932b-94bf2d1c1527" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAxNg_24be5b54-e8b8-4b6d-87b0-bd16bc053216"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNS04LTEtMS02MTQ4NjE_b4afff8e-d465-4e29-b814-b17d07bbc366" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNS04LTEtMS02MTQ4NjE_b4afff8e-d465-4e29-b814-b17d07bbc366" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMA_c38ff664-eb9f-410a-b981-1c377989408f"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNi02LTEtMS02MTQ4NjE_0933a9ee-05e4-4aee-bc13-349985415bb5" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzA0OQ_c59437bc-4d74-4876-923a-2226bf670027"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNi02LTEtMS02MTQ4NjE_0933a9ee-05e4-4aee-bc13-349985415bb5" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNi0xMC0xLTEtNjE0ODYx_fd5b8115-3388-46d7-b9ae-3ed91925007e" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzA0OQ_c59437bc-4d74-4876-923a-2226bf670027"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNi0xMC0xLTEtNjE0ODYx_fd5b8115-3388-46d7-b9ae-3ed91925007e" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfNi02LTEtMS02MTQ4NjE_14bcf1dd-ec6a-496a-81d3-1efda66cec93" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEzMDE_0446c25b-b600-4f12-9ddc-ff2fd399b19d"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfNi02LTEtMS02MTQ4NjE_14bcf1dd-ec6a-496a-81d3-1efda66cec93" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyNzQ_d25d3c78-63a3-4649-b67f-65616f3a9753"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTYtNi0xLTEtNjE0ODYx_22046236-5c27-4493-a98d-d774255636c8" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTYtNi0xLTEtNjE0ODYx_22046236-5c27-4493-a98d-d774255636c8" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAxNg_24be5b54-e8b8-4b6d-87b0-bd16bc053216"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTctMTItMS0xLTYxNDg2MQ_fea8e7f8-d862-4e54-9f3c-0f7692ccc1fc" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTctMTItMS0xLTYxNDg2MQ_fea8e7f8-d862-4e54-9f3c-0f7692ccc1fc" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAxNg_24be5b54-e8b8-4b6d-87b0-bd16bc053216"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTQtOC0xLTEtNjE0ODYx_45ad9747-fab6-4c77-b1f7-f2771a44fa1c" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTQtOC0xLTEtNjE0ODYx_45ad9747-fab6-4c77-b1f7-f2771a44fa1c" linkrole="http://www.xbrl.org/2003/role/link" order="2" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzA0OQ_c59437bc-4d74-4876-923a-2226bf670027"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RhYmxlOjMzNjk2Y2MwMjJhYjRjY2NhM2NhMTQ0ZjIxMzIyNTY0L3RhYmxlcmFuZ2U6MzM2OTZjYzAyMmFiNGNjY2EzY2ExNDRmMjEzMjI1NjRfNS00LTEtMS02MTQ4NjE_cf8e7458-7f96-48e5-ab33-a3672ae9b6c8 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RhYmxlOjMzNjk2Y2MwMjJhYjRjY2NhM2NhMTQ0ZjIxMzIyNTY0L3RhYmxlcmFuZ2U6MzM2OTZjYzAyMmFiNGNjY2EzY2ExNDRmMjEzMjI1NjRfNS0yLTEtMS02MTQ4NjE_9128c948-73f6-4ca3-abec-be9f2cffb4b3" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RleHRyZWdpb246NTU5YTUxNjg4NWEyNDhjMmE2OWMwZDY1ZDM0ZTIxMzVfNjMz_85ac4d4a-55f3-42e6-b663-ce227979dfac"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfNi00LTEtMS02MTQ4NjE_b77327de-15a4-42e3-bfc7-c76a6bd05e85 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfNi0yLTEtMS02MTQ4NjE_d05141c6-074d-47b2-88ab-abb14df6643f" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEzMDE_0446c25b-b600-4f12-9ddc-ff2fd399b19d"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfMi00LTEtMS02MTQ4NjE_b953c004-2713-408f-9d6e-8dc802c66fd8 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfMi0yLTEtMS02MTQ4NjE_2cc4a44c-a3d4-4e2c-b278-d6a7719d7a79 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfMi04LTEtMS02MTQ4NjE_37cac345-b2e1-433c-a1eb-8aff15cac98a id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfMi02LTEtMS02MTQ4NjE_7798747f-f39f-47b3-896b-5ab9104eadd4" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDA4Mg_66d9887a-2e69-452d-9cbb-96d551187dee"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDktNi0xLTEtNjE0ODYx_e6c2d3b2-1989-42e4-917c-4e70529ad43c id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDktNC0xLTEtNjE0ODYx_568e6cb8-2ec0-4349-a301-267ae4a78daf" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyOTk_8b0a2786-ae92-4d91-9c0f-94fe4b071f9e"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RhYmxlOjMzNjk2Y2MwMjJhYjRjY2NhM2NhMTQ0ZjIxMzIyNTY0L3RhYmxlcmFuZ2U6MzM2OTZjYzAyMmFiNGNjY2EzY2ExNDRmMjEzMjI1NjRfNi00LTEtMS02MTQ4NjE_b53ad67f-4c50-4327-a601-bd54df7717cb id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RhYmxlOjMzNjk2Y2MwMjJhYjRjY2NhM2NhMTQ0ZjIxMzIyNTY0L3RhYmxlcmFuZ2U6MzM2OTZjYzAyMmFiNGNjY2EzY2ExNDRmMjEzMjI1NjRfNi0yLTEtMS02MTQ4NjE_63a8f59f-992b-429e-a998-5b8f7ed27763" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RleHRyZWdpb246NTU5YTUxNjg4NWEyNDhjMmE2OWMwZDY1ZDM0ZTIxMzVfNjA5_1f908f71-1151-4fc9-bd70-fb77b4897a1d"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzItMTQtMS0xLTYxNDg2MQ_463034d2-cf1b-4e47-92cb-5912cfa0e763 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzItNi0xLTEtNjE0ODYx_ccf9adcc-49b1-4994-93e3-e975b8ca3f69 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzItMi0xLTEtNjE0ODYx_e7144219-f532-4fe1-a5f1-0a735a93e22e id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzItMTItMS0xLTYxNDg2MQ_1056f8bc-8734-40a1-bb0c-841d9fc0c01f id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzItMTAtMS0xLTYxNDg2MQ_bf8ba0b9-03c3-4839-b14a-f6b46b91624a id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzItNC0xLTEtNjE0ODYx_27cfcffd-100a-4164-9c75-78b554f05b32" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RleHRyZWdpb246MTFmODYyMjlhOWU4NDU5YTljZGYzYjA1NzBlNzExNTJfMTQyOQ_54ac50eb-a8ed-42d5-84c6-47d282c148e7"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfOS00LTEtMS02MTQ4NjE_ad8e94a9-410e-4e80-8a20-a71644ea3e87 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMjEtMTAtMS0xLTYxNDg2MQ_fed20567-5d83-4354-9f5d-f1f19ddd8de1 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMjEtMi0xLTEtNjE0ODYx_6db1c06d-55a8-4dba-8b18-a346d6c07859 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMjEtNi0xLTEtNjE0ODYx_3b576840-460c-405f-8afa-7d5b11ca4195 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMjEtMTItMS0xLTYxNDg2MQ_076cfc71-4cb4-4458-8ddf-e0e9df312b68 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTktMi0xLTEtNjE0ODYx_a4c17fd8-23b5-4849-9ca4-3630da64d0b5 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfOS0yLTEtMS02MTQ4NjE_8c2627cb-4d1a-4cac-8bb6-d0a8e91dbd77 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTktNC0xLTEtNjE0ODYx_f20143f1-1d69-4f86-9dec-9ab267bab767 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMjEtNC0xLTEtNjE0ODYx_94a02936-96c7-4913-981d-914ba9ecb4fa id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTMtOC0xLTEtNjE0ODYx_acce1aa7-d35a-4b15-bf72-c9914cae2471 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMjEtOC0xLTEtNjE0ODYx_4a52102f-b562-4958-8b97-2a0340357664 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTMtNi0xLTEtNjE0ODYx_57e276ac-5dde-4db0-ae78-c74144e2d2dd id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfOC00LTEtMS02MTQ4NjE_acb6e52e-d571-4dd0-b2eb-d6a80e3f7507 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTMtMTItMS0xLTYxNDg2MQ_0e1db184-0240-48da-ab22-57bdc1f1c741 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTMtMTAtMS0xLTYxNDg2MQ_d18e245c-4a4a-4b3f-a866-6eec7c3c74d0 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfOC0yLTEtMS02MTQ4NjE_d01374e7-74a1-49be-8b08-bc5a5df34e5d" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTktNi0xLTEtNjE0ODYx_c3b3d2c8-43fb-440f-b79e-be249a9df1ff id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTktMTAtMS0xLTYxNDg2MQ_e4706c19-63e6-4c1e-9ef4-3c85fa2c2801 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTktMTItMS0xLTYxNDg2MQ_223882dd-a16b-4d30-b4f4-94fcf4f33db1 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTktMi0xLTEtNjE0ODYx_bf788760-7ed8-49d4-94d6-2d31663b2f0c id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTktNC0xLTEtNjE0ODYx_c08bce5b-b428-40c6-ade7-487a332e582b id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTktMTQtMS0xLTYxNDg2MQ_5293cd7c-7372-4e6e-b5a7-00a2cda862ba" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RleHRyZWdpb246MTFmODYyMjlhOWU4NDU5YTljZGYzYjA1NzBlNzExNTJfMTQyOA_80a64ba7-2b8b-4227-beed-1f65939adbf9"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNTMtNi0xLTEtNjE0ODYx_cf6ab472-0238-474e-b227-2732d7f893c6 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMy02LTEtMS02MTQ4NjE_4a1f3dc1-7ad8-418c-a08f-c656116f9eca id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNTMtNC0xLTEtNjE0ODYx_326ad3ee-ba38-4175-ade2-fd76034ba436 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMy00LTEtMS02MTQ4NjE_c72309a4-1482-4d1b-b1a6-7e67f3ce83da" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyOTQ_fa5e87e0-5470-4bbc-952a-b0d9b39938ee"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNTMtNC0xLTEtNjQ3NDI2_de55c985-a855-4d81-9681-af92522c1b35 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNTMtNi0xLTEtNjQ3NTA4_be869e91-e46b-4b98-8cd3-f5f41799b4ee" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTQ4NDM0MDcwMTMwOTE_5e1367ba-2545-4c99-9213-d3143b257668"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNS04LTEtMS02MTQ4NjE_d9b29fb1-3333-4581-a3a9-24d105c643d5 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNS0yLTEtMS02MTQ4NjE_313f4ea6-fbd1-4197-9273-ce06c391dbd8 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNS00LTEtMS02MTQ4NjE_22cef129-a1a0-4f16-9b83-1353d780f2cb id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNS02LTEtMS02MTQ4NjE_bbb9f6ab-d001-4026-9eb4-377316e72e98" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NQ_efff7e59-fd15-468f-9e0e-11694d4c9ef9"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfOC04LTEtMS02MTQ4NjE_2a8066ba-5eaf-4188-ba12-7b839088035b id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfOC02LTEtMS02MTQ4NjE_330c9fc6-7412-40e3-8410-447fe5c5963c" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk4Ng_33be42cc-452b-4e0c-b0b5-23381dc1f1c2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNS02LTEtMS02MTQ4NjE_a5379aae-a893-4c63-8585-e786a37acac4 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNS00LTEtMS02MTQ4NjE_f82a2bf1-6712-4312-8a1c-d15ab0237633 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNS0yLTEtMS02MTQ4NjE_68e4ab33-1a03-4d2b-b21d-e5bd94077e16 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNS0xMC0xLTEtNjE0ODYx_b6cece36-b914-4baa-bfcf-92d2ae5e0fba id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNS04LTEtMS02MTQ4NjE_03d7820a-1a80-4832-aac6-080be5b49c22 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNS0xMi0xLTEtNjE0ODYx_e790dcd9-520c-415d-a394-4b4d9d460a42" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzA1Mg_173afdc4-ac0d-41ff-bff0-33f30628801e"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNS02LTEtMS02MTQ4NjE_6b59251e-7126-4e6a-8288-74bd35150bf0 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNS00LTEtMS02MTQ4NjE_de8eaa37-bc96-4bd6-a013-a6b3a80163ff" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyNjQ_67f0a2ef-90a1-4d3a-91a5-a4545ce80714"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfNy02LTEtMS02MTQ4NjE_27074bfe-32e8-4f78-8607-52f8aca3fe1f id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfNy04LTEtMS02MTQ4NjE_e563126a-7120-444f-b128-5d77397dbcd3" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDEyMA_a7ac0843-d9e0-4717-ae98-c1b5822660b8"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfOC04LTEtMS02MTQ4NjE_0904b9f0-19bc-409d-8db7-74728f2e0bb2 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfOC02LTEtMS02MTQ4NjE_640a805a-f35d-45ff-9aa5-28b3da3cd778" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDA3Ng_a1af0502-263e-4cef-b1ea-865c8e794c2d"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfOC02LTEtMS02MTQ4NjE_9167e622-24e8-42ae-9449-62ead92ddd05 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfOS04LTEtMS02MTQ4NjE_9ec0474e-8cf1-4591-810c-02f9241d061e id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfNS04LTEtMS02MTQ4NjE_c639596d-280f-4ee5-b626-38dea8ad3219 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfMTEtOC0xLTEtNjE0ODYx_b943dd4c-98e0-469f-8791-f1112afae224 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfMTEtNi0xLTEtNjE0ODYx_9166ac0a-66ab-4b07-bf18-4061763a7e4b id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfOS02LTEtMS02MTQ4NjE_a8d06473-86e7-468e-99b1-5ba00c42140a id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfNS02LTEtMS02MTQ4NjE_3edb7fa5-8360-4e21-b107-3e5d2e1daf1e id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfOC04LTEtMS02MTQ4NjE_25f9fc93-e0ad-4d99-8ce4-35f5e0e9d0f2" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyNzQ_d25d3c78-63a3-4649-b67f-65616f3a9753"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfMy0yLTEtMS02MTQ4NjE_71da4ebb-e127-4b2f-83ef-b026fb7f8edb id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfMy00LTEtMS02MTQ4NjE_c86ecbd9-3f43-4949-bfb6-cb604d9e0537" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RleHRyZWdpb246OWRhNzRiYWEyNzY4NGY0ZGFkZDFlZDFmNzFiMGJhOGNfNzYx_86f4fb24-9db2-4bfc-8b48-ba2809aa32c3"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMTMtOC0xLTEtNjE0ODYx_336354b8-e527-4af6-9bfc-91cf384499e5 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMTMtNi0xLTEtNjE0ODYx_6995537d-9f28-4b44-a53c-17ba5e276b88" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk4MA_182e6155-307f-4c9c-8f98-22d7a0346d5f"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfMTktOC0xLTEtNjE0ODYx_f81440fe-7939-4d30-9643-6cd751077d85 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfMTktNi0xLTEtNjE0ODYx_377dc3a7-b52c-42a7-b51c-9f1d20e2bdbd" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RleHRyZWdpb246ZTE1OTIwNjQyN2ZiNDFkMTg1YjI0NTE1ZmE3NjQ2YTdfMjQ0_b4fc65e4-091f-4f21-a678-197fd201034a"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMTEtNi0xLTEtNjE0ODYx_dea9e2ba-543a-4c78-b4f8-5e014853e9a6 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMTEtOC0xLTEtNjE0ODYx_aac4b631-2e22-4d2a-92f9-d7bbb07205f4" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTQ4NDM0MDY5ODUzNTI_5387de25-ae3a-4c5f-8259-be60bef783cf"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMTQtOC0xLTEtNjE0ODYx_22df781a-068d-49cd-bec7-224bce181885 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMTQtNi0xLTEtNjE0ODYx_0a3a7736-da6a-41ca-9b62-b40bc5200289" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTQ4NDM0MDY5ODUzNTQ_557156a9-13f7-48b8-bc51-384a72dc6f75"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMTYtNi0xLTEtNjE0ODYx_cbb6cfca-b14c-4ec9-b350-377853fb2971 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMTYtOC0xLTEtNjE0ODYx_56f4c987-3fb3-48b1-9ea4-62aeda2a2f70" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDA1OA_43c730c8-cc94-44fa-af74-1c29a8fd054c"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMjItNi0xLTEtNjE0ODYx_ae47a9d3-f27b-4c4f-bd3b-3ae6e074f7b6 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMTktNi0xLTEtNjE0ODYx_3004a1e6-8ade-4877-9e0c-f56c095a9170 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMjAtOC0xLTEtNjE0ODYx_3bd6fa05-16ea-4254-934a-561c4d3710e2 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMTktOC0xLTEtNjE0ODYx_bcb170d6-a4e0-4e10-9f3c-5a362832ab3d id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMTgtNi0xLTEtNjE0ODYx_45189143-80bf-44c5-b214-fe7bcb26a444 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMjItOC0xLTEtNjE0ODYx_e04c98e9-2519-474d-8a04-fe6ced9c5443 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMjAtNi0xLTEtNjE0ODYx_17db11b2-4bdd-44a7-8929-8f2cff103407 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMTgtOC0xLTEtNjE0ODYx_6fcf9afb-4002-4ea7-a5ed-bf43c6ea47ba" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDA3MA_3ad48e11-92b4-4747-93be-3b8e8be06690"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfNC00LTEtMS02MTQ4NjE_04915349-854c-48f7-bff9-7b4fa4670381 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfNC0yLTEtMS02MTQ4NjE_cc7e6c25-23fc-4b89-b58f-df5445195cdd id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfNC02LTEtMS02MTQ4NjE_50caf7b7-9c8e-4601-88e0-3ee5288261de id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfNC04LTEtMS02MTQ4NjE_d84bae25-a2f4-4d7e-a5c9-1069e902cb58" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDA5NA_b66da65a-1e28-4002-9355-b166371d4767"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82NC9mcmFnOjljYzM1ODllNzIxODQ5Yzk4ODc0OGNiMzM3OWNiODY0L3RhYmxlOjk1ZDgwZTFiYWI4YTQyNGI5YzJhZWQwZDMzYjFmYzM5L3RhYmxlcmFuZ2U6OTVkODBlMWJhYjhhNDI0YjljMmFlZDBkMzNiMWZjMzlfNC0yLTEtMS02MTQ4NjE_fc2eaddd-8e71-4920-a13d-e1d062ddd606 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82NC9mcmFnOjljYzM1ODllNzIxODQ5Yzk4ODc0OGNiMzM3OWNiODY0L3RhYmxlOjk1ZDgwZTFiYWI4YTQyNGI5YzJhZWQwZDMzYjFmYzM5L3RhYmxlcmFuZ2U6OTVkODBlMWJhYjhhNDI0YjljMmFlZDBkMzNiMWZjMzlfNC00LTEtMS02MTQ4NjE_083e92ce-96d5-46a8-b0de-e6d294c33ab7" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82NC9mcmFnOjljYzM1ODllNzIxODQ5Yzk4ODc0OGNiMzM3OWNiODY0L3RleHRyZWdpb246OWNjMzU4OWU3MjE4NDljOTg4NzQ4Y2IzMzc5Y2I4NjRfODY_9b03a664-74d8-4dd2-860e-fa85af621b0f"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfOC02LTEtMS02MTQ4NjE_58f0eb0a-ad62-4df1-8782-a32487c49401 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfOC04LTEtMS02MTQ4NjE_ce455d09-6250-4ced-8f97-b3b1a3c6aff6" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RleHRyZWdpb246ODY3ZTU1OThiMTVmNDE1M2E0MDUwMTk3MmQxZTRjYTJfMjY3_f0ff6601-8fe7-4091-9066-6c7f796b09cc"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfNS0yLTEtMS02MTQ4NjE_64161a5d-cc7f-45ca-a585-280990fe77c4 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfNS00LTEtMS02MTQ4NjE_924e902e-db65-43a9-b782-b847e6a7f689 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfNS04LTEtMS02MTQ4NjE_04779caf-8345-45fd-b123-a22114b060ad id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfNS02LTEtMS02MTQ4NjE_77a78978-a6bd-4b1f-b88d-f68c36980de7" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDExOA_a40938b5-2979-4de5-8e79-146f8575ea0c"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmRiN2ZlNzc3MTAzYzRkMjdiOWVhNzJkM2YzY2U0YzJmL3RhYmxlcmFuZ2U6ZGI3ZmU3NzcxMDNjNGQyN2I5ZWE3MmQzZjNjZTRjMmZfNy04LTEtMS02MTQ4NjE_2b67fa9a-24ce-446e-b486-065d2b890fa0 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmRiN2ZlNzc3MTAzYzRkMjdiOWVhNzJkM2YzY2U0YzJmL3RhYmxlcmFuZ2U6ZGI3ZmU3NzcxMDNjNGQyN2I5ZWE3MmQzZjNjZTRjMmZfNi0yLTEtMS02MTQ4NjE_eb5e4395-620e-4385-9e28-453287973d0a id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmRiN2ZlNzc3MTAzYzRkMjdiOWVhNzJkM2YzY2U0YzJmL3RhYmxlcmFuZ2U6ZGI3ZmU3NzcxMDNjNGQyN2I5ZWE3MmQzZjNjZTRjMmZfNi04LTEtMS02MTQ4NjE_258ed37a-151a-4269-8d6c-cfce5ef3ecbf id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmRiN2ZlNzc3MTAzYzRkMjdiOWVhNzJkM2YzY2U0YzJmL3RhYmxlcmFuZ2U6ZGI3ZmU3NzcxMDNjNGQyN2I5ZWE3MmQzZjNjZTRjMmZfNy0yLTEtMS02MTQ4NjE_9a49da0e-9f3e-4ac1-a3be-7eaf84e52943" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAyMQ_ef3ed581-7c29-47a2-8f39-a0d00590afdd"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfMTMtMi0xLTEtNjE0ODYx_8fa5bca7-2625-41f2-9347-65756e50828b id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfOS00LTEtMS02MTQ4NjE_c9fb49fe-5389-41a1-a986-68232a54123d id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfOS0yLTEtMS02MTQ4NjE_ce9a34d6-3535-4e9c-93fc-4c67de4a58b1 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfMTMtNC0xLTEtNjE0ODYx_fde68610-8f64-424d-b946-0f458b1052ff" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RleHRyZWdpb246OWRhNzRiYWEyNzY4NGY0ZGFkZDFlZDFmNzFiMGJhOGNfNzUw_7293320e-c8f8-4781-9a72-d8d2a28cdcc3"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfNC0xMC0xLTEtNjE0ODYx_8c77178e-4a48-40b4-8649-337680e0fdcb id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfNC00LTEtMS02MTQ4NjE_f9a49a66-f035-4e41-92f9-5161cc1dd318 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfNC02LTEtMS02MTQ4NjE_7d37d31a-28ef-4a54-a89a-b8294362ac31 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfNC0xMi0xLTEtNjE0ODYx_d18a6043-f44c-4630-808d-fb3d29397fe6" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RleHRyZWdpb246MWQwYWUyNjBlYWMwNDRkMTk2NDJjM2RmMTg5OWY2NzlfMzQ4_8e2f8f71-e075-40d2-8b3c-63da28965877"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfNC02LTEtMS02MTQ4NjE_c9a1be2a-bc01-4e11-9fbe-a349ab067556 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfNi04LTEtMS02MTQ4NjE_f3826f39-41ed-412b-815b-b25a72af7c2c id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfNC04LTEtMS02MTQ4NjE_64256be1-69a0-47a0-97ca-aed47e02f6a9 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfNS02LTEtMS02MTQ4NjE_16d74c94-232c-4d0a-8e74-e070ead7f81c id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfNi02LTEtMS02MTQ4NjE_4e65063e-d227-405a-96a5-9e247bfa21c6 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfNS04LTEtMS02MTQ4NjE_8a3a8d5f-1d0a-40b5-9a56-657161a775ed" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RleHRyZWdpb246YzRhMzUxNmU4ZmYwNDQwMmJlMGI3NTk1NTQzNWZjYjhfMTkz_d5a12e59-89e0-4f34-854e-7430be52ad8e"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC0xMC0xLTEtNjE0ODYx_6df62a9d-ce1d-486b-a32c-7bed898a9229 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC0xMC0xLTEtNjc2ODk4_8b1ab299-5bc5-4840-a83b-45b4a0e6b9b8 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTY0OTI2NzQ0ODc2Nw_b72127af-3cb8-451e-849b-d3fb7eb16a03 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfMy0xMC0xLTEtNjE0ODYx_c7c53f2f-4d6d-438a-9980-03298a6258ab" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NA_034f4111-ff43-4e4b-9029-668d23b72473"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMTEtNi0xLTEtNjE0ODYx_7ddc7b70-dedc-4d4a-9483-3d2b2a5e5e58 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMTEtOC0xLTEtNjE0ODYx_926b41dd-feb7-4a5c-98d5-08613a2e7720" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RleHRyZWdpb246ODY3ZTU1OThiMTVmNDE1M2E0MDUwMTk3MmQxZTRjYTJfMjY4_05aba6f5-6651-4fc3-bf16-1301a825ef0e"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjNjY2EyOTE3NTdkMTQ0NzE5YjMwOTUwODk3NzVjMzgxL3RhYmxlcmFuZ2U6M2NjYTI5MTc1N2QxNDQ3MTliMzA5NTA4OTc3NWMzODFfNS02LTEtMS02MTQ4NjE_b87b07d3-90fd-4027-ba31-2192958f7a79 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjNjY2EyOTE3NTdkMTQ0NzE5YjMwOTUwODk3NzVjMzgxL3RhYmxlcmFuZ2U6M2NjYTI5MTc1N2QxNDQ3MTliMzA5NTA4OTc3NWMzODFfNS04LTEtMS02MTQ4NjE_b297f652-9d41-415b-b653-2a73a84f9536" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RleHRyZWdpb246OWRhNzRiYWEyNzY4NGY0ZGFkZDFlZDFmNzFiMGJhOGNfNzU3_a7c09b2b-99e6-4904-9baa-52568e872960"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMTItNi0xLTEtNjE0ODYx_30e3eb94-32c0-40f9-8b8f-8955b309389c id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMTItOC0xLTEtNjE0ODYx_dbc63a4f-fd13-486e-a0d2-9592694759f3" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3OQ_9594fb42-f248-48c5-9de8-89fb935cb09f"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfOS02LTEtMS02MTQ4NjE_e5a59743-d5c7-42a6-9ef7-d0f3f0dcc1b0 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfOS04LTEtMS02MTQ4NjE_c8402829-bb29-4871-b06b-3812336dc950" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDEzMA_468e4122-41d0-47d0-a3ec-12f50b33e3b3"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjNjY2EyOTE3NTdkMTQ0NzE5YjMwOTUwODk3NzVjMzgxL3RhYmxlcmFuZ2U6M2NjYTI5MTc1N2QxNDQ3MTliMzA5NTA4OTc3NWMzODFfMy02LTEtMS02MTQ4NjE_654273ab-8b37-464a-b662-33c402d32357 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjNjY2EyOTE3NTdkMTQ0NzE5YjMwOTUwODk3NzVjMzgxL3RhYmxlcmFuZ2U6M2NjYTI5MTc1N2QxNDQ3MTliMzA5NTA4OTc3NWMzODFfMy04LTEtMS02MTQ4NjE_ee57f094-43e1-4b48-a7fe-e26d4631d7de" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RleHRyZWdpb246OWRhNzRiYWEyNzY4NGY0ZGFkZDFlZDFmNzFiMGJhOGNfNzQ4_9c30552a-9749-4883-b3f2-38dbe8d8f94d"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTQtMTItMS0xLTYxNDg2MQ_46cdc9b8-e870-4d88-9cdb-7ee6fd8d7302 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTQtMTAtMS0xLTYxNDg2MQ_c35d7d30-6cfd-4723-94cb-da7147a0a4a6 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTQtMi0xLTEtNjE0ODYx_bc8319e5-aa1c-4db2-9aaa-747dc696545a id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTQtNi0xLTEtNjE0ODYx_990cb2f5-fc62-4afe-a72f-648193fc0e25 id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTQtOC0xLTEtNjE0ODYx_eb4dde8b-7f51-487b-9de8-73bf1a5d217f id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTQtNC0xLTEtNjE0ODYx_395fda01-c22e-4efd-bcdf-2e7e55e101a5" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RleHRyZWdpb246YWIwYmY2YzZjM2I2NDdmNWE5MDcyYTI5NTkzZDcyOTZfMTEwNg_2e3fb9db-ec30-414c-8ec3-84c055decc20"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfMy0yLTEtMS02MTQ4NjE_320f6be1-5400-4ee1-a1eb-0498b16b6edd id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfNS0yLTEtMS02MTQ4NjE_45dbcab7-3ad3-47c9-9d09-44ad0a0329dd" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RleHRyZWdpb246MWQwYWUyNjBlYWMwNDRkMTk2NDJjM2RmMTg5OWY2NzlfMTQ4NDM0MDY5NzUzOTc_35caf586-a2e2-4584-a335-b5dfe8fb6772"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfMy02LTEtMS02MTQ4NjE_2f3e3b09-e9eb-4ffc-9236-5e89ad820b6b id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfMy04LTEtMS02MTQ4NjE_f215541f-fa33-4687-98f5-b828b395f113" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RleHRyZWdpb246MTFjMGExMWUzY2NkNGFiMThhNDViYjA1ZTExNjQyNTlfMjc1MQ_a6b6bef0-e1c8-4d32-9241-f28755c3d35c"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjMtNi0xLTEtNjE0ODYx_026c398c-acb9-4c33-960b-8bfdfdf3b69c id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjMtNC0xLTEtNjE0ODYx_2673b280-d63c-4844-88b7-d9182354cadd" linkrole="http://www.xbrl.org/2003/role/link" order="1" torefs="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyNTU_9b5c7f61-d7e5-4d67-8075-7b780581a2f1"></ix:relationship></ix:resources></ix:header></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%">FORM <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGV4dHJlZ2lvbjo1YjY2OWMwY2NiODc0MmYxYjNhMTliMDU4ZDk1ODliNl84Mg_fb1741a0-98b1-4bec-944e-e20f489966e7" name="dei:DocumentType">10-Q</ix:nonnumeric> </span></div><div><span><br/></span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGV4dHJlZ2lvbjo1YjY2OWMwY2NiODc0MmYxYjNhMTliMDU4ZDk1ODliNl84Nw_d58daeeb-5ea2-4b65-b1d1-45ed4120339e" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonnumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGV4dHJlZ2lvbjo1YjY2OWMwY2NiODc0MmYxYjNhMTliMDU4ZDk1ODliNl8yMTE_c85df55c-a500-42ea-8de7-a38db102a97f" name="dei:DocumentPeriodEndDate">April&#160;2, 2023</ix:nonnumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">OR</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGV4dHJlZ2lvbjo1YjY2OWMwY2NiODc0MmYxYjNhMTliMDU4ZDk1ODliNl8yMjA_2d973893-17d5-42bc-8840-bf1351dcf6ea" name="dei:DocumentTransitionReport">&#9744;</ix:nonnumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  TRANSITION REPORT PURSUANT TO SECTION 13</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For the transition period from _______ to _______</span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">COMMISSION FILE NUMBER </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGV4dHJlZ2lvbjo1YjY2OWMwY2NiODc0MmYxYjNhMTliMDU4ZDk1ODliNl8zOTI_26f623d5-98d0-43f2-b4d7-1452a721bfc0" name="dei:EntityFileNumber">1-3619</ix:nonnumeric></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">----</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGV4dHJlZ2lvbjo1YjY2OWMwY2NiODc0MmYxYjNhMTliMDU4ZDk1ODliNl80MDI_861b984f-7ce8-4857-9bae-896156b4a764" name="dei:EntityRegistrantName">PFIZER INC</ix:nonnumeric>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGFibGU6ZDRjMzQ0ZTZmZDNkNDU5Yjg1MmEwNjcyMjY4Yzc5NzQvdGFibGVyYW5nZTpkNGMzNDRlNmZkM2Q0NTliODUyYTA2NzIyNjhjNzk3NF8wLTAtMS0xLTYxNDg2MQ_4bb20e64-9372-4170-a149-7ddc8063ec2a" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGFibGU6ZDRjMzQ0ZTZmZDNkNDU5Yjg1MmEwNjcyMjY4Yzc5NzQvdGFibGVyYW5nZTpkNGMzNDRlNmZkM2Q0NTliODUyYTA2NzIyNjhjNzk3NF8wLTEtMS0xLTYxNDg2MQ_081963f4-87aa-42a1-8f12-1fe9209a140c" name="dei:EntityTaxIdentificationNumber">13-5315170</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(State of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGV4dHJlZ2lvbjo1YjY2OWMwY2NiODc0MmYxYjNhMTliMDU4ZDk1ODliNl80NjU_734fdf3f-fe90-446d-b452-7eddca4e38e1" name="dei:EntityAddressAddressLine1">66 Hudson Boulevard East</ix:nonnumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGV4dHJlZ2lvbjo1YjY2OWMwY2NiODc0MmYxYjNhMTliMDU4ZDk1ODliNl80Njk_1753b5fd-5c1e-4926-8ce2-4fe1aa6cc13a" name="dei:EntityAddressCityOrTown">New York</ix:nonnumeric>, <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGV4dHJlZ2lvbjo1YjY2OWMwY2NiODc0MmYxYjNhMTliMDU4ZDk1ODliNl80NzM_292ed581-449f-4c3b-b366-c51148dab704" name="dei:EntityAddressStateOrProvince">New York</ix:nonnumeric>&#160;&#160;<ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGV4dHJlZ2lvbjo1YjY2OWMwY2NiODc0MmYxYjNhMTliMDU4ZDk1ODliNl80Nzc_183b9823-380a-4aad-a66a-267239a18326" name="dei:EntityAddressPostalZipCode">10001-2192</ix:nonnumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Address of principal executive offices)&#160;&#160;(zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGV4dHJlZ2lvbjo1YjY2OWMwY2NiODc0MmYxYjNhMTliMDU4ZDk1ODliNl81MzU_b260d171-3f1f-4ca9-9895-082012dcfb28" name="dei:CityAreaCode">212</ix:nonnumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">) <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGV4dHJlZ2lvbjo1YjY2OWMwY2NiODc0MmYxYjNhMTliMDU4ZDk1ODliNl81Mzk_e4ef56ac-5f7e-4737-b440-1c486e5dd0bd" name="dei:LocalPhoneNumber">733-2323</ix:nonnumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number including area code)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:30.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ibcd151dd3f214701babfebf86e922d7a_D20230101-20230402" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGFibGU6OTBhY2U2OGNiNGFlNDVhZjgzZGQ3MzYzOTc4ZTBlY2QvdGFibGVyYW5nZTo5MGFjZTY4Y2I0YWU0NWFmODNkZDczNjM5NzhlMGVjZF8zLTAtMS0xLTYxNDg2MQ_acbbdcc1-eda8-4eb3-bf78-70b9090284c8" name="dei:Security12bTitle">Common Stock, $0.05 par value</ix:nonnumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ibcd151dd3f214701babfebf86e922d7a_D20230101-20230402" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGFibGU6OTBhY2U2OGNiNGFlNDVhZjgzZGQ3MzYzOTc4ZTBlY2QvdGFibGVyYW5nZTo5MGFjZTY4Y2I0YWU0NWFmODNkZDczNjM5NzhlMGVjZF8zLTItMS0xLTYxNDg2MQ_94a2cb14-3362-49a7-816b-2b9ba139e65e" name="dei:TradingSymbol">PFE</ix:nonnumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ibcd151dd3f214701babfebf86e922d7a_D20230101-20230402" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGFibGU6OTBhY2U2OGNiNGFlNDVhZjgzZGQ3MzYzOTc4ZTBlY2QvdGFibGVyYW5nZTo5MGFjZTY4Y2I0YWU0NWFmODNkZDczNjM5NzhlMGVjZF8zLTQtMS0xLTYxNDg2MQ_3298b5d8-d5f3-4b25-bcb9-a47a51c13cb3" name="dei:SecurityExchangeName">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i0603609d3bec4a6a87253aad5ea4b471_D20230101-20230402" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGFibGU6OTBhY2U2OGNiNGFlNDVhZjgzZGQ3MzYzOTc4ZTBlY2QvdGFibGVyYW5nZTo5MGFjZTY4Y2I0YWU0NWFmODNkZDczNjM5NzhlMGVjZF80LTAtMS0xLTYxNDg2MQ_59822793-2e25-4bac-82af-415c02d79f51" name="dei:Security12bTitle">1.000% Notes due 2027</ix:nonnumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i0603609d3bec4a6a87253aad5ea4b471_D20230101-20230402" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGFibGU6OTBhY2U2OGNiNGFlNDVhZjgzZGQ3MzYzOTc4ZTBlY2QvdGFibGVyYW5nZTo5MGFjZTY4Y2I0YWU0NWFmODNkZDczNjM5NzhlMGVjZF80LTItMS0xLTYxNDg2MQ_4efb983c-8e80-47cb-a89b-90e8f95a796a" name="dei:TradingSymbol">PFE27</ix:nonnumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i0603609d3bec4a6a87253aad5ea4b471_D20230101-20230402" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGFibGU6OTBhY2U2OGNiNGFlNDVhZjgzZGQ3MzYzOTc4ZTBlY2QvdGFibGVyYW5nZTo5MGFjZTY4Y2I0YWU0NWFmODNkZDczNjM5NzhlMGVjZF80LTQtMS0xLTYxNDg2MQ_c202fe8f-9815-4b63-9a9b-948368ab1bed" name="dei:SecurityExchangeName">New York Stock Exchange</ix:nonnumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.345%"><tr><td style="width:1.0%"></td><td style="width:29.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGFibGU6ZDBiNjk0NjU1YWI3NDc5NGFhMWRmM2M3ZTZkZTM1MGIvdGFibGVyYW5nZTpkMGI2OTQ2NTVhYjc0Nzk0YWExZGYzYzdlNmRlMzUwYl8wLTAtMS0xLTYxNDg2MQ_dfd56f06-424b-4cf6-b151-68fcf49a2bcd" name="dei:EntityCurrentReportingStatus">Yes</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.345%"><tr><td style="width:1.0%"></td><td style="width:29.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGFibGU6ZmIwYjU1M2ZmYTZkNDVhYWJiOGFmOGNkZjAyZDhmM2IvdGFibGVyYW5nZTpmYjBiNTUzZmZhNmQ0NWFhYmI4YWY4Y2RmMDJkOGYzYl8wLTAtMS0xLTYxNDg2MQ_d29e40aa-338d-44b2-b94d-feed8f3d037d" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGV4dHJlZ2lvbjo1YjY2OWMwY2NiODc0MmYxYjNhMTliMDU4ZDk1ODliNl8xNTg2_3f792590-cd29-4ffb-ae67-10fa52faaa8b" name="dei:EntityFilerCategory">Large Accelerated filer</ix:nonnumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accelerated filer  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Non-accelerated filer&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Smaller reporting company&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGV4dHJlZ2lvbjo1YjY2OWMwY2NiODc0MmYxYjNhMTliMDU4ZDk1ODliNl8xNzAz_ef56c673-71b3-4405-8d3f-4075d5e643df" name="dei:EntitySmallBusiness">&#9744;</ix:nonnumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Emerging growth company&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGV4dHJlZ2lvbjo1YjY2OWMwY2NiODc0MmYxYjNhMTliMDU4ZDk1ODliNl8xNzMx_823f9c8e-88ec-4a25-be53-458cca7f0632" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonnumeric> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.345%"><tr><td style="width:1.0%"></td><td style="width:29.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGFibGU6NWE3ZDM1NzVhZTdmNDE1OWE3ZTVkNDI4MmE0Y2MzMzQvdGFibGVyYW5nZTo1YTdkMzU3NWFlN2Y0MTU5YTdlNWQ0MjgyYTRjYzMzNF8wLTEtMS0xLTYxNDg2MQ_f505df70-1057-47ef-b6bb-040952ac58c5" name="dei:EntityShellCompany">&#9744;</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At May&#160;5, 2023,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonfraction contextref="i98345eeda59b40e1bf683199e6621b70_I20230505" decimals="INF" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xL2ZyYWc6NWI2NjljMGNjYjg3NDJmMWIzYTE5YjA1OGQ5NTg5YjYvdGV4dHJlZ2lvbjo1YjY2OWMwY2NiODc0MmYxYjNhMTliMDU4ZDk1ODliNl8yMTEz_efcb6056-5f6e-40f4-9bea-95e7ff6f4bd6" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitref="shares">5,645,307,020</ix:nonfraction> shares of the issuer&#8217;s voting common stock were outstanding.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_4"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.111%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #0a2299;border-top:1pt dotted #0a2299;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</span></td></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:92.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none">PART I.&#160;&#160;FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_16" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_16" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_19" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Condensed Consolidated Statements of Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_19" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">5</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_22" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Condensed Consolidated Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_22" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">6</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_25" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">7</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_28" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Condensed Consolidated Statements of Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_28" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">8</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">9</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_34" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">10</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Management&#8217;<a href="#idfe6e72973fb4e83b28a5bb34d34299f_103" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_103" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">34</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_157" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_157" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_157" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">53</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_160" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_160" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_160" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">53</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_163" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none">PART II.&#160;&#160;OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_166" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_166" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_166" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">53</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_169" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_169" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_169" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">53</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_172" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_172" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">54</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mine Safety Disclosures</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_184" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Item </a><a href="#idfe6e72973fb4e83b28a5bb34d34299f_184" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">6</a><a href="#idfe6e72973fb4e83b28a5bb34d34299f_184" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_184" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_184" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">54</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_187" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">Signature</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_187" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">54</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A = Not Applicable</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_7"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.111%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #05497c;border-top:1pt dotted #05497c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEFINED TERMS </span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless the context requires otherwise, references to &#8220;Pfizer,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer&#8217;s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February&#160;26, 2023 and February&#160;27, 2022, and for U.S. subsidiaries is as of and for the three months ended April&#160;2, 2023 and April&#160;3, 2022. References to &#8220;Notes&#8221; in this Form 10-Q are to the Notes to the Condensed or Consolidated Financial Statements in this Form 10-Q or in our 2022 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined below:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:21.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">2022 Form 10-K</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Annual Report on Form 10-K for the fiscal year ended December 31, 2022</span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ACIP</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Advisory Committee on Immunization Practices</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ALK</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">anaplastic lymphoma kinase</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Alliance revenues</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Arena</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arena Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Astellas</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc. </span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ATTR-CM</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">transthyretin amyloid cardiomyopathy</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Biohaven</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Biohaven Pharmaceutical Holding Company Ltd.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BioNTech</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BioNTech SE</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Biopharma</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global Biopharmaceuticals Business</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BMS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bristol-Myers Squibb Company</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BOD</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Board of Directors</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">CDC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Centers for Disease Control and Prevention</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">CMA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">conditional marketing authorisation</span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Comirnaty*</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unless otherwise noted, refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine, the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), the Comirnaty Original/Omicron BA.1 Vaccine, and Comirnaty Original/Omicron BA.4/BA.5 Vaccine. In the U.S., monovalent mRNA COVID-19 vaccines are no longer emergency use authorized or CDC-recommended, although Comirnaty remains a licensed vaccine.</span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Cond. J-NDA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Conditional Japan New Drug Application</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Consumer Healthcare JV</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK Consumer Healthcare JV</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">novel coronavirus disease of 2019</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes the following markets: Western Europe, Scandinavian countries and Finland</span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Developed Markets</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes the following markets: U.S., Developed Europe, Japan, South Korea, Canada, Australia and New Zealand</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes the following markets: Japan, South Korea, Canada, Australia and New Zealand</span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">European Commission</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EMA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">European Medicines Agency</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Central Europe, the Middle East, Africa and Turkey</span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EPS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">earnings per share</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ESG</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Environmental, Social and Governance</span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">European Union</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EUA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">emergency use authorization</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Exchange Act</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities Exchange Act of 1934, as amended</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">FASB</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial Accounting Standards Board</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">FDA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Food and Drug Administration</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">FFDCA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Federal Food, Drug and Cosmetic Act</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Form 10-Q</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">This Quarterly Report on Form 10-Q for the quarterly period ended April 2, 2023</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Generally Accepted Accounting Principles</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">GBT</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global Blood Therapeutics, Inc. </span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">GPD</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global Product Development organization</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">GSK</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK plc</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Haleon</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Haleon plc</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">HIPAA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Health Insurance Portability and Accountability Act of 1996 </span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Hospira</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Hospira, Inc.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">in-process research and development</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">IRA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inflation Reduction Act of 2022</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">IRS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Internal Revenue Service</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">JAK</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Janus kinase</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">JV</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">joint venture</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">King</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">LIBOR</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">London Interbank Offered Rate</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">LOE</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">loss of exclusivity</span></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">mCRC</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">metastatic colorectal cancer</span></td></tr></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:21.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">mCRPC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">metastatic castration-resistant prostate cancer </span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">mCSPC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">metastatic castration-sensitive prostate cancer</span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">MDL</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Multi-District Litigation</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Meridian</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Meridian Medical Technologies, Inc.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">mRNA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">messenger ribonucleic acid</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">MSA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Manufacturing Supply Agreement</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Mylan</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Mylan N.V.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Myovant</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Myovant Sciences Ltd.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">NDA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">New Drug Application</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Nimbus</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Nimbus Therapeutics, LLC</span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">nmCRPC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">non-metastatic castration-resistant prostate cancer </span></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">NSCLC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">non-small cell lung cancer</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ODT</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">oral disintegrating tablet</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Ono</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ono Pharmaceutical Co., Ltd.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">OPKO</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">OPKO Health, Inc.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">OTC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">over-the-counter</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Paxlovid*</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">an oral COVID-19 treatment (nirmatrelvir [PF-07321332] tablets and ritonavir tablets)</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">PC1</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pfizer CentreOne</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Pharmacia</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmacia Corporation</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Prevnar family</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20/Apexxnar (adult)</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">PsA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">psoriatic arthritis</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">RA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">rheumatoid arthritis</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">RCC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">renal cell carcinoma</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">research and development</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Seagen</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Seagen Inc.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">SEC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Securities and Exchange Commission</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">SI&amp;A</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">selling, informational and administrative</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">TSAs</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">transition service arrangements</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">UC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ulcerative colitis</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">U.K.</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United Kingdom</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United States</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Upjohn Business</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pfizer&#8217;s former global, primarily off-patent branded and generics business, which included a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Viatris</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Viatris Inc.</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ViiV</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ViiV Healthcare Limited</span></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Vyndaqel family</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes Vyndaqel, Vyndamax and Vynmac</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">WRDM</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide Research, Development and Medical</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:5.5pt">Paxlovid and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) have not been approved or licensed by the FDA. Paxlovid has been authorized for emergency use by the FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with a current diagnosis of mild-to-moderate COVID-19 and who are at high risk for progression to severe COVID-19, including hospitalization or death. The Pfizer-BioNTech COVID-19 Vaccine, Bivalent has been authorized by the FDA under an EUA to prevent COVID-19 in individuals aged 6 months and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the COVID-19 pandemic under Section 564(b)(1) of the FFDCA unless the declaration is terminated or authorization revoked sooner. Please see the EUA Fact Sheets at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">www.covid19oralrx.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">www.cvdvaccine-us.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our Twitter accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_10"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #0a2299;border-top:1pt dotted #0a2299;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PART I.&#160; FINANCIAL INFORMATION</span></td></tr></table></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_16"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_19"></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT PER SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMi02LTEtMS02MTQ4NjE_c12c987b-9c67-465d-bbaa-33b30d31e2a4" name="us-gaap:Revenues" scale="6" unitref="usd">18,282</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMi04LTEtMS02MTQ4NjE_3266cce6-8453-4239-91ea-954c73b5c55b" name="us-gaap:Revenues" scale="6" unitref="usd">25,661</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfNC02LTEtMS02MTQ4NjE_c9a1be2a-bc01-4e11-9fbe-a349ab067556" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" unitref="usd">4,886</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfNC04LTEtMS02MTQ4NjE_64256be1-69a0-47a0-97ca-aed47e02f6a9" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" unitref="usd">9,984</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfNS02LTEtMS02MTQ4NjE_16d74c94-232c-4d0a-8e74-e070ead7f81c" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" unitref="usd">3,418</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfNS04LTEtMS02MTQ4NjE_8a3a8d5f-1d0a-40b5-9a56-657161a775ed" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" unitref="usd">2,593</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfNi02LTEtMS02MTQ4NjE_4e65063e-d227-405a-96a5-9e247bfa21c6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" unitref="usd">2,505</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfNi04LTEtMS02MTQ4NjE_f3826f39-41ed-412b-815b-b25a72af7c2c" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" unitref="usd">2,301</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfNy02LTEtMS02MTQ4NjE_e7e5a2b0-e683-4916-ae71-3d148832a976" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" unitref="usd">21</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfNy04LTEtMS02MTQ4NjE_75cdb876-402f-4f84-a803-bd55f5687f0d" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" unitref="usd">355</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfOC02LTEtMS02MTQ4NjE_e54beff5-0570-4f76-be57-0ae4b5729f35" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" scale="6" unitref="usd">1,103</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfOC04LTEtMS02MTQ4NjE_f4d2f54d-4b64-4493-a4e1-7f8bd1dca49c" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" scale="6" unitref="usd">835</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfOS02LTEtMS02MTQ4NjE_d2de8e2d-97a2-48d9-b3b6-d698e054ebd8" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" unitref="usd">9</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfOS04LTEtMS02MTQ4NjE_92604d9a-b071-4ee4-9da4-ad526fcb43d3" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" unitref="usd">192</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMTEtNi0xLTEtNjE0ODYx_6d1a6350-45df-43e2-9410-a4a9bb431248" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" sign="-" unitref="usd">70</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMTEtOC0xLTEtNjE0ODYx_81ca2122-9004-4b1c-9c95-e8156452e009" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" sign="-" unitref="usd">350</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before provision/(benefit) for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMTItNi0xLTEtNjE0ODYx_a4430c53-1bb2-4953-b9eb-c6b0416235aa" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" unitref="usd">6,270</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMTItOC0xLTEtNjE0ODYx_f0da6e23-b80b-4f54-a8a9-c186cda5e7f3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" unitref="usd">9,050</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMTMtNi0xLTEtNjE0ODYx_56ecd270-bbb3-43da-b1a6-ff33d8f52406" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" unitref="usd">715</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMTMtOC0xLTEtNjE0ODYx_ed3821eb-ccf3-416f-b142-614c9dd99b46" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" unitref="usd">1,172</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMTQtNi0xLTEtNjE0ODYx_1ea41a2b-5703-4514-98a4-28d7da20f89b" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">5,555</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMTQtOC0xLTEtNjE0ODYx_aa69f3af-d60f-4672-b37d-e6c46255de85" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">7,879</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMTYtNi0xLTEtNjE0ODYx_54e4bbf2-d086-49e9-8c0f-0076834da9b9" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" unitref="usd">1</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMTYtOC0xLTEtNjE0ODYx_c9ff8af1-a63f-44ec-934d-d7cc6a3c8c2b" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" sign="-" unitref="usd">9</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMTktNi0xLTEtNjE0ODYx_cf583e60-c2ca-4f8f-8e50-834e94674874" name="us-gaap:ProfitLoss" scale="6" unitref="usd">5,556</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMTktOC0xLTEtNjE0ODYx_247ea363-9c79-4520-8e58-b2260cb11437" name="us-gaap:ProfitLoss" scale="6" unitref="usd">7,870</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMjAtNi0xLTEtNjE0ODYx_29f6652d-5f9e-4f2f-a60e-79e498264280" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" unitref="usd">13</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMjAtOC0xLTEtNjE0ODYx_c496648d-dd45-4c41-b4cd-89151c762e76" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" unitref="usd">6</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMjEtNi0xLTEtNjE0ODYx_b66aacd9-c7f8-4f8b-95a5-8c8c144b3225" name="us-gaap:NetIncomeLoss" scale="6" unitref="usd">5,543</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMjEtOC0xLTEtNjE0ODYx_9bbdb56e-4568-4d6a-b542-7788934d8af0" name="us-gaap:NetIncomeLoss" scale="6" unitref="usd">7,864</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share&#8211;&#8211;basic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMjQtNi0xLTEtNjE0ODYx_c0687b78-b25f-4ed5-836e-54ba0663830f" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" unitref="usdPerShare">0.98</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMjQtOC0xLTEtNjE0ODYx_f6c662ef-e48e-4326-abe6-213d0e54ad43" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" unitref="usdPerShare">1.40</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="2" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMjUtNi0xLTEtNjE0ODYx_d351a346-f03d-47ad-a8c6-77ffedd115e0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" unitref="usdPerShare">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="2" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMjUtOC0xLTEtNjE0ODYx_6cdab2db-76eb-4782-9639-08c986407d28" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" unitref="usdPerShare">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMjYtNi0xLTEtNjE0ODYx_aec4ccac-22f9-47a5-8816-d613c9e4a873" name="us-gaap:EarningsPerShareBasic" scale="0" unitref="usdPerShare">0.98</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMjYtOC0xLTEtNjE0ODYx_23f918d2-95af-4622-a084-e9509bb0c97a" name="us-gaap:EarningsPerShareBasic" scale="0" unitref="usdPerShare">1.40</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share&#8211;&#8211;diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMjktNi0xLTEtNjE0ODYx_7ef7f45e-948c-4f49-94a2-dbec39e3217b" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" unitref="usdPerShare">0.97</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMjktOC0xLTEtNjE0ODYx_f39a430f-f992-4aaa-a2de-bbbf899e7f4b" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" unitref="usdPerShare">1.37</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="2" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMzAtNi0xLTEtNjE0ODYx_46159901-b494-475d-b943-84f54c607e6d" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" unitref="usdPerShare">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="2" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMzAtOC0xLTEtNjE0ODYx_4b7b5aa6-a7da-4a07-8d7a-9157745f024c" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" unitref="usdPerShare">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMzEtNi0xLTEtNjE0ODYx_b8f084b3-e8dc-462b-8c9d-04527fd791e5" name="us-gaap:EarningsPerShareDiluted" scale="0" unitref="usdPerShare">0.97</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMzEtOC0xLTEtNjE0ODYx_57e1d89b-09a4-4d60-837b-7c5c0251c64f" name="us-gaap:EarningsPerShareDiluted" scale="0" unitref="usdPerShare">1.37</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares&#8211;&#8211;basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMzMtNi0xLTEtNjE0ODYx_6df10bc2-44c9-49dd-9730-a1a296fcbea6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" unitref="shares">5,634</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMzMtOC0xLTEtNjE0ODYx_39385474-3f28-47a4-b038-940800fef38d" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" unitref="shares">5,617</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares&#8211;&#8211;diluted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMzQtNi0xLTEtNjE0ODYx_f6947243-7f59-45d7-941e-7bb2acf7dee0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" unitref="shares">5,727</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RhYmxlOmVlMmU4ZjU0Y2RkODRmN2NiMzYzMzE4OGZhZjFkOGNjL3RhYmxlcmFuZ2U6ZWUyZThmNTRjZGQ4NGY3Y2IzNjMzMTg4ZmFmMWQ4Y2NfMzQtOC0xLTEtNjE0ODYx_fef7d30a-eae5-4518-928c-ec739e37aa25" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" unitref="shares">5,758</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8xOS9mcmFnOmM0YTM1MTZlOGZmMDQ0MDJiZTBiNzU5NTU0MzVmY2I4L3RleHRyZWdpb246YzRhMzUxNmU4ZmYwNDQwMmJlMGI3NTk1NTQzNWZjYjhfMTkz_d5a12e59-89e0-4f34-854e-7430be52ad8e">Exclusive of amortization of intangible assets.</ix:footnote></span></div><div style="text-indent:9pt"><span><br/></span></div><div style="margin-top:135pt;padding-right:-13.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_22"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER&#160;INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMi02LTEtMS02MTQ4NjE_cf583e60-c2ca-4f8f-8e50-834e94674874" name="us-gaap:ProfitLoss" scale="6" unitref="usd">5,556</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMi04LTEtMS02MTQ4NjE_247ea363-9c79-4520-8e58-b2260cb11437" name="us-gaap:ProfitLoss" scale="6" unitref="usd">7,870</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfNC02LTEtMS02MTQ4NjE_ff5a4f36-21e6-414f-8a48-a99b2cf9d919" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" unitref="usd">101</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfNC04LTEtMS02MTQ4NjE_9bf6df1c-31f8-4ea9-9b78-a2346886b29c" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" sign="-" unitref="usd">363</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfNy02LTEtMS02MTQ4NjE_543bf98c-46b4-41f9-bb0d-db7b8eec40d9" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" unitref="usd">2</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfNy04LTEtMS02MTQ4NjE_4fef812e-8d91-4a30-bba4-b783c16fb1c2" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" unitref="usd">203</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfOC02LTEtMS02MTQ4NjE_58f0eb0a-ad62-4df1-8782-a32487c49401" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" sign="-" unitref="usd">303</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfOC04LTEtMS02MTQ4NjE_ce455d09-6250-4ced-8f97-b3b1a3c6aff6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" unitref="usd">213</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfOS02LTEtMS02MTQ4NjE_d6baea71-c9cc-4e9d-92fa-186da838c709" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" unitref="usd">305</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfOS04LTEtMS02MTQ4NjE_4c63a306-9fe2-47e5-a1b0-a150c8c35300" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" sign="-" unitref="usd">10</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMTAtNi0xLTEtNjE0ODYx_d03003d0-b924-49d7-9991-05622139968e" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" unitref="usd">87</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMTAtOC0xLTEtNjE0ODYx_1ffd5eec-f232-4799-aa7c-d86f4298dd4c" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" sign="-" unitref="usd">133</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMTEtNi0xLTEtNjE0ODYx_7ddc7b70-dedc-4d4a-9483-3d2b2a5e5e58" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" unitref="usd">509</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMTEtOC0xLTEtNjE0ODYx_926b41dd-feb7-4a5c-98d5-08613a2e7720" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" sign="-" unitref="usd">233</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMTMtNi0xLTEtNjE0ODYx_7ef3e570-30f7-4cef-8130-d39a78df9dc5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" sign="-" unitref="usd">422</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMTMtOC0xLTEtNjE0ODYx_6277adc3-186f-43a9-8822-ba07bc53a510" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" unitref="usd">99</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments related to amortization of prior service costs and other, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMTUtNi0xLTEtNjE0ODYx_85b2d30e-c940-4641-b78a-300849dea1a2" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" sign="-" unitref="usd">30</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMTUtOC0xLTEtNjE0ODYx_c5adeeeb-c380-44cb-9745-2c092c8cd60d" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" sign="-" unitref="usd">36</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments related to curtailments of prior service costs and other, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMTYtNi0xLTEtNjE0ODYx_1f4a90b7-67d1-4c00-9bf7-b926992f9db7" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" scale="6" sign="-" unitref="usd">5</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMTYtOC0xLTEtNjE0ODYx_29ab2324-13f4-44a1-9fef-72d75af34d72" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" scale="6" sign="-" unitref="usd">11</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMTgtNi0xLTEtNjE0ODYx_8611013f-c24f-404b-b925-ac64721d5af2" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" unitref="usd">35</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMTgtOC0xLTEtNjE0ODYx_67a81360-6330-4d2e-8576-586b8661ccb1" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" unitref="usd">47</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income/(loss), before tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMTktNi0xLTEtNjE0ODYx_2f0c9f74-1fb1-4b28-8cb3-cdbb1abe6e9b" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" sign="-" unitref="usd">50</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMTktOC0xLTEtNjE0ODYx_d79a476c-c649-4c0e-bb9a-a3b9ea0b4a51" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" sign="-" unitref="usd">321</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMjAtNi0xLTEtNjE0ODYx_6c5dcb23-305a-44bd-8030-852e56064966" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" sign="-" unitref="usd">63</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMjAtOC0xLTEtNjE0ODYx_fc518e38-acc6-42f5-bc3f-96eb505ade6c" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" sign="-" unitref="usd">60</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income/(loss) before allocation to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMjEtNi0xLTEtNjE0ODYx_cdbe6f7c-c750-43d5-877f-f61b54c75b1f" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" unitref="usd">12</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMjEtOC0xLTEtNjE0ODYx_8dbc1c15-3283-46ca-afd0-8e70fb54f76f" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" sign="-" unitref="usd">260</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income/(loss) before allocation to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMjMtNi0xLTEtNjE0ODYx_c852a0a1-b04a-4f3d-80a3-7b6d4b530319" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">5,569</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMjMtOC0xLTEtNjE0ODYx_6b01b8ca-181c-40c4-ba8f-4c26759bb042" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">7,610</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Comprehensive income/(loss) attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMjQtNi0xLTEtNjE0ODYx_61968f22-719e-4fae-adfa-db46371a626f" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" unitref="usd">10</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMjQtOC0xLTEtNjE0ODYx_04a163d8-1340-4447-8d04-a474d4107741" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" unitref="usd">6</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income/(loss) attributable to Pfizer Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMjUtNi0xLTEtNjE0ODYx_df17c6f2-42c3-4c6e-b05f-3f7ad01a0f6e" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" unitref="usd">5,558</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RhYmxlOmRkMzkwMGUyNWIzNDQ3Yzc4NjI2NTU3ZGMzZDc1MTMyL3RhYmxlcmFuZ2U6ZGQzOTAwZTI1YjM0NDdjNzg2MjY1NTdkYzNkNzUxMzJfMjUtOC0xLTEtNjE0ODYx_6a91cb59-408b-4cd8-b53e-cb71549ac3a1" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" unitref="usd">7,604</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RleHRyZWdpb246ODY3ZTU1OThiMTVmNDE1M2E0MDUwMTk3MmQxZTRjYTJfMjY3_f0ff6601-8fe7-4091-9066-6c7f796b09cc"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_70" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7E</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yMi9mcmFnOjg2N2U1NTk4YjE1ZjQxNTNhNDA1MDE5NzJkMWU0Y2EyL3RleHRyZWdpb246ODY3ZTU1OThiMTVmNDE1M2E0MDUwMTk3MmQxZTRjYTJfMjY4_05aba6f5-6651-4fc3-bf16-1301a825ef0e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net.</span></ix:footnote></div><div style="margin-top:310pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMy0yLTEtMS02MTQ4NjE_a3bbc898-ba36-4096-a21a-c2f4478129b1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" unitref="usd">2,166</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMy00LTEtMS02MTQ4NjE_538ba1bb-b8a0-43e1-9b1a-f5800bd2f9e2" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" unitref="usd">416</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNC0yLTEtMS02MTQ4NjE_e3296a8f-01a2-4b4c-a7df-afb503813fc4" name="us-gaap:OtherShortTermInvestments" scale="6" unitref="usd">17,806</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNC00LTEtMS02MTQ4NjE_f8cdd41f-fe56-4ac1-a381-9162f223aec5" name="us-gaap:OtherShortTermInvestments" scale="6" unitref="usd">22,316</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts receivable, less allowance for doubtful accounts: 2023&#8212;$<ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNS0wLTEtMS02MTQ4NjEvdGV4dHJlZ2lvbjo1NTRiYTBjMzI2ODg0ZWVmYjFmYTIwMDY5MTkyNTg5N183Mg_00193c56-e590-4e10-b45d-6b6312589504" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" unitref="usd">465</ix:nonfraction>; 2022&#8212;$<ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNS0wLTEtMS02MTQ4NjEvdGV4dHJlZ2lvbjo1NTRiYTBjMzI2ODg0ZWVmYjFmYTIwMDY5MTkyNTg5N183OQ_58638d4f-ebc3-417c-989b-183931902899" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" unitref="usd">449</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNS0yLTEtMS02MTQ4NjE_0c6a40de-504f-4ba9-95e9-d04f5840ba2d" name="us-gaap:AccountsReceivableNetCurrent" scale="6" unitref="usd">12,305</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNS00LTEtMS02MTQ4NjE_99bd017a-979e-4a5c-8d85-1c1bef6f61f0" name="us-gaap:AccountsReceivableNetCurrent" scale="6" unitref="usd">10,952</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNi0yLTEtMS02MTQ4NjE_531c3cdd-c5a2-4b13-b5ad-abfd8e156ac8" name="us-gaap:InventoryNet" scale="6" unitref="usd">9,541</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNi00LTEtMS02MTQ4NjE_46249a8d-50c5-4e0c-a4d7-c773cbf04521" name="us-gaap:InventoryNet" scale="6" unitref="usd">8,981</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNy0yLTEtMS02MTQ4NjE_3fbcb760-1422-4ffe-be99-0cfa2d53a2c4" name="pfe:OtherTaxAssetsCurrent" scale="6" unitref="usd">3,140</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNy00LTEtMS02MTQ4NjE_410c99e1-c366-42f8-a19c-a31598a1fff6" name="pfe:OtherTaxAssetsCurrent" scale="6" unitref="usd">3,577</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfOC0yLTEtMS02MTQ4NjE_b06d61bc-d435-4885-a8ef-a83cb0cd9535" name="us-gaap:OtherAssetsCurrent" scale="6" unitref="usd">5,120</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfOC00LTEtMS02MTQ4NjE_31c748e1-cc7f-4267-8b0c-a1954e9cd337" name="us-gaap:OtherAssetsCurrent" scale="6" unitref="usd">5,017</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfOS0yLTEtMS02MTQ4NjE_e052cd61-d836-4a7e-b191-9193499e672c" name="us-gaap:AssetsCurrent" scale="6" unitref="usd">50,078</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfOS00LTEtMS02MTQ4NjE_1733d957-fe23-4259-9c60-a08e52b34f02" name="us-gaap:AssetsCurrent" scale="6" unitref="usd">51,259</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMTAtMi0xLTEtNjE0ODYx_e17892db-f174-4249-872b-d179c59f7e95" name="us-gaap:EquityMethodInvestments" scale="6" unitref="usd">11,175</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMTAtNC0xLTEtNjE0ODYx_f05d7daa-e3a2-40ae-99da-166a9377f8bb" name="us-gaap:EquityMethodInvestments" scale="6" unitref="usd">11,033</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMTEtMi0xLTEtNjE0ODYx_a2945c46-c7c0-45f2-8e3a-5463502d2353" name="us-gaap:OtherLongTermInvestments" scale="6" unitref="usd">3,568</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMTEtNC0xLTEtNjE0ODYx_201ab75a-1f18-491e-9b96-1b0ce6f0aa69" name="us-gaap:OtherLongTermInvestments" scale="6" unitref="usd">4,036</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, less accumulated depreciation: 2023&#8212;$<ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMTItMC0xLTEtNjE0ODYxL3RleHRyZWdpb246YTg3ZTdmYzE0MmE0NGFkOTgyNzAzNmIxNzJhYzA5ZjFfNjk_81c3c069-94b3-42fa-b21a-4126874caf59" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" unitref="usd">15,514</ix:nonfraction>; 2022&#8212;$<ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMTItMC0xLTEtNjE0ODYxL3RleHRyZWdpb246YTg3ZTdmYzE0MmE0NGFkOTgyNzAzNmIxNzJhYzA5ZjFfNzY_e2d01377-78bc-40ad-bf8a-c8e1112e2ace" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" unitref="usd">15,174</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMTItMi0xLTEtNjE0ODYx_f4169206-e72c-43c2-a86f-ac79a48f405a" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" unitref="usd">17,052</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMTItNC0xLTEtNjE0ODYx_1e6143a5-2aef-4e38-99b5-b4cca59d098d" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" unitref="usd">16,274</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMTMtMi0xLTEtNjE0ODYx_ccb74f1b-9020-4c0b-b82d-f3f1c858b03d" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" unitref="usd">42,002</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMTMtNC0xLTEtNjE0ODYx_f95dc7dd-77f8-4cd4-8a1b-68f5cb4868ff" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" unitref="usd">43,370</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMTQtMi0xLTEtNjE0ODYx_177dd985-6584-4dc6-bd9c-73ebcac6ff42" name="us-gaap:Goodwill" scale="6" unitref="usd">51,476</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMTQtNC0xLTEtNjE0ODYx_9599ddff-6107-440d-bb39-9f8fcb379991" name="us-gaap:Goodwill" scale="6" unitref="usd">51,375</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent deferred tax assets and other noncurrent tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMTUtMi0xLTEtNjE0ODYx_786a0779-b20f-42f1-8d2c-90e69513fd02" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" scale="6" unitref="usd">7,302</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMTUtNC0xLTEtNjE0ODYx_910660aa-03b6-47db-afd1-d2016314d845" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" scale="6" unitref="usd">6,693</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMTYtMi0xLTEtNjE0ODYx_3280167c-7b82-4e69-a39c-60fecdc58cae" name="us-gaap:OtherAssetsNoncurrent" scale="6" unitref="usd">12,965</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMTYtNC0xLTEtNjE0ODYx_2ee1445e-0788-4900-88af-03efd67af851" name="us-gaap:OtherAssetsNoncurrent" scale="6" unitref="usd">13,163</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMTgtMi0xLTEtNjE0ODYx_2b6437b0-a31f-4e5c-89d9-2ee98c24dcdd" name="us-gaap:Assets" scale="6" unitref="usd">195,617</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMTgtNC0xLTEtNjE0ODYx_32e57568-b813-41f9-b5ff-cbd1906510f6" name="us-gaap:Assets" scale="6" unitref="usd">197,205</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities and Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt: 2023&#8212;$<ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMjEtMC0xLTEtNjE0ODYxL3RleHRyZWdpb246MzNhM2FiZGMwNGMyNGU5YTg1NTExNDlkZDdiODc1YTNfNzU_317e2166-1d8b-4ab9-b643-3b08291d011a" name="us-gaap:LongTermDebtCurrent" scale="6" unitref="usd">3,567</ix:nonfraction>; 2022&#8212;$<ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMjEtMC0xLTEtNjE0ODYxL3RleHRyZWdpb246MzNhM2FiZGMwNGMyNGU5YTg1NTExNDlkZDdiODc1YTNfODI_29519402-a51d-46cd-9b49-07e4305eafce" name="us-gaap:LongTermDebtCurrent" scale="6" unitref="usd">2,560</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMjEtMi0xLTEtNjE0ODYx_faf76aa9-641a-4f0d-99d1-5caa6231a4f0" name="us-gaap:DebtCurrent" scale="6" unitref="usd">4,188</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMjEtNC0xLTEtNjE0ODYx_7b8cd531-271c-4ac4-848f-16d6e935a1e5" name="us-gaap:DebtCurrent" scale="6" unitref="usd">2,945</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMjItMi0xLTEtNjE0ODYx_950f7e6f-e077-4cfd-a03b-ad6739efe3e7" name="us-gaap:AccountsPayableCurrent" scale="6" unitref="usd">6,123</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMjItNC0xLTEtNjE0ODYx_4ece83e9-cd76-4d54-9fdc-f92ab0bc1f30" name="us-gaap:AccountsPayableCurrent" scale="6" unitref="usd">6,809</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMjMtMi0xLTEtNjE0ODYx_9d330d53-f86d-4676-b9e9-d0b3ed82afac" name="us-gaap:DividendsPayableCurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMjMtNC0xLTEtNjE0ODYx_7664e9b9-a292-46b9-b5e2-6f7ba3bd2011" name="us-gaap:DividendsPayableCurrent" scale="6" unitref="usd">2,303</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMjQtMi0xLTEtNjE0ODYx_a7a925ee-6709-4524-9805-4bca79dd884e" name="us-gaap:TaxesPayableCurrent" scale="6" unitref="usd">1,969</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMjQtNC0xLTEtNjE0ODYx_39df1f02-2ca4-4954-b435-2517a976f996" name="us-gaap:TaxesPayableCurrent" scale="6" unitref="usd">1,587</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMjUtMi0xLTEtNjE0ODYx_45ada1a6-24a6-49cd-a3e8-b448b30421fc" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" unitref="usd">2,277</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMjUtNC0xLTEtNjE0ODYx_518b57ae-31b2-4127-93b3-7139fe48c5c5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" unitref="usd">3,407</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMjYtMi0xLTEtNjE0ODYx_7f255b96-d295-481c-9dac-bf2e09712735" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" unitref="usd">1,750</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMjYtNC0xLTEtNjE0ODYx_43896916-4200-4fab-96b8-58398c096af6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" unitref="usd">2,520</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMjctMi0xLTEtNjE0ODYx_7df33ed3-1d05-4373-9217-a53d413c292e" name="us-gaap:OtherLiabilitiesCurrent" scale="6" unitref="usd">20,255</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMjctNC0xLTEtNjE0ODYx_60bdbc86-e6db-4ecf-af22-dac9b754e6a0" name="us-gaap:OtherLiabilitiesCurrent" scale="6" unitref="usd">22,568</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMjktMi0xLTEtNjE0ODYx_94f0c575-0915-45d9-b26a-ff880ca8c949" name="us-gaap:LiabilitiesCurrent" scale="6" unitref="usd">36,562</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMjktNC0xLTEtNjE0ODYx_d740b579-d5f4-4474-a36c-2064601ee59a" name="us-gaap:LiabilitiesCurrent" scale="6" unitref="usd">42,138</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMzEtMi0xLTEtNjE0ODYx_ea97378d-fea1-47f1-82d7-2dd7b2d854c9" name="us-gaap:LongTermDebtNoncurrent" scale="6" unitref="usd">31,704</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMzEtNC0xLTEtNjE0ODYx_f58c277d-4256-4b15-b11b-ee4bce8384c4" name="us-gaap:LongTermDebtNoncurrent" scale="6" unitref="usd">32,884</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension and postretirement benefit obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMzItMi0xLTEtNjE0ODYx_2b6d6027-b74e-4aed-a5c8-7ba93775db06" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" unitref="usd">2,179</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMzItNC0xLTEtNjE0ODYx_311a86d6-7c95-4bd8-9317-4b3f0943bfd6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" unitref="usd">2,250</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent deferred tax liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMzQtMi0xLTEtNjE0ODYx_f88508e6-7c20-4e3a-b035-13cbe3b3ae50" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" unitref="usd">1,067</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMzQtNC0xLTEtNjE0ODYx_bbab38fd-a459-453d-b7f7-ee33094e206b" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" unitref="usd">1,023</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other taxes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMzUtMi0xLTEtNjE0ODYx_8d9853bd-51c7-4e72-a8fb-9a951fa3ff2b" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" scale="6" unitref="usd">9,860</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMzUtNC0xLTEtNjE0ODYx_0dfb3a91-f66b-4348-a0b7-c9cb5d7b59d7" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" scale="6" unitref="usd">9,812</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMzYtMi0xLTEtNjE0ODYx_3b091c3e-9456-4c70-976c-7d1864d8e92d" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" unitref="usd">13,009</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMzYtNC0xLTEtNjE0ODYx_3a6f4b3d-6807-441c-aabe-f0c67a49c526" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" unitref="usd">13,180</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMzctMi0xLTEtNjE0ODYx_9e0fb43b-0373-4137-a549-bb1492d6d4f9" name="us-gaap:Liabilities" scale="6" unitref="usd">94,381</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMzctNC0xLTEtNjE0ODYx_40d941d0-c1ac-48b4-a584-3029427311c1" name="us-gaap:Liabilities" scale="6" unitref="usd">101,288</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and Contingencies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMzktMi0xLTEtNjE0ODYx_9a56a33c-4fbf-4754-9ead-639236c0f8b4" name="us-gaap:CommitmentsAndContingencies" unitref="usd" xsi:nil="true"></ix:nonfraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfMzktNC0xLTEtNjE0ODYx_0fc4331a-2c9a-4c23-857b-baca0124017b" name="us-gaap:CommitmentsAndContingencies" unitref="usd" xsi:nil="true"></ix:nonfraction></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNDItMi0xLTEtNjE0ODYx_37860cf4-8677-4b78-bd79-29baa25d0e25" name="us-gaap:CommonStockValue" scale="6" unitref="usd">478</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNDItNC0xLTEtNjE0ODYx_1b6dea60-9651-428b-8a56-0731b4df98b1" name="us-gaap:CommonStockValue" scale="6" unitref="usd">476</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNDMtMi0xLTEtNjE0ODYx_034f6ad8-e652-463c-b089-bab7df2097ef" name="us-gaap:AdditionalPaidInCapital" scale="6" unitref="usd">92,153</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNDMtNC0xLTEtNjE0ODYx_d1b67495-ad2f-422f-b630-efe016cab0da" name="us-gaap:AdditionalPaidInCapital" scale="6" unitref="usd">91,802</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNDUtMi0xLTEtNjE0ODYx_48ccb558-9717-4c8f-a86b-ac293644a6cb" name="us-gaap:TreasuryStockValue" scale="6" unitref="usd">114,473</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNDUtNC0xLTEtNjE0ODYx_0bd3f6d7-32ae-4194-88b3-0e9b998adf40" name="us-gaap:TreasuryStockValue" scale="6" unitref="usd">113,969</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNDYtMi0xLTEtNjE0ODYx_08de475a-1292-45e5-9019-3642ead9ce31" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" unitref="usd">131,102</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNDYtNC0xLTEtNjE0ODYx_db1e4c66-86bc-4308-a758-3527a71bf2e1" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" unitref="usd">125,656</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNDctMi0xLTEtNjE0ODYx_16c19f28-2c97-4ac0-b83a-452e92005ae4" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" sign="-" unitref="usd">8,289</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNDctNC0xLTEtNjE0ODYx_0a8a65c2-4384-4b99-8555-32ce3e3813c8" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" sign="-" unitref="usd">8,304</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Pfizer Inc. shareholders&#8217; equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNDgtMi0xLTEtNjE0ODYx_e25fa3ee-ef23-4a29-8ec1-b334e7009e7a" name="us-gaap:StockholdersEquity" scale="6" unitref="usd">100,970</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNDgtNC0xLTEtNjE0ODYx_9bf54383-fc36-4239-be6d-6a42c24331e2" name="us-gaap:StockholdersEquity" scale="6" unitref="usd">95,661</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNDktMi0xLTEtNjE0ODYx_91c2fe9e-4754-43bd-aa50-2780afc1039e" name="us-gaap:MinorityInterest" scale="6" unitref="usd">266</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNDktNC0xLTEtNjE0ODYx_d0546083-7b44-4d07-a42e-a0275d2d1f9c" name="us-gaap:MinorityInterest" scale="6" unitref="usd">256</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNTAtMi0xLTEtNjE0ODYx_b35edac7-57b9-457e-89da-de4bc36d981e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">101,236</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNTAtNC0xLTEtNjE0ODYx_51c70f30-1479-4258-b030-150b3fea1877" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">95,916</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNTEtMi0xLTEtNjE0ODYx_2ef356bd-73eb-4735-becd-7f82a583507b" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" unitref="usd">195,617</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yNS9mcmFnOjE0YjE1MzM3NjY0ZjQwZjdiZjY2NTg3NTdmYzY4OTRiL3RhYmxlOmMwMWEwMDJkMDQ1ZjRjYTFiMDA1MWRjMTZhNTJjMDk0L3RhYmxlcmFuZ2U6YzAxYTAwMmQwNDVmNGNhMWIwMDUxZGMxNmE1MmMwOTRfNTEtNC0xLTEtNjE0ODYx_ec519108-a3ba-473a-b4cc-d0cb9197e9a0" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" unitref="usd">197,205</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:76pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_28"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:26.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:4.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="63" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:26.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:4.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="45" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PFIZER INC. SHAREHOLDERS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Add&#8217;l<br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Accum. Other Comp.<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Share-<br/>holders&#8217; Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Balance, January&#160;1, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i70d6d5a20e1d40cba199341b3b73b075_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMy02LTEtMS02MTQ4NjE_1a592a0d-b5ee-4a2f-81f4-1ad054fd9f87" name="us-gaap:CommonStockSharesIssued" scale="6" unitref="shares">9,519</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i70d6d5a20e1d40cba199341b3b73b075_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMy04LTEtMS02MTQ4NjE_aa324151-a18b-42d7-8148-35b35507241f" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">476</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ie5bdebedec26437f8cbbbdce5b21d21c_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMy0xMC0xLTEtNjE0ODYx_a67fe951-d8e7-4cb9-8482-f0f978554222" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">91,802</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i2f03522ae364485796d05257a1b6db08_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMy0xMi0xLTEtNjE0ODYx_cfab7cfc-0a5e-45d7-b1f7-755926142e16" name="us-gaap:TreasuryStockShares" scale="6" unitref="shares">3,903</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i2f03522ae364485796d05257a1b6db08_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMy0xNC0xLTEtNjE0ODYx_ffff0eeb-abd8-493d-9a29-5560bbdbde0d" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" sign="-" unitref="usd">113,969</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i261e12058ffe48059a8a12445930d2a2_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMy0xNi0xLTEtNjE0ODYx_03aecb31-e0ad-4aae-930e-434d7bc96200" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">125,656</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="ic8190f97254a4b67b0ea33cef0e90617_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMy0xOC0xLTEtNjE0ODYx_71f6e9ae-0b03-429a-b363-c1251ca369a5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" sign="-" unitref="usd">8,304</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibbabb6e3c4954e1f8070b22d9961be09_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMy0yMC0xLTEtNjE0ODYx_e9dc7ed5-ffdf-4793-90a1-6cc561dfc287" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">95,661</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ida9c1b5f32d74a9096e75c2c6f0ac461_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMy0yMi0xLTEtNjE0ODYx_ab092064-59b1-4437-8a12-69f2d4d43d0b" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">256</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMy0yNC0xLTEtNjE0ODYx_514220e0-4849-4996-bd4e-580ad7c343c3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">95,916</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5bf219d82ee94bca8aef5121ea78402f_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfNC0xNi0xLTEtNjE0ODYx_693944a5-b4a3-43c1-9cda-0f4d91c206bb" name="us-gaap:ProfitLoss" scale="6" unitref="usd">5,543</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="idc96417637d64170bd5c537156fa67a4_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfNC0yMC0xLTEtNjE0ODYx_190f5d8b-9bee-43ce-9de4-dd6652b206e0" name="us-gaap:ProfitLoss" scale="6" unitref="usd">5,543</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3b2a02412cfa42b99a1c0fca37814fa6_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfNC0yMi0xLTEtNjE0ODYx_3d7eb86e-c983-4d3d-b0f3-93f36c03a548" name="us-gaap:ProfitLoss" scale="6" unitref="usd">13</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfNC0yNC0xLTEtNjE0ODYx_d92e35f9-950e-4864-a086-bf79906b3582" name="us-gaap:ProfitLoss" scale="6" unitref="usd">5,556</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Other&#160;comprehensive income/(loss), net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic1dc28ef83404ef286e672b1e3544189_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfNS0xOC0xLTEtNjE0ODYx_bde23858-56f1-4331-85f5-b8ffddb8d75c" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" unitref="usd">15</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="idc96417637d64170bd5c537156fa67a4_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfNS0yMC0xLTEtNjE0ODYx_81887357-0d6b-4e03-8488-2ba022d9f1ec" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" unitref="usd">15</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3b2a02412cfa42b99a1c0fca37814fa6_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfNS0yMi0xLTEtNjE0ODYx_eef8b2c2-23bd-422b-aa88-619ff0dbff25" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" sign="-" unitref="usd">3</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfNS0yNC0xLTEtNjE0ODYx_d8e41c0f-c23d-4ca4-a0d7-465361212216" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" unitref="usd">12</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Cash dividends declared, per share: $<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="2" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfNi0wLTEtMS02MTQ4NjEvdGV4dHJlZ2lvbjpiZDVmYzMxYWJkNzc0NGQyYjVlZWRjMzA4ZDlkNzRiNl80MA_a08c7ca3-0ff8-448a-96ef-fcd79dc394f8" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" unitref="usdPerShare">&#8212;</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfNy0yNC0xLTEtNjE0ODYx_1c14b3ce-aada-49d2-aba0-7cd61f98f33a" name="us-gaap:DividendsCommonStockCash" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Share-based payment transactions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ie3ad02e451334330b79a341af46dec8e_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTAtNi0xLTEtNjE0ODYx_13437565-fcb7-4189-a946-0707f2fce36b" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" unitref="shares">41</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ie3ad02e451334330b79a341af46dec8e_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTAtOC0xLTEtNjE0ODYx_9cbbea98-018a-4d25-bddf-92e5e58d0b3b" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" unitref="usd">2</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i55e5b495c0304bf2a27da7ded92c9d0b_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTAtMTAtMS0xLTYxNDg2MQ_37ed05a0-0a57-4947-9487-389a5d9b74a0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" unitref="usd">350</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i559872c075ee4a26bea2162cc9c64559_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTAtMTItMS0xLTYxNDg2MQ_32672903-d6bf-4eed-b6c7-686e8e6a6005" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" sign="-" unitref="shares">12</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i559872c075ee4a26bea2162cc9c64559_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTAtMTQtMS0xLTYxNDg2MQ_0bc1524e-8b3d-42b3-a856-8f459fd123f8" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" sign="-" unitref="usd">504</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i5bf219d82ee94bca8aef5121ea78402f_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTAtMTYtMS0xLTYxNDg2MQ_abdeb44a-2544-432c-85af-6e5d0663aca3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" sign="-" unitref="usd">97</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="idc96417637d64170bd5c537156fa67a4_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTAtMjAtMS0xLTYxNDg2MQ_d9980017-bc5f-4208-a298-21cab57a2788" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" sign="-" unitref="usd">249</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTAtMjQtMS0xLTYxNDg2MQ_c0e139b3-6c7e-4fd6-9dad-a39c1a13f868" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" sign="-" unitref="usd">249</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTMtMjQtMS0xLTYxNDg2MQ_f66f8121-d7f2-413c-b428-2908902b0cab" name="us-gaap:StockholdersEquityOther" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Balance, April&#160;2, 2023</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibd06635aa84f4f1eafbd6daa01d1ec5f_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTQtNi0xLTEtNjE0ODYx_baa676b6-9840-43bd-9dc8-4a5c1705a534" name="us-gaap:CommonStockSharesIssued" scale="6" unitref="shares">9,560</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibd06635aa84f4f1eafbd6daa01d1ec5f_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTQtOC0xLTEtNjE0ODYx_1c6cf819-e2d3-46cc-9bf6-3c26e81c1e30" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">478</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i595d0c9b83914c939b87b9422a11c0bc_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTQtMTAtMS0xLTYxNDg2MQ_7c34707c-7c5c-4605-ac9e-1c393a1bad45" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">92,153</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="id80c77441aa04de88b6f4fcfa3924b16_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTQtMTItMS0xLTYxNDg2MQ_f3f87ad9-1a83-4b22-8e99-889c83d4ea73" name="us-gaap:TreasuryStockShares" scale="6" unitref="shares">3,915</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="id80c77441aa04de88b6f4fcfa3924b16_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTQtMTQtMS0xLTYxNDg2MQ_a3d0bf57-3e0a-4e60-8f8c-9e6c96d5d8c2" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" sign="-" unitref="usd">114,473</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i0b3f31bb3146428db3b31dd357e1038b_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTQtMTYtMS0xLTYxNDg2MQ_dc22a2d6-f71a-421b-8089-34076ee01780" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">131,102</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="id86c995eba51451eaa0b5251fe10bb38_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTQtMTgtMS0xLTYxNDg2MQ_5e474339-9715-42d9-9a10-ea3995e11d51" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" sign="-" unitref="usd">8,289</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="id66ed0a340cd4e61a832ab5f54048d3b_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTQtMjAtMS0xLTYxNDg2MQ_1cd2bbb1-8dae-49cd-862a-74824774adb1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">100,970</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3b028541801148348adb94e8c78bfe72_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTQtMjItMS0xLTYxNDg2MQ_fc1bde10-555b-4e29-9bcf-4eba51702586" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">266</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTQtMjQtMS0xLTYxNDg2MQ_4f6d15cf-7176-411c-8955-b1e7833e9bbe" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">101,236</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="63" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="45" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PFIZER INC. SHAREHOLDERS</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Add&#8217;l<br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Accum. Other Comp.<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Share-<br/>holders&#8217; Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Balance, January&#160;1, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i7b2ec5ba17d244748a7c2878368847c3_I20211231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTktNi0xLTEtNjE0ODYx_404ec6fd-cadf-487b-aad8-40ff47219464" name="us-gaap:CommonStockSharesIssued" scale="6" unitref="shares">9,471</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i7b2ec5ba17d244748a7c2878368847c3_I20211231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTktOC0xLTEtNjE0ODYx_65d77c92-93b7-4ee7-bf13-15ead86a5e64" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">473</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic6fcde9afeff496597110980c3bf762b_I20211231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTktMTAtMS0xLTYxNDg2MQ_83c5ee24-6f0f-4203-ad94-2c01bfdaaaf9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">90,591</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="id90e1b0cb0ff4c459c9a846fb1d1cadf_I20211231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTktMTItMS0xLTYxNDg2MQ_4c571d60-1808-492c-a490-cad8742b63bc" name="us-gaap:TreasuryStockShares" scale="6" unitref="shares">3,851</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="id90e1b0cb0ff4c459c9a846fb1d1cadf_I20211231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTktMTQtMS0xLTYxNDg2MQ_bda0fbe6-1cc6-4f91-8798-8c7fc8ce2a3f" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" sign="-" unitref="usd">111,361</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ifb46cde3f7da4c84ab951adfaee1d495_I20211231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTktMTYtMS0xLTYxNDg2MQ_4f45f43a-3d13-4765-8b05-e38a8a54231a" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">103,394</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i4031987465804d71afb53f1719495e8f_I20211231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTktMTgtMS0xLTYxNDg2MQ_2862a872-13f2-4d89-a13d-75ef26777042" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" sign="-" unitref="usd">5,897</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i64827359d1254cb5a23ef4ab99e9b4a1_I20211231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTktMjAtMS0xLTYxNDg2MQ_6dcd24e1-e453-4d0f-b375-f747106c623c" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">77,201</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic1474ecbf5b04969be2c6f95d35ad5c7_I20211231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTktMjItMS0xLTYxNDg2MQ_947e8f23-bf97-4fe7-8655-2a2f171a6c8b" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">262</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i42818567227049ae86716dcfa81be15a_I20211231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMTktMjQtMS0xLTYxNDg2MQ_fe4d3a6d-6496-4725-8aeb-5d011cc8a31e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">77,462</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ie36984cd4c2542f287d6333783d3c9bb_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjAtMTYtMS0xLTYxNDg2MQ_03ff13d1-7999-4769-8624-f1c9d91cfbc2" name="us-gaap:ProfitLoss" scale="6" unitref="usd">7,864</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i212875c91a504755b1b31552f587a1f5_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjAtMjAtMS0xLTYxNDg2MQ_2f181a3f-31f2-4a5d-8a2d-67fbb5ad2b97" name="us-gaap:ProfitLoss" scale="6" unitref="usd">7,864</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if6c09adb5a184b1f817106477f3ac00d_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjAtMjItMS0xLTYxNDg2MQ_7c160a1d-2bc3-429d-9998-1551b8ce299e" name="us-gaap:ProfitLoss" scale="6" unitref="usd">6</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjAtMjQtMS0xLTYxNDg2MQ_9f191354-5186-4e80-a318-118a19218b2a" name="us-gaap:ProfitLoss" scale="6" unitref="usd">7,870</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Other&#160;comprehensive income/(loss), net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="icfaef4cce36c4acaab6465881acc8595_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjEtMTgtMS0xLTYxNDg2MQ_7a7f6f99-ffd0-4026-b253-93c254bbed80" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" sign="-" unitref="usd">260</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i212875c91a504755b1b31552f587a1f5_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjEtMjAtMS0xLTYxNDg2MQ_f591308a-5f10-4b32-8f3c-daa134be1100" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" sign="-" unitref="usd">260</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjEtMjQtMS0xLTYxNDg2MQ_f19d952a-d7c2-4b13-aa02-ddf331d97f2a" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" sign="-" unitref="usd">260</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Cash dividends declared, per share: $<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="2" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjItMC0xLTEtNjE0ODYxL3RleHRyZWdpb246YzQ4ZDY1M2FiMTViNDQ3M2I0OGEyMjJhNGUwMjU3NzBfNDA_e78a1d33-c2d9-496b-beb3-b0902280cd89" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" unitref="usdPerShare">&#8212;</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Common stock </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjMtMjQtMS0xLTYxNDg2MQ_dcc47f20-b46e-4c14-8480-da7bcf16f929" name="us-gaap:DividendsCommonStockCash" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Share-based payment transactions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i6a440eee62b846e980ce6a650594b2e5_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjYtNi0xLTEtNjE0ODYx_2f308bae-218c-417b-9835-1de72ba7a578" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" unitref="shares">23</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i6a440eee62b846e980ce6a650594b2e5_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjYtOC0xLTEtNjE0ODYx_0dfbb1cd-c407-4422-add3-0ac15bba5b97" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" unitref="usd">2</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i20bc9c7efd6c45008d4b8416a5e76092_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjYtMTAtMS0xLTYxNDg2MQ_7f1981a0-217d-4369-ba78-8a4b1d1c1a18" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" unitref="usd">249</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i2f1e593a96da49818806f331d10248b6_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjYtMTItMS0xLTYxNDg2MQ_a868732c-d7b1-42b0-86cd-c6d72cbc1e63" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" sign="-" unitref="shares">12</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i2f1e593a96da49818806f331d10248b6_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjYtMTQtMS0xLTYxNDg2MQ_d2ea0b0f-a29b-4f54-b742-1b984d5283bf" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" sign="-" unitref="usd">570</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="ie36984cd4c2542f287d6333783d3c9bb_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjYtMTYtMS0xLTYxNDg2MQ_57d38efd-f46b-49f1-8e9a-cf09da9f121e" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" sign="-" unitref="usd">65</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i212875c91a504755b1b31552f587a1f5_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjYtMjAtMS0xLTYxNDg2MQ_0203d5d5-e862-48fa-93e5-5a6a15e9ee5c" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" sign="-" unitref="usd">383</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjYtMjQtMS0xLTYxNDg2MQ_e9d62ec7-a618-41d1-b396-421179d3189e" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" sign="-" unitref="usd">383</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Purchases of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i2f1e593a96da49818806f331d10248b6_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjctMTItMS0xLTYxNDg2MQ_9f395745-9230-4b57-8591-b5e982b404ca" name="us-gaap:TreasuryStockSharesAcquired" scale="6" unitref="shares">39</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i2f1e593a96da49818806f331d10248b6_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjctMTQtMS0xLTYxNDg2MQ_42d392be-ecdc-43a8-840a-5f38ee47486c" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" unitref="usd">2,000</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i212875c91a504755b1b31552f587a1f5_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjctMjAtMS0xLTYxNDg2MQ_062aff82-5a28-400f-a950-b07a8ff4743c" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" unitref="usd">2,000</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjctMjQtMS0xLTYxNDg2MQ_7148f10b-1728-4a6b-b020-fc5f53c4cc83" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" unitref="usd">2,000</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i20bc9c7efd6c45008d4b8416a5e76092_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjktMTAtMS0xLTYxNDg2MQ_ff89ff5f-0d0c-4b9d-8d6a-120605d4cfda" name="us-gaap:StockholdersEquityOther" scale="6" sign="-" unitref="usd">3</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i212875c91a504755b1b31552f587a1f5_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjktMjAtMS0xLTYxNDg2MQ_bdb71970-5ca7-4f2a-8cee-3242590e1394" name="us-gaap:StockholdersEquityOther" scale="6" sign="-" unitref="usd">3</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="if6c09adb5a184b1f817106477f3ac00d_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjktMjItMS0xLTYxNDg2MQ_02b569f1-18de-4328-b34f-505beb51d06c" name="us-gaap:StockholdersEquityOther" scale="6" unitref="usd">7</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMjktMjQtMS0xLTYxNDg2MQ_c4c8a686-7a90-4fe9-942f-e5776c5cfdda" name="us-gaap:StockholdersEquityOther" scale="6" unitref="usd">4</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Balance, April 3, 2022</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i74b3d0f2769e476e90a954e83a028866_I20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMzAtNi0xLTEtNjE0ODYx_d86abb6a-2b39-4a02-a206-296ad61e7c0b" name="us-gaap:CommonStockSharesIssued" scale="6" unitref="shares">9,494</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i74b3d0f2769e476e90a954e83a028866_I20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMzAtOC0xLTEtNjE0ODYx_588b1d30-1d9b-44d4-8d18-dc991f15a420" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">476</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3aac7e1c9e764ff797561f2e43bd3b76_I20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMzAtMTAtMS0xLTYxNDg2MQ_96de9bf1-a6e4-405b-8e20-70074e3cfb50" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">90,844</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i8b8ab74deec64ca3b90f9ad6f6ffeacb_I20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMzAtMTItMS0xLTYxNDg2MQ_5d00cb70-394d-4b91-bd87-241fce4d1427" name="us-gaap:TreasuryStockShares" scale="6" unitref="shares">3,903</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i8b8ab74deec64ca3b90f9ad6f6ffeacb_I20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMzAtMTQtMS0xLTYxNDg2MQ_c87c7e67-24c1-4a53-bdd4-4cd218f82c67" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" sign="-" unitref="usd">113,931</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i8760b8f797fe46f2b2d41e752a5dc5b8_I20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMzAtMTYtMS0xLTYxNDg2MQ_a033240a-0d99-4c04-8798-2d2d16ae8eed" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">111,193</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i4501537c703041ef8eddb2b307f0d45a_I20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMzAtMTgtMS0xLTYxNDg2MQ_64d68fe3-99e3-4c8c-9775-d3c64cafbf5e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" sign="-" unitref="usd">6,157</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic5af5a3ee4e64e8288837d331207a533_I20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMzAtMjAtMS0xLTYxNDg2MQ_acbb3f8a-00b6-45fb-9f3f-439f7e9006a6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">82,424</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i9db1fa85f21540c69fc0f8788087f2e0_I20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMzAtMjItMS0xLTYxNDg2MQ_d0a9696b-3d08-469a-b4ad-355f326ea030" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">261</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i1264e68793a244719dccb7ff8c8de271_I20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8yOC9mcmFnOjY2M2M0ZjFkYWJmNTQzOGRiNzc2NzhkMTMzYTViOTQ5L3RhYmxlOmFiOGIyYWVlNmM0YTRiY2Q5YjU0NGUzMjdiZGNhOTlmL3RhYmxlcmFuZ2U6YWI4YjJhZWU2YzRhNGJjZDliNTQ0ZTMyN2JkY2E5OWZfMzAtMjQtMS0xLTYxNDg2MQ_b042e247-7a3b-4b27-b77a-210d9f93776e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">82,685</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:313pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_31"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Operating Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMy0yLTEtMS02MTQ4NjE_cf583e60-c2ca-4f8f-8e50-834e94674874" name="us-gaap:ProfitLoss" scale="6" unitref="usd">5,556</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMy00LTEtMS02MTQ4NjE_247ea363-9c79-4520-8e58-b2260cb11437" name="us-gaap:ProfitLoss" scale="6" unitref="usd">7,870</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Discontinued operations&#8212;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNC0yLTEtMS02MTQ4NjE_47a85f84-096b-4f08-90c7-6bc06e922512" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" unitref="usd">1</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNC00LTEtMS02MTQ4NjE_548355a7-a771-41d1-b326-bd3d42c1d8ce" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" sign="-" unitref="usd">9</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income from continuing operations before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNS0yLTEtMS02MTQ4NjE_60b1e879-b0db-4f4d-be28-e4665a88d394" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">5,555</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNS00LTEtMS02MTQ4NjE_83686962-6987-45b8-b4bc-e08c9977aeb6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">7,879</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNy0yLTEtMS02MTQ4NjE_2eac9534-071e-4081-9b4b-4db429e1ce5e" name="pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" scale="6" unitref="usd">1,487</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNy00LTEtMS02MTQ4NjE_4b9b668b-2b85-40ce-8e00-49e158d137aa" name="pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" scale="6" unitref="usd">1,187</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Asset write-offs and impairments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfOC0yLTEtMS02MTQ4NjE_3a2dad91-9535-403d-8263-46bbcbb55148" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" scale="6" unitref="usd">270</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfOC00LTEtMS02MTQ4NjE_299d575f-1f8d-41a6-b449-9f3bc8948b2f" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" scale="6" unitref="usd">31</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfOS0yLTEtMS02MTQ4NjE_0d688d5d-0850-4e35-9cbb-b4bbbf3dd0de" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" sign="-" unitref="usd">598</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfOS00LTEtMS02MTQ4NjE_194f81b8-bdb6-406a-9215-b1803e270c23" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" sign="-" unitref="usd">2,321</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMTEtMi0xLTEtNjE0ODYx_547dbd56-20eb-44dd-a13d-73a41c0b3d8a" name="us-gaap:ShareBasedCompensation" scale="6" unitref="usd">105</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMTEtNC0xLTEtNjE0ODYx_9d6d40c7-b5a9-4663-a5c7-22c2a1bd790d" name="us-gaap:ShareBasedCompensation" scale="6" unitref="usd">86</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Benefit plan contributions in excess of expense/income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMTItMi0xLTEtNjE0ODYx_5da8e4a8-4d07-4fb0-a040-7b10537b5391" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" unitref="usd">200</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMTItNC0xLTEtNjE0ODYx_f7eaaa6b-fcf3-4020-8e94-72c5161371c5" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" unitref="usd">404</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other adjustments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMTMtMi0xLTEtNjE0ODYx_1417a91d-81e3-45a9-910f-bfcca68d5369" name="us-gaap:OtherNoncashIncomeExpense" scale="6" sign="-" unitref="usd">99</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMTMtNC0xLTEtNjE0ODYx_8aba0d7b-e97d-4c84-82e7-d6d7c9bf4f94" name="us-gaap:OtherNoncashIncomeExpense" scale="6" sign="-" unitref="usd">815</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other changes in assets and liabilities, net of acquisitions and divestitures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMTQtMi0xLTEtNjE0ODYx_55df5ee3-4c87-4f64-b673-6454402520b2" name="us-gaap:IncreaseDecreaseInOperatingCapital" scale="6" unitref="usd">5,507</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMTQtNC0xLTEtNjE0ODYx_fec27d6c-06ec-4d07-afc3-464227a847ae" name="us-gaap:IncreaseDecreaseInOperatingCapital" scale="6" unitref="usd">730</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMTctMi0xLTEtNjE0ODYx_84b788e2-e006-4639-b583-35d28554415d" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" unitref="usd">1,212</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMTctNC0xLTEtNjE0ODYx_292f73b9-803d-42f6-a165-83dd943ea011" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" unitref="usd">6,541</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Investing Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMjAtMi0xLTEtNjE0ODYx_457c255e-15f6-44ed-bd05-0b40ba900764" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" unitref="usd">1,139</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMjAtNC0xLTEtNjE0ODYx_effa4eee-baab-4693-adc5-2d91b0c2dc79" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" unitref="usd">643</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMjEtMi0xLTEtNjE0ODYx_07fa170a-b561-4753-901f-bfa394223d1d" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" unitref="usd">6,665</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMjEtNC0xLTEtNjE0ODYx_dcecb8b7-57bb-424d-bcb0-4653d398992f" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" unitref="usd">8,758</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from redemptions/sales of short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMjItMi0xLTEtNjE0ODYx_7e140ecd-bc15-4fae-bc90-d1c437dbe35a" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" scale="6" unitref="usd">6,400</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMjItNC0xLTEtNjE0ODYx_38393b3a-4724-433e-a0c2-3b53afbbba02" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" scale="6" unitref="usd">13,421</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMjMtMi0xLTEtNjE0ODYx_5ef4c089-894a-49bc-b84f-4318facb9193" name="pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" scale="6" sign="-" unitref="usd">4,665</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMjMtNC0xLTEtNjE0ODYx_8230f95e-8a26-47f6-b486-8fffc040adbe" name="pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" scale="6" sign="-" unitref="usd">3,409</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMjQtMi0xLTEtNjE0ODYx_dadc3c26-c846-46b9-bd54-f4aa37b5f091" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" unitref="usd">51</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMjQtNC0xLTEtNjE0ODYx_c0b96f98-9687-4d34-95ec-5f3d1a919b67" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" unitref="usd">676</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from redemptions/sales of long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMjUtMi0xLTEtNjE0ODYx_9b265c5d-831c-4b2c-acaf-adcea01e1d54" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" scale="6" unitref="usd">124</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMjUtNC0xLTEtNjE0ODYx_910eabfe-095e-47c9-9c67-e4f446217b61" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" scale="6" unitref="usd">52</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Acquisition of business, net of cash acquired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMjYtMi0xLTEtNjE0ODYx_759b96f1-2f2c-4251-a220-391dbdfdee4f" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMjYtNC0xLTEtNjE0ODYx_11dd6b34-9bb6-4547-ae9a-f21126e9b445" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" unitref="usd">6,225</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other investing activities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMjgtMi0xLTEtNjE0ODYx_e3bcda67-b59c-46d7-835a-b4e90ef92eaf" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" unitref="usd">18</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMjgtNC0xLTEtNjE0ODYx_33955b3b-8a62-46fc-a4f2-3b6f207eb2df" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" unitref="usd">13</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMzEtMi0xLTEtNjE0ODYx_c566e6b1-a497-4d22-a763-aade99eed05b" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" unitref="usd">3,315</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMzEtNC0xLTEtNjE0ODYx_35f69731-141d-45e9-89fe-9cb22f2a84f6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" unitref="usd">567</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Financing Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMzQtMi0xLTEtNjE0ODYx_215d652b-be53-4f86-9ae0-473b60c80406" name="us-gaap:ProceedsFromShortTermDebt" scale="6" unitref="usd">11</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMzQtNC0xLTEtNjE0ODYx_b0180a0d-13ac-4445-aba5-894d62080149" name="us-gaap:ProceedsFromShortTermDebt" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMzYtMi0xLTEtNjE0ODYx_1a72c39f-8538-49e6-a800-dcab8e454489" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" scale="6" unitref="usd">226</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMzYtNC0xLTEtNjE0ODYx_b4cd5fca-8719-4802-8fc7-f24aea9e6de8" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" scale="6" sign="-" unitref="usd">220</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Payments on long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMzgtMi0xLTEtNjE0ODYx_4ae60775-777c-4fa6-9111-a61a82cc0226" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" unitref="usd">269</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMzgtNC0xLTEtNjE0ODYx_3e914730-0c02-4551-b99c-05c627b81afb" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" unitref="usd">1,609</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMzktMi0xLTEtNjE0ODYx_bd21d61b-5f6c-40dc-9ed3-4f4b324f4748" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfMzktNC0xLTEtNjE0ODYx_8da1616a-6610-45c7-8635-eb89335f70f5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" unitref="usd">2,000</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash dividends paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNDAtMi0xLTEtNjE0ODYx_a7acd682-d375-4524-af46-b085bd932e35" name="us-gaap:PaymentsOfOrdinaryDividends" scale="6" unitref="usd">2,303</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNDAtNC0xLTEtNjE0ODYx_3cb73cc4-b869-4286-b1d8-c361fcd51d3e" name="us-gaap:PaymentsOfOrdinaryDividends" scale="6" unitref="usd">2,249</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other financing activities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNDEtMi0xLTEtNjE0ODYx_a9071c14-1833-4bd8-9186-f2f28bcd3022" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" sign="-" unitref="usd">436</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNDEtNC0xLTEtNjE0ODYx_d789c9a0-478e-4647-9073-24709c8deb7f" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" sign="-" unitref="usd">501</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNDQtMi0xLTEtNjE0ODYx_720b3fb1-58e0-47f9-ab2d-d2efc04a92e4" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" sign="-" unitref="usd">2,771</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNDQtNC0xLTEtNjE0ODYx_82a7f51f-fba0-499a-aac3-3a98e1d34944" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" sign="-" unitref="usd">6,578</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNDUtMi0xLTEtNjE0ODYx_a528ae47-ab16-485b-a7e6-c80fd57bffc5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" sign="-" unitref="usd">2</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNDUtNC0xLTEtNjE0ODYx_cb493e70-c07f-4d63-bedc-abb8932dc314" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" sign="-" unitref="usd">1</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNDYtMi0xLTEtNjE0ODYx_c3bd7ca0-5654-46da-b142-63c373da050f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" unitref="usd">1,754</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNDYtNC0xLTEtNjE0ODYx_5ccf9724-fb10-4501-8f27-53d54a2e8c03" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" unitref="usd">529</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNDctMi0xLTEtNjE0ODYx_ac4abf55-e81f-4512-91e0-dda2041ad5d6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" unitref="usd">468</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i42818567227049ae86716dcfa81be15a_I20211231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNDctNC0xLTEtNjE0ODYx_1f0fa8a8-a2e7-4393-b4c4-f8d2c5bd4ef2" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" unitref="usd">1,983</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash and cash equivalents, at end of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNDgtMi0xLTEtNjE0ODYx_0c53d9b7-39b6-4db5-aa22-25722ffaac8a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" unitref="usd">2,222</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i1264e68793a244719dccb7ff8c8de271_I20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNDgtNC0xLTEtNjE0ODYx_0339065b-ece5-4e7d-906f-46880f148df0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" unitref="usd">2,513</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Supplemental Cash Flow Information</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash paid during the period for:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Income taxes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNTQtMi0xLTEtNjE0ODYx_c6dcc6d3-d99f-47e9-90d2-a2fc35127988" name="us-gaap:IncomeTaxesPaidNet" scale="6" unitref="usd">329</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNTQtNC0xLTEtNjE0ODYx_ae60e06a-2f4e-40d5-9e65-102cdb4a9603" name="us-gaap:IncomeTaxesPaidNet" scale="6" unitref="usd">354</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Interest paid</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNTUtMi0xLTEtNjE0ODYx_123120b3-1a84-4e0c-ab5d-7c24eea57965" name="us-gaap:InterestPaidNet" scale="6" unitref="usd">419</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNTUtNC0xLTEtNjE0ODYx_f32f6b17-6af4-407d-abc1-ffc1a1182123" name="us-gaap:InterestPaidNet" scale="6" unitref="usd">453</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Interest rate hedges</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNTYtMi0xLTEtNjE0ODYx_16a9d9de-3d22-46f9-9f0f-b5a381925c83" name="pfe:InterestPaidReceivedInterestRateHedges" scale="6" unitref="usd">60</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zMS9mcmFnOmJlOTRhMDFhZWZiMTQ5NDc5ZmZkYjdhZmUxYmI0MzBlL3RhYmxlOjhlN2RmNjRjNzYyOTRhMmZhYTlmNWY4OGFiNWViOTE3L3RhYmxlcmFuZ2U6OGU3ZGY2NGM3NjI5NGEyZmFhOWY1Zjg4YWI1ZWI5MTdfNTYtNC0xLTEtNjE0ODYx_85fe3f6a-471c-4bb0-9d1e-19a31076d8ca" name="pfe:InterestPaidReceivedInterestRateHedges" scale="6" unitref="usd">26</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:119pt;padding-right:-13.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_34"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><div><span><br/></span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_37"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="i5f84f6365e8b40bb8fd9e353d5ae1da0" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zNy9mcmFnOmU2YjE4Yjg3NzM4NDQ5Y2RiYjA3YWFhY2M2NGZhODgzL3RleHRyZWdpb246ZTZiMThiODc3Mzg0NDljZGJiMDdhYWFjYzY0ZmE4ODNfODMxOQ_65fec2ac-d6e8-4253-b47b-ccfce4ff0dbb" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">Basis of Presentation and Significant Accounting Policies</ix:nonnumeric></span></div><div><span><br/></span></div><ix:continuation continuedat="i601f8d8589ee46e783b5f7a753a1ea61" id="i5f84f6365e8b40bb8fd9e353d5ae1da0"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="i7c34d1fbe04948e1a58e234f9b1f3ad7" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zNy9mcmFnOmU2YjE4Yjg3NzM4NDQ5Y2RiYjA3YWFhY2M2NGZhODgzL3RleHRyZWdpb246ZTZiMThiODc3Mzg0NDljZGJiMDdhYWFjYzY0ZmE4ODNfODMxMw_9e15ee72-bced-43a5-8e16-c77948cd4156" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock">Basis of Presentation</ix:nonnumeric></span></div><ix:continuation id="i7c34d1fbe04948e1a58e234f9b1f3ad7"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2022 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2022 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer&#8217;s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February&#160;26, 2023 and February&#160;27, 2022, and for U.S. subsidiaries is as of and for the three months ended April&#160;2, 2023 and April&#160;3, 2022.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our commercial operations through <ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="INF" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zNy9mcmFnOmU2YjE4Yjg3NzM4NDQ5Y2RiYjA3YWFhY2M2NGZhODgzL3RleHRyZWdpb246ZTZiMThiODc3Mzg0NDljZGJiMDdhYWFjYzY0ZmE4ODNfMTI1Nw_bd9e90b7-41d0-4e03-94d6-3a2bd4bef9df" name="us-gaap:NumberOfOperatingSegments" scale="0" unitref="operatingsegment">two</ix:nonfraction> operating segments, each led by a single manager: Biopharma and Business Innovation. Biopharma is the only reportable segment. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_91" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 13A</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2022 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business development activities impacted financial results in the periods presented. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Notes 2A</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2B</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below as well as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2022 Form 10-K.</span></div><div style="margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for segment reporting.</span></div></ix:continuation><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="id58698cca0eb4b8494c9aa68de700e37" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zNy9mcmFnOmU2YjE4Yjg3NzM4NDQ5Y2RiYjA3YWFhY2M2NGZhODgzL3RleHRyZWdpb246ZTZiMThiODc3Mzg0NDljZGJiMDdhYWFjYzY0ZmE4ODNfODM1NA_55a737e2-9c3e-49a6-9489-47322a303c41" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock">New Accounting Standard Adopted in 2023</ix:nonnumeric></span></div><div style="margin-top:8pt"><ix:continuation id="id58698cca0eb4b8494c9aa68de700e37"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2023, we adopted a new accounting standard for supplier finance programs which requires increased disclosures in the notes to our financial statements. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_76" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 8C</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></ix:continuation></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="i959adf10bb5840ef9570e069cf8e4b03" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zNy9mcmFnOmU2YjE4Yjg3NzM4NDQ5Y2RiYjA3YWFhY2M2NGZhODgzL3RleHRyZWdpb246ZTZiMThiODc3Mzg0NDljZGJiMDdhYWFjYzY0ZmE4ODNfODM1MA_be0cf277-87a7-4ad6-b130-74294fbd01ac" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock">Revenues and Trade Accounts Receivable</ix:nonnumeric></span></div><ix:continuation continuedat="i77e271d7262d4f85b9430af7ba5704c0" id="i959adf10bb5840ef9570e069cf8e4b03"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customers&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prescription biopharmaceutical products, with the exception of Paxlovid, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. We principally sell Paxlovid to government agencies and distributors. In the U.S., we primarily sell our vaccines directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery systems. Outside the U.S., we primarily sell our vaccines to government and non-government institutions.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deductions from Revenues&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="iff545562ba404d4b9060c71f83711ade" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zNy9mcmFnOmU2YjE4Yjg3NzM4NDQ5Y2RiYjA3YWFhY2M2NGZhODgzL3RleHRyZWdpb246ZTZiMThiODc3Mzg0NDljZGJiMDdhYWFjYzY0ZmE4ODNfODM1Ng_8e76a236-c086-4910-b749-7319d4a371a4" name="pfe:ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock">Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:</ix:nonnumeric></span></div><div><ix:continuation id="iff545562ba404d4b9060c71f83711ade"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve against </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i53ef084cb9aa479f93fde209ac7953c7_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zNy9mcmFnOmU2YjE4Yjg3NzM4NDQ5Y2RiYjA3YWFhY2M2NGZhODgzL3RhYmxlOmIyNmRhYWUyMTg2NDRjYWM5YTNiOTFlZTcyZjliMGYxL3RhYmxlcmFuZ2U6YjI2ZGFhZTIxODY0NGNhYzlhM2I5MWVlNzJmOWIwZjFfMS0yLTEtMS02MTQ4NjE_c193770e-d918-4cb6-8079-d332b2078b72" name="pfe:RebatesAndOtherSalesRelatedAccruals" scale="6" unitref="usd">1,068</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i6ac95719c6e9404daf6bf462bd06569d_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zNy9mcmFnOmU2YjE4Yjg3NzM4NDQ5Y2RiYjA3YWFhY2M2NGZhODgzL3RhYmxlOmIyNmRhYWUyMTg2NDRjYWM5YTNiOTFlZTcyZjliMGYxL3RhYmxlcmFuZ2U6YjI2ZGFhZTIxODY0NGNhYzlhM2I5MWVlNzJmOWIwZjFfMS00LTEtMS02MTQ4NjE_66d610f0-ef7a-4da7-b5c8-b21802e58455" name="pfe:RebatesAndOtherSalesRelatedAccruals" scale="6" unitref="usd">1,200</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i74bb48599a6f4bc3801d3f73331a259b_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zNy9mcmFnOmU2YjE4Yjg3NzM4NDQ5Y2RiYjA3YWFhY2M2NGZhODgzL3RhYmxlOmIyNmRhYWUyMTg2NDRjYWM5YTNiOTFlZTcyZjliMGYxL3RhYmxlcmFuZ2U6YjI2ZGFhZTIxODY0NGNhYzlhM2I5MWVlNzJmOWIwZjFfMy0yLTEtMS02MTQ4NjE_5c507c57-3c1a-4357-8e69-ce90d043f6b6" name="pfe:AccruedRebates" scale="6" unitref="usd">4,743</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if49206e13d134dfda6216a41c3b8a6ff_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zNy9mcmFnOmU2YjE4Yjg3NzM4NDQ5Y2RiYjA3YWFhY2M2NGZhODgzL3RhYmxlOmIyNmRhYWUyMTg2NDRjYWM5YTNiOTFlZTcyZjliMGYxL3RhYmxlcmFuZ2U6YjI2ZGFhZTIxODY0NGNhYzlhM2I5MWVlNzJmOWIwZjFfMy00LTEtMS02MTQ4NjE_067909c0-8a05-423a-bdcb-a20873dea8f1" name="pfe:AccruedRebates" scale="6" unitref="usd">4,479</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i74bb48599a6f4bc3801d3f73331a259b_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zNy9mcmFnOmU2YjE4Yjg3NzM4NDQ5Y2RiYjA3YWFhY2M2NGZhODgzL3RhYmxlOmIyNmRhYWUyMTg2NDRjYWM5YTNiOTFlZTcyZjliMGYxL3RhYmxlcmFuZ2U6YjI2ZGFhZTIxODY0NGNhYzlhM2I5MWVlNzJmOWIwZjFfNC0yLTEtMS02MTQ4NjE_cc10d98d-7e00-4e31-b69f-0154268f7196" name="pfe:OtherAccruals" scale="6" unitref="usd">521</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if49206e13d134dfda6216a41c3b8a6ff_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zNy9mcmFnOmU2YjE4Yjg3NzM4NDQ5Y2RiYjA3YWFhY2M2NGZhODgzL3RhYmxlOmIyNmRhYWUyMTg2NDRjYWM5YTNiOTFlZTcyZjliMGYxL3RhYmxlcmFuZ2U6YjI2ZGFhZTIxODY0NGNhYzlhM2I5MWVlNzJmOWIwZjFfNC00LTEtMS02MTQ4NjE_95493c55-f20c-49ea-80ce-b1a9b8d104e6" name="pfe:OtherAccruals" scale="6" unitref="usd">430</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5d8c414e5fef44a6b7c25acd4bac30ba_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zNy9mcmFnOmU2YjE4Yjg3NzM4NDQ5Y2RiYjA3YWFhY2M2NGZhODgzL3RhYmxlOmIyNmRhYWUyMTg2NDRjYWM5YTNiOTFlZTcyZjliMGYxL3RhYmxlcmFuZ2U6YjI2ZGFhZTIxODY0NGNhYzlhM2I5MWVlNzJmOWIwZjFfNS0yLTEtMS02MTQ4NjE_8f983fe1-23eb-4bb8-9686-d8509b51ef79" name="pfe:RebatesAndOtherSalesRelatedAccruals" scale="6" unitref="usd">324</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="iaedb0f64969b481c84e4f6fbd2d4bb46_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zNy9mcmFnOmU2YjE4Yjg3NzM4NDQ5Y2RiYjA3YWFhY2M2NGZhODgzL3RhYmxlOmIyNmRhYWUyMTg2NDRjYWM5YTNiOTFlZTcyZjliMGYxL3RhYmxlcmFuZ2U6YjI2ZGFhZTIxODY0NGNhYzlhM2I5MWVlNzJmOWIwZjFfNS00LTEtMS02MTQ4NjE_01ce2789-f4fb-4fe4-b1d3-ba5441fbf591" name="pfe:RebatesAndOtherSalesRelatedAccruals" scale="6" unitref="usd">612</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued rebates and other sales-related accruals</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zNy9mcmFnOmU2YjE4Yjg3NzM4NDQ5Y2RiYjA3YWFhY2M2NGZhODgzL3RhYmxlOmIyNmRhYWUyMTg2NDRjYWM5YTNiOTFlZTcyZjliMGYxL3RhYmxlcmFuZ2U6YjI2ZGFhZTIxODY0NGNhYzlhM2I5MWVlNzJmOWIwZjFfNi0yLTEtMS02MTQ4NjE_d460699a-e863-4678-b181-2781e65a12f5" name="pfe:RebatesAndOtherSalesRelatedAccruals" scale="6" unitref="usd">6,656</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl8zNy9mcmFnOmU2YjE4Yjg3NzM4NDQ5Y2RiYjA3YWFhY2M2NGZhODgzL3RhYmxlOmIyNmRhYWUyMTg2NDRjYWM5YTNiOTFlZTcyZjliMGYxL3RhYmxlcmFuZ2U6YjI2ZGFhZTIxODY0NGNhYzlhM2I5MWVlNzJmOWIwZjFfNi00LTEtMS02MTQ4NjE_46173cbe-16f1-4f19-9f11-eeff93546d1b" name="pfe:RebatesAndOtherSalesRelatedAccruals" scale="6" unitref="usd">6,722</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade Accounts Receivable&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i601f8d8589ee46e783b5f7a753a1ea61"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i77e271d7262d4f85b9430af7ba5704c0">and future forecasted macroeconomic factors. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded.</ix:continuation></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended April&#160;2, 2023 and April&#160;3, 2022, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2022 Form 10-K.</span></div></ix:continuation><div id="idfe6e72973fb4e83b28a5bb34d34299f_40"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="ie7f143b6fcf14df0988db53fb116e6d7" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfMTAzODc_d4d58d93-88bb-412e-809c-d3257469feec" name="pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock">Acquisitions, Discontinued Operations and Equity-Method Investment</ix:nonnumeric></span></div><ix:continuation continuedat="ideac3fec4ad74756b9c639c349a796d9" id="ie7f143b6fcf14df0988db53fb116e6d7"><div style="margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Acquisitions</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GBT&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2022, we acquired GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient communities, starting with sickle cell disease. The total fair value of the consideration transferred was $<ix:nonfraction contextref="id14e153b5d344b928f40eaf62587c627_D20221005-20221005" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODM4NzA5_3fda886f-db8f-445f-a4ac-cca786a73349" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="9" unitref="usd">5.7</ix:nonfraction> billion ($<ix:nonfraction contextref="id14e153b5d344b928f40eaf62587c627_D20221005-20221005" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODM4NzE0_ebd2893f-aba1-4ddf-a775-902caee32f73" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="9" unitref="usd">5.2</ix:nonfraction> billion, net of cash acquired). In connection with this business combination, we provisionally recorded: (i) $<ix:nonfraction contextref="i15d9a21578c64a228860f837d5cf557a_I20221005" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODM5MDc2_ce9e0986-5907-455b-91a7-80010a545e68" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" unitref="usd">4.4</ix:nonfraction> billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consisting of $<ix:nonfraction contextref="i4bccc70dd1fe4389b244d15026f2c2b3_I20221005" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODM5MTI5_f4dc8107-d6fa-450c-879e-ab39dc479930" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" unitref="usd">3.0</ix:nonfraction> billion of IPR&amp;D and $<ix:nonfraction contextref="i7d4579612b1043cd9649f54d1edcacb1_I20221005" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODM5MTQ2_36723ac1-e8f7-46e2-99be-9dbafbf04d6b" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" unitref="usd">1.4</ix:nonfraction> billion of developed technology rights with a useful life of <ix:nonnumeric contextref="ic1ee0785cf9247fdb4e3d1a937467cd7_D20221005-20221005" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODM5MjAz_693a19b8-1135-49c9-8d8e-84c5378043bf" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">six years</ix:nonnumeric>, (ii) $<ix:nonfraction contextref="i15d9a21578c64a228860f837d5cf557a_I20221005" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODM5MjEz_db807a0f-b665-4323-bf4f-90f5f4514e07" name="us-gaap:Goodwill" scale="9" unitref="usd">1.1</ix:nonfraction> billion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) $<ix:nonfraction contextref="i15d9a21578c64a228860f837d5cf557a_I20221005" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODM5MjM2_f239d25d-fd41-467f-88ef-50ef5ba146e5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="6" unitref="usd">672</ix:nonfraction> million of inventories to be sold over approximately <ix:nonnumeric contextref="id14e153b5d344b928f40eaf62587c627_D20221005-20221005" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODM5Mjg1_f663c0b6-5aad-4f94-8f5e-0c8434ac4acb" name="pfe:AcquiredInventorySellingPeriod">three years</ix:nonnumeric>, (iv) $<ix:nonfraction contextref="i15d9a21578c64a228860f837d5cf557a_I20221005" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODM5Mjk1_a05eb591-6e43-4c1b-90df-a5d2431d6538" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" unitref="usd">568</ix:nonfraction> million of net deferred tax liabilities and (v) $<ix:nonfraction contextref="i15d9a21578c64a228860f837d5cf557a_I20221005" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODM5MzM5_da18d044-7cfa-44dd-924f-ed1e58ba2382" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" scale="6" unitref="usd">331</ix:nonfraction> million of assumed long-term debt that was paid in full in the fourth quarter of 2022. The allocation of the consideration transferred to the assets acquired and liabilities assumed has not yet been finalized.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biohaven&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2022, we acquired Biohaven, the maker of Nurtec ODT/Vydura (rimegepant), an innovative therapy approved for both acute treatment of migraine and prevention of episodic migraine in adults. The total fair value of the consideration transferred was $<ix:nonfraction contextref="i20f51dc72dd747ce86bcf503d86ac0a3_D20221003-20221003" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODQxNjMy_2a5a7455-085f-4c34-be3c-dee4fbb53ea7" name="us-gaap:BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" scale="9" unitref="usd">11.8</ix:nonfraction> billion, which includes the fair value of Pfizer&#8217;s previous investment in Biohaven on the acquisition date of approximately $<ix:nonfraction contextref="i20f51dc72dd747ce86bcf503d86ac0a3_D20221003-20221003" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODQxNzUy_417e72f1-08ea-432d-a556-6b864665f84a" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" scale="6" unitref="usd">300</ix:nonfraction> million. In connection with this business combination, we provisionally recorded: (i) $<ix:nonfraction contextref="ia96ebcfc61a44fa19d17aefdb43b29dc_I20221003" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODQxODM0_a9d6acdc-c819-47c9-9f8e-a52396ecc24d" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" unitref="usd">12.1</ix:nonfraction> billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consisting of $<ix:nonfraction contextref="i3e7bf15e610e44fa8e9437efe4f62103_I20221003" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODQxODg3_b092c6b2-716d-4b86-b397-e8a18a72878f" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" unitref="usd">11.6</ix:nonfraction> billion of developed technology rights with a useful life of <ix:nonnumeric contextref="i6390c994a17b4a5b8ce8821c9fc82f12_D20221003-20221003" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODQxOTQ0_d2915d81-ea6f-4dd9-b5f5-95151fa09500" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">11</ix:nonnumeric> years and $<ix:nonfraction contextref="i83509965137c436db600b7c5a56f2bdf_I20221003" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODQxOTUy_071ad9ab-9902-4e60-b2c2-5accb333753c" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" unitref="usd">450</ix:nonfraction> million of IPR&amp;D, (ii) $<ix:nonfraction contextref="ia96ebcfc61a44fa19d17aefdb43b29dc_I20221003" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODQxOTcx_e379f7db-8a76-448e-ad07-763e1ef6226d" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="6" unitref="usd">817</ix:nonfraction> million of inventories to be sold over approximately <ix:nonnumeric contextref="i20f51dc72dd747ce86bcf503d86ac0a3_D20221003-20221003" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODQyMDIw_ad428285-2744-4a8a-b79f-456b0873d314" name="pfe:AcquiredInventorySellingPeriod">two years</ix:nonnumeric>, (iii) $<ix:nonfraction contextref="ia96ebcfc61a44fa19d17aefdb43b29dc_I20221003" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODQyMDMx_81f6c6c9-4e21-4c58-841e-559246deb25b" name="us-gaap:Goodwill" scale="6" unitref="usd">797</ix:nonfraction> million of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv) $<ix:nonfraction contextref="ia96ebcfc61a44fa19d17aefdb43b29dc_I20221003" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODQyMDUz_742c5b7b-e37c-4e07-8527-5614c824057f" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" unitref="usd">398</ix:nonfraction> million of trade accounts receivable, (v) $<ix:nonfraction contextref="ia96ebcfc61a44fa19d17aefdb43b29dc_I20221003" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODQyMDkx_d736637c-02e0-4105-970e-bdc2c39f83e1" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" scale="9" unitref="usd">1.4</ix:nonfraction> billion of assumed long-term debt that was paid in full in the fourth quarter of 2022, (vi) $<ix:nonfraction contextref="ia96ebcfc61a44fa19d17aefdb43b29dc_I20221003" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODQyMTc5_a9098ae9-f9d5-4942-a307-5aa89c1aa5cd" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" unitref="usd">566</ix:nonfraction> million of net deferred tax liabilities and (vii) $<ix:nonfraction contextref="ia96ebcfc61a44fa19d17aefdb43b29dc_I20221003" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODQyMjI1_7e6c87bd-6a33-4728-8e95-b185a3e22eab" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" scale="6" unitref="usd">476</ix:nonfraction> million of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The allocation of the consideration transferred to the assets acquired and liabilities assumed has not yet been finalized.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arena&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2022, we acquired Arena, a clinical stage company with development-stage therapeutic candidates in gastroenterology, dermatology and cardiology. The total fair value of the consideration transferred was $<ix:nonfraction contextref="i19befe23ac00436590104096f9c04d08_D20220311-20220311" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODgxNzc2_6ad91cfd-d2c0-4ffb-9f99-d1b0dc6f5c9b" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="9" unitref="usd">6.6</ix:nonfraction>&#160;billion ($<ix:nonfraction contextref="i19befe23ac00436590104096f9c04d08_D20220311-20220311" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODgxNzgx_4d91efb2-e785-4d24-a67b-c2792f364d78" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="9" unitref="usd">6.2</ix:nonfraction> billion, net of cash acquired). The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in the first quarter of 2023. In connection with this business combination, we recorded: (i) $<ix:nonfraction contextref="i4f56fd894373416d8484b87702511be5_I20220311" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODgyMDIx_a1461390-c307-4462-9b98-a75d60f8308f" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" unitref="usd">5.5</ix:nonfraction> billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consisting of $<ix:nonfraction contextref="i73849b5e38fe445886e1403af608d42f_I20220311" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODgyMDc0_69d077a7-9039-41ec-b287-34b9d9b8bc14" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" unitref="usd">5.0</ix:nonfraction> billion of IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonfraction contextref="i9b047b35887f49b2bd8f996ea23ae6f4_I20220311" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODgyMDkx_b19f43e4-7daf-48aa-9a84-d923bdaf4022" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" unitref="usd">460</ix:nonfraction> million of indefinite-lived licensing agreements and other, (ii) $<ix:nonfraction contextref="i4f56fd894373416d8484b87702511be5_I20220311" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODgyMTUy_731d4d74-6ab5-4b58-a698-8afc7a691872" name="us-gaap:Goodwill" scale="9" unitref="usd">1.0</ix:nonfraction> billion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and (iii) $<ix:nonfraction contextref="i4f56fd894373416d8484b87702511be5_I20220311" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5NzU1ODgyMTc4_062abe96-bae8-4136-b6a8-f2c31002bf35" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" unitref="usd">490</ix:nonfraction> million of net deferred tax liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Discontinued Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8211;&#8211;net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the periods presented are post-close adjustments related to the previously disposed discontinued Meridian subsidiary and the Upjohn Business. In the three months ended April&#160;2, 2023 and April&#160;3, 2022, amounts recorded under interim agreements, including TSAs and MSAs, associated with these disposals were not material. Under agreements related to the 2020 spin-off and the combination of the Upjohn Business with Mylan to form Viatris, net amounts due from Viatris were approximately $<ix:nonfraction contextref="i9606172460e446fa94e858e88d105ceb_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfMzI0Mw_2e3c4501-c053-4d75-b531-7e1a5122d136" name="us-gaap:NontradeReceivablesCurrent" scale="6" unitref="usd">57</ix:nonfraction> million as of April&#160;2, 2023 and net amounts due to Viatris were $<ix:nonfraction contextref="i2f718193e68c40368f374983948b0629_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfMzI1OQ_74533225-c151-40cb-bf16-ea2e71e5eaef" name="us-gaap:AccountsPayableOtherCurrent" scale="6" unitref="usd">94</ix:nonfraction> million as of December 31, 2022. The cash flows associated with the agreements are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For information about the nature of these agreements, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2022 Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Equity-Method Investment</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Haleon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consumer Healthcare JV&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 18, 2022, GSK completed a demerger of the Consumer Healthcare JV which became Haleon, an independent, publicly traded company listed on the London Stock Exchange that holds the joint historical consumer healthcare business of GSK and Pfizer following the demerger. We continue to own <ix:nonfraction contextref="i40ac168f544d411b8d314f2a8adb5220_I20220718" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTA3NQ_efcbd8aa-7b84-4d1a-a771-98452903a73f" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitref="number">32</ix:nonfraction>% of the ordinary shares of Haleon after the demerger.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of our</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment in Haleon as of April&#160;2, 2023 and as of December 31, 2022 is $<ix:nonfraction contextref="icdd92e027b2b41b8a762d6449cf3f5a0_I20230402" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTMxNQ_435f4788-476c-4495-9526-a3a62a9a41e8" name="us-gaap:EquityMethodInvestments" scale="9" unitref="usd">11.0</ix:nonfraction> billion and $<ix:nonfraction contextref="i543e6671e5af4fbea60527c817946d61_I20221231" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTMyMg_6b45de98-5e3a-4df1-ba2b-04993e65355b" name="us-gaap:EquityMethodInvestments" scale="9" unitref="usd">10.8</ix:nonfraction> billion, respectively, and is reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity-method investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The fair value of our investment in Haleon as of April&#160;2, 2023, based on quoted market prices of Haleon stock, was $<ix:nonfraction contextref="icdd92e027b2b41b8a762d6449cf3f5a0_I20230402" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNTQ5MA_2d8ba27b-d4e0-452c-a550-bdbbb8a729a6" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" scale="9" unitref="usd">11.8</ix:nonfraction> billion. Haleon/the Consumer Healthcare JV is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. The increase in the value of our investment from December 31, 2022 is primarily due to $<ix:nonfraction contextref="ie50e162a989c436485c1ce071b9178aa_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNjEyMg_bb964b0e-4ce7-4178-a438-9ca21051aad7" name="pfe:EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" scale="6" unitref="usd">90</ix:nonfraction> million in </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ideac3fec4ad74756b9c639c349a796d9"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pre-tax foreign currency translation adjustments (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_55" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and our share of Haleon&#8217;s earnings. We record our share of earnings from Haleon/the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our total share of Haleon&#8217;s earnings generated in the fourth quarter of 2022, which we recorded in our operating results in the first quarter of 2023, was $<ix:nonfraction contextref="ie50e162a989c436485c1ce071b9178aa_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNjUzMQ_3bcf0940-7140-4a39-b367-b48a108929c7" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" unitref="usd">68</ix:nonfraction> million. Our total share of the JV&#8217;s earnings generated in the fourth quarter of 2021, which we recorded in our operating results in the first quarter of 2022, was $<ix:nonfraction contextref="ia51c01f32fe149eea64c684e5bc3f164_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfNjg0NQ_db5b8d17-3682-4171-baf9-a69e207196ac" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" unitref="usd">185</ix:nonfraction> million. The total amortization and adjustment of basis differences resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of Haleon/the Consumer Healthcare JV was not material to our results of operations in the periods presented. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_49" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-right:9pt"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RleHRyZWdpb246NGE5OWEyYThkYzE4NGJmMmI3YzkwNzVlZDhjMGZlN2JfMTAzODM_213cd41b-dc6c-425b-86af-70fa600d938b" name="us-gaap:EquityMethodInvestmentsTextBlock"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:53.499%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:21.006%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.009%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summarized financial information for our equity-method investee, Haleon/the Consumer Healthcare JV, for the three months ending December 31, 2022, the most recent period available, and for the three months ending December 31, 2021, is as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i7a0f02fad816440ea104abcf9ee938e4_D20221001-20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RhYmxlOmU1N2Q3N2UwNGY1NDQyODBhNjQ5NzNjMThmNGJjMTBjL3RhYmxlcmFuZ2U6ZTU3ZDc3ZTA0ZjU0NDI4MGE2NDk3M2MxOGY0YmMxMGNfNC02LTEtMS02MTQ4NjE_c8575775-77c8-4a22-870b-10aed15bd248" name="us-gaap:Revenues" scale="6" unitref="usd">3,261</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibd5559567aed4bc6b3cdc90bfb24932f_D20211001-20211231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RhYmxlOmU1N2Q3N2UwNGY1NDQyODBhNjQ5NzNjMThmNGJjMTBjL3RhYmxlcmFuZ2U6ZTU3ZDc3ZTA0ZjU0NDI4MGE2NDk3M2MxOGY0YmMxMGNfNC04LTEtMS02MTQ4NjE_87145d1a-9d8f-4612-9898-0ca41ecf7c98" name="us-gaap:Revenues" scale="6" unitref="usd">3,420</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i7a0f02fad816440ea104abcf9ee938e4_D20221001-20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RhYmxlOmU1N2Q3N2UwNGY1NDQyODBhNjQ5NzNjMThmNGJjMTBjL3RhYmxlcmFuZ2U6ZTU3ZDc3ZTA0ZjU0NDI4MGE2NDk3M2MxOGY0YmMxMGNfNS02LTEtMS02MTQ4NjE_e9f2cfe2-5164-4f01-961d-242d80326e59" name="us-gaap:CostOfRevenue" scale="6" unitref="usd">1,496</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="ibd5559567aed4bc6b3cdc90bfb24932f_D20211001-20211231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RhYmxlOmU1N2Q3N2UwNGY1NDQyODBhNjQ5NzNjMThmNGJjMTBjL3RhYmxlcmFuZ2U6ZTU3ZDc3ZTA0ZjU0NDI4MGE2NDk3M2MxOGY0YmMxMGNfNS04LTEtMS02MTQ4NjE_9980e427-9ac5-413c-8ee3-bc4f0b3741e5" name="us-gaap:CostOfRevenue" scale="6" unitref="usd">1,312</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i7a0f02fad816440ea104abcf9ee938e4_D20221001-20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RhYmxlOmU1N2Q3N2UwNGY1NDQyODBhNjQ5NzNjMThmNGJjMTBjL3RhYmxlcmFuZ2U6ZTU3ZDc3ZTA0ZjU0NDI4MGE2NDk3M2MxOGY0YmMxMGNfNi02LTEtMS02MTQ4NjE_c6ab7280-7f0f-4f71-9300-154359637e2d" name="us-gaap:GrossProfit" scale="6" unitref="usd">1,766</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibd5559567aed4bc6b3cdc90bfb24932f_D20211001-20211231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RhYmxlOmU1N2Q3N2UwNGY1NDQyODBhNjQ5NzNjMThmNGJjMTBjL3RhYmxlcmFuZ2U6ZTU3ZDc3ZTA0ZjU0NDI4MGE2NDk3M2MxOGY0YmMxMGNfNi04LTEtMS02MTQ4NjE_781335ab-5327-4bf9-867e-d4b6514fc275" name="us-gaap:GrossProfit" scale="6" unitref="usd">2,108</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i7a0f02fad816440ea104abcf9ee938e4_D20221001-20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RhYmxlOmU1N2Q3N2UwNGY1NDQyODBhNjQ5NzNjMThmNGJjMTBjL3RhYmxlcmFuZ2U6ZTU3ZDc3ZTA0ZjU0NDI4MGE2NDk3M2MxOGY0YmMxMGNfNy02LTEtMS02MTQ4NjE_0c0e906f-bc19-46f9-939c-2b42e730d2ad" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">225</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibd5559567aed4bc6b3cdc90bfb24932f_D20211001-20211231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RhYmxlOmU1N2Q3N2UwNGY1NDQyODBhNjQ5NzNjMThmNGJjMTBjL3RhYmxlcmFuZ2U6ZTU3ZDc3ZTA0ZjU0NDI4MGE2NDk3M2MxOGY0YmMxMGNfNy04LTEtMS02MTQ4NjE_055e742e-0573-44e6-9738-e3bd3ab04a68" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">590</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i7a0f02fad816440ea104abcf9ee938e4_D20221001-20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RhYmxlOmU1N2Q3N2UwNGY1NDQyODBhNjQ5NzNjMThmNGJjMTBjL3RhYmxlcmFuZ2U6ZTU3ZDc3ZTA0ZjU0NDI4MGE2NDk3M2MxOGY0YmMxMGNfOC02LTEtMS02MTQ4NjE_ab0e20ad-3f15-4f13-9a66-68109ac8957e" name="us-gaap:ProfitLoss" scale="6" unitref="usd">225</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibd5559567aed4bc6b3cdc90bfb24932f_D20211001-20211231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RhYmxlOmU1N2Q3N2UwNGY1NDQyODBhNjQ5NzNjMThmNGJjMTBjL3RhYmxlcmFuZ2U6ZTU3ZDc3ZTA0ZjU0NDI4MGE2NDk3M2MxOGY0YmMxMGNfOC04LTEtMS02MTQ4NjE_45be4d90-d644-405d-9c7b-053ddd7d8448" name="us-gaap:ProfitLoss" scale="6" unitref="usd">590</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income attributable to shareholders</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i7a0f02fad816440ea104abcf9ee938e4_D20221001-20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RhYmxlOmU1N2Q3N2UwNGY1NDQyODBhNjQ5NzNjMThmNGJjMTBjL3RhYmxlcmFuZ2U6ZTU3ZDc3ZTA0ZjU0NDI4MGE2NDk3M2MxOGY0YmMxMGNfOS02LTEtMS02MTQ4NjE_29118caa-6556-40e0-a086-faa9bc4df1dd" name="us-gaap:NetIncomeLoss" scale="6" unitref="usd">211</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibd5559567aed4bc6b3cdc90bfb24932f_D20211001-20211231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80MC9mcmFnOjRhOTlhMmE4ZGMxODRiZjJiN2M5MDc1ZWQ4YzBmZTdiL3RhYmxlOmU1N2Q3N2UwNGY1NDQyODBhNjQ5NzNjMThmNGJjMTBjL3RhYmxlcmFuZ2U6ZTU3ZDc3ZTA0ZjU0NDI4MGE2NDk3M2MxOGY0YmMxMGNfOS04LTEtMS02MTQ4NjE_1893097e-d846-4175-92ab-ac652091ad4c" name="us-gaap:NetIncomeLoss" scale="6" unitref="usd">578</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonnumeric></div></ix:continuation><div id="idfe6e72973fb4e83b28a5bb34d34299f_46"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="i600db3675876494298d89dea08ac6cab" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDEwNw_921f5cb8-3fb3-4b5d-a182-44eb1ea63e4d" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</ix:nonnumeric></span></div><ix:continuation continuedat="if2cafc4e6a9b409ea18245b501232b91" id="i600db3675876494298d89dea08ac6cab"><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Transforming to a More Focused Company Program</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we announced that we would be incurring costs associated with our Transforming to a More Focused Company Program, a multi-year effort to ensure our cost base aligns appropriately with our operating structure following Pfizer&#8217;s transformation into a more focused, innovative science-based global biopharmaceutical business. This program includes activities to (i) restructure our corporate enabling functions to appropriately support our operating structure; (ii) transform our commercial go-to-market model; and (iii) optimize our manufacturing network and R&amp;D operations. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities associated with transforming our commercial go-to-market model are substantially complete. Activities associated with restructuring our corporate enabling functions and optimizing our manufacturing network and R&amp;D operations are ongoing and are expected to be substantially completed by the end of 2023. The costs to restructure our corporate enabling functions, and to optimize our R&amp;D operations and reduce cycle times, as well as to further prioritize our internal R&amp;D portfolio, primarily include severance and implementation costs. The costs to optimize our manufacturing network largely include severance, implementation costs, product transfer costs, site exit costs, and accelerated depreciation.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the start of this program in the fourth quarter of 2019 through April&#160;2, 2023, we incurred costs of $<ix:nonfraction contextref="i8db9385fd11b4f34a9a00ad99b96ee74_I20230402" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfMjY1Nw_93decb34-859f-43b9-a419-8873ee9b60d4" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" scale="9" unitref="usd">3.5</ix:nonfraction>&#160;billion, of which $<ix:nonfraction contextref="i06738249302c478d802b2593c91103fd_I20230402" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfMjY3MA_9606e5ec-3c75-4413-9570-714f0143b4bc" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" scale="9" unitref="usd">1.4</ix:nonfraction> billion ($<ix:nonfraction contextref="i06738249302c478d802b2593c91103fd_I20230402" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfMjY3NA_d7e2f4eb-b74a-4810-882e-c8141bd21179" name="pfe:RestructuringChargesChargesIncurredToDate" scale="9" unitref="usd">1.1</ix:nonfraction>&#160;billion of restructuring charges) is associated with Biopharma. We have incurred approximately <ix:nonfraction contextref="i8db9385fd11b4f34a9a00ad99b96ee74_I20230402" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfMjc0ODc3OTA3NjcyNA_50901d17-25ae-42ab-9a4f-59f5c32598d6" name="pfe:RestructuringAndRelatedCostCostIncurredToDatePercentOfTotalExpectedCost" scale="-2" unitref="number">85</ix:nonfraction>% of total expected costs to date, and we expect the remaining costs to be substantially incurred through 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="if2cafc4e6a9b409ea18245b501232b91"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Key Activities</span></div><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDA5Mg_5d499d47-a50c-4d15-a8a0-7e2cb8939936" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restructuring charges/(credits):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee terminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfNC02LTEtMS02MTQ4NjE_6ff6577d-ee61-4244-90a7-6c58444d2433" name="us-gaap:SeveranceCosts1" scale="6" sign="-" unitref="usd">36</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfNC04LTEtMS02MTQ4NjE_7729d792-28af-457a-b57a-74d8b21f95a4" name="us-gaap:SeveranceCosts1" scale="6" unitref="usd">25</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfNS02LTEtMS02MTQ4NjE_7d032065-a2ad-46c0-ae0a-e8c5ac063f2c" name="pfe:RestructuringAssetImpairmentCharges" scale="6" sign="-" unitref="usd">10</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfNS04LTEtMS02MTQ4NjE_cf2eb939-9259-491a-a131-0adee0b71c96" name="pfe:RestructuringAssetImpairmentCharges" scale="6" unitref="usd">8</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exit costs/(credits)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfNi02LTEtMS02MTQ4NjE_04cb91e5-94d5-4d2e-998b-91aed50df39a" name="us-gaap:BusinessExitCosts1" scale="6" unitref="usd">2</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfNi04LTEtMS02MTQ4NjE_7e444bcf-cdd3-4503-9c32-5f7ffb20977f" name="us-gaap:BusinessExitCosts1" scale="6" unitref="usd">11</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restructuring charges/(credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfNy02LTEtMS02MTQ4NjE_27074bfe-32e8-4f78-8607-52f8aca3fe1f" name="us-gaap:RestructuringCharges" scale="6" sign="-" unitref="usd">44</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfNy04LTEtMS02MTQ4NjE_e563126a-7120-444f-b128-5d77397dbcd3" name="us-gaap:RestructuringCharges" scale="6" unitref="usd">43</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Transaction costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfOC02LTEtMS02MTQ4NjE_640a805a-f35d-45ff-9aa5-28b3da3cd778" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfOC04LTEtMS02MTQ4NjE_0904b9f0-19bc-409d-8db7-74728f2e0bb2" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" scale="6" unitref="usd">6</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Integration costs and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfOS02LTEtMS02MTQ4NjE_e5a59743-d5c7-42a6-9ef7-d0f3f0dcc1b0" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" unitref="usd">52</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfOS04LTEtMS02MTQ4NjE_c8402829-bb29-4871-b06b-3812336dc950" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" unitref="usd">142</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMTAtNi0xLTEtNjE0ODYx_d2de8e2d-97a2-48d9-b3b6-d698e054ebd8" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" unitref="usd">9</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMTAtOC0xLTEtNjE0ODYx_92604d9a-b071-4ee4-9da4-ad526fcb43d3" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" unitref="usd">192</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net periodic benefit costs/(credits) recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i8e058f03345d43f689a94b97da6cd9c9_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMTEtNi0xLTEtNjE0ODYx_9a861406-fb85-4f2a-bb5f-c2f0555310e7" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" sign="-" unitref="usd">5</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="if0451d8a803648f78c3f5b829fb2b882_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMTEtOC0xLTEtNjE0ODYx_e19e155b-a56f-4e54-a647-c78a97067122" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" sign="-" unitref="usd">6</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Additional depreciation&#8211;&#8211;asset restructuring recorded in our condensed consolidated statements of income, mainly in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i4425b4566be44b0c82ea48bffac35b0b_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMTYtNi0xLTEtNjE0ODYx_cbb6cfca-b14c-4ec9-b350-377853fb2971" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" unitref="usd">18</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i1c0346762e1e4d89ae68f7c0434a757b_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMTYtOC0xLTEtNjE0ODYx_56f4c987-3fb3-48b1-9ea4-62aeda2a2f70" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" unitref="usd">9</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Implementation costs recorded in our condensed consolidated statements of income as follows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i4425b4566be44b0c82ea48bffac35b0b_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMTgtNi0xLTEtNjE0ODYx_45189143-80bf-44c5-b214-fe7bcb26a444" name="pfe:ImplementationCosts" scale="6" unitref="usd">15</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i1c0346762e1e4d89ae68f7c0434a757b_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMTgtOC0xLTEtNjE0ODYx_6fcf9afb-4002-4ea7-a5ed-bf43c6ea47ba" name="pfe:ImplementationCosts" scale="6" unitref="usd">12</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i91a85b0bab2a4a25a80b150460d4175b_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMTktNi0xLTEtNjE0ODYx_3004a1e6-8ade-4877-9e0c-f56c095a9170" name="pfe:ImplementationCosts" scale="6" unitref="usd">59</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ie15edb16dff343adb61bbb6cf1f06a67_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMTktOC0xLTEtNjE0ODYx_bcb170d6-a4e0-4e10-9f3c-5a362832ab3d" name="pfe:ImplementationCosts" scale="6" unitref="usd">74</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if3137b642ecd48d3ac8fbc6639f747f7_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMjAtNi0xLTEtNjE0ODYx_17db11b2-4bdd-44a7-8929-8f2cff103407" name="pfe:ImplementationCosts" scale="6" unitref="usd">11</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i48f5884165aa44be8f684791c8a08fbb_D20220101-20220403" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMjAtOC0xLTEtNjE0ODYx_3bd6fa05-16ea-4254-934a-561c4d3710e2" name="pfe:ImplementationCosts" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total implementation costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMjItNi0xLTEtNjE0ODYx_ae47a9d3-f27b-4c4f-bd3b-3ae6e074f7b6" name="pfe:ImplementationCosts" scale="6" unitref="usd">85</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMjItOC0xLTEtNjE0ODYx_e04c98e9-2519-474d-8a04-fe6ced9c5443" name="pfe:ImplementationCosts" scale="6" unitref="usd">85</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMjMtNi0xLTEtNjE0ODYx_b3f06299-96e0-420a-aa19-d3f7e0b3d540" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" scale="6" unitref="usd">107</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjFlNjQwNzcyMWRkNjQ4ODBhMDg4OWMzYzYxNTZkZTQ4L3RhYmxlcmFuZ2U6MWU2NDA3NzIxZGQ2NDg4MGEwODg5YzNjNjE1NmRlNDhfMjMtOC0xLTEtNjE0ODYx_86361aeb-f935-4bcd-838f-fa72c31a7666" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" scale="6" unitref="usd">280</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDEyMA_a7ac0843-d9e0-4717-ae98-c1b5822660b8">Primarily represents cost reduction initiatives. Restructuring charges/(credits) associated with Biopharma: credits of $<ix:nonfraction contextref="i2c138911a1d04f5d8ed218c8b37ed1d2_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfMjg3NA_10cbb69f-328b-4c14-9280-cec9e599381f" name="us-gaap:RestructuringCharges" scale="6" sign="-" unitref="usd">28</ix:nonfraction>&#160;million for the three months ended April&#160;2, 2023 and credits of $<ix:nonfraction contextref="i9c1193f1a4714912a5d71e60826acdac_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfMjk1MQ_bc3e92d9-cb46-42c2-98c2-a450a6357643" name="us-gaap:RestructuringCharges" scale="6" sign="-" unitref="usd">4</ix:nonfraction>&#160;million for the three months ended April&#160;3, 2022.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDA3Ng_a1af0502-263e-4cef-b1ea-865c8e794c2d">Represents external costs for banking, legal, accounting and other similar services.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDEzMA_468e4122-41d0-47d0-a3ec-12f50b33e3b3">Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the first quarter of 2022, integration costs and other were mostly related to our acquisition of Arena, including $<ix:nonfraction contextref="ib27bcc9d493049d8abe864e62fb64d25_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfMjc0ODc3OTA3Njk5NQ_1bcd9d97-e7c9-4832-aa9d-51829c99dd6e" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" scale="6" unitref="usd">138</ix:nonfraction> million in payments to Arena employees for the fair value of previously unvested long-term incentive awards that was recognized as post-closing compensation expense.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDA1OA_43c730c8-cc94-44fa-af74-1c29a8fd054c">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDA3MA_3ad48e11-92b4-4747-93be-3b8e8be06690">Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</ix:footnote></span></div></ix:nonnumeric><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDEyNQ_8093f390-de6b-4f4b-b2f4-67a51fbfdbaf" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:40.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.362%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.096%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components and changes in restructuring accruals:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee<br/>Termination<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Asset<br/>Impairment<br/>Charges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exit Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrual</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="iaef57a77f73c40c2a69a601492af0dd1_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfMi0yLTEtMS02MTQ4NjE_2cc4a44c-a3d4-4e2c-b278-d6a7719d7a79" name="us-gaap:RestructuringReserve" scale="6" unitref="usd">1,196</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i153f75c15e9942659dc27e0ad196f97b_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfMi00LTEtMS02MTQ4NjE_b953c004-2713-408f-9d6e-8dc802c66fd8" name="us-gaap:RestructuringReserve" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i48c28c40ac824eeb9ac2a1816c6a9a52_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfMi02LTEtMS02MTQ4NjE_7798747f-f39f-47b3-896b-5ab9104eadd4" name="us-gaap:RestructuringReserve" scale="6" unitref="usd">8</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfMi04LTEtMS02MTQ4NjE_37cac345-b2e1-433c-a1eb-8aff15cac98a" name="us-gaap:RestructuringReserve" scale="6" unitref="usd">1,204</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Provision/(credit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i368e6697c57a4f37beb8d7b70ff5899b_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfMy0yLTEtMS02MTQ4NjE_7e9c361b-88e1-49a8-823d-890a9be6edd3" name="us-gaap:RestructuringCharges" scale="6" sign="-" unitref="usd">36</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i11d465c2222f44d9a33767557caa2a0d_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfMy00LTEtMS02MTQ4NjE_ac5ab80e-b102-4e68-a123-f7ef47df576d" name="us-gaap:RestructuringCharges" scale="6" sign="-" unitref="usd">10</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic2161e17146141d2aa15a69116852f3f_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfMy02LTEtMS02MTQ4NjE_a7438fd0-87dc-491e-83f2-a362786acfa6" name="us-gaap:RestructuringCharges" scale="6" unitref="usd">2</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfMy04LTEtMS02MTQ4NjE_f3aa7a93-079a-44fe-9973-b82eb8e8b284" name="us-gaap:RestructuringCharges" scale="6" sign="-" unitref="usd">44</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Utilization and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i368e6697c57a4f37beb8d7b70ff5899b_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfNC0yLTEtMS02MTQ4NjE_cc7e6c25-23fc-4b89-b58f-df5445195cdd" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" unitref="usd">420</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i11d465c2222f44d9a33767557caa2a0d_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfNC00LTEtMS02MTQ4NjE_04915349-854c-48f7-bff9-7b4fa4670381" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" sign="-" unitref="usd">10</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="ic2161e17146141d2aa15a69116852f3f_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfNC02LTEtMS02MTQ4NjE_50caf7b7-9c8e-4601-88e0-3ee5288261de" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" unitref="usd">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfNC04LTEtMS02MTQ4NjE_d84bae25-a2f4-4d7e-a5c9-1069e902cb58" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" unitref="usd">411</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, April&#160;2, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i856c15cefad24430994db47f81fce0c6_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfNS0yLTEtMS02MTQ4NjE_64161a5d-cc7f-45ca-a585-280990fe77c4" name="us-gaap:RestructuringReserve" scale="6" unitref="usd">740</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i0d4fa6526f2e42cca30abe7b32f896e2_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfNS00LTEtMS02MTQ4NjE_924e902e-db65-43a9-b782-b847e6a7f689" name="us-gaap:RestructuringReserve" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i706a5dc562734084a9a495cb02b91211_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfNS02LTEtMS02MTQ4NjE_77a78978-a6bd-4b1f-b88d-f68c36980de7" name="us-gaap:RestructuringReserve" scale="6" unitref="usd">9</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RhYmxlOjZjZWZmY2RhNmM3ODQ2MjU5ZjlmNzc4NTg0ZGNiODUyL3RhYmxlcmFuZ2U6NmNlZmZjZGE2Yzc4NDYyNTlmOWY3Nzg1ODRkY2I4NTJfNS04LTEtMS02MTQ4NjE_04779caf-8345-45fd-b123-a22114b060ad" name="us-gaap:RestructuringReserve" scale="6" unitref="usd">750</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDA4Mg_66d9887a-2e69-452d-9cbb-96d551187dee"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($<ix:nonfraction contextref="if49206e13d134dfda6216a41c3b8a6ff_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfMzg2OQ_4a77ef09-56f8-4b37-af32-97e3d4d68ec7" name="us-gaap:RestructuringReserve" scale="6" unitref="usd">991</ix:nonfraction> million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($<ix:nonfraction contextref="iaedb0f64969b481c84e4f6fbd2d4bb46_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfMzkwNw_345be5e5-86e1-4a07-afe4-6727fb95c2ce" name="us-gaap:RestructuringReserve" scale="6" unitref="usd">213</ix:nonfraction> million).</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDA5NA_b66da65a-1e28-4002-9355-b166371d4767">Includes adjustments for foreign currency translation.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDExOA_a40938b5-2979-4de5-8e79-146f8575ea0c"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($<ix:nonfraction contextref="i74bb48599a6f4bc3801d3f73331a259b_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDAwNg_a914fd0b-2fa9-4942-af37-206043c2c731" name="us-gaap:RestructuringReserve" scale="6" unitref="usd">548</ix:nonfraction> million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($<ix:nonfraction contextref="i5d8c414e5fef44a6b7c25acd4bac30ba_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80Ni9mcmFnOjM3ZDNmZDA3MDViODRjZmFiMDdjZDcwYWYxZDNiMmYyL3RleHRyZWdpb246MzdkM2ZkMDcwNWI4NGNmYWIwN2NkNzBhZjFkM2IyZjJfNDA0NA_0ed303a5-3a9c-47ce-b3fc-096fa32fec46" name="us-gaap:RestructuringReserve" scale="6" unitref="usd">202</ix:nonfraction> million).</span></ix:footnote></div></ix:nonnumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_49"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="i2d954c4ac13d41cc860ff3d5a9bdbb2c" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk2Ng_5f427e6f-5cce-4e5d-9d2f-ed2921c04f7e" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock">Other (Income)/Deductions&#8212;Net</ix:nonnumeric></span></div><ix:continuation id="i2d954c4ac13d41cc860ff3d5a9bdbb2c"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk5Mg_8e42bf5d-0c51-4095-a01d-68ab94f155ad" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:73.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMy02LTEtMS02MTQ4NjE_b370eb83-6f73-4e21-9ba4-195bd0c00c61" name="us-gaap:InvestmentIncomeInterest" scale="6" unitref="usd">177</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMy04LTEtMS02MTQ4NjE_a649bec1-55b8-44ed-bb8e-7698cb02c3ac" name="us-gaap:InvestmentIncomeInterest" scale="6" unitref="usd">14</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfNC02LTEtMS02MTQ4NjE_a783a3d9-7213-421a-b3b6-d92bee9869b4" name="us-gaap:InterestExpense" scale="6" unitref="usd">318</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfNC04LTEtMS02MTQ4NjE_5fbf2b53-be12-48a8-a16a-0799f858d2b4" name="us-gaap:InterestExpense" scale="6" unitref="usd">322</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfNS02LTEtMS02MTQ4NjE_bdb5caae-f458-4061-85dd-52c9edf24874" name="us-gaap:InterestRevenueExpenseNet" scale="6" sign="-" unitref="usd">141</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfNS04LTEtMS02MTQ4NjE_4d5272f2-508c-4b3d-94f9-5af247cb82ab" name="us-gaap:InterestRevenueExpenseNet" scale="6" sign="-" unitref="usd">308</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty-related income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfNi02LTEtMS02MTQ4NjE_6e9d1b49-8dc3-4e5b-abc0-2fa4ccdcd48e" name="us-gaap:RoyaltyIncomeNonoperating" scale="6" unitref="usd">204</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfNi04LTEtMS02MTQ4NjE_9ebee024-b799-4a23-9267-6b590af55b93" name="us-gaap:RoyaltyIncomeNonoperating" scale="6" unitref="usd">173</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains)/losses on asset disposals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfNy02LTEtMS02MTQ4NjE_c6d0a71c-c4de-4a46-add5-f9b8e354a143" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" unitref="usd">7</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfNy04LTEtMS02MTQ4NjE_64c86679-1108-4f2b-b8dd-3c1b544572b5" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" unitref="usd">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfOC02LTEtMS02MTQ4NjE_330c9fc6-7412-40e3-8410-447fe5c5963c" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" sign="-" unitref="usd">451</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfOC04LTEtMS02MTQ4NjE_2a8066ba-5eaf-4188-ba12-7b839088035b" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" sign="-" unitref="usd">699</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from collaborations, out-licensing arrangements and sales of compound/product rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfOS02LTEtMS02MTQ4NjE_597d0eef-d0ad-4693-97e4-a8dd5bff6ea2" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" scale="6" unitref="usd">68</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfOS04LTEtMS02MTQ4NjE_d4abbd1a-7872-419e-b69a-d5efb881ccd7" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" scale="6" unitref="usd">9</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit costs/(credits) other than service costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMTAtNi0xLTEtNjE0ODYx_4bdd2b4d-67b4-42a0-a98e-596ee15c913b" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" sign="-" unitref="usd">80</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMTAtOC0xLTEtNjE0ODYx_72548b44-1452-4ee4-a26d-37a0fc037173" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" sign="-" unitref="usd">283</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain legal matters, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMTEtNi0xLTEtNjE0ODYx_dea9e2ba-543a-4c78-b4f8-5e014853e9a6" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" sign="-" unitref="usd">36</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMTEtOC0xLTEtNjE0ODYx_aac4b631-2e22-4d2a-92f9-d7bbb07205f4" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" sign="-" unitref="usd">79</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain asset impairments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMTItNi0xLTEtNjE0ODYx_30e3eb94-32c0-40f9-8b8f-8955b309389c" name="us-gaap:AssetImpairmentCharges" scale="6" unitref="usd">264</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMTItOC0xLTEtNjE0ODYx_dbc63a4f-fd13-486e-a0d2-9592694759f3" name="us-gaap:AssetImpairmentCharges" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Haleon/Consumer Healthcare JV equity method (income)/loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMTMtNi0xLTEtNjE0ODYx_6995537d-9f28-4b44-a53c-17ba5e276b88" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" scale="6" unitref="usd">68</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMTMtOC0xLTEtNjE0ODYx_336354b8-e527-4af6-9bfc-91cf384499e5" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" scale="6" unitref="usd">184</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMTQtNi0xLTEtNjE0ODYx_0a3a7736-da6a-41ca-9b62-b40bc5200289" name="pfe:OtherNonoperatingIncomeExpenseNet" scale="6" unitref="usd">396</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMTQtOC0xLTEtNjE0ODYx_22df781a-068d-49cd-bec7-224bce181885" name="pfe:OtherNonoperatingIncomeExpenseNet" scale="6" unitref="usd">88</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMTUtNi0xLTEtNjE0ODYx_6d1a6350-45df-43e2-9410-a4a9bb431248" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" sign="-" unitref="usd">70</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOjZiZTk3ODRjN2M1YjQ0NzlhMzZjZmU3ZGNlMTViYjZlL3RhYmxlcmFuZ2U6NmJlOTc4NGM3YzViNDQ3OWEzNmNmZTdkY2UxNWJiNmVfMTUtOC0xLTEtNjE0ODYx_81ca2122-9004-4b1c-9c95-e8156452e009" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" sign="-" unitref="usd">350</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk4Ng_33be42cc-452b-4e0c-b0b5-23381dc1f1c2">The losses in the first quarter of 2023 include, among other things, unrealized losses of $<ix:nonfraction contextref="i5a4b74c508194edd9e71424cfe35e881_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTY0OTI2NzQ0NDIyOA_313dba34-25b9-4757-ac71-1d5c2de32998" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" sign="-" unitref="usd">363</ix:nonfraction>&#160;million related to our investments in Cerevel Therapeutics Holdings, Inc. and BioNTech. The losses in the first quarter of 2022 included, among other things, unrealized losses of $<ix:nonfraction contextref="if4108bffa817457b9f4f93f3df5b3b5a_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTY0OTI2NzQ0Mzc3MA_3f38bd97-b73b-43ba-83c1-d1ac2cace70b" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" sign="-" unitref="usd">473</ix:nonfraction>&#160;million related to our investment in BioNTech.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTQ4NDM0MDY5ODUzNTI_5387de25-ae3a-4c5f-8259-be60bef783cf">The first quarter of 2023 primarily includes certain product liability expenses related to products discontinued and/or divested by Pfizer. The first quarter of 2022 includes certain product liability expenses related to products discontinued and/or divested by Pfizer, and to a lesser extent, legal obligations related to pre-acquisition commitments.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3OQ_9594fb42-f248-48c5-9de8-89fb935cb09f">The first quarter of 2023 primarily represents intangible asset impairment charges, including $<ix:nonfraction contextref="iece3f81689ed43ed8131977e5397a8b5_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTY0OTI2NzQ0ODc2Nw_b72127af-3cb8-451e-849b-d3fb7eb16a03" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">128</ix:nonfraction> million associated with Other business activities, related to IPR&amp;D and developed technology rights for acquired software assets and reflects unfavorable pivotal trial results and updated commercial forecasts, and $<ix:nonfraction contextref="ic5128331c6f7443784a0eceb48c89a99_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTY0OTI2NzQ0Njg2NQ_f9e60229-4c90-40ac-a37e-cb4702f35d06" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">120</ix:nonfraction>&#160;million associated with our Biopharma segment due to the discontinuation of a study related to an out-licensed IPR&amp;D asset for the treatment of prostate cancer, acquired in our Array BioPharma Inc. acquisition.  </ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk4MA_182e6155-307f-4c9c-8f98-22d7a0346d5f"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a><a href="#idfe6e72973fb4e83b28a5bb34d34299f_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C</a></span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTQ4NDM0MDY5ODUzNTQ_557156a9-13f7-48b8-bc51-384a72dc6f75"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The first quarter of 2023 primarily includes, among other things, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">dividend income of $<ix:nonfraction contextref="i26a1855fa83845c58c5e96adbae43a8a_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfNjA0NzMxMzk1OTM0MA_e2462127-8146-4c89-a89b-2aa392f162b8" name="us-gaap:InvestmentIncomeDividend" scale="6" unitref="usd">211</ix:nonfraction>&#160;million from our investment in Nimbus resulting from Takeda Pharmaceutical Company Limited&#8217;s acquisition of Nimbus&#8217;s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary, and $<ix:nonfraction contextref="i50b8a990e8d945a991c47c03ad000ded_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfNjA0NzMxMzk1OTQ4Mg_e635b427-8769-49eb-9e2b-2df0a520fe10" name="us-gaap:InvestmentIncomeDividend" scale="6" unitref="usd">92</ix:nonfraction>&#160;million from our investment in ViiV.</span></ix:footnote></div></ix:nonnumeric><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk4NQ_0f883170-e81e-4ed9-8c47-d0f12876cdf6" name="us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional information about the intangible assets that were impaired during 2023 follows:</span></div></td></tr><tr><td colspan="30" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets&#8211;&#8211;Licensing agreements and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3a9c8665ecc2474ca39f0f97addda98f_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC0yLTEtMS02NzY4OTg_eac3406b-7c62-4a1c-a47a-ac568294b241" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5d9efa631eb349daafaf29d270f1c7ff_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC00LTEtMS02NzY4OTg_72a8ea85-8438-4687-9db8-750c7ad23bb7" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib15c5b5368114b4fa2a9617c1936084c_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC02LTEtMS02NzY4OTg_3c57a6b5-58bc-4ddc-9529-9d4e9f92d6cf" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i11e8ce6ff1b04567943de7da6408d022_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC04LTEtMS02NzY4OTg_bbbe0dd3-d5d0-4aa3-ac49-56a2a6861357" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5961b2a105b04fa99c374113d2d3b409_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC0xMC0xLTEtNjc2ODk4_8b1ab299-5bc5-4840-a83b-45b4a0e6b9b8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">120</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets&#8211;&#8211;IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i7b15c009527b405a90632ab077451178_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfMy0yLTEtMS02MTQ4NjE_501fa62c-f7e0-4fc5-9c8d-f09114c9b4a1" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="icd26ebcbc96b4b52b9bb151e168773bb_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfMy00LTEtMS02MTQ4NjE_f1c04cbe-9d08-4c7e-84b5-451c58dfdf2e" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="iaa4e5719a8f74b069fef9b1b80758cdd_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfMy02LTEtMS02MTQ4NjE_ea804fd2-c4dc-4227-8e9d-7888c58b77fe" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i44bfc66b5faa4451b77492ea0cf703d1_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfMy04LTEtMS02MTQ4NjE_4182e2a2-e178-4538-a4cd-51b56db152cc" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i481af342fa644071b566691370861280_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfMy0xMC0xLTEtNjE0ODYx_c7c53f2f-4d6d-438a-9980-03298a6258ab" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">94</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets&#8211;&#8211;Developed technology rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ie6e2d5620afa435e8c12a808e5a20a45_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC0yLTEtMS02MTQ4NjE_297343f3-8f5f-4d18-8d9a-fe06e4029965" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="id2de7039d729496a9d132d5ed4b7a2df_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC00LTEtMS02MTQ4NjE_d0ecd745-d37e-4c83-81a4-6de71427014b" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib951119d7c294b8e943132d574990796_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC02LTEtMS02MTQ4NjE_2a55468a-a3ea-4b85-82a4-d3bbf9200372" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="iec0c75cf014d48c6b822f51540a69197_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC04LTEtMS02MTQ4NjE_2ea0291b-2feb-4fea-bec8-ae8dc8d5752b" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib120fd43f21647ddb9c5494438dfb27e_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNC0xMC0xLTEtNjE0ODYx_6df62a9d-ce1d-486b-a32c-7bed898a9229" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">34</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNS0yLTEtMS02MTQ4NjE_313f4ea6-fbd1-4197-9273-ce06c391dbd8" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5f655837df224047b8fb5f3b4ad5b104_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNS00LTEtMS02MTQ4NjE_22cef129-a1a0-4f16-9b83-1353d780f2cb" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i716dec095fa343959adf62bbbcc3ce7a_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNS02LTEtMS02MTQ4NjE_bbb9f6ab-d001-4026-9eb4-377316e72e98" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i4ed5041454dc4cf5aad5955d010fc8a9_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNS04LTEtMS02MTQ4NjE_d9b29fb1-3333-4581-a3a9-24d105c643d5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RhYmxlOmFlOWQwZjE3MWUwNjRmMWFhNWYzMTlkZjAzMjJlYTg0L3RhYmxlcmFuZ2U6YWU5ZDBmMTcxZTA2NGYxYWE1ZjMxOWRmMDMyMmVhODRfNS0xMC0xLTEtNjE0ODYx_8308979a-5aff-4680-a57a-e5af450babb1" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">248</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NQ_efff7e59-fd15-468f-9e0e-11694d4c9ef9"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">The fair value amount is presented as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1E </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our 2022 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl80OS9mcmFnOjRkNTQxNTU0YTljOTRiMjBiYTMzY2RmMWIxYzNlZWRjL3RleHRyZWdpb246NGQ1NDE1NTRhOWM5NGIyMGJhMzNjZGYxYjFjM2VlZGNfMTk3NA_034f4111-ff43-4e4b-9029-668d23b72473">Reflects intangible assets written down to fair value in 2023. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</ix:footnote></span></div></ix:nonnumeric></ix:continuation><div id="idfe6e72973fb4e83b28a5bb34d34299f_52"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="i8361f00a93304d91be8cfd3db5e91328" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RleHRyZWdpb246MTFjMGExMWUzY2NkNGFiMThhNDViYjA1ZTExNjQyNTlfMjc2MQ_eaf0016b-6497-4e46-bf1f-d37f2efe23f3" name="us-gaap:IncomeTaxDisclosureTextBlock">Tax Matters</ix:nonnumeric></span></div><ix:continuation continuedat="i36fc0ce0b1144b30907ea305b1ace460" id="i8361f00a93304d91be8cfd3db5e91328"><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Taxes on Income from Continuing Operations</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for continuing operations was <ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RleHRyZWdpb246MTFjMGExMWUzY2NkNGFiMThhNDViYjA1ZTExNjQyNTlfMTE1_558de20a-2a08-493f-b26a-1fdbf78c11d7" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitref="number">11.4</ix:nonfraction>% for the first quarter of 2023, compared to <ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="3" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RleHRyZWdpb246MTFjMGExMWUzY2NkNGFiMThhNDViYjA1ZTExNjQyNTlfMTU2_3ba877c3-b8b7-4053-babe-f7a62c2888b2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitref="number">12.9</ix:nonfraction>% for the first quarter of 2022. The lower effective tax rate for the first quarter of 2023, was due to a favorable change in the jurisdictional mix of earnings.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i36fc0ce0b1144b30907ea305b1ace460"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $<ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-9" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RleHRyZWdpb246MTFjMGExMWUzY2NkNGFiMThhNDViYjA1ZTExNjQyNTlfODQ3_689677aa-07ee-46bc-a389-fad04ba3feb7" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" scale="9" unitref="usd">15</ix:nonfraction> billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The fifth annual installment of this liability was paid by its April 18, 2023 due date and is reported in current </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the remaining liability is reported in noncurrent </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of April&#160;2, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Tax Contingencies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, tax years 2016-2018 are under audit. Tax years 2019-2023 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years and certain related audits, appeals and investigations in certain major international tax jurisdictions dating back to 2012.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5D </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2022 Form 10-K.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)</span></div><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RleHRyZWdpb246MTFjMGExMWUzY2NkNGFiMThhNDViYjA1ZTExNjQyNTlfMjc0MQ_76e517ff-af20-4982-a5fe-25ca6fd85ba9" name="pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfMy02LTEtMS02MTQ4NjE_2f3e3b09-e9eb-4ffc-9236-5e89ad820b6b" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" sign="-" unitref="usd">25</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfMy04LTEtMS02MTQ4NjE_f215541f-fa33-4687-98f5-b828b395f113" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" sign="-" unitref="usd">72</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfNC02LTEtMS02MTQ4NjE_be48b6e3-1f7b-4cc5-9519-55c51ddeedf0" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" unitref="usd">3</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfNC04LTEtMS02MTQ4NjE_34eeb326-8b90-4fbf-8b8b-d418fdaf8a6e" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" unitref="usd">32</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfNS02LTEtMS02MTQ4NjE_69f4d771-6454-4c6b-9e85-04f3efa8ac46" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" sign="-" unitref="usd">21</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfNS04LTEtMS02MTQ4NjE_ddddbaea-fb50-46e1-a5a1-98a243526e5f" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" unitref="usd">22</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfNi02LTEtMS02MTQ4NjE_6779bcb5-b523-4dc7-a495-bc5058f05bdb" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" unitref="usd">24</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfNi04LTEtMS02MTQ4NjE_3923fc98-ee0d-4cb5-9281-ca4859645f45" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" unitref="usd">10</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfNy02LTEtMS02MTQ4NjE_3cd57410-9bfa-4821-b6a1-6b2d9d5db1a4" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" unitref="usd">11</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfNy04LTEtMS02MTQ4NjE_90f5eb6b-6c03-4c51-8fd6-164424e1a048" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" sign="-" unitref="usd">17</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfOC02LTEtMS02MTQ4NjE_1ceb624c-4189-4054-a302-2d4bdc102819" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" unitref="usd">64</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfOC04LTEtMS02MTQ4NjE_94e1f334-4381-4c39-b308-21b8b74556fa" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" sign="-" unitref="usd">29</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfOS02LTEtMS02MTQ4NjE_ce2b41d5-ebfa-41f6-a48c-009b71080637" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="6" sign="-" unitref="usd">53</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfOS04LTEtMS02MTQ4NjE_09a2c9fa-34e6-49d2-b000-8a210f99b561" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="6" unitref="usd">12</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments related to amortization of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfMTYtNi0xLTEtNjE0ODYx_41528cb6-0fb8-486c-8c00-3f1c2650d27f" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" sign="-" unitref="usd">7</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfMTYtOC0xLTEtNjE0ODYx_fcd2181f-31e5-4f2a-8cbc-f47677213f4f" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" sign="-" unitref="usd">9</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments related to curtailments of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfMTctNi0xLTEtNjE0ODYx_3ef4ec7c-228e-43e5-bd48-fac6d1f10ea9" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" sign="-" unitref="usd">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfMTctOC0xLTEtNjE0ODYx_1f133758-ce88-413e-b4ea-4c223a55dbbb" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" sign="-" unitref="usd">2</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfMTktNi0xLTEtNjE0ODYx_d78661c9-6fa0-4f9d-a23b-99ddaf5a43c4" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" scale="6" unitref="usd">9</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfMTktOC0xLTEtNjE0ODYx_0ea5fb66-5c83-4b85-8ac5-912ed4b20894" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" scale="6" unitref="usd">11</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfMjAtNi0xLTEtNjE0ODYx_5485f97c-cb42-4db2-8520-6c49e244e0fc" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" sign="-" unitref="usd">63</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RhYmxlOjMzM2QzZjgyN2JmOTQyYmVhZTcwYmI1YWRkOWQzMWQxL3RhYmxlcmFuZ2U6MzMzZDNmODI3YmY5NDJiZWFlNzBiYjVhZGQ5ZDMxZDFfMjAtOC0xLTEtNjE0ODYx_8341f129-f188-4e05-8b1b-3f7e61ff92cb" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" sign="-" unitref="usd">60</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81Mi9mcmFnOjExYzBhMTFlM2NjZDRhYjE4YTQ1YmIwNWUxMTY0MjU5L3RleHRyZWdpb246MTFjMGExMWUzY2NkNGFiMThhNDViYjA1ZTExNjQyNTlfMjc1MQ_a6b6bef0-e1c8-4d32-9241-f28755c3d35c">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.</ix:footnote></span></div></ix:nonnumeric></ix:continuation><div id="idfe6e72973fb4e83b28a5bb34d34299f_55"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="i21d64f5fe3a14ffe8af14d8021b057d8" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RleHRyZWdpb246MWQwYWUyNjBlYWMwNDRkMTk2NDJjM2RmMTg5OWY2NzlfMzQ2_293d7046-9a79-42e4-a463-735cefcc2c67" name="us-gaap:ComprehensiveIncomeNoteTextBlock">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</ix:nonnumeric></span></div><ix:continuation id="i21d64f5fe3a14ffe8af14d8021b057d8"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RleHRyZWdpb246MWQwYWUyNjBlYWMwNDRkMTk2NDJjM2RmMTg5OWY2NzlfMzM2_a8c50b2c-482d-4f75-ad8b-2ac057b6da2c" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the changes, net of tax, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Unrealized Gains/(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-For-Sale Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior Service (Costs)/Credits and Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income/(Loss)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i70be0839ad7e48599085d6446707c05a_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfMy0yLTEtMS02MTQ4NjE_320f6be1-5400-4ee1-a1eb-0498b16b6edd" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" sign="-" unitref="usd">8,360</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i73e5d62d81bc499da2aca918e59eb08a_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfMy00LTEtMS02MTQ4NjE_e9ed2779-a7b0-40cc-b4a2-0dbc6726995f" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" sign="-" unitref="usd">412</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i73d6c2bb40234687bf1e772888a62827_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfMy02LTEtMS02MTQ4NjE_bcdf30d5-cd09-4492-bffb-76a56f711338" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">220</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ifc11023bbf49477c9abadf68c2fdafad_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfMy0xMC0xLTEtNjE0ODYx_341cf283-ca35-4825-b922-b22222a959f0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">248</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="ic8190f97254a4b67b0ea33cef0e90617_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfMy0xMi0xLTEtNjE0ODYx_f3d43017-fe88-4d2a-9a86-fd93ad941978" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" sign="-" unitref="usd">8,304</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i28aec41f275d40739620a1ffc1732fbe_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfNC0yLTEtMS02MTQ4NjE_cd7e06a4-c039-4529-8caf-f0b15e806506" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" unitref="usd">129</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i097ebc813b09417eb7b6094a4e02d882_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfNC00LTEtMS02MTQ4NjE_f9a49a66-f035-4e41-92f9-5161cc1dd318" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" unitref="usd">281</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i61abe8ecaa42466ebb9062a884933adf_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfNC02LTEtMS02MTQ4NjE_7d37d31a-28ef-4a54-a89a-b8294362ac31" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" sign="-" unitref="usd">369</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i7fcb2dc9e0dc462baa886c47dacaed5d_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfNC0xMC0xLTEtNjE0ODYx_8c77178e-4a48-40b4-8649-337680e0fdcb" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" sign="-" unitref="usd">27</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic1dc28ef83404ef286e672b1e3544189_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfNC0xMi0xLTEtNjE0ODYx_d18a6043-f44c-4630-808d-fb3d29397fe6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" unitref="usd">15</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, April 2, 2023</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i9b8f808c40014053974afeae95dcc5fc_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfNS0yLTEtMS02MTQ4NjE_45dbcab7-3ad3-47c9-9d09-44ad0a0329dd" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" sign="-" unitref="usd">8,231</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="ibe58268f6d3743d78ce8f6aaef3189cc_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfNS00LTEtMS02MTQ4NjE_b187021e-476a-494a-bc61-2e9d79bd6067" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" sign="-" unitref="usd">131</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i51efada37c9e4f8a869567aaff2988a6_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfNS02LTEtMS02MTQ4NjE_1a598003-56d5-425b-8691-214247af7865" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" sign="-" unitref="usd">149</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i4b50745be4b54f9497e8f094b4dd8f76_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfNS0xMC0xLTEtNjE0ODYx_bee7bc0c-7a04-4d87-a7cd-e8e3eb40fd57" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" unitref="usd">222</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="id86c995eba51451eaa0b5251fe10bb38_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RhYmxlOjg4MzQxODJiM2NkYjRiYzc5ZTE3MzZmZWRjMDk1ZDZkL3RhYmxlcmFuZ2U6ODgzNDE4MmIzY2RiNGJjNzllMTczNmZlZGMwOTVkNmRfNS0xMi0xLTEtNjE0ODYx_96c4cd86-3071-49b4-ab4b-b9c256260658" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" sign="-" unitref="usd">8,289</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RleHRyZWdpb246MWQwYWUyNjBlYWMwNDRkMTk2NDJjM2RmMTg5OWY2NzlfMTQ4NDM0MDY5NzUzOTc_35caf586-a2e2-4584-a335-b5dfe8fb6772">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. </ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81NS9mcmFnOjFkMGFlMjYwZWFjMDQ0ZDE5NjQyYzNkZjE4OTlmNjc5L3RleHRyZWdpb246MWQwYWUyNjBlYWMwNDRkMTk2NDJjM2RmMTg5OWY2NzlfMzQ4_8e2f8f71-e075-40d2-8b3c-63da28965877"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Foreign currency translation adjustments include net gains related to our equity-method investment in Haleon (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a><a href="#idfe6e72973fb4e83b28a5bb34d34299f_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and the impact of our net investment hedging program.</span></ix:footnote></div></ix:nonnumeric></ix:continuation><div style="text-indent:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_58"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="ieea505590cd3474abe5b46895144ad97" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RleHRyZWdpb246MTFmODYyMjlhOWU4NDU5YTljZGYzYjA1NzBlNzExNTJfMTQyNA_8036a4da-d38e-4a17-8467-0e162ebacf2e" name="us-gaap:FinancialInstrumentsDisclosureTextBlock">Financial Instruments</ix:nonnumeric></span></div><ix:continuation continuedat="if1f00a109af641e498bf2537fe3e796a" id="ieea505590cd3474abe5b46895144ad97"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Fair Value Measurements</span></div><div><span><br/></span></div><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RleHRyZWdpb246MTFmODYyMjlhOWU4NDU5YTljZGYzYjA1NzBlNzExNTJfMTQzNg_9fb683c8-6521-447d-ab84-bbd0e52c8374" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i6d606c945f7549d5bc3f5f1f8665adf9_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNS0yLTEtMS02MTQ4NjE_78b88931-0407-4a27-a259-61460a81b62f" name="us-gaap:EquitySecuritiesFvNi" scale="6" unitref="usd">1,165</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ia46504589b004d6fa2609cecc9012836_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNS00LTEtMS02MTQ4NjE_3ef4b029-a423-47b7-9ceb-e41b07a41ee5" name="us-gaap:EquitySecuritiesFvNi" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i58b21a4b85f4482795c2771776ba8633_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNS02LTEtMS02MTQ4NjE_6004ade5-bd15-4c37-8f89-1771a280d972" name="us-gaap:EquitySecuritiesFvNi" scale="6" unitref="usd">1,165</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ie46b930976e249fdaea796d4fa2b7b8c_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNS0xMC0xLTEtNjE0ODYx_a295a746-b6ee-4d9f-ac62-28d565f15ff2" name="us-gaap:EquitySecuritiesFvNi" scale="6" unitref="usd">1,588</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i565b6fcf9ae64ce39bcbab011f8dd7d1_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNS0xMi0xLTEtNjE0ODYx_e3760dac-caba-4350-8cc8-3747eb117983" name="us-gaap:EquitySecuritiesFvNi" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i192980577b0c4f0981555fd501a1d150_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNS0xNC0xLTEtNjE0ODYx_07ec761d-cf7a-4d9f-ac49-acdc7fb8c9d7" name="us-gaap:EquitySecuritiesFvNi" scale="6" unitref="usd">1,588</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="iecc885f49b7d45a9b934afd40fe3006d_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfOC0yLTEtMS02MTQ4NjE_e9346f06-5297-4dcc-8ffa-4cc419a3640b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">13,278</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib5904d7defc84b3084a0fd70092bdb4f_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfOC00LTEtMS02MTQ4NjE_c8bace2d-3dab-40c0-b339-e052cefcd090" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i0f92a9a413b644978ffcd1ae87c971b8_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfOC02LTEtMS02MTQ4NjE_c3531d56-6842-4a1d-bbae-db5026affad5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">13,278</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i9972d1eb40ed45b9821d96a0b8ba5241_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfOC0xMC0xLTEtNjE0ODYx_14555a54-526f-4b49-b05d-bb866076ad85" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">15,915</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i90b766324f684d5baf778cb5ab2d8410_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfOC0xMi0xLTEtNjE0ODYx_d02936b4-a19d-45d0-8d73-31ceaf3b6018" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i92b39d6ab4e5439792f6377a57331e5a_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfOC0xNC0xLTEtNjE0ODYx_fbe51561-5c7d-454b-9862-3570d4a04a62" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">15,915</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib3ff63be924144e7ac9fd6beaf47befa_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfOS0yLTEtMS02MTQ4NjE_676db253-8f64-4baa-9d1e-edcab4bf7904" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">927</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i39cc63e230cf425a936cad5d0717822e_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfOS00LTEtMS02MTQ4NjE_e75c0113-6a75-4750-81c2-6b2b7dac0f8a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i9ec58cfb00e34e75a2f3d433e6cdfb11_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfOS02LTEtMS02MTQ4NjE_0296acbf-3948-4769-8fc5-128207ef62bc" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">927</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i9c65e147ec6e4bc69f19a1a7d0e3a7d0_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfOS0xMC0xLTEtNjE0ODYx_67d6967c-5274-4a4d-baaf-309ea9fe734e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">1,313</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i781190e221ff4ddca6902a13f2b4dd90_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfOS0xMi0xLTEtNjE0ODYx_631329cb-1c92-4ec9-9311-b3ea43bec1d1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3432d9c7ecea4b49864e9e66b1baf99b_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfOS0xNC0xLTEtNjE0ODYx_53a8a9ff-16f9-47a6-8fe6-29d1b735191f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">1,313</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic5c5c9c817834a0caeb2a147527ed138_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTAtMi0xLTEtNjE0ODYx_f0119171-3a9a-43e9-a5de-9abefb07a040" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">1,914</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i6b21e5b5246d46ad974f05d903d8b4dd_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTAtNC0xLTEtNjE0ODYx_c999c3f9-e3b2-4879-9924-3f9d5c22c3ab" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="id0a87850f2aa405a9345270e91d26958_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTAtNi0xLTEtNjE0ODYx_12ffff68-934d-47b4-8745-050532e1f6b5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">1,914</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i7b9719f9edd849cdab5ecc23dd4e7c9f_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTAtMTAtMS0xLTYxNDg2MQ_915dd2b6-04a4-4264-b51f-ca163c60cf3e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">1,514</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i769dc7c8abe042c3a951e960a1ddac25_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTAtMTItMS0xLTYxNDg2MQ_74eacd46-406f-4853-851d-3c3f4a9865aa" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="idce6ccc9da564c1992278f6a300ad0d7_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTAtMTQtMS0xLTYxNDg2MQ_1b9a4d21-1593-47e5-8078-281f2ffd3f04" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">1,514</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="icc2ce490fbee48ea9689f31c8a73d04d_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTEtMi0xLTEtNjE0ODYx_a6106e60-794f-4b9c-a382-425795b5b123" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">16,118</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2e8357c0f19e454599d090ded0557281_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTEtNC0xLTEtNjE0ODYx_ab1e85ac-efe7-44c8-9c48-577aec90d743" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ife57ae03c0fe4843ac1b83037b5ff4ac_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTEtNi0xLTEtNjE0ODYx_e897c505-070c-4fa9-b0a3-29d120c9d7c1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">16,118</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i864fc4705f944124b1eba4d1de555e08_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTEtMTAtMS0xLTYxNDg2MQ_e981734e-21b0-4a10-adeb-a60b8dbc000a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">18,743</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i0f55508de5fb4336952f9147cbc6c137_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTEtMTItMS0xLTYxNDg2MQ_542bf84e-1f0b-4e1e-ab6b-36368fa49c97" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2132291dc8354e1499b96bcef2a202d9_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTEtMTQtMS0xLTYxNDg2MQ_43bca67d-2d52-4263-b9f1-1d10a3c867aa" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">18,743</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="icc2ce490fbee48ea9689f31c8a73d04d_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTItMi0xLTEtNjE0ODYx_47c4d762-8a86-4d58-a43b-d86ed75ea615" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" scale="6" unitref="usd">17,283</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2e8357c0f19e454599d090ded0557281_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTItNC0xLTEtNjE0ODYx_2ce826d5-0109-4ea2-a42d-f884cb28bd86" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ife57ae03c0fe4843ac1b83037b5ff4ac_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTItNi0xLTEtNjE0ODYx_c3b4c332-92a6-4016-8414-1ec271dde55e" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" scale="6" unitref="usd">17,283</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i864fc4705f944124b1eba4d1de555e08_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTItMTAtMS0xLTYxNDg2MQ_012876d4-83d5-4811-a9e6-1d25869ea947" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" scale="6" unitref="usd">20,331</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i0f55508de5fb4336952f9147cbc6c137_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTItMTItMS0xLTYxNDg2MQ_a948e8f7-2739-4f91-872a-70b3762f6143" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2132291dc8354e1499b96bcef2a202d9_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTItMTQtMS0xLTYxNDg2MQ_15520b68-2b4f-40e8-b572-d863878c26fb" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" scale="6" unitref="usd">20,331</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib8d699dfc3fa4866b42a913ae8c98024_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTYtMi0xLTEtNjE0ODYx_559c1aea-f78e-4dbd-8dd6-75ed3e680de2" name="us-gaap:DerivativeAssetsCurrent" scale="6" unitref="usd">734</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i22b956d13b1545e08061dca9e2ca06fc_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTYtNC0xLTEtNjE0ODYx_db5ae4cc-9091-4b85-9552-d9a178f2fcf1" name="us-gaap:DerivativeAssetsCurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i29046713fe024bafabb44075d5d8584e_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTYtNi0xLTEtNjE0ODYx_d017b206-f15f-481f-af8c-31db70ef5b2d" name="us-gaap:DerivativeAssetsCurrent" scale="6" unitref="usd">734</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5fa43fc6fd3944da9bb513aabe0ab04a_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTYtMTAtMS0xLTYxNDg2MQ_cce03482-581b-4227-a4fe-2b0661d94160" name="us-gaap:DerivativeAssetsCurrent" scale="6" unitref="usd">714</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i10f14a77c0704f2b947c0c286d7b7d6a_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTYtMTItMS0xLTYxNDg2MQ_212a8de7-0fa5-4cf9-a45c-c9dca0e02e08" name="us-gaap:DerivativeAssetsCurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i401894b5618f4f6ab973ca8531f20c67_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTYtMTQtMS0xLTYxNDg2MQ_2de9cdb3-1006-4139-b8b4-6713a4951850" name="us-gaap:DerivativeAssetsCurrent" scale="6" unitref="usd">714</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibf663226f0a44897b1344e21006095e5_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTctMi0xLTEtNjE0ODYx_17f3ff1d-9ecd-4421-9e3e-37161ffbf38c" name="us-gaap:DerivativeAssetsCurrent" scale="6" unitref="usd">734</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic908d1a89ce64f1b861fa9f902325473_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTctNC0xLTEtNjE0ODYx_33782cc9-250e-4dfb-8e0d-1a21b17c6acc" name="us-gaap:DerivativeAssetsCurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i99f5dba2972b401f92b964ce16601abf_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTctNi0xLTEtNjE0ODYx_e248eaa6-c122-43ae-9daf-0ca14c04591c" name="us-gaap:DerivativeAssetsCurrent" scale="6" unitref="usd">734</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2cb751f97e434348994191a1a74967f5_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTctMTAtMS0xLTYxNDg2MQ_e0b99bd7-e8f7-4ceb-aacf-4837eeddc6c0" name="us-gaap:DerivativeAssetsCurrent" scale="6" unitref="usd">714</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib9855a29ecb747f19d2f9ab60bade6d4_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTctMTItMS0xLTYxNDg2MQ_7c24dc44-0275-4a0a-9242-04ed659877b1" name="us-gaap:DerivativeAssetsCurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if7062657ec9f48e7bdf45c670efa169a_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTctMTQtMS0xLTYxNDg2MQ_515396e7-bf35-41b9-bb7e-20c9e7d0aa46" name="us-gaap:DerivativeAssetsCurrent" scale="6" unitref="usd">714</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="iee604dbe45724d1db52a74f05df5081a_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTktMi0xLTEtNjE0ODYx_bf788760-7ed8-49d4-94d6-2d31663b2f0c" name="us-gaap:EquitySecuritiesFvNi" scale="6" unitref="usd">2,355</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5f8561ec5412432c9b16babf091d4a61_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTktNC0xLTEtNjE0ODYx_c08bce5b-b428-40c6-ade7-487a332e582b" name="us-gaap:EquitySecuritiesFvNi" scale="6" unitref="usd">2,348</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i1753a6ccbf134ef8a340a2a0b5cfc10a_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTktNi0xLTEtNjE0ODYx_c3b3d2c8-43fb-440f-b79e-be249a9df1ff" name="us-gaap:EquitySecuritiesFvNi" scale="6" unitref="usd">7</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic733693e0d044ad1803f32b2cb02dc78_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTktMTAtMS0xLTYxNDg2MQ_e4706c19-63e6-4c1e-9ef4-3c85fa2c2801" name="us-gaap:EquitySecuritiesFvNi" scale="6" unitref="usd">2,836</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i02e9eee4872f4799a567067b60388073_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTktMTItMS0xLTYxNDg2MQ_223882dd-a16b-4d30-b4f4-94fcf4f33db1" name="us-gaap:EquitySecuritiesFvNi" scale="6" unitref="usd">2,823</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibc606e152567469cbd54e263cb16cb8a_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMTktMTQtMS0xLTYxNDg2MQ_5293cd7c-7372-4e6e-b5a7-00a2cda862ba" name="us-gaap:EquitySecuritiesFvNi" scale="6" unitref="usd">13</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="iff5c651c676441a88c310767e186683b_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjItMi0xLTEtNjE0ODYx_24629225-c546-4755-8a0f-2c8502c58525" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">261</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i250d6371ddb146ebb7dbbf6cf6cf8160_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjItNC0xLTEtNjE0ODYx_28f8213a-6648-4c31-81db-9f6a6fcabf43" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="icd249c12adde4a8aaa7404e5f28b3010_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjItNi0xLTEtNjE0ODYx_41a4b2aa-00b0-4cbe-8050-f3ac92189692" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">261</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if44d68b42d9b45c382f432e3bf32a000_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjItMTAtMS0xLTYxNDg2MQ_e858a4c8-daae-4529-9da6-a18e7104779d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">280</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="iecee9657c34c499c965713cb427a1768_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjItMTItMS0xLTYxNDg2MQ_1aec62b4-2f72-4c58-a972-2c36cccdc6d5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ia7b5afc63cf549c9b1c787dcac9721bd_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjItMTQtMS0xLTYxNDg2MQ_cd79c5c9-49d5-4d5e-b870-f1e4c0146599" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">280</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i7e49e53cba5241169d36b0f20e4d6aae_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjQtMi0xLTEtNjE0ODYx_6796521e-7fe7-48b0-baf8-ec00fc8a055d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">72</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic5dffd587e3f4f62bc262afbb7d2d350_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjQtNC0xLTEtNjE0ODYx_3f735ade-4222-4aee-b6b5-2f26bef2f66f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i4bf89d5536d346ca9712c32543b25fda_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjQtNi0xLTEtNjE0ODYx_31126d4d-05d0-447e-a9b4-192ea82e8d45" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">72</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="iae0be8ee2cae44f2889e654da82c15af_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjQtMTAtMS0xLTYxNDg2MQ_3170a57e-8bca-4667-9b36-1cfc1a5f82e4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">72</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i09cab9a4f13d4d5aae7fba72a9f1b74a_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjQtMTItMS0xLTYxNDg2MQ_2a978b7a-6502-4a9c-a084-1b8fc5294a39" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i63d5f34336a2433fbae846b80449195e_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjQtMTQtMS0xLTYxNDg2MQ_07fa0a92-52a0-4c77-b635-fe1aa96b2caf" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">72</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="iee604dbe45724d1db52a74f05df5081a_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjUtMi0xLTEtNjE0ODYx_22690185-5056-4a40-bb9a-aa9d0e3918e9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">333</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5f8561ec5412432c9b16babf091d4a61_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjUtNC0xLTEtNjE0ODYx_5e337f36-073e-4bb1-8a66-14caa5448ac1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i1753a6ccbf134ef8a340a2a0b5cfc10a_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjUtNi0xLTEtNjE0ODYx_833dbe57-f867-44a4-8258-4092247fdcb7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">333</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic733693e0d044ad1803f32b2cb02dc78_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjUtMTAtMS0xLTYxNDg2MQ_00b7e85e-5aae-41b2-882a-dc5bddf2664a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">352</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i02e9eee4872f4799a567067b60388073_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjUtMTItMS0xLTYxNDg2MQ_af287b50-bcbd-4779-b259-6a89505f017b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibc606e152567469cbd54e263cb16cb8a_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjUtMTQtMS0xLTYxNDg2MQ_051e63c0-86a2-4738-a80d-b5c70414aaf1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">352</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="iee604dbe45724d1db52a74f05df5081a_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjYtMi0xLTEtNjE0ODYx_c8960f9b-aa80-410a-a2d6-5e3bfe52d497" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" unitref="usd">2,688</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5f8561ec5412432c9b16babf091d4a61_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjYtNC0xLTEtNjE0ODYx_306557c2-d136-4140-991e-89b27f1ec993" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" unitref="usd">2,348</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i1753a6ccbf134ef8a340a2a0b5cfc10a_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjYtNi0xLTEtNjE0ODYx_e4de18dd-5d17-4768-85ad-dd7b888888e2" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" unitref="usd">340</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic733693e0d044ad1803f32b2cb02dc78_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjYtMTAtMS0xLTYxNDg2MQ_5d788423-3462-4067-a25e-496eb7dbd40f" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" unitref="usd">3,188</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i02e9eee4872f4799a567067b60388073_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjYtMTItMS0xLTYxNDg2MQ_01f86a5f-a058-4f94-b769-c37e5fad70ac" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" unitref="usd">2,823</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibc606e152567469cbd54e263cb16cb8a_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMjYtMTQtMS0xLTYxNDg2MQ_88814ef6-540e-44c4-b977-5f8d58a9473b" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" unitref="usd">365</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib8d699dfc3fa4866b42a913ae8c98024_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzAtMi0xLTEtNjE0ODYx_8d8412c8-dd4e-44b6-96c3-1ab1b0543055" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" unitref="usd">295</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i22b956d13b1545e08061dca9e2ca06fc_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzAtNC0xLTEtNjE0ODYx_6a98cc3c-be04-46f8-92b6-a748601614b9" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i29046713fe024bafabb44075d5d8584e_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzAtNi0xLTEtNjE0ODYx_b2df5b11-4c46-4958-a88d-09f0fdb5b5c2" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" unitref="usd">295</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5fa43fc6fd3944da9bb513aabe0ab04a_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzAtMTAtMS0xLTYxNDg2MQ_6385090a-7cee-4404-8c95-eb8d8660910e" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" unitref="usd">364</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i10f14a77c0704f2b947c0c286d7b7d6a_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzAtMTItMS0xLTYxNDg2MQ_cf6f6f11-6bc7-4f92-baa3-68d94cf70a6d" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i401894b5618f4f6ab973ca8531f20c67_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzAtMTQtMS0xLTYxNDg2MQ_f2fd84a3-1b1a-4033-bb0f-8eb0d20c2270" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" unitref="usd">364</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibf663226f0a44897b1344e21006095e5_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzEtMi0xLTEtNjE0ODYx_0fc5db07-2ef3-433f-b0e9-2acef8debe1c" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" unitref="usd">295</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic908d1a89ce64f1b861fa9f902325473_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzEtNC0xLTEtNjE0ODYx_c60f73ac-4463-43ec-92b6-3b483f4e011f" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i99f5dba2972b401f92b964ce16601abf_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzEtNi0xLTEtNjE0ODYx_9a032b6f-5c63-4760-afb4-cbb4bd9a696a" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" unitref="usd">295</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2cb751f97e434348994191a1a74967f5_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzEtMTAtMS0xLTYxNDg2MQ_75dc386f-8e84-4719-8726-adb67e492e24" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" unitref="usd">364</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib9855a29ecb747f19d2f9ab60bade6d4_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzEtMTItMS0xLTYxNDg2MQ_23777bdb-c9a0-4676-a6d8-7f5c169a773e" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if7062657ec9f48e7bdf45c670efa169a_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzEtMTQtMS0xLTYxNDg2MQ_28f73c0d-7f70-4371-a785-6516e2d70d0f" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" unitref="usd">364</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibf663226f0a44897b1344e21006095e5_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzItMi0xLTEtNjE0ODYx_e7144219-f532-4fe1-a5f1-0a735a93e22e" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" unitref="usd">700</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic908d1a89ce64f1b861fa9f902325473_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzItNC0xLTEtNjE0ODYx_27cfcffd-100a-4164-9c75-78b554f05b32" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i99f5dba2972b401f92b964ce16601abf_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzItNi0xLTEtNjE0ODYx_ccf9adcc-49b1-4994-93e3-e975b8ca3f69" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" unitref="usd">700</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2cb751f97e434348994191a1a74967f5_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzItMTAtMS0xLTYxNDg2MQ_bf8ba0b9-03c3-4839-b14a-f6b46b91624a" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" unitref="usd">665</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib9855a29ecb747f19d2f9ab60bade6d4_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzItMTItMS0xLTYxNDg2MQ_1056f8bc-8734-40a1-bb0c-841d9fc0c01f" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if7062657ec9f48e7bdf45c670efa169a_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzItMTQtMS0xLTYxNDg2MQ_463034d2-cf1b-4e47-92cb-5912cfa0e763" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" unitref="usd">665</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibf663226f0a44897b1344e21006095e5_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzMtMi0xLTEtNjE0ODYx_5866e304-8f1e-493e-ad2b-cbc86011a4dc" name="us-gaap:OtherAssetsNoncurrent" scale="6" unitref="usd">995</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic908d1a89ce64f1b861fa9f902325473_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzMtNC0xLTEtNjE0ODYx_44c317ec-9b0b-4e35-a715-990dacdff23f" name="us-gaap:OtherAssetsNoncurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i99f5dba2972b401f92b964ce16601abf_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzMtNi0xLTEtNjE0ODYx_7b1d16be-b300-4182-b46f-a85eb16f2ac8" name="us-gaap:OtherAssetsNoncurrent" scale="6" unitref="usd">995</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2cb751f97e434348994191a1a74967f5_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzMtMTAtMS0xLTYxNDg2MQ_c17b1711-60b1-4e02-aefa-82555da74910" name="us-gaap:OtherAssetsNoncurrent" scale="6" unitref="usd">1,028</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib9855a29ecb747f19d2f9ab60bade6d4_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzMtMTItMS0xLTYxNDg2MQ_265fe74f-46cc-43df-b9af-e60f03b014d6" name="us-gaap:OtherAssetsNoncurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if7062657ec9f48e7bdf45c670efa169a_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzMtMTQtMS0xLTYxNDg2MQ_8d95bc78-7375-4550-8652-68a822e92264" name="us-gaap:OtherAssetsNoncurrent" scale="6" unitref="usd">1,028</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibf663226f0a44897b1344e21006095e5_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzQtMi0xLTEtNjE0ODYx_37d38f42-1767-48c4-b575-21e7eb3b4a58" name="us-gaap:Assets" scale="6" unitref="usd">21,699</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic908d1a89ce64f1b861fa9f902325473_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzQtNC0xLTEtNjE0ODYx_76ca51dd-c42c-4ec0-ae82-68a63fbf1780" name="us-gaap:Assets" scale="6" unitref="usd">2,348</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i99f5dba2972b401f92b964ce16601abf_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzQtNi0xLTEtNjE0ODYx_be987e98-66cd-40dd-8041-8757ee03ba81" name="us-gaap:Assets" scale="6" unitref="usd">19,352</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2cb751f97e434348994191a1a74967f5_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzQtMTAtMS0xLTYxNDg2MQ_97e536dd-5b3d-4d40-9fc8-99a38907cbc7" name="us-gaap:Assets" scale="6" unitref="usd">25,261</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib9855a29ecb747f19d2f9ab60bade6d4_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzQtMTItMS0xLTYxNDg2MQ_0243b0d5-6b7e-4c1b-a557-907ea88f7741" name="us-gaap:Assets" scale="6" unitref="usd">2,823</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if7062657ec9f48e7bdf45c670efa169a_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzQtMTQtMS0xLTYxNDg2MQ_7f15b2e3-05a0-4e0b-9658-bc37915a1b38" name="us-gaap:Assets" scale="6" unitref="usd">22,439</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ie99ba1cb8cad4c95aba0f37d9954899c_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzktMi0xLTEtNjE0ODYx_af851fe1-f0c0-4d3b-ab1d-56b4667b0afe" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i1257fd1c5a9a4af5a4cefa2e7aeff2de_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzktNC0xLTEtNjE0ODYx_70c55f8f-ce9c-4fe4-a1e7-d0f5b1943dac" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i368fb3b063904d93ac238f87f334805f_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzktNi0xLTEtNjE0ODYx_d403ff8b-e7ee-4534-9de1-f74aefaa7f8f" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib881931063d349bd8f09ed1011114106_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzktMTAtMS0xLTYxNDg2MQ_7e998bc3-5d94-42e6-90d2-c632d808d623" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" unitref="usd">10</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if1e7f5ee536f4910b00145c02b95b137_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzktMTItMS0xLTYxNDg2MQ_ad58ee55-efc1-4dd7-b09c-d05a4a39952a" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5935b162be79465ab3653c973b48c873_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfMzktMTQtMS0xLTYxNDg2MQ_817727c5-1ead-4d89-9ec3-4806aef3aeb4" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" unitref="usd">10</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib8d699dfc3fa4866b42a913ae8c98024_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDAtMi0xLTEtNjE0ODYx_6fa36a7c-d691-4094-a2be-dcad22c31960" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" unitref="usd">382</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i22b956d13b1545e08061dca9e2ca06fc_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDAtNC0xLTEtNjE0ODYx_1509df7b-1c55-4d92-a420-80dc8dd0918b" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i29046713fe024bafabb44075d5d8584e_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDAtNi0xLTEtNjE0ODYx_398b1ee2-688e-426b-a302-33a299879f5f" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" unitref="usd">382</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5fa43fc6fd3944da9bb513aabe0ab04a_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDAtMTAtMS0xLTYxNDg2MQ_6166d82f-fa19-421e-b253-b718dec38025" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" unitref="usd">694</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i10f14a77c0704f2b947c0c286d7b7d6a_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDAtMTItMS0xLTYxNDg2MQ_630ae426-d826-4870-bd2f-12a48c920aef" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i401894b5618f4f6ab973ca8531f20c67_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDAtMTQtMS0xLTYxNDg2MQ_18324cde-b220-467e-b4fc-f05bb41fd5a0" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" unitref="usd">694</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibf663226f0a44897b1344e21006095e5_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDEtMi0xLTEtNjE0ODYx_623872e0-bbe6-426f-8e1c-4ffb237bb2d2" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" unitref="usd">383</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic908d1a89ce64f1b861fa9f902325473_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDEtNC0xLTEtNjE0ODYx_e698395b-df32-4491-b903-7f4ab69bbb46" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i99f5dba2972b401f92b964ce16601abf_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDEtNi0xLTEtNjE0ODYx_20f16423-969b-4fec-8ccd-3b46605eb1a9" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" unitref="usd">383</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2cb751f97e434348994191a1a74967f5_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDEtMTAtMS0xLTYxNDg2MQ_56fa9afd-c407-49f5-8e94-93fe08c02f9a" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" unitref="usd">704</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib9855a29ecb747f19d2f9ab60bade6d4_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDEtMTItMS0xLTYxNDg2MQ_a20471f5-c1b7-4514-af8b-35377d0998a5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if7062657ec9f48e7bdf45c670efa169a_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDEtMTQtMS0xLTYxNDg2MQ_55e8fe77-9398-48e4-b88f-836fb56da3f8" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" unitref="usd">704</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ie99ba1cb8cad4c95aba0f37d9954899c_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDQtMi0xLTEtNjE0ODYx_26793e50-85bc-4ba9-b1c3-c83bba190fba" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" unitref="usd">274</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i1257fd1c5a9a4af5a4cefa2e7aeff2de_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDQtNC0xLTEtNjE0ODYx_371e9eb6-29b4-44e4-a30b-f97409548325" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i368fb3b063904d93ac238f87f334805f_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDQtNi0xLTEtNjE0ODYx_28bb37ea-b0af-4297-b986-d220f9c8c3d9" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" unitref="usd">274</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib881931063d349bd8f09ed1011114106_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDQtMTAtMS0xLTYxNDg2MQ_b415be6a-c9dd-423f-ad6b-2076bb8b79e6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" unitref="usd">321</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if1e7f5ee536f4910b00145c02b95b137_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDQtMTItMS0xLTYxNDg2MQ_20d07048-1053-4237-af01-92b185ec7743" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5935b162be79465ab3653c973b48c873_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDQtMTQtMS0xLTYxNDg2MQ_ec57af5a-1c1f-4e1b-876d-5a5674b52d1c" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" unitref="usd">321</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib8d699dfc3fa4866b42a913ae8c98024_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDUtMi0xLTEtNjE0ODYx_c469d5e7-ec2f-4f68-8247-9ca6e775d9db" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" unitref="usd">832</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i22b956d13b1545e08061dca9e2ca06fc_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDUtNC0xLTEtNjE0ODYx_d73ab0b2-647f-4fcb-b8cf-a21a919e7f6c" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i29046713fe024bafabb44075d5d8584e_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDUtNi0xLTEtNjE0ODYx_4be919d7-2a4f-464f-ba0c-569e8b68e3a6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" unitref="usd">832</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5fa43fc6fd3944da9bb513aabe0ab04a_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDUtMTAtMS0xLTYxNDg2MQ_7b4d96e0-82a3-418b-ad8b-077591cd4715" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" unitref="usd">864</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i10f14a77c0704f2b947c0c286d7b7d6a_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDUtMTItMS0xLTYxNDg2MQ_5854c845-c529-4cc4-9e02-fc3bf1fd1dff" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i401894b5618f4f6ab973ca8531f20c67_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDUtMTQtMS0xLTYxNDg2MQ_d46b5d63-a28a-48f4-a364-540bf52f65bb" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" unitref="usd">864</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibf663226f0a44897b1344e21006095e5_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDYtMi0xLTEtNjE0ODYx_bd26bd08-c010-4b5d-9135-1ed5220e1dcf" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" unitref="usd">1,105</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic908d1a89ce64f1b861fa9f902325473_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDYtNC0xLTEtNjE0ODYx_c7d7c5a2-d08d-4f51-b7a8-13e5d79d81fe" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i99f5dba2972b401f92b964ce16601abf_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDYtNi0xLTEtNjE0ODYx_3a16fcb2-4e37-429f-a729-c7ba3f351bf7" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" unitref="usd">1,105</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2cb751f97e434348994191a1a74967f5_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDYtMTAtMS0xLTYxNDg2MQ_3debf09a-1141-4add-8d00-666c2d987af6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" unitref="usd">1,185</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib9855a29ecb747f19d2f9ab60bade6d4_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDYtMTItMS0xLTYxNDg2MQ_e766bd7c-93f5-4d54-a5af-0841b8b1785f" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if7062657ec9f48e7bdf45c670efa169a_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDYtMTQtMS0xLTYxNDg2MQ_4b4fe2fd-1079-4f24-9b3b-4c9e4275c8db" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" unitref="usd">1,185</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibf663226f0a44897b1344e21006095e5_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDctMi0xLTEtNjE0ODYx_ff94a7bb-f01b-4e18-86ee-daf235732492" name="us-gaap:DerivativeLiabilities" scale="6" unitref="usd">1,488</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic908d1a89ce64f1b861fa9f902325473_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDctNC0xLTEtNjE0ODYx_af916178-03d8-4d06-8d16-127e103b6c91" name="us-gaap:DerivativeLiabilities" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i99f5dba2972b401f92b964ce16601abf_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDctNi0xLTEtNjE0ODYx_123d8349-a735-4a10-bfcc-eb5cc3ab23be" name="us-gaap:DerivativeLiabilities" scale="6" unitref="usd">1,488</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2cb751f97e434348994191a1a74967f5_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDctMTAtMS0xLTYxNDg2MQ_c240ccd7-a956-4d7b-805c-58c4ff1b4c59" name="us-gaap:DerivativeLiabilities" scale="6" unitref="usd">1,889</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib9855a29ecb747f19d2f9ab60bade6d4_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDctMTItMS0xLTYxNDg2MQ_79435b31-bd48-4a59-8a25-b295cc3e05cf" name="us-gaap:DerivativeLiabilities" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if7062657ec9f48e7bdf45c670efa169a_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RhYmxlOjU2OTg2ZDM0MDEwNjQ0NDM4NTFmNWRiNGQxMmJjZWU0L3RhYmxlcmFuZ2U6NTY5ODZkMzQwMTA2NDQ0Mzg1MWY1ZGI0ZDEyYmNlZTRfNDctMTQtMS0xLTYxNDg2MQ_96e2fd34-8669-4786-a81e-af219680e673" name="us-gaap:DerivativeLiabilities" scale="6" unitref="usd">1,889</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RleHRyZWdpb246MTFmODYyMjlhOWU4NDU5YTljZGYzYjA1NzBlNzExNTJfMTQyOA_80a64ba7-2b8b-4227-beed-1f65939adbf9">Long-term equity securities of $<ix:nonfraction contextref="ibf663226f0a44897b1344e21006095e5_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RleHRyZWdpb246MTFmODYyMjlhOWU4NDU5YTljZGYzYjA1NzBlNzExNTJfMjA2_f16a4937-22f0-4db7-bfac-e381af09a522" name="pfe:EquitySecuritiesFVNIRestrictedNoncurrent" scale="6" unitref="usd">115</ix:nonfraction> million as of April&#160;2, 2023 and $<ix:nonfraction contextref="i2cb751f97e434348994191a1a74967f5_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RleHRyZWdpb246MTFmODYyMjlhOWU4NDU5YTljZGYzYjA1NzBlNzExNTJfMjIy_7f668e2c-d666-4ace-910a-ae0b7a5506af" name="pfe:EquitySecuritiesFVNIRestrictedNoncurrent" scale="6" unitref="usd">143</ix:nonfraction> million as of December 31, 2022 were held in restricted trusts for U.S. non-qualified employee benefit plans.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RleHRyZWdpb246MTFmODYyMjlhOWU4NDU5YTljZGYzYjA1NzBlNzExNTJfMTQyOQ_54ac50eb-a8ed-42d5-84c6-47d282c148e7"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_49" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></ix:footnote></div></ix:nonnumeric><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of Long-term debt, excluding the current portion was $<ix:nonfraction contextref="ie24fac8d934c453db027f78b65a6fae1_I20230402" decimals="-9" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RleHRyZWdpb246MTFmODYyMjlhOWU4NDU5YTljZGYzYjA1NzBlNzExNTJfNzY3_a6145eaf-21f2-4ca6-a93a-cf0255d41c37" name="us-gaap:LongTermDebtFairValue" scale="9" unitref="usd">32</ix:nonfraction>&#160;billion as of April&#160;2, 2023 and $<ix:nonfraction contextref="ibd0cba878a1d480aa706fed19765b8b2_I20221231" decimals="-9" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RleHRyZWdpb246MTFmODYyMjlhOWU4NDU5YTljZGYzYjA1NzBlNzExNTJfNzgz_234a6d3a-43fe-4416-9153-5d2b9adb5d4f" name="us-gaap:LongTermDebtFairValue" scale="9" unitref="usd">33</ix:nonfraction>&#160;billion as of December 31, 2022. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $<ix:nonfraction contextref="i1c67bdd88afa47bc9af801dd825ae9f3_I20230402" decimals="-9" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RleHRyZWdpb246MTFmODYyMjlhOWU4NDU5YTljZGYzYjA1NzBlNzExNTJfODgz_e5a3a29b-d270-46d5-b303-4fa9d15d1e28" name="us-gaap:LongTermDebtFairValue" scale="9" unitref="usd">30</ix:nonfraction>&#160;billion as of April&#160;2, 2023 and $<ix:nonfraction contextref="i21bbff20f21e4991bc76884f8ea69d2c_I20221231" decimals="-9" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl81OC9mcmFnOjExZjg2MjI5YTllODQ1OWE5Y2RmM2IwNTcwZTcxMTUyL3RleHRyZWdpb246MTFmODYyMjlhOWU4NDU5YTljZGYzYjA1NzBlNzExNTJfODk5_c96b0a35-9ac6-4c89-b54c-b6e756a11454" name="us-gaap:LongTermDebtFairValue" scale="9" unitref="usd">30</ix:nonfraction>&#160;billion as of December 31, 2022.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation continuedat="id0650623a0734fb4948089f8d5697a84" id="if1f00a109af641e498bf2537fe3e796a">as of April&#160;2, 2023 and December 31, 2022. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.</ix:continuation></span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_61"></div><ix:continuation continuedat="i4c732f31f7c84937b4bbc43796b71420" id="id0650623a0734fb4948089f8d5697a84"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Investments</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Short-Term, Long-Term and Equity-Method Investments</span></div><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RleHRyZWdpb246OWRhNzRiYWEyNzY4NGY0ZGFkZDFlZDFmNzFiMGJhOGNfNzUz_114c2dc7-a982-471c-b8c4-aa0c63a29f2a" name="us-gaap:MarketableSecuritiesTextBlock"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:62.764%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.863%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes our investments by classification type:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfMy0yLTEtMS02MTQ4NjE_71da4ebb-e127-4b2f-83ef-b026fb7f8edb" name="us-gaap:EquitySecuritiesFvNi" scale="6" unitref="usd">1,165</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfMy00LTEtMS02MTQ4NjE_c86ecbd9-3f43-4949-bfb6-cb604d9e0537" name="us-gaap:EquitySecuritiesFvNi" scale="6" unitref="usd">1,588</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfNC0yLTEtMS02MTQ4NjE_b6b17ad1-d543-40b7-874e-59cf5ac4aa91" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" unitref="usd">16,118</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfNC00LTEtMS02MTQ4NjE_4f52b293-580e-408a-8e49-0f5c498075ba" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" unitref="usd">18,743</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfNS0yLTEtMS02MTQ4NjE_215d46d6-80b3-4369-a8ce-c2281e5f70f6" name="us-gaap:HeldToMaturitySecuritiesCurrent" scale="6" unitref="usd">523</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfNS00LTEtMS02MTQ4NjE_414abd52-e149-4b66-a7bd-e63efc6a948c" name="us-gaap:HeldToMaturitySecuritiesCurrent" scale="6" unitref="usd">1,985</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfNi0yLTEtMS02MTQ4NjE_e3296a8f-01a2-4b4c-a7df-afb503813fc4" name="us-gaap:OtherShortTermInvestments" scale="6" unitref="usd">17,806</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfNi00LTEtMS02MTQ4NjE_f8cdd41f-fe56-4ac1-a381-9162f223aec5" name="us-gaap:OtherShortTermInvestments" scale="6" unitref="usd">22,316</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfOS0yLTEtMS02MTQ4NjE_ce9a34d6-3535-4e9c-93fc-4c67de4a58b1" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" unitref="usd">2,355</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfOS00LTEtMS02MTQ4NjE_c9fb49fe-5389-41a1-a986-68232a54123d" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" unitref="usd">2,836</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfMTEtMi0xLTEtNjE0ODYx_d16726b0-de75-487d-82ab-2945420926ce" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" unitref="usd">333</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfMTEtNC0xLTEtNjE0ODYx_9928f4c1-5cd0-4366-b1c6-c303cedb3fa5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" unitref="usd">352</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfMTItMi0xLTEtNjE0ODYx_e1760ffc-9b61-486d-82d7-c6b044c40229" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" scale="6" unitref="usd">52</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfMTItNC0xLTEtNjE0ODYx_6ab64ea6-5b7d-44e2-a561-829b843ab84e" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" scale="6" unitref="usd">48</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities at cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfMTMtMi0xLTEtNjE0ODYx_8fa5bca7-2625-41f2-9347-65756e50828b" name="pfe:PrivateEquityInvestments" scale="6" unitref="usd">828</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfMTMtNC0xLTEtNjE0ODYx_fde68610-8f64-424d-b946-0f458b1052ff" name="pfe:PrivateEquityInvestments" scale="6" unitref="usd">800</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfMTQtMi0xLTEtNjE0ODYx_a2945c46-c7c0-45f2-8e3a-5463502d2353" name="us-gaap:OtherLongTermInvestments" scale="6" unitref="usd">3,568</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfMTQtNC0xLTEtNjE0ODYx_201ab75a-1f18-491e-9b96-1b0ce6f0aa69" name="us-gaap:OtherLongTermInvestments" scale="6" unitref="usd">4,036</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Equity-method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfMTUtMi0xLTEtNjE0ODYx_e17892db-f174-4249-872b-d179c59f7e95" name="us-gaap:EquityMethodInvestments" scale="6" unitref="usd">11,175</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfMTUtNC0xLTEtNjE0ODYx_f05d7daa-e3a2-40ae-99da-166a9377f8bb" name="us-gaap:EquityMethodInvestments" scale="6" unitref="usd">11,033</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term investments and equity-method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfMTYtMi0xLTEtNjE0ODYx_fe966e9e-39f3-4588-a1a2-4908c1b85501" name="us-gaap:LongTermInvestments" scale="6" unitref="usd">14,743</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfMTYtNC0xLTEtNjE0ODYx_6e025e21-347c-4753-bb27-a7574b74a99d" name="us-gaap:LongTermInvestments" scale="6" unitref="usd">15,069</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity cash equivalents</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfMTctMi0xLTEtNjE0ODYx_3966853a-d7c3-4f5a-a079-ebcb88c4d415" name="pfe:HeldToMaturityCashEquivalents" scale="6" unitref="usd">436</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjQzOWMxYmI5OTIzZTRhMjRiMGM1OGI4OTBkMDYxM2FjL3RhYmxlcmFuZ2U6NDM5YzFiYjk5MjNlNGEyNGIwYzU4Yjg5MGQwNjEzYWNfMTctNC0xLTEtNjE0ODYx_4779e6e8-d7d3-4093-9515-07f53102d93c" name="pfe:HeldToMaturityCashEquivalents" scale="6" unitref="usd">679</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RleHRyZWdpb246OWRhNzRiYWEyNzY4NGY0ZGFkZDFlZDFmNzFiMGJhOGNfNzYx_86f4fb24-9db2-4bfc-8b48-ba2809aa32c3">Includes money market funds primarily invested in U.S. Treasury and government debt.</ix:footnote> </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RleHRyZWdpb246OWRhNzRiYWEyNzY4NGY0ZGFkZDFlZDFmNzFiMGJhOGNfNzUw_7293320e-c8f8-4781-9a72-d8d2a28cdcc3">Represent investments in the life sciences sector</ix:footnote>.</span></div></ix:nonnumeric><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities</span></div><div style="margin-bottom:5pt;margin-top:3pt"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RleHRyZWdpb246OWRhNzRiYWEyNzY4NGY0ZGFkZDFlZDFmNzFiMGJhOGNfNzUx_9c2ec4a7-dcc2-4dd4-a15a-e7049458a38d" name="us-gaap:HeldToMaturitySecuritiesTextBlock"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RleHRyZWdpb246OWRhNzRiYWEyNzY4NGY0ZGFkZDFlZDFmNzFiMGJhOGNfNzYy_301d289e-aa14-4e9a-a32b-4de204e27e24" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RleHRyZWdpb246OWRhNzRiYWEyNzY4NGY0ZGFkZDFlZDFmNzFiMGJhOGNfNzc3_7b50b04b-f53c-448e-877e-5c382963b96b" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:23.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.920%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.920%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Contractual or Estimated Maturities (in Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Within 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 1<br/>to 5</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 5</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i210c72d001c34f5b95af4b5c4d917483_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNS0yLTEtMS02MTQ4NjE_8adbacbb-f477-45b3-a706-6c75ca2e3c96" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" unitref="usd">13,702</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i210c72d001c34f5b95af4b5c4d917483_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNS00LTEtMS02MTQ4NjE_0d0e01d0-c253-4a03-9e6c-ea840fc38a11" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" unitref="usd">51</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i210c72d001c34f5b95af4b5c4d917483_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNS02LTEtMS02MTQ4NjE_db6878f3-0fcf-4112-b564-dc4500e2c828" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" unitref="usd">214</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i210c72d001c34f5b95af4b5c4d917483_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNS04LTEtMS02MTQ4NjE_ddbd7ed0-238e-47d4-b650-d9cb43039792" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">13,539</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i210c72d001c34f5b95af4b5c4d917483_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNS0xMC0xLTEtNjE0ODYx_a2cb967e-fbba-4869-8fc2-ae2d1e25067e" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" unitref="usd">13,278</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i210c72d001c34f5b95af4b5c4d917483_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNS0xMi0xLTEtNjE0ODYx_0ccaec57-5f84-4be6-8994-de630b291869" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" unitref="usd">261</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i210c72d001c34f5b95af4b5c4d917483_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNS0xNC0xLTEtNjE0ODYx_6b1b11fa-7fa0-427b-b413-fca6505d8db1" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i92ce9efcdfc14d63ab7f16c619432fba_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNS0xNy0xLTEtNjE0ODYx_a46da52e-da26-46d7-9acb-8ae87b15bcf4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" unitref="usd">15,946</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i92ce9efcdfc14d63ab7f16c619432fba_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNS0xOS0xLTEtNjE0ODYx_4ea11f69-2d22-4996-b889-dc9bd50a3218" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" unitref="usd">297</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i92ce9efcdfc14d63ab7f16c619432fba_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNS0yMS0xLTEtNjE0ODYx_4670efbd-9031-4f1f-8858-f13c20f7bdf7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" unitref="usd">48</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i92ce9efcdfc14d63ab7f16c619432fba_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNS0yMy0xLTEtNjE0ODYx_c0a176b5-2dc7-4b28-b8c0-f521bd56d427" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">16,195</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency&#8211;&#8211;U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if7344a643d1c4c50b2b6819ae77eff62_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNi0yLTEtMS02MTQ4NjE_bab03f4f-5a78-4dae-b518-b2b273d0e01e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" unitref="usd">927</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if7344a643d1c4c50b2b6819ae77eff62_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNi00LTEtMS02MTQ4NjE_8e261894-882f-4354-85af-dc9f35475191" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if7344a643d1c4c50b2b6819ae77eff62_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNi02LTEtMS02MTQ4NjE_08255839-5379-43a0-9120-c59d83d01784" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if7344a643d1c4c50b2b6819ae77eff62_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNi04LTEtMS02MTQ4NjE_b32cbf7a-d485-431f-8973-959550b4b553" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">927</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if7344a643d1c4c50b2b6819ae77eff62_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNi0xMC0xLTEtNjE0ODYx_ced977c7-ca2b-4c84-ad4e-b9382e024197" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" unitref="usd">927</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if7344a643d1c4c50b2b6819ae77eff62_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNi0xMi0xLTEtNjE0ODYx_b6635fd6-f718-4b35-8c64-b599c963df35" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if7344a643d1c4c50b2b6819ae77eff62_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNi0xNC0xLTEtNjE0ODYx_b24fc77e-4536-4782-8261-a3a2314c171d" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i574c50d8ce5d41ce9c8bb578961580ff_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNi0xNy0xLTEtNjE0ODYx_925a9be0-5db0-4c40-b067-d58d510c2ce6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" unitref="usd">1,313</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i574c50d8ce5d41ce9c8bb578961580ff_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNi0xOS0xLTEtNjE0ODYx_10df2af5-f038-44cc-a0d1-45b4882ae5a3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i574c50d8ce5d41ce9c8bb578961580ff_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNi0yMS0xLTEtNjE0ODYx_053ffe73-9690-4cb6-96cb-82f429bbe533" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i574c50d8ce5d41ce9c8bb578961580ff_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNi0yMy0xLTEtNjE0ODYx_9b00dea0-59d4-42bb-953b-aa9e0214764a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">1,313</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="idd1041c914fb4bf08a322e2bb1d57c54_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNy0yLTEtMS02MTQ4NjE_0b35d95f-062b-4f2a-b168-20fc98d05f3e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" unitref="usd">1,992</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="idd1041c914fb4bf08a322e2bb1d57c54_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNy00LTEtMS02MTQ4NjE_83c0573e-65bc-4c67-88e6-66cf88161b75" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="idd1041c914fb4bf08a322e2bb1d57c54_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNy02LTEtMS02MTQ4NjE_38bba6fc-157d-42e8-87b0-c1b58cd9a12b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" unitref="usd">7</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="idd1041c914fb4bf08a322e2bb1d57c54_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNy04LTEtMS02MTQ4NjE_9e1da111-759c-448f-8941-b9921a0480d1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">1,985</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="idd1041c914fb4bf08a322e2bb1d57c54_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNy0xMC0xLTEtNjE0ODYx_d9b873e0-d766-4638-ba88-d1926fe02e46" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" unitref="usd">1,914</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="idd1041c914fb4bf08a322e2bb1d57c54_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNy0xMi0xLTEtNjE0ODYx_616a2f24-676b-4369-9d05-295910ad19c8" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" unitref="usd">72</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="idd1041c914fb4bf08a322e2bb1d57c54_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNy0xNC0xLTEtNjE0ODYx_fc45d806-23cd-4c09-822f-8df07acb49bc" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i50eb5b5f439a4f408e8814dcd78406eb_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNy0xNy0xLTEtNjE0ODYx_8624f12d-30f8-429b-ba44-2b6ebaa3e3ad" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" unitref="usd">1,584</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i50eb5b5f439a4f408e8814dcd78406eb_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNy0xOS0xLTEtNjE0ODYx_757748cf-2879-4b73-8a6e-a2afd4f55dd9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" unitref="usd">7</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i50eb5b5f439a4f408e8814dcd78406eb_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNy0yMS0xLTEtNjE0ODYx_35e39af0-2cea-4f5b-9545-ae241d7b4f8e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" unitref="usd">4</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i50eb5b5f439a4f408e8814dcd78406eb_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfNy0yMy0xLTEtNjE0ODYx_faef5106-b75b-4c1f-b8b1-c59f8b26bd71" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" unitref="usd">1,586</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if0276ef4a58a49189a96eb0b86e12f67_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfOS0yLTEtMS02MTQ4NjE_918e3c8c-9916-42d6-92bb-9c3dda58e509" name="us-gaap:HeldToMaturitySecurities" scale="6" unitref="usd">936</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if0276ef4a58a49189a96eb0b86e12f67_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfOS00LTEtMS02MTQ4NjE_e99b4c35-6d03-4f41-ba1d-525fd7765a20" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if0276ef4a58a49189a96eb0b86e12f67_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfOS02LTEtMS02MTQ4NjE_d2410920-6e46-4c1b-9426-649e7005ffc6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if0276ef4a58a49189a96eb0b86e12f67_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfOS04LTEtMS02MTQ4NjE_7ec1c345-340d-4c2a-936f-c43da29a5539" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" unitref="usd">936</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if0276ef4a58a49189a96eb0b86e12f67_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfOS0xMC0xLTEtNjE0ODYx_b4c93cb2-c23d-4faf-b6cd-bd8a37c0ddfb" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" unitref="usd">888</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if0276ef4a58a49189a96eb0b86e12f67_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfOS0xMi0xLTEtNjE0ODYx_e01ddc4a-327d-48ea-ab0e-0169d3a4518c" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" unitref="usd">34</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if0276ef4a58a49189a96eb0b86e12f67_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfOS0xNC0xLTEtNjE0ODYx_34fbfd46-0332-4d27-9476-206c88129e1d" name="pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" unitref="usd">14</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ia718855a6cad4e90a5c1afdd2d69bcb3_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfOS0xNy0xLTEtNjE0ODYx_d2bc3882-37d3-4ec1-ab3e-d8006efb7fd5" name="us-gaap:HeldToMaturitySecurities" scale="6" unitref="usd">1,171</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ia718855a6cad4e90a5c1afdd2d69bcb3_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfOS0xOS0xLTEtNjE0ODYx_d582f613-d91d-4857-90e1-c6e53df045c4" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ia718855a6cad4e90a5c1afdd2d69bcb3_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfOS0yMS0xLTEtNjE0ODYx_40f0f368-ef17-4d06-a984-68c2284cc77b" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ia718855a6cad4e90a5c1afdd2d69bcb3_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfOS0yMy0xLTEtNjE0ODYx_7fbdddf2-6c26-4a07-821d-0c932515e99a" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" unitref="usd">1,171</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i210c72d001c34f5b95af4b5c4d917483_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTAtMi0xLTEtNjE0ODYx_ba90f369-7687-4705-9d1c-0d5402acf3b6" name="us-gaap:HeldToMaturitySecurities" scale="6" unitref="usd">75</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i210c72d001c34f5b95af4b5c4d917483_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTAtNC0xLTEtNjE0ODYx_2239fdfe-1aaf-447a-8bbe-1f1dcfd061de" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i210c72d001c34f5b95af4b5c4d917483_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTAtNi0xLTEtNjE0ODYx_dbe0b481-cc12-42fa-877d-57ebd6c0ef0e" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i210c72d001c34f5b95af4b5c4d917483_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTAtOC0xLTEtNjE0ODYx_a3de0ccb-e89b-46dd-b0b9-9fee9a4fa654" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" unitref="usd">75</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i210c72d001c34f5b95af4b5c4d917483_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTAtMTAtMS0xLTYxNDg2MQ_1139c0da-0a8a-4729-ba1d-7503f1d5612b" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" unitref="usd">71</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i210c72d001c34f5b95af4b5c4d917483_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTAtMTItMS0xLTYxNDg2MQ_270d9cc4-0bae-4dca-a047-4e5f32da1711" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" unitref="usd">3</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i210c72d001c34f5b95af4b5c4d917483_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTAtMTQtMS0xLTYxNDg2MQ_b86f48cd-5f60-4b45-b666-b5e9355961a0" name="pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" unitref="usd">1</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i92ce9efcdfc14d63ab7f16c619432fba_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTAtMTctMS0xLTYxNDg2MQ_4954171d-ce5a-446b-8e4c-7f5f9e6ec846" name="us-gaap:HeldToMaturitySecurities" scale="6" unitref="usd">1,542</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i92ce9efcdfc14d63ab7f16c619432fba_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTAtMTktMS0xLTYxNDg2MQ_1c6c4d77-35ab-4f07-94fe-ca51eaef0cc4" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i92ce9efcdfc14d63ab7f16c619432fba_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTAtMjEtMS0xLTYxNDg2MQ_90e57e9f-ee44-4bbd-bcca-7141ce6d6d8d" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i92ce9efcdfc14d63ab7f16c619432fba_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTAtMjMtMS0xLTYxNDg2MQ_c66b773a-4960-44c1-9fe8-aeb3c2d77589" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" unitref="usd">1,542</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTEtMi0xLTEtNjE0ODYx_b37ac7a6-af49-4233-bce3-e25cfdf830cb" name="pfe:DebtSecuritiesAmortizedCostBasis" scale="6" unitref="usd">17,632</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTEtNC0xLTEtNjE0ODYx_ac66e707-5512-4165-8742-6af6fe55b672" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain" scale="6" unitref="usd">51</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTEtNi0xLTEtNjE0ODYx_088fb546-1d11-4f91-8000-afbf806a98c5" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss" scale="6" unitref="usd">221</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTEtOC0xLTEtNjE0ODYx_27bd6d14-d9a9-4753-a157-7dfb88d55f39" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity" scale="6" unitref="usd">17,462</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTEtMTAtMS0xLTYxNDg2MQ_e4849684-2a1d-41e0-82de-de62ab9b787f" name="pfe:DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" scale="6" unitref="usd">17,077</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTEtMTItMS0xLTYxNDg2MQ_6dbee9c2-5c6e-40c9-881a-f9fc900470f8" name="pfe:DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" scale="6" unitref="usd">371</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTEtMTQtMS0xLTYxNDg2MQ_5f763216-2478-41ab-8208-effb725e8d4a" name="pfe:DebtSecuritiesMaturitiesAfterYearFiveFairValue" scale="6" unitref="usd">15</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTEtMTctMS0xLTYxNDg2MQ_857564a9-a9e8-4fe7-b17b-99e73feccac8" name="pfe:DebtSecuritiesAmortizedCostBasis" scale="6" unitref="usd">21,556</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTEtMTktMS0xLTYxNDg2MQ_79bb77d8-8674-4525-9f0b-e2c44418e058" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain" scale="6" unitref="usd">304</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTEtMjEtMS0xLTYxNDg2MQ_c06c07fe-884e-431a-ab5a-956003c4dc07" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss" scale="6" unitref="usd">53</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjVhOWM2ZGJmZjQ5ODQ0YjdiYWE1ODlkNjI3NjFhNmQ2L3RhYmxlcmFuZ2U6NWE5YzZkYmZmNDk4NDRiN2JhYTU4OWQ2Mjc2MWE2ZDZfMTEtMjMtMS0xLTYxNDg2MQ_38f28515-7bd1-4909-97c7-ba00ca780266" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity" scale="6" unitref="usd">21,807</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonnumeric></ix:nonnumeric></ix:nonnumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any expected credit losses to these portfolios would be immaterial to our financial statements. </span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Securities</span></div><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="i420a472350c74ab099f6554258131ddc" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RleHRyZWdpb246OWRhNzRiYWEyNzY4NGY0ZGFkZDFlZDFmNzFiMGJhOGNfNzY1_83ca6cb7-d07e-49a5-99a6-4eefec78a2c9" name="pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjNjY2EyOTE3NTdkMTQ0NzE5YjMwOTUwODk3NzVjMzgxL3RhYmxlcmFuZ2U6M2NjYTI5MTc1N2QxNDQ3MTliMzA5NTA4OTc3NWMzODFfMy02LTEtMS02MTQ4NjE_654273ab-8b37-464a-b662-33c402d32357" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" sign="-" unitref="usd">451</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjNjY2EyOTE3NTdkMTQ0NzE5YjMwOTUwODk3NzVjMzgxL3RhYmxlcmFuZ2U6M2NjYTI5MTc1N2QxNDQ3MTliMzA5NTA4OTc3NWMzODFfMy04LTEtMS02MTQ4NjE_ee57f094-43e1-4b48-a7fe-e26d4631d7de" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" sign="-" unitref="usd">699</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjNjY2EyOTE3NTdkMTQ0NzE5YjMwOTUwODk3NzVjMzgxL3RhYmxlcmFuZ2U6M2NjYTI5MTc1N2QxNDQ3MTliMzA5NTA4OTc3NWMzODFfNC02LTEtMS02MTQ4NjE_8e32eb37-5a32-4d36-822e-2e42f41f9e5e" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" unitref="usd">33</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjNjY2EyOTE3NTdkMTQ0NzE5YjMwOTUwODk3NzVjMzgxL3RhYmxlcmFuZ2U6M2NjYTI5MTc1N2QxNDQ3MTliMzA5NTA4OTc3NWMzODFfNC04LTEtMS02MTQ4NjE_9a3aa772-285a-4e8f-babc-07423758c9db" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" unitref="usd">11</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjNjY2EyOTE3NTdkMTQ0NzE5YjMwOTUwODk3NzVjMzgxL3RhYmxlcmFuZ2U6M2NjYTI5MTc1N2QxNDQ3MTliMzA5NTA4OTc3NWMzODFfNS02LTEtMS02MTQ4NjE_b87b07d3-90fd-4027-ba31-2192958f7a79" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" sign="-" unitref="usd">485</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RhYmxlOjNjY2EyOTE3NTdkMTQ0NzE5YjMwOTUwODk3NzVjMzgxL3RhYmxlcmFuZ2U6M2NjYTI5MTc1N2QxNDQ3MTliMzA5NTA4OTc3NWMzODFfNS04LTEtMS02MTQ4NjE_b297f652-9d41-415b-b653-2a73a84f9536" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" sign="-" unitref="usd">710</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RleHRyZWdpb246OWRhNzRiYWEyNzY4NGY0ZGFkZDFlZDFmNzFiMGJhOGNfNzQ4_9c30552a-9749-4883-b3f2-38dbe8d8f94d"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_49" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div></ix:nonnumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><div style="padding-left:9pt;text-indent:-9pt"><ix:continuation continuedat="iabfdcd6b92714080bfae2e809a2caeff" id="i4c732f31f7c84937b4bbc43796b71420"><ix:continuation id="i420a472350c74ab099f6554258131ddc"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RleHRyZWdpb246OWRhNzRiYWEyNzY4NGY0ZGFkZDFlZDFmNzFiMGJhOGNfNzU3_a7c09b2b-99e6-4904-9baa-52568e872960">Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of April&#160;2, 2023, there were cumulative impairments and downward adjustments of $<ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RleHRyZWdpb246OWRhNzRiYWEyNzY4NGY0ZGFkZDFlZDFmNzFiMGJhOGNfNjE2_b2a4b72d-ec9d-4dc5-b718-e3bad7df8c7d" name="pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" scale="6" unitref="usd">171</ix:nonfraction> million and upward adjustments of $<ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82MS9mcmFnOjlkYTc0YmFhMjc2ODRmNGRhZGQxZWQxZjcxYjBiYThjL3RleHRyZWdpb246OWRhNzRiYWEyNzY4NGY0ZGFkZDFlZDFmNzFiMGJhOGNfNjQ1_2c6f9198-1fde-426d-8fe1-9c5c15edc993" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" scale="6" unitref="usd">203</ix:nonfraction> million. Impairments, downward and upward adjustments were not significant in the first quarters of 2023 and 2022.</ix:footnote></span></ix:continuation></ix:continuation></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_64"></div><ix:continuation continuedat="if543ece897154e70b02bea06928a3efa" id="iabfdcd6b92714080bfae2e809a2caeff"><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Short-Term Borrowings</span></div><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82NC9mcmFnOjljYzM1ODllNzIxODQ5Yzk4ODc0OGNiMzM3OWNiODY0L3RleHRyZWdpb246OWNjMzU4OWU3MjE4NDljOTg4NzQ4Y2IzMzc5Y2I4NjRfODU_28e65561-9bee-4c84-b210-846e9156af81" name="us-gaap:ScheduleOfShortTermDebtTextBlock"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:67.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings include:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82NC9mcmFnOjljYzM1ODllNzIxODQ5Yzk4ODc0OGNiMzM3OWNiODY0L3RhYmxlOjk1ZDgwZTFiYWI4YTQyNGI5YzJhZWQwZDMzYjFmYzM5L3RhYmxlcmFuZ2U6OTVkODBlMWJhYjhhNDI0YjljMmFlZDBkMzNiMWZjMzlfMy0yLTEtMS02MTQ4NjE_941d2d9f-cd3e-43fe-8540-4dff109c0b7c" name="pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" scale="6" unitref="usd">3,550</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82NC9mcmFnOjljYzM1ODllNzIxODQ5Yzk4ODc0OGNiMzM3OWNiODY0L3RhYmxlOjk1ZDgwZTFiYWI4YTQyNGI5YzJhZWQwZDMzYjFmYzM5L3RhYmxlcmFuZ2U6OTVkODBlMWJhYjhhNDI0YjljMmFlZDBkMzNiMWZjMzlfMy00LTEtMS02MTQ4NjE_4a243356-542b-4b20-91a2-f99cb9ad4289" name="pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" scale="6" unitref="usd">2,550</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term borrowings, principal amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82NC9mcmFnOjljYzM1ODllNzIxODQ5Yzk4ODc0OGNiMzM3OWNiODY0L3RhYmxlOjk1ZDgwZTFiYWI4YTQyNGI5YzJhZWQwZDMzYjFmYzM5L3RhYmxlcmFuZ2U6OTVkODBlMWJhYjhhNDI0YjljMmFlZDBkMzNiMWZjMzlfNC0yLTEtMS02MTQ4NjE_fc2eaddd-8e71-4920-a13d-e1d062ddd606" name="us-gaap:OtherShortTermBorrowings" scale="6" unitref="usd">622</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82NC9mcmFnOjljYzM1ODllNzIxODQ5Yzk4ODc0OGNiMzM3OWNiODY0L3RhYmxlOjk1ZDgwZTFiYWI4YTQyNGI5YzJhZWQwZDMzYjFmYzM5L3RhYmxlcmFuZ2U6OTVkODBlMWJhYjhhNDI0YjljMmFlZDBkMzNiMWZjMzlfNC00LTEtMS02MTQ4NjE_083e92ce-96d5-46a8-b0de-e6d294c33ab7" name="us-gaap:OtherShortTermBorrowings" scale="6" unitref="usd">385</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term borrowings, principal amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82NC9mcmFnOjljYzM1ODllNzIxODQ5Yzk4ODc0OGNiMzM3OWNiODY0L3RhYmxlOjk1ZDgwZTFiYWI4YTQyNGI5YzJhZWQwZDMzYjFmYzM5L3RhYmxlcmFuZ2U6OTVkODBlMWJhYjhhNDI0YjljMmFlZDBkMzNiMWZjMzlfNS0yLTEtMS02MTQ4NjE_507baa32-c87a-46ee-a284-84144dc648f8" name="pfe:ShorttermDebtGross" scale="6" unitref="usd">4,172</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82NC9mcmFnOjljYzM1ODllNzIxODQ5Yzk4ODc0OGNiMzM3OWNiODY0L3RhYmxlOjk1ZDgwZTFiYWI4YTQyNGI5YzJhZWQwZDMzYjFmYzM5L3RhYmxlcmFuZ2U6OTVkODBlMWJhYjhhNDI0YjljMmFlZDBkMzNiMWZjMzlfNS00LTEtMS02MTQ4NjE_dce2a1be-0eaa-4371-aff5-a7d50206fd8a" name="pfe:ShorttermDebtGross" scale="6" unitref="usd">2,935</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82NC9mcmFnOjljYzM1ODllNzIxODQ5Yzk4ODc0OGNiMzM3OWNiODY0L3RhYmxlOjk1ZDgwZTFiYWI4YTQyNGI5YzJhZWQwZDMzYjFmYzM5L3RhYmxlcmFuZ2U6OTVkODBlMWJhYjhhNDI0YjljMmFlZDBkMzNiMWZjMzlfNi0yLTEtMS02MTQ4NjE_1e31d6d1-dda1-4511-a2ba-e912c168c1b2" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" scale="6" unitref="usd">17</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82NC9mcmFnOjljYzM1ODllNzIxODQ5Yzk4ODc0OGNiMzM3OWNiODY0L3RhYmxlOjk1ZDgwZTFiYWI4YTQyNGI5YzJhZWQwZDMzYjFmYzM5L3RhYmxlcmFuZ2U6OTVkODBlMWJhYjhhNDI0YjljMmFlZDBkMzNiMWZjMzlfNi00LTEtMS02MTQ4NjE_19f05f1f-5c96-4c1b-9440-857f168a27b3" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" scale="6" unitref="usd">10</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, carried at historical proceeds, as adjusted</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82NC9mcmFnOjljYzM1ODllNzIxODQ5Yzk4ODc0OGNiMzM3OWNiODY0L3RhYmxlOjk1ZDgwZTFiYWI4YTQyNGI5YzJhZWQwZDMzYjFmYzM5L3RhYmxlcmFuZ2U6OTVkODBlMWJhYjhhNDI0YjljMmFlZDBkMzNiMWZjMzlfOC0yLTEtMS02MTQ4NjE_7d0ed528-538b-4019-b1dd-30c5f859b1d1" name="us-gaap:DebtCurrent" scale="6" unitref="usd">4,188</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82NC9mcmFnOjljYzM1ODllNzIxODQ5Yzk4ODc0OGNiMzM3OWNiODY0L3RhYmxlOjk1ZDgwZTFiYWI4YTQyNGI5YzJhZWQwZDMzYjFmYzM5L3RhYmxlcmFuZ2U6OTVkODBlMWJhYjhhNDI0YjljMmFlZDBkMzNiMWZjMzlfOC00LTEtMS02MTQ4NjE_b8656dd5-f828-459a-a2ce-9d187917fc86" name="us-gaap:DebtCurrent" scale="6" unitref="usd">2,945</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82NC9mcmFnOjljYzM1ODllNzIxODQ5Yzk4ODc0OGNiMzM3OWNiODY0L3RleHRyZWdpb246OWNjMzU4OWU3MjE4NDljOTg4NzQ4Y2IzMzc5Y2I4NjRfODY_9b03a664-74d8-4dd2-860e-fa85af621b0f"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Primarily includes cash collateral. See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7F</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div></ix:nonnumeric></ix:continuation><div id="idfe6e72973fb4e83b28a5bb34d34299f_67"></div><ix:continuation continuedat="i13668568d14d49599f7d1dec02923670" id="if543ece897154e70b02bea06928a3efa"><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Long-Term Debt</span></div><div style="margin-bottom:8pt"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82Ny9mcmFnOmRhYTM4ZDQ4ODFlNTQ0YzBhMmYyYzdlMzJjN2FlYzI1L3RleHRyZWdpb246ZGFhMzhkNDg4MWU1NDRjMGEyZjJjN2UzMmM3YWVjMjVfMzI_1e918db5-1b27-48e8-9142-d2e2f9362056" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:67.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2b7e1cceac144343ab580a8feeb62b10_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82Ny9mcmFnOmRhYTM4ZDQ4ODFlNTQ0YzBhMmYyYzdlMzJjN2FlYzI1L3RhYmxlOjE2ZTY0YjEyMzY0ZjQ1NDZiMmJhYzA5NjljZmRlYmQ0L3RhYmxlcmFuZ2U6MTZlNjRiMTIzNjRmNDU0NmIyYmFjMDk2OWNmZGViZDRfMi0yLTEtMS02MTQ4NjE_072325c5-159e-4fe6-a8bb-4e624611a0b2" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" unitref="usd">30,909</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ifbaea048f6dd4b4c9f2628db0fcd2ff2_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82Ny9mcmFnOmRhYTM4ZDQ4ODFlNTQ0YzBhMmYyYzdlMzJjN2FlYzI1L3RhYmxlOjE2ZTY0YjEyMzY0ZjQ1NDZiMmJhYzA5NjljZmRlYmQ0L3RhYmxlcmFuZ2U6MTZlNjRiMTIzNjRmNDU0NmIyYmFjMDk2OWNmZGViZDRfMi00LTEtMS02MTQ4NjE_f00ab327-bf09-4537-892f-7be737a309f0" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" unitref="usd">32,080</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2b7e1cceac144343ab580a8feeb62b10_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82Ny9mcmFnOmRhYTM4ZDQ4ODFlNTQ0YzBhMmYyYzdlMzJjN2FlYzI1L3RhYmxlOjE2ZTY0YjEyMzY0ZjQ1NDZiMmJhYzA5NjljZmRlYmQ0L3RhYmxlcmFuZ2U6MTZlNjRiMTIzNjRmNDU0NmIyYmFjMDk2OWNmZGViZDRfMy0yLTEtMS02MTQ4NjE_92af9ddd-9823-4208-a814-5441178720cd" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" scale="6" unitref="usd">966</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ifbaea048f6dd4b4c9f2628db0fcd2ff2_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82Ny9mcmFnOmRhYTM4ZDQ4ODFlNTQ0YzBhMmYyYzdlMzJjN2FlYzI1L3RhYmxlOjE2ZTY0YjEyMzY0ZjQ1NDZiMmJhYzA5NjljZmRlYmQ0L3RhYmxlcmFuZ2U6MTZlNjRiMTIzNjRmNDU0NmIyYmFjMDk2OWNmZGViZDRfMy00LTEtMS02MTQ4NjE_97b79e0e-bd8f-4d9a-8c67-f28270aa8570" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" scale="6" unitref="usd">959</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i2b7e1cceac144343ab580a8feeb62b10_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82Ny9mcmFnOmRhYTM4ZDQ4ODFlNTQ0YzBhMmYyYzdlMzJjN2FlYzI1L3RhYmxlOjE2ZTY0YjEyMzY0ZjQ1NDZiMmJhYzA5NjljZmRlYmQ0L3RhYmxlcmFuZ2U6MTZlNjRiMTIzNjRmNDU0NmIyYmFjMDk2OWNmZGViZDRfNC0yLTEtMS02MTQ4NjE_26a8f7e5-73ca-4a61-a574-add1a1a8827e" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" unitref="usd">171</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="ifbaea048f6dd4b4c9f2628db0fcd2ff2_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82Ny9mcmFnOmRhYTM4ZDQ4ODFlNTQ0YzBhMmYyYzdlMzJjN2FlYzI1L3RhYmxlOjE2ZTY0YjEyMzY0ZjQ1NDZiMmJhYzA5NjljZmRlYmQ0L3RhYmxlcmFuZ2U6MTZlNjRiMTIzNjRmNDU0NmIyYmFjMDk2OWNmZGViZDRfNC00LTEtMS02MTQ4NjE_dafe20c3-fa3d-4127-8f92-2c35177f0b8e" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" unitref="usd">175</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2b7e1cceac144343ab580a8feeb62b10_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82Ny9mcmFnOmRhYTM4ZDQ4ODFlNTQ0YzBhMmYyYzdlMzJjN2FlYzI1L3RhYmxlOjE2ZTY0YjEyMzY0ZjQ1NDZiMmJhYzA5NjljZmRlYmQ0L3RhYmxlcmFuZ2U6MTZlNjRiMTIzNjRmNDU0NmIyYmFjMDk2OWNmZGViZDRfNS0yLTEtMS02MTQ4NjE_83731662-6b5a-49bf-8ce7-3b087a3f8937" name="us-gaap:OtherLongTermDebt" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ifbaea048f6dd4b4c9f2628db0fcd2ff2_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82Ny9mcmFnOmRhYTM4ZDQ4ODFlNTQ0YzBhMmYyYzdlMzJjN2FlYzI1L3RhYmxlOjE2ZTY0YjEyMzY0ZjQ1NDZiMmJhYzA5NjljZmRlYmQ0L3RhYmxlcmFuZ2U6MTZlNjRiMTIzNjRmNDU0NmIyYmFjMDk2OWNmZGViZDRfNS00LTEtMS02MTQ4NjE_9c131fa9-56ec-4332-b354-c5ba246a39da" name="us-gaap:OtherLongTermDebt" scale="6" unitref="usd">20</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, carried at historical proceeds, as adjusted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2b7e1cceac144343ab580a8feeb62b10_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82Ny9mcmFnOmRhYTM4ZDQ4ODFlNTQ0YzBhMmYyYzdlMzJjN2FlYzI1L3RhYmxlOjE2ZTY0YjEyMzY0ZjQ1NDZiMmJhYzA5NjljZmRlYmQ0L3RhYmxlcmFuZ2U6MTZlNjRiMTIzNjRmNDU0NmIyYmFjMDk2OWNmZGViZDRfNi0yLTEtMS02MTQ4NjE_0e0a9d07-afd6-408b-84c5-a8fb29ce348e" name="us-gaap:LongTermDebtNoncurrent" scale="6" unitref="usd">31,704</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ifbaea048f6dd4b4c9f2628db0fcd2ff2_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl82Ny9mcmFnOmRhYTM4ZDQ4ODFlNTQ0YzBhMmYyYzdlMzJjN2FlYzI1L3RhYmxlOjE2ZTY0YjEyMzY0ZjQ1NDZiMmJhYzA5NjljZmRlYmQ0L3RhYmxlcmFuZ2U6MTZlNjRiMTIzNjRmNDU0NmIyYmFjMDk2OWNmZGViZDRfNi00LTEtMS02MTQ4NjE_d43212c1-46ae-4d66-a57d-2b44d2eef23a" name="us-gaap:LongTermDebtNoncurrent" scale="6" unitref="usd">32,884</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonnumeric></div></ix:continuation><div id="idfe6e72973fb4e83b28a5bb34d34299f_70"></div><ix:continuation continuedat="idf0c42bef8a44ff0a992a9cb581fe5d9" id="i13668568d14d49599f7d1dec02923670"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Derivative Financial Instruments and Hedging Activities</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Exchange Risk&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. Where foreign exchange risk is not offset by other exposures, we manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen, Chinese renminbi, Canadian dollar and Singapore dollar, and include a portion of our forecasted foreign exchange-denominated intercompany inventory sales hedged up to <ix:nonnumeric contextref="i55a99842f0f54e7d90dda5512ae6cda5_D20230101-20230402" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfODQy_0d70f94d-d82a-4aa2-9cea-f005245a1a41" name="us-gaap:DerivativeTermOfContract">two years</ix:nonnumeric>. We may seek to protect against possible declines in the reported net investments of our foreign business entities.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.</span></div></ix:continuation><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="i85effc1cb3954a23b91978e9c0b0d0e2" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAxMw_21bc231e-c930-43d6-bed0-0b994b69c2a0" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock"></ix:nonnumeric><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="i97e61f5df66d49c3898b81f0a008f716" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAxNA_a540fe19-2792-4668-bd41-df32cba4deb7" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"></ix:nonnumeric><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="i9248cb58e74f43b696997fcc6287d120" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzA0MQ_48b76c85-cb2c-466b-97c9-a0024212b6af" name="us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock"></ix:nonnumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation continuedat="ie570ea1d8efb43d29d3c4bb393c578b4" id="idf0c42bef8a44ff0a992a9cb581fe5d9"><ix:continuation id="i85effc1cb3954a23b91978e9c0b0d0e2"><ix:continuation id="i97e61f5df66d49c3898b81f0a008f716"><ix:continuation id="i9248cb58e74f43b696997fcc6287d120"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:41.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the fair value of the derivative financial instruments and notional amounts: </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> April 2, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i0b68a7a1360743aea85f2e90df318303_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNS0yLTEtMS02MTQ4NjE_68e4ab33-1a03-4d2b-b21d-e5bd94077e16" name="us-gaap:DerivativeNotionalAmount" scale="6" unitref="usd">26,179</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i0b68a7a1360743aea85f2e90df318303_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNS00LTEtMS02MTQ4NjE_f82a2bf1-6712-4312-8a1c-d15ab0237633" name="us-gaap:DerivativeAssets" scale="6" unitref="usd">809</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i0b68a7a1360743aea85f2e90df318303_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNS02LTEtMS02MTQ4NjE_a5379aae-a893-4c63-8585-e786a37acac4" name="us-gaap:DerivativeLiabilities" scale="6" unitref="usd">1,038</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic8e08a3bcc664863a2de2d5d8e095957_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNS04LTEtMS02MTQ4NjE_03d7820a-1a80-4832-aac6-080be5b49c22" name="us-gaap:DerivativeNotionalAmount" scale="6" unitref="usd">26,603</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic8e08a3bcc664863a2de2d5d8e095957_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNS0xMC0xLTEtNjE0ODYx_b6cece36-b914-4baa-bfcf-92d2ae5e0fba" name="us-gaap:DerivativeAssets" scale="6" unitref="usd">838</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic8e08a3bcc664863a2de2d5d8e095957_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNS0xMi0xLTEtNjE0ODYx_e790dcd9-520c-415d-a394-4b4d9d460a42" name="us-gaap:DerivativeLiabilities" scale="6" unitref="usd">1,196</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i7047fc651abb407b95b0e414a4b1ff86_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNi0yLTEtMS02MTQ4NjE_c6b441cc-b9c1-4846-b7db-38ae8b201691" name="us-gaap:DerivativeNotionalAmount" scale="6" unitref="usd">2,250</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i7047fc651abb407b95b0e414a4b1ff86_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNi00LTEtMS02MTQ4NjE_7a1dc896-fca1-450b-ac7a-fd351342176a" name="us-gaap:DerivativeAssets" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i7047fc651abb407b95b0e414a4b1ff86_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNi02LTEtMS02MTQ4NjE_abe30af4-bbc1-4cd5-a44d-b6c50e4f8aa2" name="us-gaap:DerivativeLiabilities" scale="6" unitref="usd">274</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ie11fd9ae0e5d4b23917b2737bdb19811_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNi04LTEtMS02MTQ4NjE_2e03f135-d43f-4d11-83b7-6b338c5919f9" name="us-gaap:DerivativeNotionalAmount" scale="6" unitref="usd">2,250</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ie11fd9ae0e5d4b23917b2737bdb19811_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNi0xMC0xLTEtNjE0ODYx_d846ffba-1bfe-46df-98da-799dce964d6b" name="us-gaap:DerivativeAssets" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ie11fd9ae0e5d4b23917b2737bdb19811_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNi0xMi0xLTEtNjE0ODYx_e5007d9a-98fd-46a6-8b6f-6d1e8beba04a" name="us-gaap:DerivativeLiabilities" scale="6" unitref="usd">331</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i575da8208e1845289afd26828dfb95e7_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNy00LTEtMS02MTQ4NjE_17e0673f-bb92-4e79-9951-12a8f89c60be" name="us-gaap:DerivativeAssets" scale="6" unitref="usd">809</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i575da8208e1845289afd26828dfb95e7_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNy02LTEtMS02MTQ4NjE_3619bf39-305e-4c5b-a45a-b6165e70d46c" name="us-gaap:DerivativeLiabilities" scale="6" unitref="usd">1,311</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ia1dff75245484d3bba5fe84c1d63611a_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNy0xMC0xLTEtNjE0ODYx_4359d13c-8d31-45a7-9d79-18dadca13a87" name="us-gaap:DerivativeAssets" scale="6" unitref="usd">838</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ia1dff75245484d3bba5fe84c1d63611a_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfNy0xMi0xLTEtNjE0ODYx_570f73bf-5ecb-4056-b8b3-1d593e7e1148" name="us-gaap:DerivativeLiabilities" scale="6" unitref="usd">1,527</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i00f38c7951e44b5cae17839d79ede5d7_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfOS0yLTEtMS02MTQ4NjE_8171fd2c-0068-4fab-9167-7915d7c3bac0" name="us-gaap:DerivativeNotionalAmount" scale="6" unitref="usd">21,870</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i00f38c7951e44b5cae17839d79ede5d7_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfOS00LTEtMS02MTQ4NjE_5b4b48ab-9c1e-499d-96b4-8047d2d510e1" name="us-gaap:DerivativeAssets" scale="6" unitref="usd">220</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i00f38c7951e44b5cae17839d79ede5d7_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfOS02LTEtMS02MTQ4NjE_c236fdd3-8332-4e76-b3a5-591eebd17dc6" name="us-gaap:DerivativeLiabilities" scale="6" unitref="usd">177</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i4adceb36e10947acbfe50e66edfdb800_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfOS04LTEtMS02MTQ4NjE_889dccef-346a-44db-a5d3-39424c163221" name="us-gaap:DerivativeNotionalAmount" scale="6" unitref="usd">29,814</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i4adceb36e10947acbfe50e66edfdb800_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfOS0xMC0xLTEtNjE0ODYx_85fbed46-2ad4-4836-a678-976aa2a0363a" name="us-gaap:DerivativeAssets" scale="6" unitref="usd">240</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i4adceb36e10947acbfe50e66edfdb800_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfOS0xMi0xLTEtNjE0ODYx_5e0d708a-e613-4941-a2a2-8ec42a260e2d" name="us-gaap:DerivativeLiabilities" scale="6" unitref="usd">362</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfMTAtNC0xLTEtNjE0ODYx_8297e5ba-fa1e-48c6-af78-c2cdc1878c6d" name="us-gaap:DerivativeAssets" scale="6" unitref="usd">1,029</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfMTAtNi0xLTEtNjE0ODYx_c3da3bdc-1a2e-4ebc-8c7a-ff5ff9fff409" name="us-gaap:DerivativeLiabilities" scale="6" unitref="usd">1,488</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfMTAtMTAtMS0xLTYxNDg2MQ_1b839504-36e7-4603-98f8-3a5eaf7f59ab" name="us-gaap:DerivativeAssets" scale="6" unitref="usd">1,078</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmJmZjAyMzhiZWYxYTRiOGE5YmNkMTdjMGY1Yjg2OWFmL3RhYmxlcmFuZ2U6YmZmMDIzOGJlZjFhNGI4YTliY2QxN2MwZjViODY5YWZfMTAtMTItMS0xLTYxNDg2MQ_e7fc482b-8383-44ce-9300-0e80d5dc0f32" name="us-gaap:DerivativeLiabilities" scale="6" unitref="usd">1,889</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzA1Mg_173afdc4-ac0d-41ff-bff0-33f30628801e">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $<ix:nonfraction contextref="i25ba3cba6fef459a8d23cd8dd88e4951_I20230402" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMTYxNQ_d6ede35d-96a6-42c8-82eb-81e3e4fc273e" name="us-gaap:DerivativeNotionalAmount" scale="9" unitref="usd">4.5</ix:nonfraction>&#160;billion as of April&#160;2, 2023 and $<ix:nonfraction contextref="idcdc45ae25474e52a9cc689f7943751a_I20221231" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMTYzMQ_7936aac9-69db-4c0c-8547-3858ee2bdf4f" name="us-gaap:DerivativeNotionalAmount" scale="9" unitref="usd">4.4</ix:nonfraction>&#160;billion as of December 31, 2022.</ix:footnote></span></div></ix:continuation></ix:continuation></ix:continuation><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAyMw_ca3655d3-d3c6-4d77-bcca-cc2c4bdd75a3" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Reclassified from</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">OCI into OID and COS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i79a4a6c5b5914f978e0161dc14967489_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNS02LTEtMS02MTQ4NjE_5d3f59f6-19f2-431f-a145-30c49029025d" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" sign="-" unitref="usd">53</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i4ec559a8febf4df6bd2f3a91b0d559a0_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNS04LTEtMS02MTQ4NjE_b4afff8e-d465-4e29-b814-b17d07bbc366" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" unitref="usd">187</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i79a4a6c5b5914f978e0161dc14967489_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNS0xMC0xLTEtNjE0ODYx_e6e3c342-f3b9-4d85-aa17-6afc54d73d5f" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" sign="-" unitref="usd">356</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i4ec559a8febf4df6bd2f3a91b0d559a0_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNS0xMi0xLTEtNjE0ODYx_db51b44c-b1e2-4a3e-b872-0515039bbae3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" unitref="usd">195</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i79a4a6c5b5914f978e0161dc14967489_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNi02LTEtMS02MTQ4NjE_0933a9ee-05e4-4aee-bc13-349985415bb5" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" unitref="usd">55</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i4ec559a8febf4df6bd2f3a91b0d559a0_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNi04LTEtMS02MTQ4NjE_781d0c49-a3d1-4c56-9334-7e69baf03b0c" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" unitref="usd">16</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i79a4a6c5b5914f978e0161dc14967489_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNi0xMC0xLTEtNjE0ODYx_fd5b8115-3388-46d7-b9ae-3ed91925007e" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" unitref="usd">53</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i4ec559a8febf4df6bd2f3a91b0d559a0_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfNi0xMi0xLTEtNjE0ODYx_c0607e67-192d-46b3-b23f-97a720d97216" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" unitref="usd">18</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i6e0b3cd23cfa4e079a148202064f19eb_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfOC0yLTEtMS02MTQ4NjE_d01374e7-74a1-49be-8b08-bc5a5df34e5d" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" unitref="usd">48</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="ib6b75c023f5540e9bb79fc95baf2a51c_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfOC00LTEtMS02MTQ4NjE_acb6e52e-d571-4dd0-b2eb-d6a80e3f7507" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" sign="-" unitref="usd">156</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Hedged item </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i6e0b3cd23cfa4e079a148202064f19eb_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfOS0yLTEtMS02MTQ4NjE_8c2627cb-4d1a-4cac-8bb6-d0a8e91dbd77" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" sign="-" unitref="usd">48</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib6b75c023f5540e9bb79fc95baf2a51c_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfOS00LTEtMS02MTQ4NjE_ad8e94a9-410e-4e80-8a20-a71644ea3e87" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" unitref="usd">156</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3b5cd220c52b4bceaf2a3ede95ee4b2d_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTMtNi0xLTEtNjE0ODYx_57e276ac-5dde-4db0-ae78-c74144e2d2dd" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" sign="-" unitref="usd">213</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i1a47d1927ce14e11905195dcc3ed843c_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTMtOC0xLTEtNjE0ODYx_acce1aa7-d35a-4b15-bf72-c9914cae2471" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" unitref="usd">259</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3b5cd220c52b4bceaf2a3ede95ee4b2d_D20230101-20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTMtMTAtMS0xLTYxNDg2MQ_d18e245c-4a4a-4b3f-a866-6eec7c3c74d0" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i1a47d1927ce14e11905195dcc3ed843c_D20220101-20220403" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTMtMTItMS0xLTYxNDg2MQ_0e1db184-0240-48da-ab22-57bdc1f1c741" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3b5cd220c52b4bceaf2a3ede95ee4b2d_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTQtNi0xLTEtNjE0ODYx_8c2722db-45c9-4662-933d-76cc62b2769d" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" unitref="usd">67</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i1a47d1927ce14e11905195dcc3ed843c_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTQtOC0xLTEtNjE0ODYx_45ad9747-fab6-4c77-b1f7-f2771a44fa1c" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" sign="-" unitref="usd">74</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3b5cd220c52b4bceaf2a3ede95ee4b2d_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTQtMTAtMS0xLTYxNDg2MQ_d25f5005-224e-46d2-8fc3-de775e2cf00f" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" unitref="usd">34</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i1a47d1927ce14e11905195dcc3ed843c_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTQtMTItMS0xLTYxNDg2MQ_3cd81b17-e1be-4ccf-a7c4-1bb942febebe" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" unitref="usd">30</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i43a56508200245189b6559561d72937e_D20230101-20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTYtNi0xLTEtNjE0ODYx_22046236-5c27-4493-a98d-d774255636c8" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="iefbfac3f7c3a46b2a71f1cb0891912bc_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTYtOC0xLTEtNjE0ODYx_e52db2d8-e913-44e2-b91e-f34c3ed5bb22" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" unitref="usd">26</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i43a56508200245189b6559561d72937e_D20230101-20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTYtMTAtMS0xLTYxNDg2MQ_430a09ad-89f6-4ffc-a095-ab6aa372a865" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="iefbfac3f7c3a46b2a71f1cb0891912bc_D20220101-20220403" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTYtMTItMS0xLTYxNDg2MQ_9cf69fae-dc11-4bbc-932b-94bf2d1c1527" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i9297ef5cd28e4bbaaf1e772677fa3c64_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTctNi0xLTEtNjE0ODYx_74d16b25-d672-4f34-89dd-f27042213fab" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" sign="-" unitref="usd">16</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i20a3bf5204674c29af71b88494db6878_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTctOC0xLTEtNjE0ODYx_8c8e06fa-c087-4632-84c9-fbad1e9cdd7d" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" unitref="usd">23</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i9297ef5cd28e4bbaaf1e772677fa3c64_D20230101-20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTctMTAtMS0xLTYxNDg2MQ_4918adf1-1453-48db-a246-f2c979955522" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i20a3bf5204674c29af71b88494db6878_D20220101-20220403" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTctMTItMS0xLTYxNDg2MQ_fea8e7f8-d862-4e54-9f3c-0f7692ccc1fc" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i923c886a6e4a409b802615f6993c34f3_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTktMi0xLTEtNjE0ODYx_a4c17fd8-23b5-4849-9ca4-3630da64d0b5" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" unitref="usd">17</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="ic68930364f6e421db82430af61554cea_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMTktNC0xLTEtNjE0ODYx_f20143f1-1d69-4f86-9dec-9ab267bab767" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" sign="-" unitref="usd">19</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMjEtMi0xLTEtNjE0ODYx_6db1c06d-55a8-4dba-8b18-a346d6c07859" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" unitref="usd">17</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMjEtNC0xLTEtNjE0ODYx_94a02936-96c7-4913-981d-914ba9ecb4fa" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" sign="-" unitref="usd">19</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMjEtNi0xLTEtNjE0ODYx_3b576840-460c-405f-8afa-7d5b11ca4195" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" scale="6" sign="-" unitref="usd">160</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMjEtOC0xLTEtNjE0ODYx_4a52102f-b562-4958-8b97-2a0340357664" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" scale="6" unitref="usd">436</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMjEtMTAtMS0xLTYxNDg2MQ_fed20567-5d83-4354-9f5d-f1f19ddd8de1" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" scale="6" sign="-" unitref="usd">269</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmE4ZTk4MWY0MGE3OTQ5ZTE5ZGNkMzlkNGQ5MGMxOGJlL3RhYmxlcmFuZ2U6YThlOTgxZjQwYTc5NDllMTlkY2QzOWQ0ZDkwYzE4YmVfMjEtMTItMS0xLTYxNDg2MQ_076cfc71-4cb4-4458-8ddf-e0e9df312b68" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" scale="6" unitref="usd">243</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMQ_f4277dce-caa3-48c0-bbd3-2b0ecf09ecf6"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">OID = Other (income)/deductions&#8212;net, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income</span></ix:footnote><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAzMA_c38ff664-eb9f-410a-b981-1c377989408f"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The amounts reclassified from OCI into COS were a net gain of $<ix:nonfraction contextref="i9319a48dddf84917a4e0e8d99676ff46_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMjA2OA_e5ddad58-0737-4ee3-8f5e-f48ebcb7158a" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" unitref="usd">91</ix:nonfraction> million in the first quarter of 2023 and a net gain of $<ix:nonfraction contextref="i64a45a7d126f4c59946c1cfaac8a62f1_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMjEzMA_bc059013-0878-487a-8f33-d57fc697adf6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" unitref="usd">34</ix:nonfraction> million in the first quarter of 2022. The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $<ix:nonfraction contextref="i0b68a7a1360743aea85f2e90df318303_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMjM1NQ_c09c221b-f031-4795-8caf-9a181b20b6ab" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" scale="6" unitref="usd">235</ix:nonfraction> million within the next 12 months into income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately <ix:nonnumeric contextref="id4bb66f56f034240be2d396bdb5a0da2_D20230101-20230402" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMjUzNw_eed096f6-7677-4a68-a73c-f824a402b237" name="us-gaap:DerivativeRemainingMaturity1">20</ix:nonnumeric> years and relates to foreign currency debt. </span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzA0OQ_c59437bc-4d74-4876-923a-2226bf670027">The amounts reclassified from OCI were reclassified into OID.</ix:footnote></span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAxNg_24be5b54-e8b8-4b6d-87b0-bd16bc053216">Short-term borrowings and long-term debt include foreign currency borrowings, which are used in net investment hedges. The related long-term debt carrying values as of April&#160;2, 2023 and December 31, 2022 were $<ix:nonfraction contextref="i8986081e6afe4d859ff9981809c0c41b_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMjg5MQ_62c48a42-f249-487b-b2a4-b562b230496c" name="us-gaap:LongTermDebt" scale="6" unitref="usd">811</ix:nonfraction> million and $<ix:nonfraction contextref="ie25436cb1a6a4ccda5d54fd7d841e316_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMjg5OA_b5108bc8-b7f1-45ca-9a75-0aeb044371d3" name="us-gaap:LongTermDebt" scale="6" unitref="usd">795</ix:nonfraction> million, respectively.</ix:footnote></span></div></ix:nonnumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation continuedat="ia7eae4f87c384dda91d32e25a3bf70c2" id="ie570ea1d8efb43d29d3c4bb393c578b4"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAwMA_12b06f1c-4108-4d84-b7d2-e1ff0ba1b8ae" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:27.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.655%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.35pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes cumulative basis adjustments to our debt in fair value hedges:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April 2, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i36fdcd53aa6d43d3b8ba420de4367710_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmRiN2ZlNzc3MTAzYzRkMjdiOWVhNzJkM2YzY2U0YzJmL3RhYmxlcmFuZ2U6ZGI3ZmU3NzcxMDNjNGQyN2I5ZWE3MmQzZjNjZTRjMmZfNi0yLTEtMS02MTQ4NjE_eb5e4395-620e-4385-9e28-453287973d0a" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i36fdcd53aa6d43d3b8ba420de4367710_I20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmRiN2ZlNzc3MTAzYzRkMjdiOWVhNzJkM2YzY2U0YzJmL3RhYmxlcmFuZ2U6ZGI3ZmU3NzcxMDNjNGQyN2I5ZWE3MmQzZjNjZTRjMmZfNi00LTEtMS02MTQ4NjE_e5fa3125-9040-4c6f-9db3-a52c892cee1e" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i36fdcd53aa6d43d3b8ba420de4367710_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmRiN2ZlNzc3MTAzYzRkMjdiOWVhNzJkM2YzY2U0YzJmL3RhYmxlcmFuZ2U6ZGI3ZmU3NzcxMDNjNGQyN2I5ZWE3MmQzZjNjZTRjMmZfNi02LTEtMS02MTQ4NjE_a3bfefda-93e1-44c6-ae96-2a1679d7361d" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" scale="6" unitref="usd">12</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="icaa1f325078f494ab39c94ab1fbf0b75_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmRiN2ZlNzc3MTAzYzRkMjdiOWVhNzJkM2YzY2U0YzJmL3RhYmxlcmFuZ2U6ZGI3ZmU3NzcxMDNjNGQyN2I5ZWE3MmQzZjNjZTRjMmZfNi04LTEtMS02MTQ4NjE_258ed37a-151a-4269-8d6c-cfce5ef3ecbf" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="icaa1f325078f494ab39c94ab1fbf0b75_I20221231" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmRiN2ZlNzc3MTAzYzRkMjdiOWVhNzJkM2YzY2U0YzJmL3RhYmxlcmFuZ2U6ZGI3ZmU3NzcxMDNjNGQyN2I5ZWE3MmQzZjNjZTRjMmZfNi0xMC0xLTEtNjE0ODYx_8d978a66-de92-42bf-bd33-2f28d179469e" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="icaa1f325078f494ab39c94ab1fbf0b75_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmRiN2ZlNzc3MTAzYzRkMjdiOWVhNzJkM2YzY2U0YzJmL3RhYmxlcmFuZ2U6ZGI3ZmU3NzcxMDNjNGQyN2I5ZWE3MmQzZjNjZTRjMmZfNi0xMi0xLTEtNjE0ODYx_daee5638-acdb-4e3a-85b4-b266b8a0f5da" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" scale="6" unitref="usd">10</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib23edf5b9ef34621a697cfcb5d13aad6_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmRiN2ZlNzc3MTAzYzRkMjdiOWVhNzJkM2YzY2U0YzJmL3RhYmxlcmFuZ2U6ZGI3ZmU3NzcxMDNjNGQyN2I5ZWE3MmQzZjNjZTRjMmZfNy0yLTEtMS02MTQ4NjE_9a49da0e-9f3e-4ac1-a3be-7eaf84e52943" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" unitref="usd">2,236</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="ib23edf5b9ef34621a697cfcb5d13aad6_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmRiN2ZlNzc3MTAzYzRkMjdiOWVhNzJkM2YzY2U0YzJmL3RhYmxlcmFuZ2U6ZGI3ZmU3NzcxMDNjNGQyN2I5ZWE3MmQzZjNjZTRjMmZfNy00LTEtMS02MTQ4NjE_2c4b9244-7590-4a81-94d3-20519ec48a0e" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" sign="-" unitref="usd">274</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib23edf5b9ef34621a697cfcb5d13aad6_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmRiN2ZlNzc3MTAzYzRkMjdiOWVhNzJkM2YzY2U0YzJmL3RhYmxlcmFuZ2U6ZGI3ZmU3NzcxMDNjNGQyN2I5ZWE3MmQzZjNjZTRjMmZfNy02LTEtMS02MTQ4NjE_5b042b5f-3d32-42cf-92fe-1790ad708c70" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" scale="6" unitref="usd">1,014</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i23778ed383104e048f685a44a2a2b78c_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmRiN2ZlNzc3MTAzYzRkMjdiOWVhNzJkM2YzY2U0YzJmL3RhYmxlcmFuZ2U6ZGI3ZmU3NzcxMDNjNGQyN2I5ZWE3MmQzZjNjZTRjMmZfNy04LTEtMS02MTQ4NjE_2b67fa9a-24ce-446e-b486-065d2b890fa0" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" unitref="usd">2,235</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i23778ed383104e048f685a44a2a2b78c_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmRiN2ZlNzc3MTAzYzRkMjdiOWVhNzJkM2YzY2U0YzJmL3RhYmxlcmFuZ2U6ZGI3ZmU3NzcxMDNjNGQyN2I5ZWE3MmQzZjNjZTRjMmZfNy0xMC0xLTEtNjE0ODYx_dd192cd3-5bcc-4667-b5c1-9346eb4affb5" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" sign="-" unitref="usd">321</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i23778ed383104e048f685a44a2a2b78c_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RhYmxlOmRiN2ZlNzc3MTAzYzRkMjdiOWVhNzJkM2YzY2U0YzJmL3RhYmxlcmFuZ2U6ZGI3ZmU3NzcxMDNjNGQyN2I5ZWE3MmQzZjNjZTRjMmZfNy0xMi0xLTEtNjE0ODYx_814478c6-e72d-49eb-a37f-4a889c130227" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" scale="6" unitref="usd">1,042</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83MC9mcmFnOjAyMDg2OWJjYmE1ODRiYWNiNWJkMzZlMzgwYWFkZWVkL3RleHRyZWdpb246MDIwODY5YmNiYTU4NGJhY2I1YmQzNmUzODBhYWRlZWRfMzAyMQ_ef3ed581-7c29-47a2-8f39-a0d00590afdd">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</ix:footnote></span></div></ix:nonnumeric></ix:continuation><div id="idfe6e72973fb4e83b28a5bb34d34299f_73"></div><ix:continuation continuedat="if05a03776fba42cdadc3f45152122e95" id="ia7eae4f87c384dda91d32e25a3bf70c2"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">F. Credit Risk</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our trade accounts receivable balances are due from wholesalers and governments. For additional information on our trade accounts receivables with significant customers, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_91" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 13C</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17C </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2022 Form 10-K. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;2, 2023, the largest investment exposures in our portfolio represent primarily sovereign debt instruments issued by Canada, Japan, Germany, France, the U.S., and the U.K.</span></div></ix:continuation><div><ix:continuation id="if05a03776fba42cdadc3f45152122e95"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our derivative financial instrument agreements with financial institutions, we do not expect to incur a significant loss from failure of any counterparty. Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements with credit-support annexes that contain zero threshold provisions requiring collateral to be exchanged daily depending on levels of exposure. As a result, there are no significant concentrations of credit risk with any individual financial institution. As of April&#160;2, 2023, the aggregate fair value of these derivative financial instruments that are in a net payable position was $<ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83My9mcmFnOmM0OWExMWU4NWFhMTQ0ZTJhN2IwNmZlNDI2MjQ5Njc4L3RleHRyZWdpb246YzQ5YTExZTg1YWExNDRlMmE3YjA2ZmU0MjYyNDk2NzhfMTExOA_f5d6e12c-261f-4cf4-ac64-b84a6706bb98" name="us-gaap:DerivativeNetLiabilityPositionAggregateFairValue" scale="6" unitref="usd">763</ix:nonfraction>&#160;million, for which we have posted collateral of $<ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83My9mcmFnOmM0OWExMWU4NWFhMTQ0ZTJhN2IwNmZlNDI2MjQ5Njc4L3RleHRyZWdpb246YzQ5YTExZTg1YWExNDRlMmE3YjA2ZmU0MjYyNDk2NzhfMTE2MQ_73ad884c-05cb-4c5e-9a0c-2df78250e2d2" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" scale="6" unitref="usd">831</ix:nonfraction> million with a corresponding amount reported in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of April&#160;2, 2023, the aggregate fair value of our derivative financial instruments that are in a net receivable position was $<ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83My9mcmFnOmM0OWExMWU4NWFhMTQ0ZTJhN2IwNmZlNDI2MjQ5Njc4L3RleHRyZWdpb246YzQ5YTExZTg1YWExNDRlMmE3YjA2ZmU0MjYyNDk2NzhfMTM0NQ_a9788ed6-1693-4757-ac1a-e209845baa10" name="pfe:DerivativeNetReceivablePositionAggregateFairValue" scale="6" unitref="usd">715</ix:nonfraction>&#160;million, for which we have received collateral of $<ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83My9mcmFnOmM0OWExMWU4NWFhMTQ0ZTJhN2IwNmZlNDI2MjQ5Njc4L3RleHRyZWdpb246YzQ5YTExZTg1YWExNDRlMmE3YjA2ZmU0MjYyNDk2NzhfMTM5MA_f6716508-ef9a-49c9-9d88-0cce5432691d" name="us-gaap:SecuritiesReceivedAsCollateral" scale="6" unitref="usd">530</ix:nonfraction>&#160;million with a corresponding amount reported in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Short-term borrowings, including current portion of long-term debt.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_76"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="idf37bf2614334a9b98e6a4ca09ccdf02" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RleHRyZWdpb246NTU5YTUxNjg4NWEyNDhjMmE2OWMwZDY1ZDM0ZTIxMzVfNjM4_2b5e1749-309d-417e-997e-a2f4a68c810e" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock">Other Financial Information</ix:nonnumeric></span></div><ix:continuation continuedat="id02309c89963471f92ee14501e639f00" id="idf37bf2614334a9b98e6a4ca09ccdf02"><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A.</span><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:0.4pt;text-decoration:underline"> Inventories</span></div><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RleHRyZWdpb246NTU5YTUxNjg4NWEyNDhjMmE2OWMwZDY1ZDM0ZTIxMzVfNjEz_448c05a2-5c15-484c-81d1-945609df820b" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RleHRyZWdpb246NTU5YTUxNjg4NWEyNDhjMmE2OWMwZDY1ZDM0ZTIxMzVfNjE2_46ba6456-7b69-4aea-97b9-53550085e18e" name="us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RhYmxlOjMzNjk2Y2MwMjJhYjRjY2NhM2NhMTQ0ZjIxMzIyNTY0L3RhYmxlcmFuZ2U6MzM2OTZjYzAyMmFiNGNjY2EzY2ExNDRmMjEzMjI1NjRfMi0yLTEtMS02MTQ4NjE_772fa31c-5f94-4a68-99f1-406ad80ba0de" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" unitref="usd">2,657</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RhYmxlOjMzNjk2Y2MwMjJhYjRjY2NhM2NhMTQ0ZjIxMzIyNTY0L3RhYmxlcmFuZ2U6MzM2OTZjYzAyMmFiNGNjY2EzY2ExNDRmMjEzMjI1NjRfMi00LTEtMS02MTQ4NjE_a8c520a9-1310-43b5-ae9b-ccbe6c478262" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" unitref="usd">2,603</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RhYmxlOjMzNjk2Y2MwMjJhYjRjY2NhM2NhMTQ0ZjIxMzIyNTY0L3RhYmxlcmFuZ2U6MzM2OTZjYzAyMmFiNGNjY2EzY2ExNDRmMjEzMjI1NjRfMy0yLTEtMS02MTQ4NjE_1f65f123-3297-42f2-82cc-12688cb7c57e" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" unitref="usd">6,129</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RhYmxlOjMzNjk2Y2MwMjJhYjRjY2NhM2NhMTQ0ZjIxMzIyNTY0L3RhYmxlcmFuZ2U6MzM2OTZjYzAyMmFiNGNjY2EzY2ExNDRmMjEzMjI1NjRfMy00LTEtMS02MTQ4NjE_80dcb1de-2138-4cb5-8acf-2d69ca75eea2" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" unitref="usd">5,519</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RhYmxlOjMzNjk2Y2MwMjJhYjRjY2NhM2NhMTQ0ZjIxMzIyNTY0L3RhYmxlcmFuZ2U6MzM2OTZjYzAyMmFiNGNjY2EzY2ExNDRmMjEzMjI1NjRfNC0yLTEtMS02MTQ4NjE_baa926a3-9aa4-48a7-9de1-668e9cc7449b" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" unitref="usd">755</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RhYmxlOjMzNjk2Y2MwMjJhYjRjY2NhM2NhMTQ0ZjIxMzIyNTY0L3RhYmxlcmFuZ2U6MzM2OTZjYzAyMmFiNGNjY2EzY2ExNDRmMjEzMjI1NjRfNC00LTEtMS02MTQ4NjE_83fd2f13-cc6e-4734-b566-b9f35d6b3bec" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" unitref="usd">859</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RhYmxlOjMzNjk2Y2MwMjJhYjRjY2NhM2NhMTQ0ZjIxMzIyNTY0L3RhYmxlcmFuZ2U6MzM2OTZjYzAyMmFiNGNjY2EzY2ExNDRmMjEzMjI1NjRfNS0yLTEtMS02MTQ4NjE_9128c948-73f6-4ca3-abec-be9f2cffb4b3" name="us-gaap:InventoryNet" scale="6" unitref="usd">9,541</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RhYmxlOjMzNjk2Y2MwMjJhYjRjY2NhM2NhMTQ0ZjIxMzIyNTY0L3RhYmxlcmFuZ2U6MzM2OTZjYzAyMmFiNGNjY2EzY2ExNDRmMjEzMjI1NjRfNS00LTEtMS02MTQ4NjE_cf8e7458-7f96-48e5-ab33-a3672ae9b6c8" name="us-gaap:InventoryNet" scale="6" unitref="usd">8,981</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent inventories not included above</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RhYmxlOjMzNjk2Y2MwMjJhYjRjY2NhM2NhMTQ0ZjIxMzIyNTY0L3RhYmxlcmFuZ2U6MzM2OTZjYzAyMmFiNGNjY2EzY2ExNDRmMjEzMjI1NjRfNi0yLTEtMS02MTQ4NjE_63a8f59f-992b-429e-a998-5b8f7ed27763" name="us-gaap:InventoryNoncurrent" scale="6" unitref="usd">5,616</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RhYmxlOjMzNjk2Y2MwMjJhYjRjY2NhM2NhMTQ0ZjIxMzIyNTY0L3RhYmxlcmFuZ2U6MzM2OTZjYzAyMmFiNGNjY2EzY2ExNDRmMjEzMjI1NjRfNi00LTEtMS02MTQ4NjE_b53ad67f-4c50-4327-a601-bd54df7717cb" name="us-gaap:InventoryNoncurrent" scale="6" unitref="usd">5,827</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RleHRyZWdpb246NTU5YTUxNjg4NWEyNDhjMmE2OWMwZDY1ZDM0ZTIxMzVfNjMz_85ac4d4a-55f3-42e6-b663-ce227979dfac">The increase from December 31, 2022 reflects higher inventory levels for Paxlovid and increases for certain products due to supply recovery and inventory build, partially offset by decreases due to market demand.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RleHRyZWdpb246NTU5YTUxNjg4NWEyNDhjMmE2OWMwZDY1ZDM0ZTIxMzVfNjA5_1f908f71-1151-4fc9-bd70-fb77b4897a1d"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Based on our current estimates and assumptions, there are no recoverability issues for these amounts, which are primarily related to Paxlovid.</span></ix:footnote></div></ix:nonnumeric></ix:nonnumeric><div style="margin-bottom:5pt;margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Other Current Liabilities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes, among other things, amounts payable to BioNTech for the gross profit split for Comirnaty, which totaled $<ix:nonfraction contextref="if63149af93f943bc81c8955590d63913_I20230402" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RleHRyZWdpb246NTU5YTUxNjg4NWEyNDhjMmE2OWMwZDY1ZDM0ZTIxMzVfNTgw_9b2deb9a-6c52-47d7-8ecd-ae8cc495cd35" name="us-gaap:OtherLiabilitiesCurrent" scale="9" unitref="usd">4.7</ix:nonfraction>&#160;billion as of April&#160;2, 2023 and $<ix:nonfraction contextref="i31716fa685b44d31ba4d09a270e648f1_I20221231" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RleHRyZWdpb246NTU5YTUxNjg4NWEyNDhjMmE2OWMwZDY1ZDM0ZTIxMzVfNTk2_9b2862c4-9001-4e24-955c-c2235c99bb31" name="us-gaap:OtherLiabilitiesCurrent" scale="9" unitref="usd">5.2</ix:nonfraction>&#160;billion as of December 31, 2022. </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Supplier Finance Program Obligation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain voluntary supply chain finance agreements with several participating financial institutions. Under these agreements, participating suppliers may voluntarily elect to sell their accounts receivable with Pfizer to these financial institutions. Our suppliers negotiate their financing agreements directly with the respective financial institutions and we are not a party to these agreements. We have no economic interest in our suppliers&#8217; decision to participate and we pay the financial institutions the stated amount of confirmed invoices on the original maturity dates, which is generally within <ix:nonnumeric contextref="i022ceb0775f9487f99fe2d259639c88c_I20230402" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RleHRyZWdpb246NTU5YTUxNjg4NWEyNDhjMmE2OWMwZDY1ZDM0ZTIxMzVfMTY0OTI2NzQ1MDMxMw_d27b2613-2285-4173-b469-60ad44c47d32" name="pfe:SupplierFinanceProgramPaymentTimingPeriod">90</ix:nonnumeric> to <ix:nonnumeric contextref="i7e867f30236a439d9cc3fde888440520_I20230402" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RleHRyZWdpb246NTU5YTUxNjg4NWEyNDhjMmE2OWMwZDY1ZDM0ZTIxMzVfMTY0OTI2NzQ1MDMxOQ_4d4378b1-ed91-476a-a61d-4237813abfde" name="pfe:SupplierFinanceProgramPaymentTimingPeriod">120</ix:nonnumeric> days of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id02309c89963471f92ee14501e639f00">the invoice date. The agreements with the financial institutions do not require Pfizer to provide assets pledged as security or other forms of guarantees for the supplier finance program. All outstanding amounts related to suppliers participating in such financing arrangements are recorded within trade payables in our consolidated balance sheet. As of April&#160;2, 2023 and December 31, 2022, respectively, $<ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RleHRyZWdpb246NTU5YTUxNjg4NWEyNDhjMmE2OWMwZDY1ZDM0ZTIxMzVfMTY0OTI2NzQ1MDM2MQ_9acf9478-74a6-44c7-bb39-c2efb0ad7137" name="pfe:SupplierFinanceProgramObligationCurrent" scale="6" unitref="usd">755</ix:nonfraction>&#160;million and $<ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83Ni9mcmFnOjU1OWE1MTY4ODVhMjQ4YzJhNjljMGQ2NWQzNGUyMTM1L3RleHRyZWdpb246NTU5YTUxNjg4NWEyNDhjMmE2OWMwZDY1ZDM0ZTIxMzVfMTY0OTI2NzQ1MDM3Mw_b64fb461-856b-42b0-8e8f-89445b9554ca" name="pfe:SupplierFinanceProgramObligationCurrent" scale="6" unitref="usd">849</ix:nonfraction>&#160;million of our trade payables to suppliers who participate in these financing arrangements are outstanding.</ix:continuation></span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_79"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="id6d6a5424db449b89a0f683884bcbe2b" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RleHRyZWdpb246YWIwYmY2YzZjM2I2NDdmNWE5MDcyYTI5NTkzZDcyOTZfMTE0Mg_4ae2d310-1b00-42b4-ae1b-aee1c123b194" name="us-gaap:IntangibleAssetsDisclosureTextBlock">Identifiable Intangible Assets</ix:nonnumeric></span></div><ix:continuation id="id6d6a5424db449b89a0f683884bcbe2b"><div style="margin-top:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Identifiable Intangible Assets</span></div><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RleHRyZWdpb246YWIwYmY2YzZjM2I2NDdmNWE5MDcyYTI5NTkzZDcyOTZfMTEwNA_d824b0c5-841c-4af4-bc86-fa1ee6c9bf6c" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RleHRyZWdpb246YWIwYmY2YzZjM2I2NDdmNWE5MDcyYTI5NTkzZDcyOTZfMTExNQ_3a61607f-a2fb-4cff-b380-ae2339f2d267" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:28.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Finite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed technology rights</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ie6e2d5620afa435e8c12a808e5a20a45_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfNC0yLTEtMS02MTQ4NjE_33a37d98-010d-4592-aea7-90e0bd3b57ce" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" unitref="usd">84,973</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="ie6e2d5620afa435e8c12a808e5a20a45_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfNC00LTEtMS02MTQ4NjE_b8258f7a-52f5-4f9f-8c30-a2e7671d0aab" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" unitref="usd">56,887</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ie6e2d5620afa435e8c12a808e5a20a45_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfNC02LTEtMS02MTQ4NjE_a2514c21-bc90-4280-9c4d-d42e987e725a" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" unitref="usd">28,086</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ia175e99147dc4e84b88faf8958e1ac2a_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfNC04LTEtMS02MTQ4NjE_89dbc957-5182-4029-acc2-ce9d7b251439" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" unitref="usd">85,604</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="ia175e99147dc4e84b88faf8958e1ac2a_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfNC0xMC0xLTEtNjE0ODYx_5f95e6dd-c420-4bc0-ab34-33c8c7fbac41" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" unitref="usd">56,307</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ia175e99147dc4e84b88faf8958e1ac2a_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfNC0xMi0xLTEtNjE0ODYx_33973e95-6bd8-4f61-8a9c-49865d51c24f" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" unitref="usd">29,297</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5137093847654fc0948b33ea6b027e43_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfNS0yLTEtMS02MTQ4NjE_10f8d364-9fda-4c9e-b9cb-3b266261b042" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" unitref="usd">922</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i5137093847654fc0948b33ea6b027e43_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfNS00LTEtMS02MTQ4NjE_e31fd62a-392c-4c14-8511-7c83e82bd6d2" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" unitref="usd">854</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5137093847654fc0948b33ea6b027e43_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfNS02LTEtMS02MTQ4NjE_f88a94b5-686b-4e6d-b714-acde5c7ee393" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" unitref="usd">68</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i77f1db46087441bf8d0f1e7bcbdabcbc_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfNS04LTEtMS02MTQ4NjE_f8983217-d07e-4cc6-81da-b6d57230e8cd" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" unitref="usd">922</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i77f1db46087441bf8d0f1e7bcbdabcbc_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfNS0xMC0xLTEtNjE0ODYx_8a7c6ef2-3123-45a9-aa73-11dc9a8f3069" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" unitref="usd">844</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i77f1db46087441bf8d0f1e7bcbdabcbc_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfNS0xMi0xLTEtNjE0ODYx_ad2fd813-feaf-4a4d-9375-34cc4db3c0a1" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" unitref="usd">78</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3a9c8665ecc2474ca39f0f97addda98f_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfNi0yLTEtMS02MTQ4NjE_e09f1fa7-8c1c-49c8-bd81-0664ac6172a9" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" unitref="usd">2,420</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3a9c8665ecc2474ca39f0f97addda98f_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfNi00LTEtMS02MTQ4NjE_a8149fdf-ffaf-444d-8810-1e3034e70aa8" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" unitref="usd">1,433</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3a9c8665ecc2474ca39f0f97addda98f_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfNi02LTEtMS02MTQ4NjE_86fe337c-e5c4-4d38-a714-e0670da5bdc3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" unitref="usd">987</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i759bc7d5791e4fa3abf61f7f5b948b7b_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfNi04LTEtMS02MTQ4NjE_e41fb2e1-fae3-4f9f-ae56-26b82ead275b" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" unitref="usd">2,237</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i759bc7d5791e4fa3abf61f7f5b948b7b_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfNi0xMC0xLTEtNjE0ODYx_382d4536-647a-46b3-a177-5f40e4e98c91" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" unitref="usd">1,397</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i759bc7d5791e4fa3abf61f7f5b948b7b_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfNi0xMi0xLTEtNjE0ODYx_2c4e2f85-7208-4a8c-8823-14ecc5b52c37" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" unitref="usd">841</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfOC0yLTEtMS02MTQ4NjE_bfd0c0af-064a-424b-93c3-5363359a0961" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" unitref="usd">88,315</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfOC00LTEtMS02MTQ4NjE_4e1117a4-b851-42e4-a649-b194c5c27761" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" unitref="usd">59,174</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfOC02LTEtMS02MTQ4NjE_25e65ec1-cd37-4783-bde6-94afa180255d" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" unitref="usd">29,141</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfOC04LTEtMS02MTQ4NjE_f13b7708-87da-43a9-b13a-c2671be09a25" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" unitref="usd">88,763</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfOC0xMC0xLTEtNjE0ODYx_8f503b80-f2e1-4202-8b99-fb90f7621cb2" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" unitref="usd">58,548</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfOC0xMi0xLTEtNjE0ODYx_c4dec383-9d39-4e8a-93d0-81c920858a14" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" unitref="usd">30,215</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if6b24b3a07954187b5bc84a075e08bd6_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTAtMi0xLTEtNjE0ODYx_5f984ac4-1297-4314-8d99-6ce29f48d45a" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">827</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if6b24b3a07954187b5bc84a075e08bd6_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTAtNi0xLTEtNjE0ODYx_0c43cf47-07ed-4a71-95a8-c3d4f17c6911" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">827</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ia67f90e9ee984736a03c42fa2d0f4190_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTAtOC0xLTEtNjE0ODYx_c0af35ab-dcc5-4cd8-afb7-aa5bff9fbdff" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">827</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ia67f90e9ee984736a03c42fa2d0f4190_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTAtMTItMS0xLTYxNDg2MQ_a8437cc0-fcba-4a11-ac4a-41e68c748a69" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">827</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i7b15c009527b405a90632ab077451178_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTEtMi0xLTEtNjE0ODYx_20ab01a2-d8cc-4024-acaa-2606fbeb925f" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">11,269</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i7b15c009527b405a90632ab077451178_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTEtNi0xLTEtNjE0ODYx_8ea4efe8-5b6a-4e1b-9b9a-cc1d82c0a79d" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">11,269</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i80a72b9fde2247d08e63d5c5f5b199ba_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTEtOC0xLTEtNjE0ODYx_0580d8b8-ee8a-472c-96cc-4eebdee73f61" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">11,357</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i80a72b9fde2247d08e63d5c5f5b199ba_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTEtMTItMS0xLTYxNDg2MQ_5bee3d97-37b1-47c5-8ebb-a4e08dba01d1" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">11,357</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i70f5a45c59f348ff999efa622517e19c_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTItMi0xLTEtNjE0ODYx_6e76a536-86bd-4a1d-b74f-dc9ae4bff888" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">764</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i70f5a45c59f348ff999efa622517e19c_I20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTItNi0xLTEtNjE0ODYx_22c83131-70f4-4fef-bafb-e5d71c1b5a0e" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">764</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i8023deb5656547f9b7dbeffe9ba29540_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTItOC0xLTEtNjE0ODYx_e18a02dd-f92e-4b72-92e8-450c9bd6b846" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">971</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i8023deb5656547f9b7dbeffe9ba29540_I20221231" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTItMTItMS0xLTYxNDg2MQ_fa941bc7-0502-468b-8d68-5e4b4b629044" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">971</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTMtMi0xLTEtNjE0ODYx_aa6c6af4-5135-4d2d-84ae-860b6b0b852f" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">12,860</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTMtNi0xLTEtNjE0ODYx_a3468de9-392d-44fb-a470-0d814779fdf6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">12,860</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTMtOC0xLTEtNjE0ODYx_1451ffaf-ca8e-4fbd-b34a-b55dd0cca3de" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">13,155</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTMtMTItMS0xLTYxNDg2MQ_2e837604-7134-4a8a-8201-103308a9479f" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" unitref="usd">13,155</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTQtMi0xLTEtNjE0ODYx_bc8319e5-aa1c-4db2-9aaa-747dc696545a" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" unitref="usd">101,176</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTQtNC0xLTEtNjE0ODYx_395fda01-c22e-4efd-bcdf-2e7e55e101a5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" unitref="usd">59,174</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTQtNi0xLTEtNjE0ODYx_990cb2f5-fc62-4afe-a72f-648193fc0e25" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" unitref="usd">42,002</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTQtOC0xLTEtNjE0ODYx_eb4dde8b-7f51-487b-9de8-73bf1a5d217f" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" unitref="usd">101,919</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTQtMTAtMS0xLTYxNDg2MQ_c35d7d30-6cfd-4723-94cb-da7147a0a4a6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" unitref="usd">58,548</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RhYmxlOjVmMzYxY2QzYTgwMjQ4NTNhMDhlNzBhNDhiNDkwYTRkL3RhYmxlcmFuZ2U6NWYzNjFjZDNhODAyNDg1M2EwOGU3MGE0OGI0OTBhNGRfMTQtMTItMS0xLTYxNDg2MQ_46cdc9b8-e870-4d88-9cdb-7ee6fd8d7302" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" unitref="usd">43,370</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl83OS9mcmFnOmFiMGJmNmM2YzNiNjQ3ZjVhOTA3MmEyOTU5M2Q3Mjk2L3RleHRyZWdpb246YWIwYmY2YzZjM2I2NDdmNWE5MDcyYTI5NTkzZDcyOTZfMTEwNg_2e3fb9db-ec30-414c-8ec3-84c055decc20"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.37pt">The decrease is primarily due to amortization expense and impairments (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_49" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></ix:footnote></div></ix:nonnumeric></ix:nonnumeric></ix:continuation><div id="idfe6e72973fb4e83b28a5bb34d34299f_82"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="i99e27396569940ff8e8233eaa89d3c0d" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RleHRyZWdpb246M2YxNjNiNDE5NzFmNDAwMjhmMmY5YjFlMjI2MzRmMTNfOTc0_045f20db-8e4e-4411-ab65-c9a4df105f92" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock">Pension and Postretirement Benefit Plans</ix:nonnumeric></span></div><ix:continuation id="i99e27396569940ff8e8233eaa89d3c0d"><div style="margin-bottom:5pt;margin-top:3pt"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RleHRyZWdpb246M2YxNjNiNDE5NzFmNDAwMjhmMmY5YjFlMjI2MzRmMTNfOTU4_4ef62ef3-17b1-4345-8cb0-301b04720c11" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.569%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of net periodic benefit cost/(credit):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postretirement<br/>Plans</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3358f7116d834cc8a5b54b93d6b96097_D20230101-20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMTktMi0xLTEtNjE0ODYx_2ea0852d-5cb1-422e-9ae7-ed673fe8b9b9" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic4f2b470c8b84d51984bbd3c4208ad1c_D20220101-20220403" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMTktNC0xLTEtNjE0ODYx_ac849b47-a76a-48bc-983e-6758a0e3bcfd" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic7bd2b9d3b8e4dfe94ccb01ef6c06931_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMTktNi0xLTEtNjE0ODYx_dd25a185-1e26-4bf2-b790-1f62c70da49e" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" unitref="usd">22</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i9b360f41c3eb45d099b9841bdd9aec3d_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMTktOC0xLTEtNjE0ODYx_297349e8-a9f5-4f13-8531-59647fb54f66" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" unitref="usd">30</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i40492025ce5649019eeb09c5d59d13d9_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMTktMTAtMS0xLTYxNDg2MQ_a914cf6c-f48d-4e41-a538-623e8ed792b9" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" unitref="usd">3</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i30711953403d465aae1ade1a854b3060_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMTktMTItMS0xLTYxNDg2MQ_ad98e2d3-42ed-47d3-994d-fa0edbb0c09c" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" unitref="usd">7</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3358f7116d834cc8a5b54b93d6b96097_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjAtMi0xLTEtNjE0ODYx_d4064ead-400a-4fd8-a3c5-2981779ca6a3" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" unitref="usd">148</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic4f2b470c8b84d51984bbd3c4208ad1c_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjAtNC0xLTEtNjE0ODYx_d8bb68a5-7876-4388-891b-744d3ba20384" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" unitref="usd">118</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic7bd2b9d3b8e4dfe94ccb01ef6c06931_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjAtNi0xLTEtNjE0ODYx_4e26ad24-c6b4-4da6-8d85-20dfcd554a48" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" unitref="usd">71</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i9b360f41c3eb45d099b9841bdd9aec3d_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjAtOC0xLTEtNjE0ODYx_52af0268-e03d-4579-b4bf-50d81fdfe236" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" unitref="usd">42</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i40492025ce5649019eeb09c5d59d13d9_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjAtMTAtMS0xLTYxNDg2MQ_e6915dd4-da1f-403a-bc7f-c519e481294a" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" unitref="usd">5</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i30711953403d465aae1ade1a854b3060_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjAtMTItMS0xLTYxNDg2MQ_c9815e39-c0e8-4984-ae45-37e68573feb0" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" unitref="usd">7</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3358f7116d834cc8a5b54b93d6b96097_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjEtMi0xLTEtNjE0ODYx_ebb38865-f13b-4d48-b47e-0a597f37a6db" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" unitref="usd">194</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="ic4f2b470c8b84d51984bbd3c4208ad1c_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjEtNC0xLTEtNjE0ODYx_2c17f3f2-7d53-418c-a78b-908e110d0318" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" unitref="usd">245</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="ic7bd2b9d3b8e4dfe94ccb01ef6c06931_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjEtNi0xLTEtNjE0ODYx_107563a9-d48c-4ec2-a6b2-d32a5d9dabaa" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" unitref="usd">76</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i9b360f41c3eb45d099b9841bdd9aec3d_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjEtOC0xLTEtNjE0ODYx_7fe1793b-bf12-47b4-9928-e91155593eed" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" unitref="usd">79</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i40492025ce5649019eeb09c5d59d13d9_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjEtMTAtMS0xLTYxNDg2MQ_9cbc0e07-544e-4b1c-8416-3f96342d5722" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" unitref="usd">11</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i30711953403d465aae1ade1a854b3060_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjEtMTItMS0xLTYxNDg2MQ_3cd67bc9-7ab0-4a6d-b906-5f362491baa7" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" unitref="usd">12</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3358f7116d834cc8a5b54b93d6b96097_D20230101-20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjItMi0xLTEtNjE0ODYx_06496dd2-d9c7-4511-bed9-3086d87caca7" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic4f2b470c8b84d51984bbd3c4208ad1c_D20220101-20220403" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjItNC0xLTEtNjE0ODYx_5b48c692-e5d3-42b1-a1a2-6119919f3568" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic7bd2b9d3b8e4dfe94ccb01ef6c06931_D20230101-20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjItNi0xLTEtNjE0ODYx_a8f1933e-4828-4d9e-8d01-63e29638c11c" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i9b360f41c3eb45d099b9841bdd9aec3d_D20220101-20220403" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjItOC0xLTEtNjE0ODYx_879483eb-39b0-458f-9662-be59982871c9" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i40492025ce5649019eeb09c5d59d13d9_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjItMTAtMS0xLTYxNDg2MQ_6aa624f9-4615-4af5-811e-1f8b0b7aef09" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" sign="-" unitref="usd">30</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i30711953403d465aae1ade1a854b3060_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjItMTItMS0xLTYxNDg2MQ_003573e7-1a04-4709-b1ee-2f9407db5811" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" sign="-" unitref="usd">36</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains)/losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3358f7116d834cc8a5b54b93d6b96097_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjMtMi0xLTEtNjE0ODYx_743d6fa0-411c-4601-bb75-384c8821ad42" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" sign="-" unitref="usd">9</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="ic4f2b470c8b84d51984bbd3c4208ad1c_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjMtNC0xLTEtNjE0ODYx_25741350-9014-4bcb-8100-6283b42c69f3" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" unitref="usd">65</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic7bd2b9d3b8e4dfe94ccb01ef6c06931_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjMtNi0xLTEtNjE0ODYx_e6121488-dcb0-43d7-b1fc-02544e05fc90" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" sign="-" unitref="usd">3</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i9b360f41c3eb45d099b9841bdd9aec3d_D20220101-20220403" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjMtOC0xLTEtNjE0ODYx_03de2afd-cbd0-4511-b7c8-1a11e1e8fb05" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i40492025ce5649019eeb09c5d59d13d9_D20230101-20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjMtMTAtMS0xLTYxNDg2MQ_d23dcd4b-1ea5-4773-ab92-1bd08098150b" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i30711953403d465aae1ade1a854b3060_D20220101-20220403" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjMtMTItMS0xLTYxNDg2MQ_f2b30876-a5b1-4a94-9162-492f91b62558" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3358f7116d834cc8a5b54b93d6b96097_D20230101-20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjQtMi0xLTEtNjE0ODYx_14e579e2-ec1f-42fc-9ddc-263e6eb97bee" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic4f2b470c8b84d51984bbd3c4208ad1c_D20220101-20220403" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjQtNC0xLTEtNjE0ODYx_2953695f-d054-46e0-94a0-7f172a359c86" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="ic7bd2b9d3b8e4dfe94ccb01ef6c06931_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjQtNi0xLTEtNjE0ODYx_3dd40679-5bb3-47d7-89ac-511b27c6f1b5" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" unitref="usd">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i9b360f41c3eb45d099b9841bdd9aec3d_D20220101-20220403" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjQtOC0xLTEtNjE0ODYx_914e4dcb-8aa4-4458-b7b4-3b44dda9b981" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i40492025ce5649019eeb09c5d59d13d9_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjQtMTAtMS0xLTYxNDg2MQ_71570372-18d8-46d3-971d-94a5002e184b" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" unitref="usd">5</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i30711953403d465aae1ade1a854b3060_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjQtMTItMS0xLTYxNDg2MQ_4ce1850d-f7c7-47f3-b9e7-7c7734f9f633" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" unitref="usd">13</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Special termination benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3358f7116d834cc8a5b54b93d6b96097_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjUtMi0xLTEtNjE0ODYx_a3cb5621-5736-4886-9c33-7554ed625362" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" unitref="usd">2</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic4f2b470c8b84d51984bbd3c4208ad1c_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjUtNC0xLTEtNjE0ODYx_2f077661-6f0f-4287-b2e6-78d0321551ca" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" unitref="usd">6</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic7bd2b9d3b8e4dfe94ccb01ef6c06931_D20230101-20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjUtNi0xLTEtNjE0ODYx_d8866ea9-9341-4908-a5bc-a214dfe1a669" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i9b360f41c3eb45d099b9841bdd9aec3d_D20220101-20220403" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjUtOC0xLTEtNjE0ODYx_182b72b2-54a5-4177-8d1e-1c1bee498ca9" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i40492025ce5649019eeb09c5d59d13d9_D20230101-20230402" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjUtMTAtMS0xLTYxNDg2MQ_b0d933a6-3d6a-4996-97fc-387497f352ba" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i30711953403d465aae1ade1a854b3060_D20220101-20220403" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjUtMTItMS0xLTYxNDg2MQ_d5f0049c-0663-4586-bb3d-1a8ab224878d" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit) reported in income</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3358f7116d834cc8a5b54b93d6b96097_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjYtMi0xLTEtNjE0ODYx_76d5b54e-f2f1-4d9f-99dc-4ce23e8fb6d0" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" sign="-" unitref="usd">36</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="ic4f2b470c8b84d51984bbd3c4208ad1c_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjYtNC0xLTEtNjE0ODYx_f6a16485-02a5-4f1f-81bd-5c0e18acd27c" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" sign="-" unitref="usd">186</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic7bd2b9d3b8e4dfe94ccb01ef6c06931_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjYtNi0xLTEtNjE0ODYx_addbacbf-6c2a-47c9-90e9-847cb6a0e53d" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" unitref="usd">18</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i9b360f41c3eb45d099b9841bdd9aec3d_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjYtOC0xLTEtNjE0ODYx_5ee5fc8f-e0b4-46db-8cad-8ef7d09c4baf" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" sign="-" unitref="usd">8</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i40492025ce5649019eeb09c5d59d13d9_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjYtMTAtMS0xLTYxNDg2MQ_9af72661-0380-4e69-9011-52c1d7f32938" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" sign="-" unitref="usd">37</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i30711953403d465aae1ade1a854b3060_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RhYmxlOmJmMTM0NGEyY2YxYjRlMGQ4YWQ0MGI4NDgzZTE4YzI0L3RhYmxlcmFuZ2U6YmYxMzQ0YTJjZjFiNGUwZDhhZDQwYjg0ODNlMThjMjRfMjYtMTItMS0xLTYxNDg2MQ_bead6933-7b9e-49d3-9d4d-535cac991336" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" sign="-" unitref="usd">46</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonnumeric></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost/(credit) other than the service cost component are primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_49" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended April 2, 2023, we contributed $<ix:nonfraction contextref="i3358f7116d834cc8a5b54b93d6b96097_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RleHRyZWdpb246M2YxNjNiNDE5NzFmNDAwMjhmMmY5YjFlMjI2MzRmMTNfNzcy_892dee62-8d73-4060-b064-b959fd2f3924" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" unitref="usd">85</ix:nonfraction> million, $<ix:nonfraction contextref="ic7bd2b9d3b8e4dfe94ccb01ef6c06931_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RleHRyZWdpb246M2YxNjNiNDE5NzFmNDAwMjhmMmY5YjFlMjI2MzRmMTNfNzc2_1c481bfa-456a-4a2d-8b90-82ad0ac4e3bd" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" unitref="usd">39</ix:nonfraction> million, and $<ix:nonfraction contextref="i40492025ce5649019eeb09c5d59d13d9_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84Mi9mcmFnOjNmMTYzYjQxOTcxZjQwMDI4ZjJmOWIxZTIyNjM0ZjEzL3RleHRyZWdpb246M2YxNjNiNDE5NzFmNDAwMjhmMmY5YjFlMjI2MzRmMTNfNzg0_11c80ab8-1a48-4d46-ba64-9af65fa2b852" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" unitref="usd">20</ix:nonfraction> million to our U.S. Pension Plans, International Pension Plans, and Postretirement Plans, respectively, from our general assets, which include direct employer benefit payments.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_85"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="i9d176b2e034d4db9bc6fbeb9831175e8" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RleHRyZWdpb246ZTE1OTIwNjQyN2ZiNDFkMTg1YjI0NTE1ZmE3NjQ2YTdfMjQ3_75272516-7458-4f32-9fb2-a9798eb4cd50" name="us-gaap:EarningsPerShareTextBlock">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</ix:nonnumeric></span></div><ix:continuation id="i9d176b2e034d4db9bc6fbeb9831175e8"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RleHRyZWdpb246ZTE1OTIwNjQyN2ZiNDFkMTg1YjI0NTE1ZmE3NjQ2YTdfMjU0_06411d05-c8ce-47f4-8bc7-205e9ce53e66" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents the detailed calculation of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">EPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator&#8211;&#8211;Basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfNi02LTEtMS02MTQ4NjE_5ef4ca79-7d66-43d1-ac45-b28b15aeae22" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" scale="6" unitref="usd">5,542</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfNi04LTEtMS02MTQ4NjE_01390467-859b-4fde-8ce1-d8acfe4c5bbe" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" scale="6" unitref="usd">7,872</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfNy02LTEtMS02MTQ4NjE_54e4bbf2-d086-49e9-8c0f-0076834da9b9" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" unitref="usd">1</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfNy04LTEtMS02MTQ4NjE_c9ff8af1-a63f-44ec-934d-d7cc6a3c8c2b" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" sign="-" unitref="usd">9</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfMTAtNi0xLTEtNjE0ODYx_c9829320-d359-4c82-8423-e7f78b8d41d6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" unitref="usd">5,543</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfMTAtOC0xLTEtNjE0ODYx_351e29b7-f37f-4852-8014-fe27b2493631" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" unitref="usd">7,864</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator&#8211;&#8211;Diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfMTItNi0xLTEtNjE0ODYx_f9e50702-0b06-4b2b-b1b9-ea9396e74bea" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" scale="6" unitref="usd">5,542</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfMTItOC0xLTEtNjE0ODYx_ceb88374-33b7-4603-9c80-f540f42f1c5d" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" scale="6" unitref="usd">7,872</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfMTMtNi0xLTEtNjE0ODYx_c857c528-ead6-4a79-aec6-e0795c305132" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" unitref="usd">1</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfMTMtOC0xLTEtNjE0ODYx_24a4eaa2-1fd1-40af-a5fd-aa9edebaabac" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" sign="-" unitref="usd">9</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfMTQtNi0xLTEtNjE0ODYx_2fc85aaa-0d10-4022-80ae-aedfabc91be2" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" unitref="usd">5,543</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfMTQtOC0xLTEtNjE0ODYx_97c62c45-1f0e-41dc-8225-4870a41fab80" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" unitref="usd">7,864</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Denominator</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfMTYtNi0xLTEtNjE0ODYx_6df10bc2-44c9-49dd-9730-a1a296fcbea6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" unitref="shares">5,634</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfMTYtOC0xLTEtNjE0ODYx_caea53c3-87bf-49b1-b099-40b1e1f5bdbd" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" unitref="shares">5,617</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common-share equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfMTctNi0xLTEtNjE0ODYx_0b11bd7d-6726-4de0-b168-306fc6a551e0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" unitref="shares">93</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfMTctOC0xLTEtNjE0ODYx_9f066bc3-0749-4263-9eb6-7396bbc17ae4" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" unitref="shares">141</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfMTgtNi0xLTEtNjE0ODYx_f6947243-7f59-45d7-941e-7bb2acf7dee0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" unitref="shares">5,727</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfMTgtOC0xLTEtNjE0ODYx_fef7d30a-eae5-4518-928c-ec739e37aa25" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" unitref="shares">5,758</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive common stock equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfMTktNi0xLTEtNjE0ODYx_377dc3a7-b52c-42a7-b51c-9f1d20e2bdbd" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" unitref="shares">2</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RhYmxlOmIyOWIyOGI3ZWFkMjQwZjI4MTU5YzM5YzhmYzg1ZmIyL3RhYmxlcmFuZ2U6YjI5YjI4YjdlYWQyNDBmMjgxNTljMzljOGZjODVmYjJfMTktOC0xLTEtNjE0ODYx_f81440fe-7939-4d30-9643-6cd751077d85" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" unitref="shares">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84NS9mcmFnOmUxNTkyMDY0MjdmYjQxZDE4NWIyNDUxNWZhNzY0NmE3L3RleHRyZWdpb246ZTE1OTIwNjQyN2ZiNDFkMTg1YjI0NTE1ZmE3NjQ2YTdfMjQ0_b4fc65e4-091f-4f21-a678-197fd201034a">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</ix:footnote></span></div></ix:nonnumeric></ix:continuation><div id="idfe6e72973fb4e83b28a5bb34d34299f_88"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="ib79d0ba4b3874775bdba0491eaa226a9" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84OC9mcmFnOjRmODQ5ZWZjZGIxZTRhNGJiM2Y0YzcwNzI0NDI1MTYxL3RleHRyZWdpb246NGY4NDllZmNkYjFlNGE0YmIzZjRjNzA3MjQ0MjUxNjFfNDQ3NDc_1fe86b8b-df02-4b0c-b3b9-3d0b39650ea8" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock">Contingencies and Certain Commitments</ix:nonnumeric></span></div><ix:continuation continuedat="icde52ea971b34889ab8ab88fbc3e99e7" id="ib79d0ba4b3874775bdba0491eaa226a9"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies, guarantees and indemnifications. The following outlines our legal contingencies, guarantees and indemnifications. For a discussion of our tax contingencies, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5B</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Legal Proceedings</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our legal contingencies include, but are not limited to, the following:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. An adverse outcome could result in loss of patent protection for a product, a significant loss of revenues from a product or impairment of the value of associated assets. We are the plaintiff in the majority of these actions. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Product liability and other product-related litigation related to current or former products, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, and often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Commercial and other asserted or unasserted matters, which can include acquisition-, licensing-, intellectual property-, collaboration- or co-promotion-related and product-pricing claims and environmental claims and proceedings, and can involve complexities that will vary from matter to matter.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of these contingencies could result in increased expenses and/or losses, including damages, royalty payments, fines and/or civil penalties, which could be substantial, and/or criminal charges. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation continuedat="if3b3a3ec3adf45d58a1de27bd8c11fdb" id="icde52ea971b34889ab8ab88fbc3e99e7"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For proceedings under environmental laws to which a governmental authority is a party, we have adopted a disclosure threshold of $<ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84OC9mcmFnOjRmODQ5ZWZjZGIxZTRhNGJiM2Y0YzcwNzI0NDI1MTYxL3RleHRyZWdpb246NGY4NDllZmNkYjFlNGE0YmIzZjRjNzA3MjQ0MjUxNjFfMzI0OQ_40cd0f2e-c552-4a76-b73e-d4f3e7055727" name="pfe:SiteContingencyRegulatoryProceedingsDisclosureThreshold" scale="6" unitref="usd">1</ix:nonfraction> million in potential or actual governmental monetary sanctions.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors to assess materiality, such as, among others, the amount of damages and the nature of other relief sought, if specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader&#8217;s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. Some of the matters discussed below include those which management believes that the likelihood of possible loss in excess of amounts accrued is remote.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A1. Legal Proceedings&#8211;&#8211;Patent Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in suits relating to our patents (or those of our collaboration/licensing partners to which we have licenses or co-promotion rights), including but not limited to, those discussed below. We face claims by generic drug manufacturers that patents covering our products (or those of our collaboration/licensing partners to which we have licenses or co-promotion rights and to which we may or may not be a party), processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents that are discussed below, patent rights to certain of our products or those of our collaboration/licensing partners are being challenged in various other jurisdictions. Some of our collaboration or licensing partners face challenges to the validity of their patent rights in non-U.S. jurisdictions. For example, in April 2022, the U.K. High Court issued a judgment finding invalid a BMS patent related to Eliquis due to expire in 2026. In November 2022, BMS received permission to appeal the High Court&#8217;s decision and the appeal hearing was held in April 2023. In May 2023, the Court of Appeal dismissed the appeal. Additional challenges are pending in other jurisdictions. Also, in July 2022, CureVac AG (CureVac) brought a patent infringement action against BioNTech and certain of its subsidiaries in the German Regional Court alleging that Comirnaty infringes certain German utility model patents and certain expired and unexpired European patents. Additional challenges involving Comirnaty patents may be filed against us and/or BioNTech in other jurisdictions in the future. Adverse decisions in these matters could have a material adverse effect on our results of operations.</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts, as well as court proceedings relating to our intellectual property or the intellectual property rights of others, including challenges to such rights initiated by us. Also, if one of our patents (or one of our collaboration/licensing partner&#8217;s patents) is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio have been challenged in inter partes review and post-grant review proceedings in the U.S. Patent and Trademark Office, as well as outside the U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The invalidation of any of the patents in our pneumococcal portfolio could potentially allow additional competitor vaccines, if approved, to enter the marketplace earlier than anticipated. In the event that any of the patents are found valid and infringed, a competitor&#8217;s vaccine, if approved, might be prohibited from entering the market or a competitor might be required to pay us a royalty.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. If one of our marketed products (or a product of our collaboration/licensing partners to which we have licenses or co-promotion rights) is found to infringe valid patent rights of a third party, such third party may be awarded significant damages or royalty payments, or we may be </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation continuedat="i7f4b3dbe84414c13b61ed601f05c8aec" id="if3b3a3ec3adf45d58a1de27bd8c11fdb"><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actions In Which We Are The Plaintiff</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Xeljanz (tofacitinib)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate abbreviated new drug applications (ANDAs) with the FDA seeking approval to market their generic versions of tofacitinib tablets in one or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, we have settled actions with several manufacturers on terms not material to us. The remaining action continues in the U.S. District Court for the District of Delaware as described below.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we brought a separate patent-infringement action against Sinotherapeutics Inc. (Sinotherapeutics) asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Sinotherapeutics in its ANDA seeking approval to market a generic version of tofacitinib 11 mg extended release tablets. In November 2022, we filed an additional patent-infringement action against Sinotherapeutics relating to its challenge of our extended release formulation and method of treatment patents in its ANDA seeking approval to market a generic version of tofacitinib 22 mg extended release tablets.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ibrance (palbociclib)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in January 2021, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Ibrance tablets. The generic companies challenged some or all of the following patents: (i) the composition of matter patent expiring in 2027; (ii) the composition of matter patent expiring in 2023; (iii) the method of use patent expiring in 2023; (iv) the crystalline form patent expiring in 2034; and (v) a tablet formulation patent expiring in 2036. We brought patent infringement actions against each of the generic filers in various U.S. federal courts, asserting the validity and infringement of the patents challenged by the generic companies. We have settled with one of these generic companies on terms not material to us, and we dismissed the patent infringement actions relating to the crystalline form of patent, the composition of matter patent expiring in 2023, the method of use patent, and the tablet formulation patent against the generic companies that had challenged these patents. The composition of matter patent expiring in 2027 remains in suit. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eucrisa</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2021, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Eucrisa. The companies assert the invalidity and non-infringement of a composition of matter patent expiring in 2026, two method of use patents expiring in 2027, and one other method of use patent expiring in 2030. In September 2021, we brought patent infringement actions against the generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the patents challenged by the generic companies.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Mektovi (binimetinib)</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in August 2022, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Mektovi. The companies assert the invalidity and non-infringement of <ix:nonfraction contextref="i9a76066cd27341e78cef591f9df5cd40_D20220801-20220831" decimals="INF" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84OC9mcmFnOjRmODQ5ZWZjZGIxZTRhNGJiM2Y0YzcwNzI0NDI1MTYxL3RleHRyZWdpb246NGY4NDllZmNkYjFlNGE0YmIzZjRjNzA3MjQ0MjUxNjFfMTMyMzU_9204ca35-b915-49cf-8226-3eda45a68382" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" unitref="patent">two</ix:nonfraction> method of use patents expiring in 2030, a method of use patent expiring in 2031, <ix:nonfraction contextref="i53b5aacd2ce84cfdab19c4d92d5faf64_D20220801-20220831" decimals="INF" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84OC9mcmFnOjRmODQ5ZWZjZGIxZTRhNGJiM2Y0YzcwNzI0NDI1MTYxL3RleHRyZWdpb246NGY4NDllZmNkYjFlNGE0YmIzZjRjNzA3MjQ0MjUxNjFfMTMzMTk_ced65555-9b17-405d-af65-69e18222798f" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" unitref="patent">two</ix:nonfraction> method of use patents expiring in 2033, and a product by process patent expiring in 2033. Beginning in September 2022, we brought patent infringement actions against the generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of all <ix:nonfraction contextref="i5a7b5f1bd4354a74babd4ae2171ed072_D20220801-20220831" decimals="INF" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84OC9mcmFnOjRmODQ5ZWZjZGIxZTRhNGJiM2Y0YzcwNzI0NDI1MTYxL3RleHRyZWdpb246NGY4NDllZmNkYjFlNGE0YmIzZjRjNzA3MjQ0MjUxNjFfMTM2MTE_a1de57b9-f1c7-4b04-aa9d-ad0db01338af" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" unitref="patent">six</ix:nonfraction> patents.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actions in Which We are the Defendant</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comirnaty</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Alnylam Pharmaceuticals, Inc. (Alnylam) filed a complaint in the U.S. District Court for the District of Delaware against Pfizer and Pharmacia &amp; Upjohn Co. LLC, our wholly owned subsidiary, alleging that Comirnaty infringes U.S. Patent No. 11,246,933, which was issued in February 2022, and seeking unspecified monetary damages. In July 2022, Alnylam filed a second complaint in the U.S. District Court for the District of Delaware against Pfizer, Pharmacia &amp; Upjohn Co. LLC, BioNTech and BioNTech Manufacturing GmbH, alleging that Comirnaty infringes U.S. Patent No. 11,382,979, which was issued in July 2022, and seeking unspecified monetary damages.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, ModernaTX, Inc. (ModernaTX) and Moderna US, Inc. (Moderna) sued Pfizer, BioNTech, BioNTech Manufacturing GmbH and BioNTech US Inc. in the U.S. District Court for the District of Massachusetts, alleging that Comirnaty infringes <ix:nonfraction contextref="idf5ccc1825fd445ebe4560e83a1930f9_D20220801-20220831" decimals="INF" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84OC9mcmFnOjRmODQ5ZWZjZGIxZTRhNGJiM2Y0YzcwNzI0NDI1MTYxL3RleHRyZWdpb246NGY4NDllZmNkYjFlNGE0YmIzZjRjNzA3MjQ0MjUxNjFfMzg0ODI5MDc4OTI1Nw_4935d4c5-dbba-4d04-b3d8-407e858418b6" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" scale="0" unitref="patent">three</ix:nonfraction> U.S. patents. In its complaint, Moderna stated that it is seeking damages for alleged infringement occurring after March 7, 2022.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, ModernaTX filed a patent infringement action in Germany against Pfizer and certain subsidiary companies, as well as BioNTech and certain subsidiary companies, alleging that Comirnaty infringes <ix:nonfraction contextref="i8541a2634e9345ae81ecd804da5ad468_D20220801-20220831" decimals="INF" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84OC9mcmFnOjRmODQ5ZWZjZGIxZTRhNGJiM2Y0YzcwNzI0NDI1MTYxL3RleHRyZWdpb246NGY4NDllZmNkYjFlNGE0YmIzZjRjNzA3MjQ0MjUxNjFfMjc0ODc3OTI2NDE2MA_47b4ff0b-57a4-4fa6-85e9-2c99709ae0ed" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" scale="0" unitref="patent">two</ix:nonfraction> European patents. In September 2022, ModernaTX filed patent infringement actions in the U.K. and in the Netherlands against Pfizer and certain subsidiary </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation continuedat="idf68c40646f74df392e109ebc49aae5c" id="i7f4b3dbe84414c13b61ed601f05c8aec"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies, as well as BioNTech and certain subsidiary companies, on the same <ix:nonfraction contextref="i893e8816ebcd4b80b04f031849309ef5_D20220901-20220930" decimals="INF" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84OC9mcmFnOjRmODQ5ZWZjZGIxZTRhNGJiM2Y0YzcwNzI0NDI1MTYxL3RleHRyZWdpb246NGY4NDllZmNkYjFlNGE0YmIzZjRjNzA3MjQ0MjUxNjFfMTUxNzE_b618d290-dc2f-42b7-afd7-96ca35847326" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" scale="0" unitref="patent">two</ix:nonfraction> patents. In its complaints, ModernaTX stated that it is seeking damages for alleged infringement occurring after March 7, 2022. In the U.K., Pfizer and BioNTech have brought an action against ModernaTX seeking to revoke these European patents, which was consolidated with the September 2022 action filed by ModernaTX.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, Arbutus Biopharma Corp. (Arbutus) and Genevant Sciences GmbH (Genevant) filed a complaint in the U.S. District Court for the District of New Jersey against Pfizer and BioNTech alleging that Comirnaty and its manufacture infringe <ix:nonfraction contextref="i4acda04ccc0f418c9766a62f03abaa29_D20230401-20230430" decimals="INF" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84OC9mcmFnOjRmODQ5ZWZjZGIxZTRhNGJiM2Y0YzcwNzI0NDI1MTYxL3RleHRyZWdpb246NGY4NDllZmNkYjFlNGE0YmIzZjRjNzA3MjQ0MjUxNjFfMjc0ODc3OTI1NzgzNg_79b6a985-0fcb-4fad-924b-f1b74c2cce2f" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" scale="0" unitref="patent">five</ix:nonfraction> U.S. patents, and seeking unspecified monetary damages.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paxlovid</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, Enanta Pharmaceuticals, Inc. filed a complaint in the U.S. District Court for the District of Massachusetts against Pfizer alleging that the active ingredient in Paxlovid, nirmatrelvir, infringes U.S.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patent No. 11,358,953, which was issued in June 2022, and seeking unspecified monetary damages.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matters Involving Pfizer and its Collaboration/Licensing Partners</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comirnaty</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Pfizer, BioNTech and BioNTech Manufacturing GmbH filed a declaratory judgment complaint against CureVac in the U.S. District Court for the District of Massachusetts seeking a judgment of non-infringement for the following <ix:nonfraction contextref="i81fa44c335a441e69bcbe5b0b0c2522e_D20220701-20220731" decimals="INF" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84OC9mcmFnOjRmODQ5ZWZjZGIxZTRhNGJiM2Y0YzcwNzI0NDI1MTYxL3RleHRyZWdpb246NGY4NDllZmNkYjFlNGE0YmIzZjRjNzA3MjQ0MjUxNjFfMTc2MzA_f214b44a-90c4-48eb-999f-df8bf31ff087" name="us-gaap:LossContingencyPatentsFoundNotInfringedNumber" scale="0" unitref="patent">three</ix:nonfraction> patents relating to Comirnaty: U.S. Patent Nos. 11,135,312, 11,149,278, and 11,241,493. Outside of the U.S., in the U.K., Pfizer and BioNTech have sued CureVac seeking a judgment of invalidity of several patents and CureVac has made certain infringement counterclaims.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Xtandi (enzalutamide)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Medivation LLC and Medivation Prostate Therapeutics LLC (wholly owned subsidiaries of Pfizer); Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.; and The Regents of the University of California filed a patent-infringement suit in the U.S. District Court for the District of New Jersey against Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Ltd.; and in December 2022, the same entities filed a patent-infringement suit in the U.S. District Court for the District of New Jersey against Sun in connection with those companies&#8217; respective ANDAs seeking approval to market generic versions of enzalutamide. The generic manufacturers are challenging the composition of matter patent, which expires in 2027, covering enzalutamide and pharmaceutical compositions thereof, for treating prostate cancer.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eliquis</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we and BMS brought separate patent-infringement actions in Federal Court in Delaware against each of Biocon Pharma Limited (Biocon) and ScieGen Pharmaceuticals Inc. (ScieGen) asserting the infringement and validity of the formulation patent for Eliquis, expiring in 2031, challenged by Biocon and ScieGen in their respective ANDAs seeking approval to market generic versions of Eliquis. In April 2023, we settled our action against ScieGen on terms not material to us.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A2. Legal Proceedings&#8211;&#8211;Product Litigation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asbestos</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous lawsuits against American Optical, Pfizer and certain of its previously owned subsidiaries are pending in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also&#160;are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effexor</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation continuedat="if7b989e69ab84288af4d9d64cbae7e53" id="idf68c40646f74df392e109ebc49aae5c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effexor XR from any of the defendants from June 14, 2008 until the time the defendants&#8217; allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, the District Court dismissed the direct purchaser plaintiffs&#8217; claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lipitor</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain Pfizer affiliates, and, in most of the actions, Ranbaxy Laboratories Ltd. (Ranbaxy) and certain Ranbaxy affiliates. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants&#8217; allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a MDL in the U.S. District</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Court for the District of New Jersey. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2013 and 2014, the District Court dismissed with prejudice the claims of the direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other MDL plaintiffs. All plaintiffs appealed the District Court&#8217;s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the Court of Appeals. In 2017, the Court of Appeals reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EpiPen (Direct Purchaser)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, a lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, its current and former affiliates King and Meridian, and various Mylan entities, on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants. Plaintiffs in this action generally allege that Pfizer and Mylan conspired to delay market entry of generic EpiPen through the settlement of patent litigation regarding EpiPen, and thereby delayed market entry of generic EpiPen in violation of federal antitrust law. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In July 2021, the District Court granted defendants&#8217; motion to dismiss the direct purchaser complaint, without prejudice. In September 2021, plaintiffs filed an amended complaint. In August 2022, the District Court granted Pfizer&#8217;s motion to dismiss the complaint, and plaintiffs have appealed to the U.S. Court of Appeals for the Tenth Circuit.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nexium 24HR and Protonix</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against Pfizer involve Protonix and/or Nexium 24HR and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a MDL in the U.S. District Court for </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation continuedat="i6769c373d94d41409457f4c3c60a2ef8" id="if7b989e69ab84288af4d9d64cbae7e53"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the District of New Jersey. As part of the combination of our and GSK&#8217;s consumer healthcare businesses to form Haleon, Haleon assumed, and agreed to indemnify Pfizer for, liabilities arising out of such litigation to the extent related to Nexium 24HR.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Docetaxel</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Personal Injury Actions</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages. Additional lawsuits have been filed in which plaintiffs allege they developed blocked tear ducts following their treatment with Docetaxel.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the federal cases were transferred for coordinated pre-trial proceedings to a MDL in the U.S. District Court for the Eastern District of Louisiana. In 2022, the eye injury cases were transferred for coordinated pre-trial proceedings to a MDL in the U.S. District Court for the Eastern District of Louisiana.</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Mississippi Attorney General Government Action</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and <ix:nonfraction contextref="i1b2ba49765614b829a5d721ca534a4b9_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl84OC9mcmFnOjRmODQ5ZWZjZGIxZTRhNGJiM2Y0YzcwNzI0NDI1MTYxL3RleHRyZWdpb246NGY4NDllZmNkYjFlNGE0YmIzZjRjNzA3MjQ0MjUxNjFfMjczNTU_e683a83c-7bd0-4ef4-9406-c7787d4f3709" name="pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant" scale="0" unitref="manufacturer">eight</ix:nonfraction> other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The action seeks civil penalties and injunctive relief.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zantac </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or sold Zantac. Pfizer has not sold Zantac since 2006, and only sold an OTC version of the product. In 2006, Pfizer sold the consumer business that included its Zantac OTC rights to Johnson &amp; Johnson and transferred the assets and liabilities related to Zantac OTC to Johnson &amp; Johnson in connection with the sale. Plaintiffs in these cases seek compensatory and punitive damages.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the federal actions were transferred for coordinated pre-trial proceedings to a MDL in the U.S. District Court for the Southern District of Florida (the Federal MDL Court). Plaintiffs in the MDL have filed against Pfizer and many other defendants a master personal injury complaint, asserting a consolidated consumer class action alleging, among other things, claims under consumer protection statutes of all 50 states, and a medical monitoring complaint seeking to certify medical monitoring classes under the laws of 13 states. In December 2022, the Federal MDL Court granted defendants&#8217; Daubert motions to exclude plaintiffs&#8217; expert testimony and motion for summary judgment on general causation, and dismissed the litigation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, (i) Pfizer has received service of Canadian class action complaints naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal injury and economic loss, allegedly arising from the defendants&#8217; sale of Zantac in Canada; and (ii) the State of New Mexico and the Mayor and City Council of Baltimore separately filed civil actions against Pfizer and many other defendants in state courts, alleging various state statutory and common law claims in connection with the defendants&#8217; alleged sale of Zantac in those jurisdictions. In April 2021, a Judicial Council Coordinated Proceeding was created in the Superior Court of California in Alameda County to coordinate personal injury actions against Pfizer and other defendants filed in California state court. Coordinated proceedings have also been created in other state courts. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chantix</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in August 2021, a number of putative class actions have been filed against Pfizer in various U.S. federal courts following Pfizer&#8217;s voluntary recall of Chantix due to the presence of a nitrosamine, N-nitroso-varenicline. Plaintiffs assert that they suffered economic harm purportedly as a result of purchasing Chantix or generic varenicline medicines sold by Pfizer. Plaintiffs seek to represent nationwide and state-specific classes and seek various remedies, including damages and medical monitoring. In December 2022, the federal actions were transferred for coordinated pre-trial proceedings to a MDL in the U.S. District Court for the Southern District of New York. Similar putative class actions have been filed in Canada and Israel, where the product brand is Champix.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A3. Legal Proceedings&#8211;&#8211;Commercial and Other Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Monsanto-Related Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation continuedat="i1f1c68b084784e4cb35b4c81e8e972cb" id="i6769c373d94d41409457f4c3c60a2ef8"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia&#8217;s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto&#8217;s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia&#8217;s indemnification obligations relating to Former Monsanto&#8217;s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto&#8217;s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia&#8217;s and New Monsanto&#8217;s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto&#8217;s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto&#8217;s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2009, as part of our acquisition of Wyeth, we assumed responsibility for environmental remediation at the Wyeth Holdings LLC (formerly known as, Wyeth Holdings Corporation and American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. Since that time, we have executed or have become a party to a number of administrative settlement agreements, orders on consent, and/or judicial consent decrees, with the U.S. Environmental Protection Agency and/or New Jersey Department of Environmental Protection to perform remedial design, removal and remedial actions, and related environmental remediation activities at the Bound Brook facility. We have accrued for the currently estimated costs of these activities.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contracts with Iraqi Ministry of Health</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, a number of U.S. service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2020, the District Court granted defendants&#8217; motions to dismiss and dismissed all of plaintiffs&#8217; claims. In January 2022, the Court of Appeals reversed the District Court&#8217;s decision. In February 2022, the defendants filed for en banc review of the Court of Appeals&#8217; decision. In February 2023, the Court of Appeals denied defendants&#8217; en banc petitions.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allergan Complaint for Indemnity</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Pfizer was named as a defendant in a complaint, along with King, filed by Allergan Finance LLC (Allergan) in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. This suit was voluntarily discontinued without prejudice in January 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Viatris Securities Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, a putative class action was filed in the Court of Common Pleas of Allegheny County, Pennsylvania on behalf of former Mylan N.V. shareholders who received Viatris common stock in exchange for Mylan shares in connection with the spin-off of the Upjohn Business and its combination with Mylan (the Transactions). Viatris, Pfizer, and certain of each company&#8217;s current and former officers, directors and employees are named as defendants. An amended complaint was filed in January 2023, and alleges that the defendants violated certain provisions of the Securities Act of 1933 in connection with certain disclosures made in or omitted from the registration statement and related prospectus issued in connection with the Transactions, as well as related communications. Plaintiff seeks damages, costs and expenses and other equitable and injunctive relief.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation continuedat="ic9793cd61b124423bd3aac2bf1470956" id="i1f1c68b084784e4cb35b4c81e8e972cb"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A4. Legal Proceedings&#8211;&#8211;Government Investigations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. These matters often involve government requests for information on a voluntary basis or through subpoenas after which the government may seek additional information through follow-up requests or additional subpoenas. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government. Among the investigations by government agencies are the matters discussed below.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Greenstone Investigations</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">U.S. Department of Justice Antitrust Division Investigation</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since July 2017, the U.S. Department of Justice's Antitrust Division has been investigating our former Greenstone generics business. We believe this is related to an ongoing broader antitrust investigation of the generic pharmaceutical industry. We have produced records relating to this investigation. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">State Attorneys General and Multi-District Generics Antitrust Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Greenstone received requests for information from the Antitrust Department of the Connecticut Office of the Attorney General. In May 2019, Attorneys General of more than 40 states plus the District of Columbia and Puerto Rico filed a complaint against a number of pharmaceutical companies, including Greenstone and Pfizer. The matter has been consolidated with a MDL in the Eastern District of Pennsylvania. As to Greenstone and Pfizer, the complaint alleges anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws. In June 2020, the State Attorneys General filed a new complaint against a large number of companies, including Greenstone and Pfizer, making similar allegations, but concerning a new set of drugs. This complaint was transferred to the MDL in July 2020. The MDL also includes civil complaints filed by private plaintiffs and state counties against Pfizer, Greenstone and a significant number of other defendants asserting allegations that generally overlap with those asserted by the State Attorneys General.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subpoena &amp; Civil Investigative Demand relating to Tris Pharma/Quillivant XR</span></div><div style="margin-bottom:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We responded to that subpoena in full and have had no communication with the SDNY in connection with the subpoena since June 2019. Additionally, in September 2020,&#8239;we received a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil Investigative Demand (CID)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the Texas Attorney General&#8217;s office&#8239;seeking records of a similar nature to those requested by the SDNY. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are producing records in response to this request.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Inquiries relating to Meridian Medical Technologies </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we received a CID from the U.S. Attorney&#8217;s Office for the SDNY. The CID seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at the Meridian site. In August 2019, we received a HIPAA subpoena issued by the U.S. Attorney&#8217;s Office for the Eastern District of Missouri, in coordination with the Department of Justice&#8217;s Consumer Protection Branch, seeking similar records and information. We are producing records in response to these and subsequent requests.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice/SEC Inquiry relating to Russian Operations</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we received an informal request from the U.S. Department of Justice&#8217;s Foreign Corrupt Practices Act (FCPA) Unit seeking documents relating to our operations in Russia. In September 2019, we received a similar request from the SEC&#8217;s FCPA Unit. We have produced records pursuant to these requests. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Docetaxel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mississippi Attorney General Government Investigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Docetaxel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mississippi Attorney General Government Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for information regarding a government investigation related to Docetaxel marketing practices.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice Inquiries relating to India Operations</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we received an informal request from the U.S. Department of Justice's Consumer Protection Branch seeking documents relating to our manufacturing operations in India, including at our former facility located at Irrungattukottai in India. In April 2020, we received a similar request from the U.S. Attorney&#8217;s Office for the SDNY regarding a civil investigation concerning operations at our facilities in India. We are producing records pursuant to these requests.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ic9793cd61b124423bd3aac2bf1470956"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice/SEC Inquiry relating to China Operations</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we received an informal request from the U.S. Department of Justice's FCPA Unit seeking documents relating to our operations in China. In August 2020, we received a similar request from the SEC&#8217;s FCPA Unit. We have produced records pursuant to these requests.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zantac&#8211;&#8211;State of New Mexico and Mayor and City Council of Baltimore Civil Actions</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings&#8211;&#8211;Product Litigation&#8211;&#8211;Zantac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for information regarding civil actions separately filed by the State of New Mexico and the Mayor and City Council of Baltimore alleging various state statutory and common law claims in connection with the defendants&#8217; alleged sale of Zantac in those jurisdictions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Inquiries relating to Biohaven</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the U.S. Department of Justice's Commercial Litigation Branch and the U.S. Attorney&#8217;s Office for the Western District of New York issued a CID relating to Biohaven. The CID seeks records and information related to, among other things, engagements with health care professionals and co-pay coupons cards. In March 2023, the California Department of Insurance issued a subpoena seeking records similar to those requested by the CID. Biohaven is a wholly-owned subsidiary that we acquired in October 2022. We are producing records in response to these requests.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice Inquiry relating to Mexico Operations </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we received an informal request from the U.S. Department of Justice&#8217;s FCPA Unit seeking documents relating to our operations in Mexico.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are producing records pursuant to this request.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Inquiries relating to Xeljanz </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we received a HIPAA subpoena issued by the U.S. Attorney&#8217;s Office for the Western District of Virginia, in coordination with the Department of Justice&#8217;s Commercial Litigation Branch, seeking records and information related to programs Pfizer sponsored in retail pharmacies relating to Xeljanz. We are producing records pursuant to this request. </span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Guarantees and Indemnifications</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of April&#160;2, 2023, the estimated fair value of these indemnification obligations is not material to Pfizer.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with our entry into certain agreements and other transactions, our counterparties may be obligated to indemnify us. For example, in November 2020, we and Mylan completed the transaction to spin-off our Upjohn Business and combine it with Mylan to form Viatris. As part of the transaction and as previously disclosed, each of Viatris and Pfizer has agreed to assume, and to indemnify the other for, liabilities arising out of certain matters. Also, our global agreement with BioNTech to co-develop a mRNA-based coronavirus vaccine program aimed at preventing COVID-19 infection, includes certain indemnity provisions pursuant to which each of BioNTech and Pfizer has agreed to indemnify the other for certain liabilities that may arise in connection with certain third-party claims relating to Comirnaty.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also guaranteed the long-term debt of certain companies that we acquired and that now are subsidiaries of Pfizer.</span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Contingent Consideration for Acquisitions</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be required to make payments to sellers for certain prior business combinations that are contingent upon future events or outcomes. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1D </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2022 Form 10-K.</span></div></ix:continuation><div id="idfe6e72973fb4e83b28a5bb34d34299f_91"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13. <ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="ic681a0e5a41b439fb5ad4253c64e05da" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyNjE_06eecf84-b94e-4372-b57b-3a228e6c983f" name="us-gaap:SegmentReportingDisclosureTextBlock">Segment, Geographic and Other Revenue Information</ix:nonnumeric></span></div><ix:continuation continuedat="i8dd12d83e6d141128d7a5ed0c559304b" id="ic681a0e5a41b439fb5ad4253c64e05da"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Segment Information</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our commercial operations through <ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="INF" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTMx_d26a73cb-f1fd-4a30-8647-0fcf163bfdae" name="us-gaap:NumberOfOperatingSegments" scale="0" unitref="operatingsegment">two</ix:nonfraction> operating segments, each led by a single manager: Biopharma and Business Innovation, an operating segment established in the first quarter of 2023 that </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">includes PC1, our contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Pfizer Ignite, a recently launched offering that provides strategic guidance and end-to-end R&amp;D services to select innovative biotech companies that align with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer&#8217;s R&amp;D focus areas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biopharma is the only reportable segment. Each operating segment has responsibility for its commercial activities. Regional commercial organizations market, distribute and sell our products and are </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation continuedat="i2b2904f85cd842e29b51ed8bfa9677ef" id="i8dd12d83e6d141128d7a5ed0c559304b"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">supported by global platform functions that are responsible for the research, development, manufacturing and supply of our products and global corporate enabling functions. Biopharma receives its R&amp;D services from WRDM and GPD. These services include IPR&amp;D projects for new investigational products and additional indications for in-line products. Each operating segment has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Business Activities and Reconciling Items&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other business activities include the operating results of Business Innovation as well as certain pre-tax costs not allocated to our operating segment results, such as costs associated with: (i) R&amp;D and medical expenses managed by our WRDM organization and costs associated with our GPD organization; (ii) corporate enabling functions and other corporate costs; (iii) overhead costs primarily associated with our manufacturing operations; and (iv) our share of earnings from Haleon/the Consumer Healthcare JV. Reconciling items include the following items, transactions and events that are not allocated to our operating segments: (i) all amortization of intangible assets; (ii) acquisition-related items</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Assets&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were $<ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-9" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMzQ3OQ_2e5c0f27-1c83-436a-8144-0343e9afdef2" name="us-gaap:Assets" scale="9" unitref="usd">196</ix:nonfraction> billion as of April&#160;2, 2023 and $<ix:nonfraction contextref="i5452d746bc20473cb3ddbbc1da1ee8cd_I20221231" decimals="-9" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMzQ5NQ_b32affa4-7d6c-4f3f-acf7-ff4283ed4ea6" name="us-gaap:Assets" scale="9" unitref="usd">197</ix:nonfraction> billion as of December 31, 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Selected Income Statement Information</span></div><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyNTY_fb501368-76d1-42e5-945e-dfa5354ba5e1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:46.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.257%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following provides selected income statement information by reportable segment:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reportable Segment:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biopharma</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ia3666e86c68743e3a070924a59c2de42_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfNS0yLTEtMS02MTQ4NjE_fd318c4b-baf4-427a-8eff-30ef5080d794" name="us-gaap:Revenues" scale="6" unitref="usd">17,971</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i670e31781cda409696a800a888c74490_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfNS00LTEtMS02MTQ4NjE_c9917dba-15de-402a-9a91-de86df7248f0" name="us-gaap:Revenues" scale="6" unitref="usd">25,323</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ia3666e86c68743e3a070924a59c2de42_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfNS02LTEtMS02MTQ4NjE_3edb7fa5-8360-4e21-b107-3e5d2e1daf1e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" unitref="usd">10,936</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i670e31781cda409696a800a888c74490_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfNS04LTEtMS02MTQ4NjE_c639596d-280f-4ee5-b626-38dea8ad3219" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" unitref="usd">13,391</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other business activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="iece3f81689ed43ed8131977e5397a8b5_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfNi0yLTEtMS02MTQ4NjE_d05141c6-074d-47b2-88ab-abb14df6643f" name="us-gaap:Revenues" scale="6" unitref="usd">310</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i95b1e226cff5434ebc93d3df2d02c3b1_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfNi00LTEtMS02MTQ4NjE_b77327de-15a4-42e3-bfc7-c76a6bd05e85" name="us-gaap:Revenues" scale="6" unitref="usd">338</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="iece3f81689ed43ed8131977e5397a8b5_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfNi02LTEtMS02MTQ4NjE_14bcf1dd-ec6a-496a-81d3-1efda66cec93" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" sign="-" unitref="usd">2,734</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i95b1e226cff5434ebc93d3df2d02c3b1_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfNi04LTEtMS02MTQ4NjE_6877f3a8-36d3-4228-ba11-1c3bf278a5f9" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" sign="-" unitref="usd">2,429</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reconciling Items:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i53eaca2641034b1593e2e403207d78ec_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfOC02LTEtMS02MTQ4NjE_9167e622-24e8-42ae-9449-62ead92ddd05" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" sign="-" unitref="usd">1,103</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i99fbc7d71a0c4e2483ac04c3d705e295_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfOC04LTEtMS02MTQ4NjE_25f9fc93-e0ad-4d99-8ce4-35f5e0e9d0f2" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" sign="-" unitref="usd">835</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i57e0e00856144b72a6c3eb80e5849d80_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfOS02LTEtMS02MTQ4NjE_a8d06473-86e7-468e-99b1-5ba00c42140a" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" sign="-" unitref="usd">163</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="id61874b1d7274f79a89e4ee0f9f2ec19_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfOS04LTEtMS02MTQ4NjE_9ec0474e-8cf1-4591-810c-02f9241d061e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" sign="-" unitref="usd">187</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certain significant items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="iec11a909a8d84154be6b2d58180cdaa7_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfMTAtNi0xLTEtNjE0ODYx_6eb334de-0315-4c65-8513-29007f538528" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" sign="-" unitref="usd">665</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i44167f056c7642e196f616282f12a2f1_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfMTAtOC0xLTEtNjE0ODYx_cecc7199-4473-417f-9bed-9b56e6512d2d" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" sign="-" unitref="usd">891</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfMTEtMi0xLTEtNjE0ODYx_fda2b769-9912-4932-84f4-5377f3cf1479" name="us-gaap:Revenues" scale="6" unitref="usd">18,282</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfMTEtNC0xLTEtNjE0ODYx_1bcf5e2e-c2ad-461f-8076-304431774832" name="us-gaap:Revenues" scale="6" unitref="usd">25,661</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfMTEtNi0xLTEtNjE0ODYx_9166ac0a-66ab-4b07-bf18-4061763a7e4b" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" unitref="usd">6,270</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOmFmYzBjMWFkZTg2MDQ4NWE4ODY1YWRmYWY0ZjkzNmY4L3RhYmxlcmFuZ2U6YWZjMGMxYWRlODYwNDg1YTg4NjVhZGZhZjRmOTM2ZjhfMTEtOC0xLTEtNjE0ODYx_b943dd4c-98e0-469f-8791-f1112afae224" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" unitref="usd">9,050</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyNzQ_d25d3c78-63a3-4649-b67f-65616f3a9753"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.24pt">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">ncome from continuing operations before provision/(benefit) for taxes on income.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Biopharma&#8217;s earnings include dividend income from our investment in ViiV of $<ix:nonfraction contextref="i50b8a990e8d945a991c47c03ad000ded_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMzcwNw_e635b427-8769-49eb-9e2b-2df0a520fe10" name="us-gaap:InvestmentIncomeDividend" scale="6" unitref="usd">92</ix:nonfraction> million in the first quarter of 2023 and $<ix:nonfraction contextref="i0c22bde603be40fea38a68ae24c32c3f_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMzczMA_fe4db1ba-b449-452c-a5ed-aecf5968adf3" name="us-gaap:InvestmentIncomeDividend" scale="6" unitref="usd">56</ix:nonfraction> million in the first quarter of 2022. In connection with the organizational changes effective in the third quarter of 2022, certain functions transferred between Biopharma and corporate enabling functions and certain activities were realigned within the GPD organization. We have reclassified $<ix:nonfraction contextref="if1300e53c4724633b3821ae11a7bb3e6_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfNTQ5NzU1ODMxNjI1_5aeea2a0-3115-41df-8d2c-c550a2e52b6d" name="us-gaap:OperatingExpenses" scale="6" sign="-" unitref="usd"><ix:nonfraction contextref="iab8e06a5f2fa4ac48e34ffcde10456cb_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfNTQ5NzU1ODMxNjI1_8c6fd34d-5f2c-4966-b9d5-1c489002b146" name="us-gaap:OperatingExpenses" scale="6" unitref="usd">47</ix:nonfraction></ix:nonfraction> million of costs in the first quarter of 2022 from corporate enabling functions, which are included in Other business activities, to Biopharma to conform to the current period presentation.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEzMDE_0446c25b-b600-4f12-9ddc-ff2fd399b19d"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Other business activities include revenues and costs associated with Business Innovation and costs that we do not allocate to our operating segments, per above, including acquired IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">expenses in the periods presented.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyNTI_10bc6fed-0d8b-4984-a671-75af585d806a"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in the first quarter of 2023 and 2022 include, among other items, net losses on equity securities of $<ix:nonfraction contextref="iec11a909a8d84154be6b2d58180cdaa7_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfNTI1NQ_2accd4cd-39c4-489f-b514-5019db3a40b5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" sign="-" unitref="usd">452</ix:nonfraction> million and $<ix:nonfraction contextref="i44167f056c7642e196f616282f12a2f1_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfNTQ5NzU1ODM5Mzc3_c2640d5d-63ce-4b8c-92d3-081a1cac84a2" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" sign="-" unitref="usd">698</ix:nonfraction> million, respectively, recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_49" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_49" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"> </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_49" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div></ix:nonnumeric><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Geographic Information</span></div><div style="margin-bottom:3pt"><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyNTM_913c1317-d3c2-4a1e-98aa-a4bb1066a30e" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.360%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes revenues by geographic area:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%<br/>Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="iefc2254b125b4cd985bd107f8811ff60_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjI2MmM4M2U4MGI2MDQxYTE4NTE5YTRmYjk0ZjY5N2IyL3RhYmxlcmFuZ2U6MjYyYzgzZTgwYjYwNDFhMTg1MTlhNGZiOTRmNjk3YjJfMy0yLTEtMS02MTQ4NjE_a8150933-d913-4b5e-9f19-77f340df2727" name="us-gaap:Revenues" scale="6" unitref="usd">8,507</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i645b5c8c0a5f4681997ad0138410ccc3_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjI2MmM4M2U4MGI2MDQxYTE4NTE5YTRmYjk0ZjY5N2IyL3RhYmxlcmFuZ2U6MjYyYzgzZTgwYjYwNDFhMTg1MTlhNGZiOTRmNjk3YjJfMy00LTEtMS02MTQ4NjE_1ee60004-3ef6-448b-b279-084fa415f5bc" name="us-gaap:Revenues" scale="6" unitref="usd">8,918</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="iefc2254b125b4cd985bd107f8811ff60_D20230101-20230402" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjI2MmM4M2U4MGI2MDQxYTE4NTE5YTRmYjk0ZjY5N2IyL3RhYmxlcmFuZ2U6MjYyYzgzZTgwYjYwNDFhMTg1MTlhNGZiOTRmNjk3YjJfMy02LTEtMS02MTQ4NjE_fb394365-729d-47d0-82f9-fd003f13357a" name="pfe:PercentageChangeInRevenue" scale="-2" sign="-" unitref="number">5</ix:nonfraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if89b9f6fcf2841de8dc20b376d962713_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjI2MmM4M2U4MGI2MDQxYTE4NTE5YTRmYjk0ZjY5N2IyL3RhYmxlcmFuZ2U6MjYyYzgzZTgwYjYwNDFhMTg1MTlhNGZiOTRmNjk3YjJfNC0yLTEtMS02MTQ4NjE_8c958b51-2eac-4b93-a54e-fb07ef8941fd" name="us-gaap:Revenues" scale="6" unitref="usd">2,822</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i6573754ecd3e42e48b06ddd54186fc24_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjI2MmM4M2U4MGI2MDQxYTE4NTE5YTRmYjk0ZjY5N2IyL3RhYmxlcmFuZ2U6MjYyYzgzZTgwYjYwNDFhMTg1MTlhNGZiOTRmNjk3YjJfNC00LTEtMS02MTQ4NjE_cb5c8709-0875-43af-a25f-8c6fae2bff09" name="us-gaap:Revenues" scale="6" unitref="usd">6,090</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="if89b9f6fcf2841de8dc20b376d962713_D20230101-20230402" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjI2MmM4M2U4MGI2MDQxYTE4NTE5YTRmYjk0ZjY5N2IyL3RhYmxlcmFuZ2U6MjYyYzgzZTgwYjYwNDFhMTg1MTlhNGZiOTRmNjk3YjJfNC02LTEtMS02MTQ4NjE_cbabc882-e2d1-4f4d-b1a5-55420268e3f8" name="pfe:PercentageChangeInRevenue" scale="-2" sign="-" unitref="number">54</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i128c9b41016b43909793ad8f216aff4e_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjI2MmM4M2U4MGI2MDQxYTE4NTE5YTRmYjk0ZjY5N2IyL3RhYmxlcmFuZ2U6MjYyYzgzZTgwYjYwNDFhMTg1MTlhNGZiOTRmNjk3YjJfNS0yLTEtMS02MTQ4NjE_4e6e4d39-e61e-4766-afa0-be59d588c9ad" name="us-gaap:Revenues" scale="6" unitref="usd">2,473</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if33ff7f5e9bf48d69ab7816d9ffc54c2_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjI2MmM4M2U4MGI2MDQxYTE4NTE5YTRmYjk0ZjY5N2IyL3RhYmxlcmFuZ2U6MjYyYzgzZTgwYjYwNDFhMTg1MTlhNGZiOTRmNjk3YjJfNS00LTEtMS02MTQ4NjE_6130c64f-68f6-40de-b299-b2cf60379012" name="us-gaap:Revenues" scale="6" unitref="usd">3,286</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i128c9b41016b43909793ad8f216aff4e_D20230101-20230402" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjI2MmM4M2U4MGI2MDQxYTE4NTE5YTRmYjk0ZjY5N2IyL3RhYmxlcmFuZ2U6MjYyYzgzZTgwYjYwNDFhMTg1MTlhNGZiOTRmNjk3YjJfNS02LTEtMS02MTQ4NjE_53d06a3f-eb0b-429d-8744-990c1f0ffe2d" name="pfe:PercentageChangeInRevenue" scale="-2" sign="-" unitref="number">25</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i49db5cab1bca4cfcbb1d67e745703c3b_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjI2MmM4M2U4MGI2MDQxYTE4NTE5YTRmYjk0ZjY5N2IyL3RhYmxlcmFuZ2U6MjYyYzgzZTgwYjYwNDFhMTg1MTlhNGZiOTRmNjk3YjJfNi0yLTEtMS02MTQ4NjE_e7ae1d8a-1209-4365-8fb0-7b191dd036b7" name="us-gaap:Revenues" scale="6" unitref="usd">4,480</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ifc98eadee0884b35b8dc6599365211c7_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjI2MmM4M2U4MGI2MDQxYTE4NTE5YTRmYjk0ZjY5N2IyL3RhYmxlcmFuZ2U6MjYyYzgzZTgwYjYwNDFhMTg1MTlhNGZiOTRmNjk3YjJfNi00LTEtMS02MTQ4NjE_16f0fe9d-2f3d-48a3-a52f-eb4601f4480a" name="us-gaap:Revenues" scale="6" unitref="usd">7,367</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i49db5cab1bca4cfcbb1d67e745703c3b_D20230101-20230402" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjI2MmM4M2U4MGI2MDQxYTE4NTE5YTRmYjk0ZjY5N2IyL3RhYmxlcmFuZ2U6MjYyYzgzZTgwYjYwNDFhMTg1MTlhNGZiOTRmNjk3YjJfNi02LTEtMS02MTQ4NjE_d8b148ba-521a-40ed-9fb3-57d67c5fa2fa" name="pfe:PercentageChangeInRevenue" scale="-2" sign="-" unitref="number">39</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjI2MmM4M2U4MGI2MDQxYTE4NTE5YTRmYjk0ZjY5N2IyL3RhYmxlcmFuZ2U6MjYyYzgzZTgwYjYwNDFhMTg1MTlhNGZiOTRmNjk3YjJfNy0yLTEtMS02MTQ4NjE_a8b6dfed-6843-4e9d-9f10-a8c88ce2585e" name="us-gaap:Revenues" scale="6" unitref="usd">18,282</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjI2MmM4M2U4MGI2MDQxYTE4NTE5YTRmYjk0ZjY5N2IyL3RhYmxlcmFuZ2U6MjYyYzgzZTgwYjYwNDFhMTg1MTlhNGZiOTRmNjk3YjJfNy00LTEtMS02MTQ4NjE_ad81bc27-4168-4152-8ea0-671c59eae51a" name="us-gaap:Revenues" scale="6" unitref="usd">25,661</ix:nonfraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjI2MmM4M2U4MGI2MDQxYTE4NTE5YTRmYjk0ZjY5N2IyL3RhYmxlcmFuZ2U6MjYyYzgzZTgwYjYwNDFhMTg1MTlhNGZiOTRmNjk3YjJfNy02LTEtMS02MTQ4NjE_9c36a325-b8ca-4541-ac53-c5b5c6f8b767" name="pfe:PercentageChangeInRevenue" scale="-2" sign="-" unitref="number">29</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></ix:nonnumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation continuedat="ic69ddf8a5e5c4d64b6bd8c86093685df" id="i2b2904f85cd842e29b51ed8bfa9677ef"><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;text-decoration:underline">C. Other Revenue Information</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Customers&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on our significant wholesale customers, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2022 Form 10-K. Additionally, revenues from the U.S. government represented <ix:nonfraction contextref="i348f1631a68a49bc9a4cff950a2314d3_D20230101-20230402" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfNjkzOA_b4776d2c-58fc-4163-b07b-088eb7668437" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitref="number">15</ix:nonfraction>% and <ix:nonfraction contextref="i1638235866704d47ac70fa86e8afcecc_D20220101-20220403" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfNTQ5NzU1ODM2Njc4_d3c7c4d9-00f1-438d-9dbc-663101e0ab30" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitref="number">19</ix:nonfraction>% of total revenues for the three months ended April&#160;2, 2023 and April&#160;3, 2022, respectively. Accounts receivable from the U.S. government represented <ix:nonfraction contextref="id2781bcedc0f4e15b4ff9b8d9f8dae32_D20230101-20230402" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfNzExNQ_9986298a-411e-4a20-b73f-fe26a1030620" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitref="number">17</ix:nonfraction>% and <ix:nonfraction contextref="ibeb4bdf50c6e409a9ad2229d39abf845_D20220101-20221231" decimals="2" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfNTQ5NzU1ODM2NzE1_9334a0fe-9452-4c3b-afe1-1e79aeea5f16" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitref="number">4</ix:nonfraction>% of total trade accounts receivable as of April&#160;2, 2023 and December 31, 2022, respectively. Revenues and accounts receivable from the U.S. government primarily represent sales of Paxlovid and Comirnaty.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Significant Product Revenues</span></div><ix:nonnumeric contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" continuedat="i3173da7443c344feb8d3a290759b052c" escape="true" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyNDk_b0b84e82-e03f-491f-aa2f-9f446d70fa8c" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides detailed revenue information for several of our major products:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:31.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.185%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">TOTAL REVENUES</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction contextref="i3d4f1048d02b4a489b7c7622f57180c1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMi00LTEtMS02MTQ4NjE_f1097f45-7fb4-43d5-9e3a-e674409aa8b9" name="us-gaap:Revenues" scale="6" unitref="usd">18,282</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction contextref="i676adf29a7a64d979192a9017c6fa197_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMi02LTEtMS02MTQ4NjE_86f83c97-2ae4-46d7-8a4b-8628146b5cf3" name="us-gaap:Revenues" scale="6" unitref="usd">25,661</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction contextref="i2c138911a1d04f5d8ed218c8b37ed1d2_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMy00LTEtMS02MTQ4NjE_c72309a4-1482-4d1b-b1a6-7e67f3ce83da" name="us-gaap:Revenues" scale="6" unitref="usd">17,971</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction contextref="i9c1193f1a4714912a5d71e60826acdac_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMy02LTEtMS02MTQ4NjE_4a1f3dc1-7ad8-418c-a08f-c656116f9eca" name="us-gaap:Revenues" scale="6" unitref="usd">25,323</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Primary Care</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction contextref="i2c8e95d2a03b4063b88ba80bda3c7da8_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNC00LTEtMS02MTQ4NjE_f42cc9f1-25f6-408c-b03e-ac79089e9e13" name="us-gaap:Revenues" scale="6" unitref="usd">11,505</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction contextref="i5712dec49ad742cd98de702a6f1dde5b_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNC02LTEtMS02MTQ4NjE_5345d3c1-cd5d-48a8-ad4f-f11ba817f02b" name="us-gaap:Revenues" scale="6" unitref="usd">18,851</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Paxlovid</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">COVID-19 in certain high-risk patients</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i1127cf0ab5b34ebaa36393ad7d4a552f_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNi00LTEtMS02MTQ4NjE_2a0811ab-496b-4753-9045-bb2928cc920c" name="us-gaap:Revenues" scale="6" unitref="usd">4,069</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i24695e5ff7f840c3ae48b9f34c74134a_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNi02LTEtMS02MTQ4NjE_113fa8f7-df56-4863-9883-09d6422f48b6" name="us-gaap:Revenues" scale="6" unitref="usd">1,470</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Comirnaty direct sales and alliance revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Active immunization to prevent COVID-19 </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5957d758659a4ec690ea56b1618242a1_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNS00LTEtMS02MTQ4NjE_de8eaa37-bc96-4bd6-a013-a6b3a80163ff" name="us-gaap:Revenues" scale="6" unitref="usd">3,064</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="id13997e0e5a24763b549edc0dc3fe91a_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNS02LTEtMS02MTQ4NjE_6b59251e-7126-4e6a-8288-74bd35150bf0" name="us-gaap:Revenues" scale="6" unitref="usd">13,227</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Eliquis alliance revenues and direct sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ie9e3a66284cf45b2a09e34da580d1d29_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNy00LTEtMS02MTQ4NjE_f02534b9-9bfe-4512-9387-208c0d4282eb" name="us-gaap:Revenues" scale="6" unitref="usd">1,874</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i4ba0b7fb374645928603ba9b7cebec94_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNy02LTEtMS02MTQ4NjE_fdac045e-58bc-4f52-93dd-65b00596396d" name="us-gaap:Revenues" scale="6" unitref="usd">1,793</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Prevnar family</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i389f1083a03043e88aad44b112f7be8c_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfOC00LTEtMS02MTQ4NjE_c3020d90-f413-4b74-b159-6be90befcd60" name="us-gaap:Revenues" scale="6" unitref="usd">1,593</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5f26f31de52b4e9a879e3308e11dd9f1_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfOC02LTEtMS02MTQ4NjE_3df2b6c3-f9a4-41d3-af74-0445792e6008" name="us-gaap:Revenues" scale="6" unitref="usd">1,565</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Nurtec ODT/Vydura</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Acute treatment of migraine and prevention of episodic migraine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibe1ea6419acf41f5b07a3b8f5b3896a7_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfOS00LTEtMS02MjA3OTY_61e87930-a505-4e89-8bfd-7dcfe09dd5eb" name="us-gaap:Revenues" scale="6" unitref="usd">167</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction contextref="i354de13a0bb042a2ba38dd91459c360e_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfOS02LTEtMS02MjA4MDA_056fd214-9176-4a90-a3f8-e17c8f3abd4e" name="us-gaap:Revenues" scale="6" unitref="usd">1</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Premarin family</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Symptoms of menopause</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i869f2f8a64ec4b6fa54fb3db4169e876_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfOS00LTEtMS02MTQ4NjE_10d8d6f5-8574-4519-bb7e-550677747260" name="us-gaap:Revenues" scale="6" unitref="usd">112</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction contextref="ida60af953e4241d1ac923e8d2658c098_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfOS02LTEtMS02MTQ4NjE_265acd26-9bbd-4632-a051-4e934ce1aead" name="us-gaap:Revenues" scale="6" unitref="usd">102</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">BMP2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Development of bone and cartilage</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i9c30c20ce164455da8c51e84339aa211_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMTEtNC0xLTEtNjE0ODYx_2f45c25b-40c8-475c-bea7-09753a2a67d5" name="us-gaap:Revenues" scale="6" unitref="usd">86</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3402db239e4a4405af9cab6cc9574fd2_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMTEtNi0xLTEtNjE0ODYx_2b015709-cbd1-4cce-ba63-2a849854b313" name="us-gaap:Revenues" scale="6" unitref="usd">67</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">FSME-IMMUN/TicoVac</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Active immunization to prevent tick-borne encephalitis disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i528c3830f3fc42ceb033c6c1a1451076_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMTItNC0xLTEtNjE0ODYx_68f34730-549a-419b-be31-aeba86a2ef89" name="us-gaap:Revenues" scale="6" unitref="usd">45</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i27d9bb242ddf4a63b385ead1fb0ad10b_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMTItNi0xLTEtNjE0ODYx_9eb841cf-698e-48ea-af5b-99d62f8533f3" name="us-gaap:Revenues" scale="6" unitref="usd">42</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Nimenrix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Active immunization against invasive meningococcal ACWY disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="id43bedcbb0d94ae2bb2c0aaca155cc6d_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMTAtNC0xLTEtNjE0ODYx_a8356037-894d-4032-8b04-90882cc315ce" name="us-gaap:Revenues" scale="6" unitref="usd">40</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i638b0cb14b2847fa86615a6c07ac2772_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMTAtNi0xLTEtNjE0ODYx_17e00f21-f8ff-4d59-a0b5-89dcf52040c0" name="us-gaap:Revenues" scale="6" unitref="usd">77</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Primary Care</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ia9e86d694fc34637aaf65a9a734f7750_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMTYtNC0xLTEtNjE0ODYx_bf1d4b65-213c-400e-bd85-a775b4be4ed4" name="us-gaap:Revenues" scale="6" unitref="usd">456</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction contextref="i49a9a121621742a1b69ef002bb6bce77_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMTYtNi0xLTEtNjE0ODYx_e532d1dd-84ff-4573-944d-bee590c8947b" name="us-gaap:Revenues" scale="6" unitref="usd">507</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Specialty Care</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction contextref="ia0eeb27c12964aeabe04ba88c950ede5_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMTctNC0xLTEtNjE0ODYx_005b5351-ad2a-4beb-b82c-24172400c96b" name="us-gaap:Revenues" scale="6" unitref="usd">3,612</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction contextref="i11d969a73e8b4e06915d2a823bed0f3a_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMTctNi0xLTEtNjE0ODYx_2afb334d-98da-4ed4-bc8b-c645513972d6" name="us-gaap:Revenues" scale="6" unitref="usd">3,505</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Vyndaqel family</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ATTR-CM and polyneuropathy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib93771c7f62b468a8faa5b28f2297553_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMTgtNC0xLTEtNjE0ODYx_7576c5b7-a90f-40c2-889a-1e759d8abe7a" name="us-gaap:Revenues" scale="6" unitref="usd">686</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic9904c6f00ef4e679f41f043cba7d258_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMTgtNi0xLTEtNjE0ODYx_86b10825-084a-4e40-bac1-77f9b127bb12" name="us-gaap:Revenues" scale="6" unitref="usd">612</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sulperazon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ie52e1b074ef64b888816b016a9f45c24_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjEtNC0xLTEtNjE0ODYx_1fd55916-13a7-418c-9932-36f088bb37b1" name="us-gaap:Revenues" scale="6" unitref="usd">320</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i9e64a745e7bf42e4acad26d2c6ca8d2a_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjEtNi0xLTEtNjE0ODYx_1d31460c-a687-4143-a1aa-c497b9f60c87" name="us-gaap:Revenues" scale="6" unitref="usd">210</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xeljanz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i59479af84e0e4b7bbc1814201d2f7f9b_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMTktNC0xLTEtNjE0ODYx_2a5630a1-8267-432f-a080-6fb3b7364767" name="us-gaap:Revenues" scale="6" unitref="usd">237</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="id0540ed5c04548468fa93495ce9fd793_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMTktNi0xLTEtNjE0ODYx_fe02922c-c43b-4be7-8b80-c2a0cce88933" name="us-gaap:Revenues" scale="6" unitref="usd">372</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Enbrel (Outside the U.S. and Canada)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i845f22da610444929d12887bb6ca9d0a_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjAtNC0xLTEtNjE0ODYx_7498b282-6ecc-4df8-a316-c6006cbe55a1" name="us-gaap:Revenues" scale="6" unitref="usd">199</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i817106f80d7d4d05a69740b45ab017da_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjAtNi0xLTEtNjE0ODYx_49c270ac-9967-4b37-9a0d-49fd8e3b1fb8" name="us-gaap:Revenues" scale="6" unitref="usd">280</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inflectra</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Crohn&#8217;s disease, pediatric Crohn&#8217;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if9ca52bb68fb48ae82c1c403c9766d06_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjItNC0xLTEtNjE0ODYx_614cc305-2a8c-4003-8868-ff22b9a93816" name="us-gaap:Revenues" scale="6" unitref="usd">178</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic94de054c1a6436c90321135c2724744_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjItNi0xLTEtNjE0ODYx_c815e86c-12a2-4c11-b829-3b9e3780ae7f" name="us-gaap:Revenues" scale="6" unitref="usd">135</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zithromax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if7733cbdaedd4915a78e847a76a493c1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjctNC0xLTEtNjE0ODYx_4cb8f5ce-c036-4ef9-bcb0-922486f8e4bf" name="us-gaap:Revenues" scale="6" unitref="usd">150</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i39f9e687c6b34b0990a6b0df9ad3f40a_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjctNi0xLTEtNjE0ODYx_06d23c77-1618-4c06-8654-8307b21b0f0c" name="us-gaap:Revenues" scale="6" unitref="usd">125</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Genotropin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Replacement of human growth hormone</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ie8dac551f64e41a2b1a77890b84d2c12_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjYtNC0xLTEtNjE0ODYx_1fdba5c5-984c-4bee-922a-cbccd0eb7396" name="us-gaap:Revenues" scale="6" unitref="usd">147</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i289af8f0768d4b2e889aad3b1f3e0f4f_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjYtNi0xLTEtNjE0ODYx_8c5665dc-fb9e-43c5-b993-6904e76d3dc5" name="us-gaap:Revenues" scale="6" unitref="usd">80</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ig Portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ia2a584308c6e4451a4eabaa8926603f3_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjMtNC0xLTEtNjE0ODYx_2673b280-d63c-4844-88b7-d9182354cadd" name="us-gaap:Revenues" scale="6" unitref="usd">126</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i135c45cb011440ef98a64d2a8d5e52f2_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjMtNi0xLTEtNjE0ODYx_026c398c-acb9-4c33-960b-8bfdfdf3b69c" name="us-gaap:Revenues" scale="6" unitref="usd">107</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zavicefta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if9f84c3c3f2848b38eb5462ea7a160be_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjUtNC0xLTEtNjE0ODYx_b27ecf21-8d16-4f15-b50c-a3d5fc32162b" name="us-gaap:Revenues" scale="6" unitref="usd">116</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i232cf2079c584aef90ec2a67007659d3_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjUtNi0xLTEtNjE0ODYx_475b9ca4-f821-4521-beec-76e2a0b0695e" name="us-gaap:Revenues" scale="6" unitref="usd">104</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">BeneFIX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hemophilia B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i291744920e9c4e36afa7e5168f89e573_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjQtNC0xLTEtNjE0ODYx_c4e41457-3c5b-488c-b5c4-07e788fdad26" name="us-gaap:Revenues" scale="6" unitref="usd">109</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i8fc7c3a0298d4a1088dcee3e23ef45f2_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjQtNi0xLTEtNjE0ODYx_a97c02ef-dccb-4660-b8cc-0c47bd76f369" name="us-gaap:Revenues" scale="6" unitref="usd">112</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Medrol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Anti-inflammatory glucocorticoid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="id85c2181d493450b9b95eda9c86146ce_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjgtNC0xLTEtNjE0ODYx_0083ae47-e7b7-45eb-9e2e-10b9499eb539" name="us-gaap:Revenues" scale="6" unitref="usd">93</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ifd027ccaec6546e49e8f34d03003159e_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjgtNi0xLTEtNjE0ODYx_78a070c1-92c4-4636-b254-9282782a95b5" name="us-gaap:Revenues" scale="6" unitref="usd">76</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Oxbryta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sickle cell disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ifb9366ece85d408b982207fd148b4d3e_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjktNC0xLTEtNjIwODEz_f66ca4e3-91c5-43d8-9fa3-793565fbb930" name="us-gaap:Revenues" scale="6" unitref="usd">71</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i6174ff5489684e17b545dde750a70ec4_D20220101-20220403" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjktNi0xLTEtNjIwODE3_3e87a721-cafa-4cd2-84a3-88bbd61fac6c" name="us-gaap:Revenues" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Somavert</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Acromegaly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib0a8aeea6a18419ba89076878429f31b_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMzAtNC0xLTEtNjE0ODYx_736d1a23-135e-47ed-9cae-e8b10017fa7e" name="us-gaap:Revenues" scale="6" unitref="usd">66</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i92ab0a5cba3041f6a4221763f0bb94fe_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMzAtNi0xLTEtNjE0ODYx_fb3bb9de-19c3-486e-84e6-9e94c1f6a5aa" name="us-gaap:Revenues" scale="6" unitref="usd">68</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Refacto AF/Xyntha</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hemophilia A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i344c5d90f5fa4164bdc545bc4b074dfe_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMzEtNC0xLTEtNjE0ODYx_7dcb1548-2056-4689-b775-cee57d8a3c70" name="us-gaap:Revenues" scale="6" unitref="usd">60</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5daf065159f2420b8e6c1f4fc071b36e_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMzEtNi0xLTEtNjE0ODYx_ca51b94c-c173-4f66-8ef1-4ee41c3cbcb1" name="us-gaap:Revenues" scale="6" unitref="usd">66</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Fragmin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treatment/prevention of venous thromboembolism</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ied077209200a435bb4dc6eec71ad489b_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjktNC0xLTEtNjE0ODYx_c644a19b-8706-439c-86fb-cee21f62c083" name="us-gaap:Revenues" scale="6" unitref="usd">58</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="id9a772ff20444822bb098d41d5ae65c3_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMjktNi0xLTEtNjE0ODYx_2256dbaf-b023-4ec9-908b-9471d15ec9b1" name="us-gaap:Revenues" scale="6" unitref="usd">70</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Vfend</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fungal infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i467a8ce1ecd1470ca834426c38899777_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMzItNC0xLTEtNjE0ODYx_9b37cd91-1188-41ad-820e-ae2e11c807f6" name="us-gaap:Revenues" scale="6" unitref="usd">51</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i0e528f7f630d4567ab67dea4ae44c136_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMzItNi0xLTEtNjE0ODYx_e853e7c4-5c3f-4076-bb76-606e9dc8aa6b" name="us-gaap:Revenues" scale="6" unitref="usd">65</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Anti-infectives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i727d7cc39ca54a6893b055d5d266fe85_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMzMtNC0xLTEtNjE0ODYx_fedbb3a7-15e1-4d3f-85c2-f8fe4f7fd160" name="us-gaap:Revenues" scale="6" unitref="usd">374</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if103824a352d4d4eaac336d1bc831a7f_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMzMtNi0xLTEtNjE0ODYx_2a38f7cc-e66d-465f-86f8-69ab3f8bea90" name="us-gaap:Revenues" scale="6" unitref="usd">381</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Specialty Care</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="icc3b9ed64d3a4863b154b3e5f3987914_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMzQtNC0xLTEtNjE0ODYx_76be7907-96ae-49a0-b067-9bd9ac03ed92" name="us-gaap:Revenues" scale="6" unitref="usd">569</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction contextref="i9c4b53c6463f4588b027b8d451e90e59_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMzQtNi0xLTEtNjE0ODYx_27a65e9a-84f1-4d56-b8e3-ab010d087c72" name="us-gaap:Revenues" scale="6" unitref="usd">643</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Oncology</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction contextref="i8d25b2a0fd034a989b55ded7b0193ce9_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMzUtNC0xLTEtNjE0ODYx_ea41f54d-1fff-41b1-8e1c-6d529afbb804" name="us-gaap:Revenues" scale="6" unitref="usd">2,855</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction contextref="id2121803a98d4b488ac1667823fadfc9_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMzUtNi0xLTEtNjE0ODYx_262b3f6f-618f-4039-9616-8ff293087d5c" name="us-gaap:Revenues" scale="6" unitref="usd">2,967</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ibrance</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">HR-positive/HER2-negative metastatic breast cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i58a82c91e2c4486289e3a6b7f4ce62ff_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMzYtNC0xLTEtNjE0ODYx_c94f9aeb-1ce3-44a2-a36f-2c3a98cad93b" name="us-gaap:Revenues" scale="6" unitref="usd">1,144</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i1ba3ef91c841475493a8aa4230556125_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMzYtNi0xLTEtNjE0ODYx_d7fdb2f2-b54a-412c-ac18-165197e3dff1" name="us-gaap:Revenues" scale="6" unitref="usd">1,237</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inlyta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Advanced RCC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i33f4247a54c64ffabe79f8106533d31c_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMzgtNC0xLTEtNjE0ODYx_6825a68a-f6cb-490f-aaba-7ea6a70fab9b" name="us-gaap:Revenues" scale="6" unitref="usd">259</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="id8c77f5483ef4835beb4b08df03fa0bd_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMzgtNi0xLTEtNjE0ODYx_d73741d5-2aae-4a92-9f1b-2c07062a9234" name="us-gaap:Revenues" scale="6" unitref="usd">234</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xtandi alliance revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mCRPC, nmCRPC, mCSPC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i4f591dc7d7d744189dc874ec5f23ea2d_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMzctNC0xLTEtNjE0ODYx_5010a8aa-9203-4e17-8425-c669d21dbe82" name="us-gaap:Revenues" scale="6" unitref="usd">258</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i86bfd321371a40f9b7a0bd06a3e42775_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMzctNi0xLTEtNjE0ODYx_dcda3342-4c9e-4eba-90e6-44a5c515fcbc" name="us-gaap:Revenues" scale="6" unitref="usd">268</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Bosulif</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Philadelphia&#160;chromosome&#8211;positive&#160;chronic myelogenous leukemia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="id60fd44f86a44a55bb3f3ae03ee4667e_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDAtNC0xLTEtNjE0ODYx_bb69d95b-b804-4526-98bb-200fe4ef5cf7" name="us-gaap:Revenues" scale="6" unitref="usd">150</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i75c216a7df064cf1811aaa96db8ac4d1_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDAtNi0xLTEtNjE0ODYx_091d0cfa-6ea0-4840-a959-3ee6d948dbb9" name="us-gaap:Revenues" scale="6" unitref="usd">128</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zirabev</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i50fcac2e1cd54ced9a7c3b2c5dc7190f_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMzktNC0xLTEtNjE0ODYx_349cbdca-c0e1-4301-8f22-c9a8a7fb2da2" name="us-gaap:Revenues" scale="6" unitref="usd">129</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="idebd875adcc54aa3b2628429cfa3dbc4_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfMzktNi0xLTEtNjE0ODYx_943337cd-93e3-453f-b1d6-4c7852a57f79" name="us-gaap:Revenues" scale="6" unitref="usd">147</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ruxience</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Non-hodgkin&#8217;s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener&#8217;s Granulomatosis) and microscopic polyangiitis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i4b19ccfe6bde4624bcbd202b0b8ff414_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDItNC0xLTEtNjE0ODYx_f25cef97-1d4b-4aac-a37d-02277b1e0a2d" name="us-gaap:Revenues" scale="6" unitref="usd">114</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibd6f431718c945a9a8d867fa6c6d5197_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDItNi0xLTEtNjE0ODYx_c67652d2-c3fc-48df-b4f9-4ba1d924d045" name="us-gaap:Revenues" scale="6" unitref="usd">124</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Lorbrena</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ALK-positive metastatic NSCLC</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i08c908e71c64421f80a1cb282d21aa4c_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDUtNC0xLTEtNjE0ODYx_5176fa1d-6251-4d61-92a1-cc007b27060a" name="us-gaap:Revenues" scale="6" unitref="usd">112</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ib93da2cd973e4a3fbcc6fdb3f57f7cd4_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDUtNi0xLTEtNjE0ODYx_7e940ef9-81fd-486e-a32b-a474acd8a601" name="us-gaap:Revenues" scale="6" unitref="usd">72</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xalkori</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ALK-positive and Proto-Oncogene 1, Receptor Tyrosine Kinase-positive advanced NSCLC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i659a9e5c96f84ae0804790b9ead07065_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDEtNC0xLTEtNjE0ODYx_5a956a39-aae2-4365-90ee-154e58b07701" name="us-gaap:Revenues" scale="6" unitref="usd">111</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ibb4395a058f347c8a45174512ae0fce3_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDEtNi0xLTEtNjE0ODYx_6f427a19-884b-4009-9b29-17a65769a273" name="us-gaap:Revenues" scale="6" unitref="usd">127</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonnumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ic69ddf8a5e5c4d64b6bd8c86093685df"><ix:continuation id="i3173da7443c344feb8d3a290759b052c"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:31.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.185%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Retacrit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Anemia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ia2403811901c4d05b23627f50a0526c2_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDMtNC0xLTEtNjE0ODYx_d8d051a2-cbe2-42bb-8c28-12d342349d89" name="us-gaap:Revenues" scale="6" unitref="usd">93</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="if5e834c200804fd3afe076765c81956a_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDMtNi0xLTEtNjE0ODYx_e132cfee-55dc-4444-a02b-e9ecc1d01728" name="us-gaap:Revenues" scale="6" unitref="usd">115</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Bavencio alliance revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Locally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma; immunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i69b4d270e9f04278b1dca58a4c63cf14_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDYtNC0xLTEtNjE0ODYx_375d615a-45b7-4d06-b91f-be2915de51ff" name="us-gaap:Revenues" scale="6" unitref="usd">85</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ie6aa532d58f948b6a980c1e20035d1df_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDYtNi0xLTEtNjE0ODYx_4ff0c68e-e613-4503-ab0f-d778b519b87e" name="us-gaap:Revenues" scale="6" unitref="usd">67</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Aromasin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Post-menopausal early and advanced breast cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i114d6cba7a08402eaaf457696bb70d89_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDctNC0xLTEtNjE0ODYx_d6902fb4-5f62-459b-b31f-97376e4f7659" name="us-gaap:Revenues" scale="6" unitref="usd">77</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i15d91f7557bc4fef8ff7c65f4d65a84c_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDctNi0xLTEtNjE0ODYx_e79ff7d5-637f-4c07-bfd8-c9aa579330d2" name="us-gaap:Revenues" scale="6" unitref="usd">62</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Besponsa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Relapsed or refractory B-cell acute lymphoblastic leukemia </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i16cd9778c4214c2eaf51fee4d3eb3c73_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDgtNC0xLTEtNjE0ODYx_9b653fb1-1725-40a0-a641-ba008b90ef81" name="us-gaap:Revenues" scale="6" unitref="usd">58</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i5a546d464a89465492912faeee75695e_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDgtNi0xLTEtNjE0ODYx_df907101-b230-411e-a462-899502c5087f" name="us-gaap:Revenues" scale="6" unitref="usd">51</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sutent</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Advanced and/or metastatic RCC, adjuvant RCC, refractory gastrointestinal stromal tumors (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i03abea77b6c14d6098cae50d18daa406_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDQtNC0xLTEtNjE0ODYx_01dcc2cc-64f9-4336-b31e-bc7f486b7ba8" name="us-gaap:Revenues" scale="6" unitref="usd">50</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i6da2c4e45428414b954bbf0b9fc2a247_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDQtNi0xLTEtNjE0ODYx_289e8ba4-d35d-4321-879b-dac436fcb725" name="us-gaap:Revenues" scale="6" unitref="usd">114</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Braftovi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">In combination with Mektovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mutation and, in combination with Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> (cetuximab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">, for the treatment of BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> -mutant mCRC after prior therapy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i2e6002d9f1d941eaa32b3f311c3b2992_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDktNC0xLTEtNjE0ODYx_568e6cb8-2ec0-4349-a301-267ae4a78daf" name="us-gaap:Revenues" scale="6" unitref="usd">49</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ic56f4b14084c4b61b7991d596bc14c49_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNDktNi0xLTEtNjE0ODYx_e6c2d3b2-1989-42e4-917c-4e70529ad43c" name="us-gaap:Revenues" scale="6" unitref="usd">48</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Mektovi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">In combination with Braftovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mutation</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="id1fd922b4a1641a7bde85069306fa0ec_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNTEtNC0xLTEtNjE0ODYx_8f5cb781-c7ec-4ace-8f2e-63f3f3bfac79" name="us-gaap:Revenues" scale="6" unitref="usd">40</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i530d999411e245438a38cdfd15184aaa_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNTEtNi0xLTEtNjE0ODYx_c77f34d3-20a0-43c6-abfe-5ab9a75aae2e" name="us-gaap:Revenues" scale="6" unitref="usd">40</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Trazimera</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">HER2-positive breast cancer and metastatic stomach cancers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i10b264208d264c8792dfbb8cbee54cf6_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNTAtNC0xLTEtNjE0ODYx_2a4400f2-5e4c-4a28-b07a-b343efd1185a" name="us-gaap:Revenues" scale="6" unitref="usd">34</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="idf1c7a65121d4f9e9c2e78bb9af9a121_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNTAtNi0xLTEtNjE0ODYx_3011c77d-360f-44ab-be0e-dc71d1c53950" name="us-gaap:Revenues" scale="6" unitref="usd">52</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Oncology</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i3b2f4dbfa6f441489c5facdb83064e9a_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNTItNC0xLTEtNjE0ODYx_f32911ad-d067-43dc-afb7-db0207c0785a" name="us-gaap:Revenues" scale="6" unitref="usd">92</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction contextref="i9b4a607655f34d0a8173005638136eaf_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNTItNi0xLTEtNjE0ODYx_95260c61-1f71-44ca-bcaf-89c20a99ec7d" name="us-gaap:Revenues" scale="6" unitref="usd">81</ix:nonfraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">BUSINESS INNOVATION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction contextref="ib421ce6581a645469a2501d06a96db02_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNTMtNC0xLTEtNjE0ODYx_326ad3ee-ba38-4175-ade2-fd76034ba436" name="us-gaap:Revenues" scale="6" unitref="usd">310</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction contextref="i7c676d1f835648639f85e5de4f5c0f13_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNTMtNi0xLTEtNjE0ODYx_cf6ab472-0238-474e-b227-2732d7f893c6" name="us-gaap:Revenues" scale="6" unitref="usd">338</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pfizer CentreOne</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i7da57388d26a42a2985af1ba64f42d98_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNTMtNC0xLTEtNjQ3NDI2_de55c985-a855-4d81-9681-af92522c1b35" name="us-gaap:Revenues" scale="6" unitref="usd">306</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="ie4030d39e6184e02b450995611e3f6f6_D20220101-20220403" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNTMtNi0xLTEtNjQ3NTA4_be869e91-e46b-4b98-8cd3-f5f41799b4ee" name="us-gaap:Revenues" scale="6" unitref="usd">338</ix:nonfraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pfizer Ignite</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i226e3f0a94274f62b0553d0c910082d1_D20230101-20230402" decimals="-6" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNTQtNC0xLTEtNjQ3NDMw_f0de05bd-b9c1-4f34-be06-53949aeb35ad" name="us-gaap:Revenues" scale="6" unitref="usd">4</ix:nonfraction>&#160;</span></td><td style="border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction contextref="i30d715ba3f5a4b8d9e0155525508aba3_D20220101-20220403" decimals="-6" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNTQtNi0xLTEtNjQ3NTEy_b9337187-157d-43f7-8d19-7df18c05d622" name="us-gaap:Revenues" scale="6" unitref="usd">&#8212;</ix:nonfraction>&#160;</span></td><td style="border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="21" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Alliance revenues included above</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction contextref="iecfbe8c1d41349cdb14a026a4c5eae76_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNTUtNC0xLTEtNjE0ODYx_1f6dbc3f-a657-4ecc-9a1c-171cd107deab" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" unitref="usd">2,060</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction contextref="i683dc90f3a6c40adb8a077cd9efbef56_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RhYmxlOjAyMjU2OGIyNTZmMzQ2OTRhMjEwNzEyNWIxOGU1MTBjL3RhYmxlcmFuZ2U6MDIyNTY4YjI1NmYzNDY5NGEyMTA3MTI1YjE4ZTUxMGNfNTUtNi0xLTEtNjE0ODYx_f9319a4c-e0b7-432e-abcc-34e6555c8776" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" unitref="usd">2,314</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyOTQ_fa5e87e0-5470-4bbc-952a-b0d9b39938ee"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in our 2022 Form 10-K for information about our recent organizational changes within Biopharma. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 13A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> above for information about Business Innovation. Prior-period financial information has been revised to reflect the current period presentation.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyNjQ_67f0a2ef-90a1-4d3a-91a5-a4545ce80714">Excludes revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the PC1 contract development and manufacturing organization. See footnote (e) below.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyNTU_9b5c7f61-d7e5-4d67-8075-7b780581a2f1"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Immunoglobulin (Ig) portfolio includes the revenues from</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Panzyga, Octagam and Cutaquig.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTEyOTk_8b0a2786-ae92-4d91-9c0f-94fe4b071f9e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is a registered trademark of ImClone LLC.</span></ix:footnote></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:2.65pt"><ix:footnote footnoterole="http://www.xbrl.org/2003/role/footnote" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTQ4NDM0MDcwMTMwOTE_5e1367ba-2545-4c99-9213-d3143b257668">PC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($<ix:nonfraction contextref="ie4d12f048f8447f69be50e2fcdfa49fc_D20230101-20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfNTQ5NzU1ODQwMTkx_39305f50-dbb1-4096-b650-686ce384fe46" name="us-gaap:Revenues" scale="6" unitref="usd">5</ix:nonfraction>&#160;million and $<ix:nonfraction contextref="if266e8cb9f4f47798aaf8f321af14bae_D20220101-20220403" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfNTQ5NzU1ODQwMTk5_8c2a4be9-df3e-4a94-8e63-b302577fa6c6" name="us-gaap:Revenues" scale="6" unitref="usd">47</ix:nonfraction>&#160;million for the first quarters of 2023 and 2022, respectively), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships.</ix:footnote></span></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracted revenue expected to be recognized from remaining performance obligations for firm orders in long-term contracts to supply Comirnaty to our customers totaled approximately $<ix:nonfraction contextref="i2f9d2c741a844d0cbabc9e5a3805b567_I20230402" decimals="-9" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfOTA2NA_6a4581f1-3356-4efb-a7dd-bf5d119280db" name="us-gaap:RevenueRemainingPerformanceObligation" scale="9" unitref="usd">13</ix:nonfraction>&#160;billion as of April&#160;2, 2023, which includes amounts received in advance and deferred, as well as amounts that will be invoiced as we deliver these products to our customers in future periods. Of this amount, current contract terms provide for expected delivery of product with contracted revenue in 2023 and 2024, the timing and terms of which may be renegotiated. Remaining performance obligations are based on foreign exchange rates as of the end of our fiscal first quarter of 2023 and exclude arrangements with an original expected contract duration of less than one year.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Revenues&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred revenues primarily relate to advance payments received or receivable from various government or government sponsored customers in international markets for supply of Comirnaty. The deferred revenues related to Comirnaty total $<ix:nonfraction contextref="if92711a6b5604c1db4ab5d516cfc9a54_I20230402" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfOTgzMg_c05f059a-4c74-4b97-9f27-8b7c8c8fee3b" name="us-gaap:ContractWithCustomerLiability" scale="9" unitref="usd">1.7</ix:nonfraction> billion as of April&#160;2, 2023, with $<ix:nonfraction contextref="if92711a6b5604c1db4ab5d516cfc9a54_I20230402" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfNTQ5NzU1ODUwODM3_92785a3e-781d-4cde-98b0-407f94a89ded" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="9" unitref="usd">1.6</ix:nonfraction> billion and $<ix:nonfraction contextref="if92711a6b5604c1db4ab5d516cfc9a54_I20230402" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfNTQ5NzU1ODUwODQ2_a854c46f-36e9-44f0-930e-96ccc631ff73" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" unitref="usd">34</ix:nonfraction> million recorded in current and noncurrent liabilities, respectively. The deferred revenues related to Comirnaty totaled $<ix:nonfraction contextref="i476e4b3305dd4520810b579696f19d35_I20221231" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfOTk3MQ_4b2108c8-f798-4ef8-9c6f-612b8404cb40" name="us-gaap:ContractWithCustomerLiability" scale="9" unitref="usd">2.5</ix:nonfraction> billion as of December 31, 2022, with $<ix:nonfraction contextref="i476e4b3305dd4520810b579696f19d35_I20221231" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfNTQ5NzU1ODUwODUy_35161381-3339-4849-bc32-8813a683c8e4" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="9" unitref="usd">2.4</ix:nonfraction> billion and $<ix:nonfraction contextref="i476e4b3305dd4520810b579696f19d35_I20221231" decimals="-6" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfNTQ5NzU1ODUwODYx_daa18c72-282b-4c5e-8f59-f675e10dc95b" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" unitref="usd">77</ix:nonfraction> million recorded in current liabilities and noncurrent liabilities, respectively. The decrease in Comirnaty deferred revenues during the first three months of 2023 was primarily the result of amounts recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as we delivered the products to our customers, partially offset by additional advance payments received as we entered into amended contracts and the impact of foreign exchange. During the first quarter of 2023, we recognized revenue of approximately $<ix:nonfraction contextref="ibb698020b89848d9b13f1f0a818f53b4_D20230101-20230402" decimals="-8" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRmZTZlNzI5NzNmYjRlODNiMjhhNWJiMzRkMzQyOTlmL3NlYzpkZmU2ZTcyOTczZmI0ZTgzYjI4YTViYjM0ZDM0Mjk5Zl85MS9mcmFnOmVhOTdmYTU4MDc1YjRhZjZiNjY0YzMyYmZjNmJmMmEwL3RleHRyZWdpb246ZWE5N2ZhNTgwNzViNGFmNmI2NjRjMzJiZmM2YmYyYTBfMTA1Njg_7a25b3e5-31be-407a-aeed-644f3091627d" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="9" unitref="usd">1.7</ix:nonfraction> billion that was included in the balance of Comirnaty deferred revenues as of December 31, 2022. The Comirnaty deferred revenues as of April&#160;2, 2023 will be recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proportionately as we transfer control of the product to our customers and satisfy our performance obligation under the contracts, with the amounts included in current liabilities expected to be recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within the next 12 months, and the amounts included in noncurrent liabilities expected to be recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2024. Deferred revenues associated with contracts for other products were not significant as of April&#160;2, 2023 or December 31, 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF<br/> OPERATIONS</span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_1649"></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following MD&amp;A is intended to assist the reader in understanding our financial condition and results of operations, including an evaluation of the amounts and certainty of cash flows from operations and from outside sources, and is provided as a supplement to and should be read in conjunction with the condensed consolidated financial statements and related notes in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Item 1. Financial Statements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in this Form 10-Q.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates. Although foreign exchange rate changes are part of our business, they are not within our control and because they can mask positive or negative trends in the business, we believe presenting operational variances excluding these foreign exchange changes provides useful information to evaluate our results.</span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_106"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW OF OUR PERFORMANCE, OPERATING ENVIRONMENT, STRATEGY AND OUTLOOK</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business and Strategy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives. In 2023, we are making additional investments in both R&amp;D and SI&amp;A to support Pfizer&#8217;s near- and longer-term growth plans, including to support anticipated new launches, commercial launch of COVID-19 products, potential pipeline programs and recently acquired assets. We manage our commercial operations through a global structure consisting of two operating segments: Biopharma and Business Innovation. Biopharma is the only reportable segment. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_91" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 13A</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur costs of approximately $700 million in connection with separating Upjohn, of which approximately 85% has been incurred since inception and through the first quarter of 2023. These charges include costs and expenses related to separation of legal entities and transaction costs.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2022, we began taking steps through our Transforming to a More Focused Company restructuring program to optimize our end-to-end R&amp;D operations to reduce costs and cycle times as well as to further prioritize our internal R&amp;D portfolio in areas where our capabilities are differentiated while increasing external innovation efforts to leverage an expanding and productive biotech sector. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_46" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For a description of savings related to this program, see the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_127" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Costs and Expenses&#8211;&#8211;Restructuring Charges and Other Costs Associated with Acquisitio</a><a href="#idfe6e72973fb4e83b28a5bb34d34299f_127" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ns and Cost-Reduction/Productivity Initiatives</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section within MD&amp;A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our business, strategy and operating environment, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section within MD&amp;A of our 2022 Form 10-K.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business Development Initiatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;We are committed to strategically capitalizing on growth opportunities, primarily by advancing our own product pipeline and maximizing the value of our existing products, but also through various business development activities. Our significant recent business development activities include the transactions discussed in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the following:</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Research and Development Funding Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;In April 2023, we entered into an arrangement with Blackstone Life Sciences (Blackstone) under which we will receive up to a total of $550 million in 2023 through 2026 to co-fund our quarterly development costs for specified treatments. If successful, upon regulatory approval in the U.S. or certain major markets in the EU for the indications based on the applicable clinical trials, Blackstone will be eligible to receive a combination of approval-based fixed milestone payments of up to $468 million contingent upon the successful results of the clinical trials. Following potential regulatory approval, Blackstone will be eligible to receive a combination of fixed milestone payments of up to $550 million in total based on achievement of certain levels of cumulative applicable net sales, as well as royalties based on a mid-to-high single digit percentage of the applicable net sales.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Proposed Acquisition of Seagen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;In March 2023, we and Seagen announced that the companies entered into an agreement under which we will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of approximately $43 billion. We expect to finance the transaction substantially through $31 billion of new, long-term debt, and the balance from a combination of short-term financing and existing cash. The transaction is expected to close in late 2023 or early 2024, subject to customary closing conditions, including approval of Seagen&#8217;s stockholders and receipt of required regulatory approvals.</span></div><div style="margin-bottom:3pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Termination of Collaboration Arrangement with Merck KGaA, Darmstadt, Germany (Merck KGaA)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;In March 2023, it was announced that our alliance with Merck KGaA to co-develop and co-commercialize Bavencio (avelumab) will terminate. Effective June 30, 2023, Merck KGaA will take full control of the global commercialization of Bavencio. The current profit share will be replaced by a 15% royalty to Pfizer on net sales of Bavencio. We and Merck KGaA will continue to operationalize our respective ongoing clinical trials for Bavencio; and Merck KGaA will control all future R&amp;D activities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the more significant recent transactions through February&#160;23, 2023, the filing date of our 2022 Form 10-K, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2022 Form 10-K.</span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our First Quarter 2023 Performance</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decreased $7.4 billion, or 29%, in the first quarter of 2023 to $18.3 billion from $25.7 billion in the first quarter of 2022, reflecting an operational decrease of $6.6 billion, or 26%, as well as an unfavorable impact of foreign exchange of $730 million, or 3%. The operational decrease was primarily driven by a decline in Comirnaty, partially offset by growth from Paxlovid. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding contributions from Comirnaty and Paxlovid, revenues increased 5% operationally, reflecting revenues from recently acquired products, Nurtec ODT/Vydura and Oxbryta, as well as increased Sulperazon revenues in China, and strong growth from Eliquis and the Vyndaqel family, partially offset by a decline in Xeljanz.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue growth in the first quarter of 2023 was unfavorably impacted by approximately 1% as a result of the first quarter of 2023 having one fewer selling day in international markets compared to the first quarter of 2022. This unfavorable impact is expected to reverse in the fourth quarter of 2023.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May 2, 2023, on a total company basis, we forecasted revenues in 2023 of $67 billion to $71 billion, reflecting an operational decline of 31% at the midpoint from 2022 results, which we expect will also have an unfavorable impact on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The total company expected revenue declines in 2023 are driven by an expected reduction in sales of our COVID-19 products, partially offset by expected operational growth from our non-COVID-19 in-line portfolio, anticipated new product and indication launches, and recently acquired products.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_118" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenues by</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_118" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_118" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Geography</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_121" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenues</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_121" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#8211;&#8211;</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_121" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Selected Product Discussion</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sections for more information, including a discussion of key drivers of our revenue performance. See also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Global Economic Environment&#8211;&#8211;COVID-19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section below for information about our COVID-19 products, including expectations for 2023. For information regarding the primary indications or class of certain products, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_91" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 13C</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income from Continuing Operations Before Provision/(Benefit) for Taxes on Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;The decrease in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $2.8&#160;billion, to $6.3 billion in the first quarter of 2023 from $9.1 billion in the first quarter of 2022, was primarily due to lower revenues and an increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by lower </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and lower </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development expenses.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Analysis of the Condensed Consolidated Statements of Income</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within MD&amp;A and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_49" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Global Economic Environment&#8211;&#8211;COVID-19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section below for information about our COVID-19 products, including expectations for 2023.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on our tax provision and effective tax rate, see the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_130" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Provision/(Benefit) for Taxes on Income</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Operating Environment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;We, like other businesses in our industry, are subject to certain industry-specific challenges. These include, among others, the topics listed below, as well as in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business&#8211;&#8211;Government Regulation and Price Constraints </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Item 1A. Risk Factors </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sections,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Operating Environment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section of the MD&amp;A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our 2022 Form 10-K and the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_169" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Item 1A</a><a href="#idfe6e72973fb4e83b28a5bb34d34299f_169" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">.</a><a href="#idfe6e72973fb4e83b28a5bb34d34299f_169" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> </a><a href="#idfe6e72973fb4e83b28a5bb34d34299f_169" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Risk Factors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of this Form 10-Q.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property Rights and Collaboration/Licensing Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;The loss, expiration or invalidation of intellectual property rights, patent litigation settlements and the expiration of co-promotion and licensing rights can have a material adverse effect on our revenues. Certain of our products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and we expect certain products to face increased generic competition over the next few years. While additional patent expiries will continue, we expect a moderate impact of reduced revenues due to patent expiries from 2023 through 2025. We anticipate a more significant impact of reduced revenues from patent expiries in 2026 through 2030 as several of our in-line products experience patent-based expirations. We continue to vigorously defend our patent rights against infringement, and we will continue to support efforts that strengthen worldwide recognition of patent rights while taking necessary steps to help ensure appropriate patient access.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on patent rights we consider most significant in relation to our business as a whole, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business&#8211;&#8211;Patents and Other Intellectual Property Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2022 Form 10-K. For a discussion of recent developments with respect to patent litigation, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_88" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 12A1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Environment/Pricing and Access&#8211;&#8211;Government and Other Payer Group Pressures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;Governments globally, as well as private third-party payers in the U.S., may use a variety of measures to control costs, including, among others, proposing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pricing reform or legislation, employing formularies to control costs, cross country collaboration and procurement, price cuts, mandatory rebates, health technology assessments, forced localization as a condition of market access, &#8220;international reference pricing&#8221; (i.e., the practice of a country linking its regulated medicine prices to those of other countries), quality consistency evaluation processes and volume-based procurement. We anticipate that these and similar initiatives will continue to increase pricing and access pressures globally. In the U.S., we expect to see continued focus by Congress and the Biden Administration on regulating pricing, which could result in legislative and regulatory changes designed to control costs, such as the IRA that was signed into law in August 2022. We continue to evaluate the impact of the IRA on our business, operations and financial condition and results as the full effect of the IRA on our business and the pharmaceutical industry remains uncertain. In addition, changes to the Medicaid program or the federal 340B drug pricing program, including legal or legislative developments at the federal or state level with respect to the 340B program, could have a material impact on our business. See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pricing Pressures and Managed Care Organizations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and &#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation and Price Constraints</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8211;&#8211;Pricing and Reimbursement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sections, and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Operating Environment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of the MD&amp;A of our 2022 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Supply</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;We periodically encounter supply delays, disruptions and shortages, including due to voluntary product recalls. In response to requests from various regulatory authorities, manufacturers across the pharmaceutical industry, including Pfizer, are evaluating their product portfolios for the potential presence or formation of nitrosamines. This has led to recalls, including our voluntary recall of Chantix in 2021 and additional voluntary recalls initiated for other products in 2022 due to the presence of nitrosamines above the FDA interim acceptable intake limit, and may lead to additional recalls or other market actions for Pfizer products.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regarding our supply chain generally, in the first quarter of 2023 and to date, we have not seen a significant disruption, and all of our manufacturing sites globally have continued to operate at or near normal levels; however, we continue to see heightened demand in the industry for certain components and raw materials, which could potentially result in constraining available supply leading to a possible future impact on our business. We are continuing to monitor and implement mitigation strategies in an effort to reduce any potential risk or impact including active supplier management, qualification of additional suppliers and advanced purchasing to the extent possible. For information on risks related to product manufacturing, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8211;&#8211;Product Manufacturing, Sales and Marketing Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2022 Form 10-K.</span></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Global Economic Environment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;In addition to the industry-specific factors discussed above, we, like other businesses of our size and global extent of activities, are exposed to economic cycles. See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Global Economic Environment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section of the MD&amp;A of our 2022 Form 10-K.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">COVID-19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;In response to COVID-19, we have developed Paxlovid and collaborated with BioNTech to jointly develop Comirnaty, including booster doses of an Omicron-adapted bivalent vaccine. As part of our strategy for COVID-19, we are continuing to make significant additional investments in breakthrough science and global manufacturing. This includes continuing to evaluate Comirnaty and Paxlovid, including against new variants of concern, developing variant adapted vaccine candidates and developing potential combination respiratory vaccines and potential next generation vaccines and therapies. We are also evaluating Paxlovid for additional populations. For additional information, including our continuing late-stage development efforts for Paxlovid, see the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_136" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pro</a><a href="#idfe6e72973fb4e83b28a5bb34d34299f_136" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">duct Developments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2023 and to date, we principally sold Comirnaty globally under government contracts and Paxlovid globally to government agencies and distributors. We expect Comirnaty in the U.S. will transition to traditional commercial market sales in the second half of 2023, triggered by the expiration of current contracts and the vaccines purchased through them becoming either depleted or not usable against new variants. Internationally, we expect sales of Comirnaty in international developed markets to generally be under government contracts in 2023, and in emerging markets, under a combination of private channels and government contracts; in both cases, we expect to generally transition to commercial markets starting in 2024. For Paxlovid, we expect to transition to traditional commercial markets in the second half of 2023 rather than significant government purchases. We also remain committed to helping ensure broad and equitable access to our COVID-19 products to eligible patients around the world. Revenues from our COVID-19 products are expected to go from their peak in 2022 to their low point in 2023 before potentially returning to growth in 2024. While patient demand for our COVID-19 products is expected to remain strong throughout 2023, much of that demand is expected to be fulfilled by existing supply of products that were delivered to governments and recorded as revenues in 2022. As of May 2, 2023, we forecasted Comirnaty revenues of approximately $13.5&#160;billion in 2023, down 64% from actual 2022 results, with gross profit to be split evenly with BioNTech, and Paxlovid revenues of approximately $8&#160;billion in 2023, down 58% from actual 2022 results. These forecasts are based on estimates and assumptions that are subject to significant uncertainties, including, among others, patient demand, which could be significantly impacted by the infectiousness and severity of the predominant strains of the SARS-CoV-2 virus during 2023, proportion of the population that receives a vaccine or is treated with an oral antiviral treatment, the number of doses per vaccinated person per year, number of symptomatic infections, market share of Comirnaty and Paxlovid, timing and terms for delivery of the contracted doses of Comirnaty to the EC, Paxlovid sales in China and the timing for transitioning Comirnaty and Paxlovid to commercial markets in the U.S.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on the impact of COVID-19 on our business, operations and financial conditions and results and risks associated with COVID-19 and our COVID-19 products, as well as COVID-19 intellectual property disputes, see the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Item 1A. Risk Factors&#8212;COVID-19, &#8212;Intellectual Property Protection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Third-Party Intellectual Property Claims</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sections and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section of the MD&amp;A of our 2022 Form 10-K, as well as </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_88" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a><a href="#idfe6e72973fb4e83b28a5bb34d34299f_88" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2</a><a href="#idfe6e72973fb4e83b28a5bb34d34299f_88" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Russia/Ukraine Conflict</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;Our global operations may be impacted by the armed conflict between Russia and Ukraine. For both the three months ended April 2, 2023 and the fiscal year ended December 31, 2022, the business of our Russia and Ukraine subsidiaries represented less than 1% of our consolidated revenues and assets, and while we are monitoring the effects of the armed conflict between Russia and Ukraine, the situation continues to evolve and the long-term implications, including the broader economic consequences of the conflict, are difficult to predict at this time. For additional information on our response to the armed conflict between Russia and Ukraine as well as risks associated with the conflict, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8212;Global Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section of the MD&amp;A of our 2022 Form 10-K.</span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_112"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our significant accounting policies, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2022 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of these policies, the following are considered critical to an understanding of our consolidated financial statements as they require the application of the most subjective and the most complex judgments: Acquisitions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Fair Value (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Revenues (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Asset Impairments (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Tax Assets and Liabilities and Income Tax Contingencies (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Pension and Postretirement Benefit Plans (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); and Legal and Environmental Contingencies (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion about the critical accounting estimates and assumptions impacting our consolidated financial statements, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A in our 2022 Form 10-K. See also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2022 Form 10-K for a discussion about the risks associated with estimates and assumptions.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of a recently adopted accounting standard, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_37" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1B</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_115"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_118"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues by Geography</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:17.041%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="57" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents worldwide revenues by geography:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="51" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">World-wide</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inter-national</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating segments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biopharma</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,971&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,323&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,396&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,816&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,575&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business Innovation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,282&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,661&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,507&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,918&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,775&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,743&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">First Quarter of 2023 vs. First Quarter of 2022</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following provides an analysis of the change in worldwide revenues by geographic areas in the first quarter of 2023:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended April 2, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Operational growth/(decline):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide declines from Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,967)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,986)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,981)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide growth from Paxlovid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,754&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,809&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Revenues from recently acquired products: Nurtec ODT/Vydura</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:107%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"> and Oxbryta</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Increased revenues from Sulperazon largely driven by demand in China</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide growth from Eliquis, the Vyndaqel family, the Prevnar family and Inlyta, partially offset by declines from Xeljanz, Ibrance and Xtandi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(132)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other operational factors, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operational growth/(decline), net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,650)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(411)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,238)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unfavorable impact of foreign exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(730)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(730)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> increase/(decrease)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,379)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(411)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,968)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.24pt">See the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_121" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenues&#8211;&#8211;Selected Product Discussion</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A for additional analysis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging markets revenues decreased $2.9 billion, or 39%, in the first quarter of 2023 to $4.5 billion from $7.4 billion in the first quarter of 2022, reflecting an operational decrease of $2.6 billion, or 36%, and an unfavorable impact from foreign exchange of 4%. The operational decrease in emerging markets was primarily driven by declines from Comirnaty, partially offset by growth from Paxlovid, as well as increased Sulperazon revenues largely driven by demand in China, which is not expected to be sustained.</span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_1567"></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on gross sales for a reporting period. Historically, adjustments to these estimates to reflect actual results or updated expectations, have not been material to our overall business and generally have been less than 1% of revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual product revenue growth trends.</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:71.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents information about revenue deductions:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid and related state program rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based contract rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,192&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,204&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns and cash discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,141&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,458&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue deductions are primarily a function of product sales volume, mix of products sold, contractual or legislative discounts and rebates.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on our accruals for revenue deductions, including the balance sheet classification of these accruals, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_37" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1C</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues&#8211;&#8211;Selected Product Discussion</span></div><div style="margin-bottom:3pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Biopharma</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.077%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.077%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.328%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global<br/>Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Region</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oper.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operational Results Commentary</span></td></tr><tr style="height:48pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paxlovid</span></td><td colspan="3" rowspan="54" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$4,069</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">*</span></div></td><td colspan="3" rowspan="33" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Growth primarily driven by:</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">favorable timing of final delivery associated with the U.S. government contract before anticipated transition to traditional commercial markets in the second half of 2023;</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">strong demand in China under the temporary National Reimbursement Drug List (which ended on April 1, 2023) due to surge in COVID-19 infections; and</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">launch in certain international markets.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,069&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$3,064</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Down 75%</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,314&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(86)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Global declines largely driven by lower contracted deliveries and demand in international markets, as well as lower U.S. government contracted deliveries with anticipated transition to traditional commercial market sales in the second half of 2023.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,735&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,913&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(75)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(73)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,064&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,227&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(77)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(75)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliquis</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$1,874</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Up 7%</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,261&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Growth driven primarily by continued oral anti-coagulant adoption and market share gains in the non-valvular atrial fibrillation indication in the U.S. and certain markets in Europe, partially offset by declines due to LOE and generic competition in certain international markets.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,874&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,793&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:26pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prevnar family</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$1,593</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Up 4% </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,075&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,014&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Growth primarily driven by the adult indications in the U.S. and certain markets in Europe due to strong patient demand following the launch of Prevnar 20/Apexxnar for the eligible adult population, partially offset by lower stocking and demand for Prevnar 13 pediatric indication in the U.S. due to competitor entry, as well as declines in certain emerging markets.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,593&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ibrance</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$1,144</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Down 5%</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:95%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Declines primarily driven by lower clinical trial purchases internationally, and planned price decreases in certain international developed markets.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vyndaqel family</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$686</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Up 16%</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Growth largely driven by continued strong uptake of the ATTR-CM indication, primarily in the U.S. and developed Europe, partially offset by a planned price decrease that went into effect in Japan in the second quarter of 2022.</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inlyta</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$259</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Up 14% </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Growth primarily reflects continued strong performance in the U.S. and emerging markets driven by the adoption of combinations of certain immune checkpoint inhibitors and Inlyta for the first-line treatment of patients with advanced RCC.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Xtandi</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$258</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Down 4%  </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Decline driven by lower net price mainly due to unfavorable changes in channel mix, partially offset by demand growth.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Xeljanz</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$237</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Down 33% </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(55)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Declines driven primarily by lower net price in the U.S. due to unfavorable changes in channel mix, as well as decreased prescription volumes globally resulting from ongoing shifts in prescribing patterns related to label changes.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:23pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nurtec ODT/Vydura</span></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$167</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">*</span></div></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Driven by the acquisition of Biohaven in the fourth quarter of 2022, after which Nurtec ODT/Vydura is now a Pfizer-owned product, compared to the first quarter of 2022 during which Pfizer only had commercialization rights outside of the U.S. under a collaboration and license agreement with Biohaven. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Notes 2A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">2E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> of our 2022 Form 10-K.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Business Innovation</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Segment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global<br/>Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Region</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 2, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oper.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operational Results Commentary</span></td></tr><tr style="height:21pt"><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Business Innovation</span></td><td colspan="3" rowspan="6" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">$310</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">Down 5% </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:95%">(operationally)</span></div></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Declines primarily driven by, among other things, the timing of Comirnaty supply to BioNTech, partially offset by higher manufacturing of divested products under manufacturing and supply agreements and higher COVID-19 manufacturing activities performed on behalf of customers.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Comirnaty includes direct sales and Alliance revenues related to sales of the Pfizer-BioNTech COVID-19 vaccine, which are recorded within our Primary Care customer group. It does not include revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in PC1, which is part of the Business Innovation operating segment. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_91" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 13C</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Indicates calculation not meaningful.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patents and Other Intellectual Property Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2022 Form 10-K for information regarding the expiration of various patent rights, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_88" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 12</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of recent developments concerning patent and product litigation relating to certain of the products discussed above and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_91" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 13C</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information regarding the primary indications or class of the selected products discussed above.</span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_127"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Costs and Expenses</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.835%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses follow:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%<br/>&#160;Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,886&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,984&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(51)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Percentage of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,418&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,593&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,505&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(94)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">835&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(96)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8212;net</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(80)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Cost of Sales</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decreased $5.1 billion, primarily due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">a reduction of $5.4&#160;billion due to lower sales of Comirnaty, </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">an increase of $400&#160;million due to higher sales of Paxlovid.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The decrease in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> as a percentage of revenues was primarily driven by changes in sales mix, including lower sales of Comirnaty and higher sales of Paxlovid.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Selling, Informational and Administrative Expenses</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses increased $824 million, primarily due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">a $500 million increase in marketing and promotional expenses ($280&#160;million for Paxlovid and $220&#160;million for recently acquired and launched products); and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">a $180 million increase in spending on products across multiple customer groups.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Research and Development Expenses</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses increased $203 million, primarily due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">increased investments of $420&#160;million to develop recently acquired assets and certain vaccine programs, as well as activities to support upcoming product launches, </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">lower spending of $250&#160;million on programs to prevent and treat COVID-19 and certain other late-stage clinical programs.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Acquired In-Process Research and Development Expenses</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired in-process research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses decreased $334 million, primarily reflecting the non-recurrence of (i) an upfront payment to Biohaven and a premium paid on our equity investment in Biohaven totaling $263&#160;million and (ii) a $76 million premium paid on our equity investment in BioNTech to develop a potential mRNA vaccine against shingles, both recorded in the first quarter of 2022.</span></div><div style="margin-bottom:5pt;margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Amortization of Intangible Assets</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets increased $268 million, primarily as a result of amortization of intangible assets from our acquisitions of Biohaven and GBT, partially offset by fully amortized assets.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transforming to a More Focused Company Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;For a description of our program, as well as the anticipated and actual costs, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_46" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3A</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The program savings discussed below may be rounded and represent approximations. In connection with restructuring our corporate enabling functions, we achieved gross cost savings of $1.0&#160;billion, or net cost savings, excluding merit and inflation growth and certain real estate cost increases, of $700 million, in the two year period from 2021 through 2022. In connection with transforming our commercial go-to market strategy, we expect net cost savings of $1.4&#160;billion, to be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achieved primarily from 2022 through 2024. In connection with manufacturing network optimization, we expect net cost savings of $550 million to be achieved primarily from 2020 through 2023. In connection with optimizing our end-to-end R&amp;D operations, we expect net cost savings of $2.3 billion to be achieved primarily from 2023 through 2025.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain qualifying costs for this program in all periods since inception were recorded and reflected as Certain Significant Items and excluded from our non-GAAP measure of Adjusted Income. See the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_139" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Non-GAAP Financial Measure: Adjusted Income</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to this program, we continuously monitor our operations for cost reduction and/or productivity opportunities, especially in light of the losses of exclusivity and the expiration of collaborative arrangements for various products.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Other (Income)/Deductions&#8212;Net</span><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable change of $279 million was primarily driven by (i) lower net losses on equity securities, (ii) higher dividend income and (iii) lower net interest expense, partially offset by (iv) intangible asset impairment charges recorded in the first quarter of 2023 and (v) lower net periodic benefit credits associated with pension and postretirement plans. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_49" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_130"></div><div style="margin-bottom:3pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision/(Benefit) for Taxes on Income</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:64.510%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.103%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%<br/>Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effective tax rate on continuing operations</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about our effective tax rate and the events and circumstances contributing to the changes between periods, as well as details about discrete elements that impacted our tax provisions, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_133"></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about our discontinued operations, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2B</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_136"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRODUCT DEVELOPMENTS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A comprehensive update of Pfizer&#8217;s development pipeline was published as of May&#160;2, 2023 and is available at www.pfizer.com/science/drug-product-pipeline. It includes an overview of our research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in Phase 1 and all candidates from Phase 2 through registration.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This section provides information as of the date of this filing about significant marketing application-related regulatory actions by, and filings pending with, the FDA and regulatory authorities in the EU and Japan.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below include filing and approval milestones for products that have occurred in the last twelve months and generally do not include approvals that may have occurred prior to that time. The tables include filings with regulatory decisions pending (even if the filing occurred outside of the last twelve-month period).</span></div><div style="margin-bottom:3pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Vaccine Products</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;In April 2023, in order to simplify the vaccination schedule for most individuals, the FDA amended an EUA for the emergency use of the Pfizer&#8209;BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), which has been developed in collaboration with BioNTech, for active immunization to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months of age and older. In the U.S., the monovalent Pfizer-BioNTech COVID-19 Vaccine is no longer authorized for emergency use or CDC-recommended, although Comirnaty remains a licensed vaccine. This decision relates entirely to the FDA&#8217;s strategy to harmonize COVID-19 vaccines and is not indicative of any safety-related signals or concerns.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, Pfizer and BioNTech announced the submission of a supplemental Biologics License Application (sBLA) to the FDA for approval of the companies&#8217; Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)) as a primary series and booster dose(s) for individuals 12 years of age and older.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table contains the authorized uses of the Pfizer&#8209;BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) for the various patient populations in the U.S.:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.463%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PATIENT POPULATION AND AUTHORIZATIONS (U.S. ONLY)</span></td></tr><tr style="height:27pt"><td colspan="3" rowspan="2" style="border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">AGE</span></td><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Individuals 6 months of age and older not previously vaccinated with a COVID-19 vaccine</span></td><td colspan="3" rowspan="10" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Individuals 5 years of age and older previously vaccinated with 1 or more doses of a monovalent  COVID-19 Vaccine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" rowspan="10" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Individuals 6 months through 4 years of age previously vaccinated with the monovalent Pfizer-BioNTech COVID-19 Vaccine</span></td></tr><tr style="height:27pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">One previous dose of the Pfizer-BioNTech COVID-19 Vaccine</span></td><td colspan="3" rowspan="9" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Two previous doses of the Pfizer-BioNTech COVID-19 Vaccine</span></td><td colspan="3" rowspan="9" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Three previous doses of the Pfizer-BioNTech COVID-19 Vaccine</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">6 months &#8211;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">4 years</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3 doses, 0.2 mL each</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Dose 1: Week 0</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Dose 2: Week 3</span></div><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Dose 3: &#8805; 8 weeks after Dose 2</span></div></td><td colspan="3" style="border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2 doses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, 0.2 mL each </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Dose 1: 3 weeks after receipt of the Pfizer-BioNTech COVID-19 Vaccine</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Dose 2: &#8805;8 weeks after Dose 1</span></div></td><td colspan="3" style="border-right:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Single dose, 0.2 mL<br/>&#8805;8 weeks after receipt of second dose of the Pfizer-BioNTech COVID-19 Vaccine</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Single dose, 0.2 mL</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8805;2 months</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">after receipt of third dose of the Pfizer-BioNTech COVID-19 Vaccine</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">5-11 years</span></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Single dose, 0.2 mL</span></td><td colspan="3" style="border-right:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Single dose, 0.2 mL<br/>&#8805;2 months after monovalent COVID-19 Vaccine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">12-64 years</span></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Single dose, 0.3 mL</span></td><td colspan="3" style="border-right:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Single dose, 0.3 mL<br/>&#8805;2 months after monovalent COVID-19 Vaccine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:72pt"><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8805;65 years</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-right:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Single dose, 0.3 mL.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">One additional dose, 0.3 mL, may be administered &#8805;4 months after first dose of an authorized bivalent COVID-19 vaccine</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-right:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Single dose, 0.3 mL</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8805;2 months after monovalent COVID-19 vaccine</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">One additional dose, 0.3 mL, may be administered &#8805;4 months after first dose of an authorized bivalent COVID-19 vaccine</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.97pt">Monovalent refers to a COVID-19 vaccine that contains or encodes the spike protein of only the Original SARS-CoV-2.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.71pt">Notwithstanding the age limitations for use of the vaccine, individuals turning from 4 to 5 years of age during the vaccination series should receive all doses with the Pfizer-BioNTech COVID-19 Vaccine, Bivalent.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.97pt">Notwithstanding the age limitations for use of the vaccine, individuals turning from 4 to 5 years of age during the vaccination series should receive 2 doses with the Pfizer-BioNTech COVID-19 Vaccine, Bivalent.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For individuals with certain kinds of immunocompromise 6 months through 4 years of age who have received three 0.2 mL doses (the Pfizer&#8209;BioNTech COVID-19 Vaccine or the Pfizer-BioNTech COVID-19 Vaccine, Bivalent), a fourth dose (0.2 mL) with the Pfizer-BioNTech COVID-19 Vaccine, Bivalent may be administered at least one month following the most recent dose; additional doses of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual&#8217;s clinical circumstances. For individuals with certain kinds of immunocompromise 5 years of age and older, a single additional age-appropriate dose of the Pfizer&#8209;BioNTech COVID-19 Vaccine, Bivalent may</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be administered at least 2 months following the initial dose of a bivalent COVID-19 vaccine; additional age&#8209;appropriate doses of the Pfizer&#8209;BioNTech COVID&#8209;19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual&#8217;s clinical circumstances.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">EU and Japan</span><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;In March 2023, Pfizer and BioNTech announced the submission of an application to the EMA to extend the Omicron BA.4/BA.5-adapted bivalent vaccine&#8217;s marketing authorization (MA) to include use in children six months through four years of age as both primary series (all three doses) and booster vaccination (fourth dose).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, Pfizer and BioNTech announced the submission of an application to the EMA for a variation of the</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MA to include the bivalent vaccine as a primary course of vaccination in individuals five years of age and older.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes filings and approvals for our COVID-19 vaccine products in the EU and Japan. All COVID-19 vaccine products listed in this table have been developed in collaboration with BioNTech.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.199%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.199%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="45" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PATIENT POPULATION AND DATE OF APPROVAL/FILING</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td></tr><tr style="height:36pt"><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">COVID-19 VACCINE PRODUCT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">PRIMARY SERIES<br/>OR BOOSTER</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">16 Years of age and older</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">12-15 Years of age</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">5-11 Years of age</span></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">6 Months through 4 Years </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">of age</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">EU</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">JAPAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">EU</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">JAPAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">EU</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">JAPAN</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">EU</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">JAPAN</span></td></tr><tr style="height:11pt"><td colspan="3" rowspan="4" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Comirnaty</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">30-&#181;g 2-dose primary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">10-&#181;g 2-dose primary</span></td><td colspan="6" style="border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">3-&#181;g 3-dose primary</span></td></tr><tr style="height:36pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Primary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">December</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2020</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">J-NDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> February</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2021</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">May </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2021</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">J-NDA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">May</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">November </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2021</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">J-NDA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">January</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">CMA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">October</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">J-NDA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">October</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">30-&#181;g booster dose</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">10-&#181;g booster dose</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:36pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Booster</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">October</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2021</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">J-NDA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">November</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2021</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">February </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">J-NDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">March</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> September </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">J-NDA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">August</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-right:0.5pt solid #000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" rowspan="4" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Comirnaty Original/Omicron BA.4/BA.5 Vaccine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">30-&#181;g 2-dose primary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">10-&#181;g 2-dose primary</span></td><td colspan="6" style="border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">3-&#181;g 3-dose primary</span></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Primary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">April</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">April</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">April</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">April</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">2023</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">30-&#181;g booster dose</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">10-&#181;g booster dose</span></td><td colspan="6" style="border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">3-&#181;g booster dose</span></td></tr><tr style="height:36pt"><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Booster</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">September </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">J-NDA </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">October</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">September </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">J-NDA </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">October</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">September </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">J-NDA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">February</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">April</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">2023</span></div></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Comirnaty Original/Omicron BA.1 Vaccine</span></td><td colspan="3" rowspan="2" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Booster</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">30-&#181;g booster dose</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:36pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">September</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">J-NDA </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">October</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">September</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Cond.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">J-NDA </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">October </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.97pt">All EU approvals prior to October 10, 2022 were under the CMA, and later converted to full Marketing Authorization as of October 10, 2022. Dates shown in table reflect original CMA date.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.71pt">Refers to the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) and Comirnaty Original/Omicron BA.4/BA.5 Vaccine.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Products</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.796%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PRODUCT</span></td><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">INDICATION OR PROPOSED INDICATION</span></td><td colspan="9" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">APPROVED/FILED*</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">EU</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">JAPAN</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Myfembree</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(relugolix, estradiol, and norethindrone acetate)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Moderate to severe pain associated with endometriosis</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">August</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Ngenla</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(somatrogon)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Pediatric growth hormone deficiency</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">January</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">February</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">January</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Prevnar 20/Apexxnar</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Vaccine)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae (adults)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">June</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">February</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae (pediatric)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">April</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">March</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">TicoVac<br/>(Vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Active immunization to prevent tick-borne encephalitis disease</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">August </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">March</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Paxlovid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(nirmatrelvir [PF-07321332]; ritonavir)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">COVID-19 in high-risk adults and children (12-18 years of age; &gt;88lbs)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">EUA </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">December</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">February</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">February </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td></tr><tr style="height:26pt"><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Nurtec ODT/Vydura</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(rimegepant)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Acute treatment of migraine with or without aura (adults)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">February</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2020</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">April </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:26pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Prevention of episodic migraine (adults)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> May</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">April </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">ritlecitinib (PF-06651600)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Alopecia areata</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">September</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">September</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">September</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Zavzpret (zavegepant)<br/>(intranasal)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Acute treatment of migraine with or without aura (adults)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">March</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">PF-06886992<br/>(Vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Active immunization to prevent serogroups ABCWY meningococcal infections (adolescent and young adults)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">December</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:26pt"><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">PF-06928316<br/>(Vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Active immunization to prevent respiratory syncytial virus infection (maternal)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">February</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">January</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">February</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr><tr style="height:26pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Active immunization to prevent respiratory syncytial virus infection (older adults)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">December</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">January</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">etrasimod</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Ulcerative colitis (moderately to severely active)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">December</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">November</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Braftovi (encorafenib) and Mektovi (binimetinib)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">V600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">-mutant metastatic non-small cell lung cancer</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">April</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">elranatamab (PF-06863135)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Multiple myeloma triple-class refractory</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">February</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">February</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Talzenna (talazoparib)</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Combination with Xtandi (enzalutamide) for first-line mCRPC</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">February</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">February</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.5pt">For the U.S., the filing date is the date on which the FDA accepted our submission. For the EU, the filing date is the date on which the EMA validated our submission. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.97pt">Being developed in collaboration with Myovant.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">Being developed in collaboration with OPKO. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.97pt">In October 2022, the CDC&#8217;s ACIP voted to recommend a single dose of Prevnar 20 to help protect adults previously vaccinated with Prevnar 13 or both Prevnar 13 and PPSV23 against invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae serotypes in Prevnar 20.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.71pt">In June 2022, we announced the submission of an NDA to the FDA for approval of Paxlovid for the treatment of COVID-19 in both vaccinated and unvaccinated individuals who are at high risk for progression to severe illness from COVID-19. In December 2022, Pfizer announced the FDA has extended the review period for the NDA for Paxlovid. At the request of the FDA, Pfizer submitted additional analyses of efficacy and safety data from the pivotal Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients and supportive Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients trials to be considered as part of its NDA for Paxlovid. Results from these analyses are consistent with previously disclosed efficacy and safety data for the trials. In order to allow time for a full review of the application, including the additional data analyses submitted, the FDA has extended the Prescription Drug User Fee Act goal date by three months to May 2023.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, in light of the results from the completed required postmarketing safety study of Xeljanz, ORAL Surveillance (A3921133), the U.S. label for Xeljanz was revised. In addition, in November 2022, the EMA concluded their assessment of JAK inhibitors authorized for inflammatory diseases in the EU, including Xeljanz and Cibinqo, and recommended that risk minimization measures, including special warnings and precautions for use, should be revised and harmonized for all such JAK inhibitors. The resulting EU label changes were finalized in April 2023. We continue to work with regulatory agencies worldwide to review the full results and analyses of ORAL Surveillance and their impact on product labeling. See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8212;Post-Authorization/Approval Data </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Product Development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sections of our 2022 Form 10-K.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In China, the following products received regulatory approvals in the last twelve months: Cresemba (IV formulation) for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis in June 2022; Xeljanz for the treatment of adult patients with active psoriatic arthritis in October 2022; and Prevenar 13 in infants and children aged 6 weeks to 15 months, in April 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides information about additional indications and new drug candidates in late-stage development:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.998%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.983%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt;text-indent:7.2pt"></td><td colspan="3" rowspan="15" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PRODUCT/CANDIDATE</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PROPOSED DISEASE AREA</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="14" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;padding:2px 1pt;text-align:center;text-indent:7.2pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FOR IN-LINE AND IN-REGISTRATION PRODUCTS</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Ibrance (palbociclib)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">ER+/HER2+ metastatic breast cancer</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Xtandi (enzalutamide)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Non-metastatic high-risk castration sensitive prostate cancer</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Talzenna (talazoparib)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Combination with Xtandi (enzalutamide) for DNA Damage Repair (DDR)-deficient mCSPC</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">somatrogon (PF-06836922)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adult growth hormone deficiency</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Braftovi (encorafenib) and Erbitux&#174; (cetuximab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">First-line BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">V600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-mutant mCRC</span></div></td></tr><tr style="height:30pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Braftovi (encorafenib) and Mektovi (binimetinib) and Keytruda&#174; (pembrolizumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">V600E/K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-mutant metastatic or unresectable locally advanced melanoma</span></div></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Paxlovid (nirmatrelvir [PF-07321332]; ritonavir)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 in high-risk children (6-11 years of age; &gt;88lbs)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">zavegepant (oral)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prevention of chronic migraine (adults)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ritlecitinib (PF-06651600)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Vitiligo</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">elranatamab (PF-06863135)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Multiple myeloma double-class exposed</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Newly diagnosed multiple myeloma post-transplant maintenance</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Newly diagnosed multiple myeloma transplant-ineligible </span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Voxelotor</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sickle Cell Disease (pediatric)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Eliquis (apixaban)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Venous thromboembolism (pediatric)</span></td></tr><tr style="height:21pt"><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;text-indent:5.65pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT</span></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">aztreonam-avibactam<br/>(PF-06947387)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Treatment of infections caused by Gram-negative bacteria with limited or no treatment options</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">fidanacogene elaparvovec (PF-06838435)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Hemophilia B</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">giroctocogene fitelparvovec </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(PF-07055480)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Hemophilia A</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PF-06425090 (Vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Immunization to prevent primary clostridioides difficile infection</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">sasanlimab (PF-06801591)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Combination with Bacillus Calmette-Guerin for non-muscle-invasive bladder cancer</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">fordadistrogene movaparvovec (PF-06939926)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Duchenne muscular dystrophy (ambulatory)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">marstacimab (PF-06741086)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Hemophilia</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Omicron-based mRNA vaccine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Immunization to prevent COVID-19 (adults)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">VLA15 (PF-07307405) vaccine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Immunization to prevent Lyme Disease</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">PF-07252220 (quadrivalent mRNA-based vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Immunization to prevent influenza</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Vepdegestrant (PF-07850327)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(j)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Breast Cancer Metastatic - 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> line + ER+/HER2-</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">inclacumab (PF-07940370)</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sickle Cell Disease</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Being developed in collaboration with The Alliance Foundation Trials, LLC.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">Being developed in collaboration with Astellas.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Being developed in collaboration with OPKO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.71pt">Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is a registered trademark of ImClone LLC. In the EU, we are developing in collaboration with the Pierre Fabre Group. In Japan, we are developing in collaboration with Ono. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.97pt">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is a registered trademark of Merck Sharp &amp; Dohme Corp. In the EU, we are developing in collaboration with the Pierre Fabre Group. In Japan, we are developing in collaboration with Ono.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:4.14pt">Being developed in collaboration with Spark Therapeutics, Inc.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">Being developed in collaboration with Sangamo Therapeutics, Inc.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt">Being developed in collaboration with BioNTech.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:4.41pt">Being developed in collaboration with Valneva SE.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(j)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:4.41pt">Being developed in collaboration with Arvinas, Inc.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our R&amp;D organization, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2022 Form 10-K.</span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_139"></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NON-GAAP FINANCIAL MEASURE: ADJUSTED INCOME</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted income is an alternative measure of performance used by management to evaluate our overall performance as a supplement to our GAAP Reported performance measures. As such, we believe that investors&#8217; understanding of our performance is enhanced by disclosing this measure. We use Adjusted income, certain components of Adjusted income and Adjusted diluted EPS to present the results of our major operations&#8211;&#8211;the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide&#8211;&#8211;prior to considering certain income statement elements as follows:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.879%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Measure</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Definition</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Relevance of Metrics to Our Business Performance</span></td></tr><tr style="height:72pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Provides investors useful information to:</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.81pt">evaluate the normal recurring operational activities, and their components, on a comparable year-over-year basis</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.81pt">assist in modeling expected future performance on a normalized basis</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Provides investors insight into the way we manage our budgeting and forecasting, how we evaluate and manage our recurring operations and how we reward and compensate our senior management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td></tr><tr style="height:72pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted cost of sales, Adjusted selling, informational and administrative expenses, Adjusted research and development expenses and Adjusted other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, informational and administrative expenses, Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, each before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items, which are components of the Adjusted income measure</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:72pt"><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted diluted EPS</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">EPS attributable to Pfizer Inc. common shareholders&#8211;&#8211;diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Most directly comparable GAAP measure.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The short-term incentive plans for substantially all non-sales-force employees worldwide are funded from a pool based on our performance, measured in significant part versus three budgeted metrics, one of which is Adjusted diluted EPS (as defined for annual incentive compensation purposes), which is derived from Adjusted income and accounts for 40% of the bonus pool funding tied to financial performance. Additionally, the payout for performance share awards is determined in part by Adjusted net income, which is derived from Adjusted income. Beginning in the first quarter of 2022, we no longer exclude any expenses for acquired IPR&amp;D from our non-GAAP Adjusted results but we continue to exclude certain of these expenses for our financial results for annual incentive compensation purposes. The bonus pool funding, which is largely based on financial performance, is adjusted by our R&amp;D pipeline performance, as measured by four metrics, and performance against certain of our ESG metrics, and may be further modified by our Compensation Committee&#8217;s assessment of other factors.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted income and its components and Adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, are limited in their usefulness to investors. Because of their non-standardized definitions, they may not be comparable to the calculation of similar measures of other companies and are presented to permit investors to more fully understand how management assesses performance. A limitation of these measures is that they provide a view of our operations without including all events during a period, and do not provide a comparable view of our performance to peers. These measures are not, and should not be viewed as, substitutes for their most directly comparable GAAP measures of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EPS attributable to Pfizer Inc. common shareholders&#8212;diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recognize that, as internal measures of performance, these measures have limitations, and we do not restrict our performance-management process solely to these measures. We also use other tools designed to achieve the highest levels of performance. For example, our R&amp;D organization has productivity targets, upon which its effectiveness is measured. In addition, total shareholder return, both on an absolute basis and relative to a publicly traded pharmaceutical index, plays a significant role in determining payouts under certain of our incentive compensation plans.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adjusted Income and Adjusted Diluted EPS</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Amortization of Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Adjusted income excludes all amortization of intangible assets.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquisition-Related Items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Adjusted income excludes certain acquisition-related items, which are comprised of transaction, integration, restructuring charges and additional depreciation costs for business combinations because these costs are unique to each transaction and represent costs that were incurred to restructure and integrate businesses as a result of an acquisition. We have made no adjustments for resulting synergies. Acquisition-related items may include purchase accounting impacts such as the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, depreciation related to the increase/decrease in fair value of acquired fixed assets, amortization related to the increase in fair value of acquired debt, and the fair value changes for contingent consideration. </span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Discontinued Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Adjusted income excludes the results of discontinued operations, as well as any related gains or losses on the disposal of such operations. We believe that this presentation is meaningful to investors because, while we review our product portfolio for strategic fit with our operations, we do not build or run our business with the intent to discontinue parts of our business. Restatements due to discontinued operations do not impact compensation or change the Adjusted income measure for the compensation in respect of the restated periods, but are presented for consistency across all periods.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Certain Significant Items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Adjusted income excludes certain significant items representing substantive and/or unusual items that are evaluated individually on a quantitative and qualitative basis. Certain significant items may be highly variable and difficult to predict. Furthermore, in some cases it is reasonably possible that they could reoccur in future periods. For example, although major non-acquisition-related cost-reduction programs are specific to an event or goal with a defined term, we may have subsequent programs based on reorganizations of the business, cost productivity or in response to LOE or economic conditions. Legal charges to resolve litigation are also related to specific cases, which are facts and circumstances specific and, in some cases, may also be the result of litigation matters at acquired companies that were inestimable, not probable or unresolved at the date of acquisition, or legal matters related to divested products or businesses. Gains and losses on equity securities, and pension and postretirement actuarial remeasurement gains and losses have a very high degree of inherent market volatility, which we do not control and cannot predict with any level of certainty and because we do not believe including these gains and losses assists investors in understanding our business or is reflective of our core operations and business. Unusual items represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be non-recurring; or items that relate to products we no longer sell. See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reconciliations of GAAP Reported to Non-GAAP Adjusted information&#8212;Certain Line Items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a non-inclusive list of certain significant items and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Financial Measure: Adjusted Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A of our 2022 Form 10-K.</span></div><div style="margin-bottom:3pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Reconciliations of GAAP Reported to Non-GAAP Adjusted Information&#8211;&#8211;Certain Line Items</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Three Months Ended April 2, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Data presented will not (in all cases) aggregate to totals.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER SHARE DATA)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a), (b)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Earnings per common share attributable to Pfizer Inc. common shareholders&#8211;&#8211;diluted</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">GAAP Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,886</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,418</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,543</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="12" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">0.97</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisition-related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(97)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">163&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain significant items:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(32)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(59)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain asset impairments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(264)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">264&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Gains)/losses on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(452)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial valuation and other pension and postretirement plan (gains)/losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(88)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income tax provision&#8212;non-GAAP items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(437)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-GAAP Adjusted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,746&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,350&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(528)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,036&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.23&#160;</span></td><td style="border-bottom:3pt double #000;border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.573%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="33" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:33.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Three Months Ended April 3, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Data presented will not (in all cases) aggregate to totals.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER SHARE DATA)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a), (b)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Earnings per common share attributable to Pfizer Inc. common shareholders&#8211;&#8211;diluted</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">GAAP Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,984</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,593</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">350</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,864</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1.37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">835&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisition-related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain significant items:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(74)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Gains)/losses on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(698)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial valuation and other pension and postretirement plan (gains)/losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(72)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(104)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income tax provision&#8212;non-GAAP items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(448)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-GAAP Adjusted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,958&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,496&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(406)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,338&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.62&#160;</span></td><td style="border-bottom:3pt double #000;border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Items that reconcile GAAP Reported to non-GAAP Adjusted balances are shown pre-tax. Our effective tax rates for GAAP Reported income from continuing operations were: 11.4% in the three months ended April 2, 2023 and 12.9% in the three months ended April 3, 2022. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Our effective tax rates for non-GAAP Adjusted income were 14.0% in the three months ended April 2, 2023 and 14.8% in the three months ended April 3, 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The amounts for the three months ended April 2, 2023 and April 3, 2022 include reconciling amounts for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> that are not material.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2B</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes employee termination costs, asset impairments and other exit costs related to our cost-reduction and productivity initiatives not associated with acquisitions. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_46" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_49" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.81pt">For the three months ended April 2, 2023, the total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">adjustment of $107&#160;million primarily includes dividend income of $211&#160;million related to our investment in Nimbus resulting from Takeda Pharmaceutical Company Limited&#8217;s acquisition of Nimbus&#8217;s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary, partially offset by charges of (i) $50&#160;million mostly related to our equity-method accounting pro-rata share of intangible asset amortization and impairments, costs of separating from GSK and restructuring costs recorded by Haleon, and (ii) $36&#160;million for certain legal matters, primarily for certain product liability expenses related to products discontinued and/or divested by Pfizer. For the three months ended April 3, 2022, the total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">adjustment of $104&#160;million primarily included charges of $79&#160;million for certain legal matters representing certain product liability expenses related to products discontinued and/or divested by Pfizer, and to a lesser extent, legal obligations related to pre-acquisition commitments.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="33" style="padding:0 1pt"></td></tr></table></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_145"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:49.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drivers of change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by/(used in):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,541&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The change was primarily driven by a decrease in net income adjusted for non-cash items, the timing of receipts and payments in the ordinary course of business, including timing of payments to BioNTech for the gross profit split for Comirnaty (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_76" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Note 8B</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), a decrease in advance payments for Comirnaty and Paxlovid, and a decrease in cash dividends received from equity method investments.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,315&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The change was driven mainly by $6.2 billion cash used to acquire Arena, net of cash acquired, in the first quarter of 2022, partially offset by $3.7 billion fewer net redemptions of short-term investments with original maturities less than and greater than three months in the first quarter of 2023.</span></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,771)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,578)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The change was driven mainly by $2.0 billion of purchases of common stock in the first quarter of 2022, and a $1.3 billion decrease in payments of long-term debt.</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_148"></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANALYSIS OF FINANCIAL CONDITION, LIQUIDITY, CAPITAL RESOURCES AND MARKET RISK</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our significant operating cash flows, which is a key strength of our liquidity and capital resources and our primary funding source, as well as our financial assets, access to capital markets, revolving credit agreements, and available lines of credit, we believe that we have, and will maintain, the ability to meet our liquidity needs to support ongoing operations, our capital allocation objectives, and our contractual and other obligations for the foreseeable future. For information about the sources and uses of our funds and capital resources, as well as our operating cash flows, see our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Condensed Consolidated Statements of Cash Flows</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Condensed Consolidated Balance Sheets</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_28" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Condensed Consolidated Statements of Equity</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_145" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Analysis of the Condensed Consolidated Statements of Cash Flows</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within MD&amp;A. For information on our money market funds, available-for sale-debt securities and long-term debt, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note </a><a href="#idfe6e72973fb4e83b28a5bb34d34299f_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about our diverse sources of funds, off-balance sheet arrangements, contractual and other obligations, global economic conditions, market risk and LIBOR, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within MD&amp;A in our 2022 Form 10-K. For more information on guarantees and indemnifications, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_88" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 12B</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Ratings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;The cost and availability of financing are influenced by credit ratings, and an increase or decrease in our credit rating could have a beneficial or adverse effect on financing. Our long-term debt is rated high-quality by both S&amp;P and Moody&#8217;s. In March 2023, following the announcement of the proposed acquisition of Seagen, Moody&#8217;s changed the outlook on our long-term debt to Negative; S&amp;P downgraded our short-term rating from A-1+ to A-1.</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The current ratings assigned to our commercial paper and senior unsecured long-term debt:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NAME OF RATING AGENCY</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfizer Short-Term Rating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfizer Long-Term Rating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outlook/Watch</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Moody&#8217;s</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">P-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">A1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Negative</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S&amp;P</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">A-1</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">A+</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stable</span></td></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These ratings are not recommendations to buy, sell or hold securities and the ratings are subject to revision or withdrawal at any time by the rating organizations. Each rating should be evaluated independently of any other rating.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Capacity&#8211;&#8211;Lines of Credit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;As of April&#160;2, 2023, we had access to a $7 billion committed U.S. revolving credit facility, which may be used for general corporate purposes including to support our commercial paper borrowings. Lenders under this facility have approximately $700 million of commitments maturing in November 2026 and $6.3 billion of commitments maturing in November 2027. In addition to the U.S. revolving credit facility, our lenders have provided us an additional $316 million in lines of credit, of which $287 million expire within one year. Essentially all lines of credit were unused as of April&#160;2, 2023.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Allocation Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;&#8211;Our capital allocation framework is primarily devised to facilitate the achievement of medical breakthroughs through R&amp;D investments and business development activities and returning capital to shareholders through dividends and share repurchases. We expect to finance the proposed acquisition of Seagen substantially through $31 billion of new, long-term debt, and the balance from a combination of short-term financing and existing cash. See the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_106" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">O</a><a href="#idfe6e72973fb4e83b28a5bb34d34299f_106" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">verview of Our Performance, Operating Environment, Strategy and Outlook</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section within MD&amp;A and the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_169" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Item 1A. Risk Factors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section for additional information about our proposed acquisition of Seagen. In April 2023, our BOD declared a dividend of $0.41 per share, payable on June&#160;9, 2023, to shareholders of record at the close of business on May&#160;12, 2023. At April&#160;2, 2023, our remaining share-purchase authorization was approximately $3.3 billion, with no repurchases in the first three months of 2023. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2022 Form 10-K for more information on our publicly announced share-purchase plans.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financing plan for Seagen does not involve monetizing any portion of our Haleon stake. Our intentions with respect to our Haleon stake are set out in our Schedule 13D (as amended) initially filed with the SEC on July 27, 2022.</span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_151"></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEW ACCOUNTING STANDARDS</span></div><div style="margin-bottom:3pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standard</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_37" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1B</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recently Issued Accounting Standards, Not Adopted as of April&#160;2, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard/Description</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect on the <br/>Financial Statements</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Reference rate reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> provides temporary optional expedients and exceptions to the guidance for contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued after 2021 because of reference rate reform.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The new guidance provides the following optional expedients:</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1. Simplify accounting analyses under current U.S. GAAP for contract modifications.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2. Simplify the assessment of hedge effectiveness and allow hedging relationships affected by reference rate reform to continue.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3. Allow a one-time election to sell or transfer debt securities classified as held to maturity that reference a rate affected by reference rate reform.</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Elections can be adopted prospectively at any time through December 31, 2024.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We will apply certain of the optional expedients on hedge accounting relationships and related contracts, if necessary. We do not expect this new guidance to have a material impact on our consolidated financial statements.</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In June 2022, the FASB issued final guidance to clarify that a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> contractual restriction on the sale of an equity security</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is not considered part of the unit of account of the equity security and, therefore, is not considered when measuring fair value. Recognizing a contractual sale restriction as a separate unit of account is not permitted.</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1, 2024, with early adoption permitted.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are assessing the impact, but currently do not expect this new guidance to have a material impact on our consolidated financial statements.</span></td></tr></table></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_154"></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING INFORMATION AND FACTORS THAT MAY AFFECT FUTURE RESULTS</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-Q contains forward-looking statements. We also provide forward-looking statements in other materials we release to the public, as well as public oral statements. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have tried, wherever possible, to identify such statements by using words such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;likely,&#8221; &#8220;ongoing,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;assume,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; &#8220;guidance,&#8221; &#8220;goal,&#8221; &#8220;objective,&#8221; &#8220;aim,&#8221; &#8220;seek,&#8221; &#8220;potential,&#8221; &#8220;hope&#8221; and other words and terms of similar meaning or by using future dates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include forward-looking information in our discussion of the following, among other topics:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our anticipated operating and financial performance, reorganizations, business plans, strategy and prospects;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.2pt">expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data; revenue contribution and projections; potential pricing and reimbursement; potential market dynamics and size; growth, performance, timing of exclusivity and potential benefits;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">strategic reviews, capital allocation objectives, dividends and share repurchases;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on growth opportunities and prospects; </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">sales, expenses, interest rates, foreign exchange rates and the outcome of contingencies, such as legal proceedings;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">expectations for impact of or changes to existing or new government regulations or laws;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to anticipate and respond to macroeconomic, geopolitical, health and industry trends, pandemics, acts of war and other large-scale crises; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">manufacturing and product supply. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, forward-looking information in this Form 10-Q includes statements relating to specific future actions, performance and effects, including, among others, the expected benefits of the organizational changes to our operations; our 2023 revenue expectations; our ongoing efforts to respond to COVID-19, including our plans and expectations regarding Comirnaty and Paxlovid, and any potential future vaccines or treatments; the forecasted revenue, demand, manufacturing and supply of Comirnaty and Paxlovid, including expectations for the commercial market for Comirnaty and Paxlovid; our expectations regarding the impact of COVID-19 on our business; the expected impact of patent expiries and generic competition; the expected pricing pressures on our products and the anticipated impact to our business; the availability of raw materials for 2023; the benefits expected from our business development transactions, including our proposed acquisition of Seagen; our anticipated liquidity position; the anticipated costs and savings from certain of our initiatives, including our Transforming to a More Focused Company program; and our planned capital spending.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. Actual outcomes may vary materially from past results and those anticipated, estimated, implied or projected. These forward-looking statements may be affected by underlying assumptions that may prove inaccurate or incomplete, or by known or unknown risks and uncertainties, including those described in this section and in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section in our 2022 Form 10-K and the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_169" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Item 1A. Risk Factors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Form 10-Q.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, you are cautioned not to unduly rely on forward-looking statements, which speak only as of the date of this Form  10-Q. We undertake no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. You are advised, however, to consult any further disclosures we make on related subjects.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the factors that could cause actual results to differ are identified below, as well as those discussed in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section in our 2022 Form 10-K, the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_169" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Item 1A. Risk Factors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section of this Form 10-Q and within MD&amp;A. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. The occurrence of any of the risks identified below, in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section in our 2022 Form 10-K, the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_169" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Item 1A. Risk Factors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section of this Form 10-Q or within MD&amp;A, or other risks currently unknown, could have a material adverse effect on our business, financial condition or results of operations, or we may be required to increase our accruals for contingencies. It is not possible to predict or identify all such factors. Consequently, you should not consider the following to be a complete discussion of all potential risks or uncertainties:</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business, Industry and Operations, and Business Development</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the outcome of R&amp;D activities, including, the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, and/or regulatory approval and/or launch dates; the possibility of unfavorable pre-clinical and clinical trial results, including the possibility of unfavorable new pre-clinical or clinical data and further analyses of existing pre-clinical or clinical data; risks associated with preliminary, early stage or interim data; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; and whether and when additional data from our pipeline programs will be published in scientific journal publications, and if so, when and with what modifications and interpretations;</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to successfully address comments received from regulatory authorities such as the FDA or the EMA, or obtain approval for new products and indications from regulators on a timely basis or at all; regulatory decisions impacting labeling, including the scope of indicated patient populations, product dosage, manufacturing processes, safety and/or other matters, including decisions relating to emerging developments regarding potential product impurities; the impact of, or uncertainties regarding the ability to obtain, recommendations by technical or advisory committees; and the timing of pricing approvals and product launches;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including claims and concerns that may arise from the outcome of post-approval clinical trials, which could impact marketing approval, product labeling, and/or availability or commercial potential, including uncertainties regarding the commercial or other impact of the results of the Xeljanz ORAL Surveillance (A3921133) study or actions by regulatory authorities based on analysis of ORAL Surveillance or other data, including on other JAK inhibitors in our portfolio;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the success and impact of external business development activities, including the ability to identify and execute on potential business development opportunities; the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all; the ability to realize the anticipated benefits of any such transactions in the anticipated time frame or at all; the potential need for and impact of additional equity or debt financing to pursue these opportunities, which could result in increased leverage and/or a downgrade of our credit ratings; challenges integrating the businesses and operations; disruption to business and operations relationships; risks related to growing revenues for certain acquired products; significant transaction costs; and unknown liabilities;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">risks and uncertainties related to Pfizer&#8217;s proposed acquisition of Seagen, including, among other things, risks related to the satisfaction or waiver of the conditions to closing the proposed acquisition (including the failure to obtain necessary regulatory approvals and failure to obtain the requisite vote by Seagen stockholders) in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close; the possibility that competing offers may be made; risks related to the ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships; negative effects of the announcement or the consummation of the proposed acquisition on the market price of Pfizer&#8217;s common stock and/or operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed acquisition or Seagen&#8217;s business; risks related to the financing of the transaction; other business effects and uncertainties, including the effects of industry, market, business, economic, political or regulatory conditions; future exchange and interest rates; changes in tax and other laws, regulations, rates and policies; the impact of the proposed acquisition on future business combinations or disposals; uncertainties regarding the commercial success of Pfizer&#8217;s and Seagen&#8217;s commercialized and pipeline products; the uncertainties inherent in R&amp;D; whether and when drug applications may be filed in any jurisdictions for Pfizer&#8217;s or Seagen&#8217;s pipeline products; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such products will be commercially successful; and competitive developments;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">competition, including from new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat or prevent diseases and conditions similar to those treated or intended to be prevented by our in-line products and product candidates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the ability to successfully market both new and existing products, including biosimilars;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">difficulties or delays in manufacturing, sales or marketing; supply disruptions, shortages or stock-outs at our facilities or third-party facilities that we rely on; and legal or regulatory actions; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of public health outbreaks, epidemics or pandemics (such as COVID-19) on our business, operations and financial condition and results, including impacts on our employees, manufacturing, supply chain, sales and marketing, R&amp;D and clinical trials;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">risks and uncertainties related to our efforts to continue to develop and commercialize Comirnaty and Paxlovid or any potential future COVID-19 vaccines, treatments or combinations, as well as challenges related to their manufacturing, supply and distribution;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">risks related to our ability to achieve our revenue forecasts for Comirnaty and Paxlovid or any potential future COVID-19 vaccines or treatments, including, among other things, whether and when additional supply or purchase agreements will be reached and the risk that demand for any products may be reduced, no longer exist or not meet expectations, which may lead to excess inventory on-hand and/or in the channel or reduced revenues;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">interest rate and foreign currency exchange rate fluctuations, including the impact of possible currency devaluations and monetary policy actions in countries experiencing high inflation rates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant issues involving our largest wholesale distributors or government customers, which account for a substantial portion of our revenues;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of the increased presence of counterfeit medicines or vaccines in the pharmaceutical supply chain;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant issues related to the outsourcing of certain operational and staff functions to third parties; and any significant issues related to our JVs and other third-party business arrangements;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions, such as inflation, and recent and possible future changes in global financial markets;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any changes in business, political and economic conditions due to actual or threatened terrorist activity, geopolitical instability, civil unrest or military action;</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of product recalls, withdrawals and other unusual items, including uncertainties related to regulator-directed risk evaluations and assessments, including our ongoing evaluation of our product portfolio for the potential presence or formation of nitrosamines;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">trade buying patterns;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of, and risks and uncertainties related to, restructurings and internal reorganizations, as well as any other corporate strategic initiatives and growth strategies, and cost-reduction and productivity initiatives, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs or organizational disruption;</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the ability to successfully achieve our climate goals and progress our environmental sustainability and other ESG priorities;</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation and Legal Proceedings</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of any U.S. healthcare reform or legislation or any significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs, including the IRA, or changes in the tax treatment of employer-sponsored health insurance that may be implemented;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, intellectual property, reimbursement or access or restrictions on U.S. direct-to-consumer advertising; limitations on interactions with healthcare professionals and other industry stakeholders; as well as pricing pressures for our products as a result of highly competitive insurance markets;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">legislation or regulatory action in markets outside of the U.S., such as China or Europe, including, without limitation, laws related to pharmaceutical product pricing, intellectual property, medicine safety, environmental impact of medicines, reimbursement or access, including, in particular, continued government-mandated reductions in prices and access restrictions for certain biopharmaceutical products to control costs in those markets;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the exposure of our operations globally to possible capital and exchange controls, economic conditions, expropriation and other restrictive government actions, changes in intellectual property legal protections and remedies, the impact of political or civil unrest or military action, including the ongoing conflict between Russia and Ukraine and its economic consequences, unstable governments and legal systems, inter-governmental disputes and natural disasters or disruptions related to climate change;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">legal defense costs, insurance expenses, settlement costs and contingencies, including those related to actual or alleged environmental contamination;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk and impact of an adverse decision or settlement and the risk related to adequacy of reserves related to legal proceedings;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk and impact of tax related litigation and investigations;</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">governmental laws and regulations affecting our operations, including, without limitation, the recently enacted IRA, changes in laws and regulations or their interpretation, including, among others, changes in tax laws and regulations internationally and in the U.S., the adoption of global minimum taxation requirements outside the U.S. and potential changes to existing tax law by the current U.S. Presidential administration and Congress;</span></div><div style="margin-bottom:3pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property, Technology and Security</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant breakdown or interruption of our information technology systems and infrastructure (including cloud services);</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any business disruption, theft of confidential or proprietary information, security threats on facilities or infrastructure, extortion or integrity compromise resulting from a cyber-attack or other malfeasance by, but not limited to, nation states, employees, business partners or others;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk that our currently pending or future patent applications may not be granted on a timely basis or at all, or any patent-term extensions that we seek may not be granted on a timely basis, if at all; and</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">risks to our products, patents and other intellectual property, such as: (i) claims of invalidity that could result in LOE; (ii) claims of patent infringement, including asserted and/or unasserted intellectual property claims; (iii) claims we may assert against intellectual property rights held by third parties; (iv) challenges faced by our collaboration or licensing partners to the validity of their patent rights; or (v) any pressure, or legal or regulatory action by, various stakeholders or governments that could potentially result in us not seeking intellectual property protection or agreeing not to enforce or being restricted from enforcing intellectual property rights related to our products, including Comirnaty and Paxlovid.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item is incorporated by reference from the discussion in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section within MD&amp;A of our 2022 Form 10-K.</span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_160"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective in alerting them in a timely manner to material information required to be disclosed in our periodic reports filed with the SEC.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During our most recent fiscal quarter, there has not been any change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_163"></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.111%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #05497c;border-top:1pt dotted #05497c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PART II.&#160; OTHER INFORMATION</span></td></tr></table></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_166"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain legal proceedings in which we are involved are discussed in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_88" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 12A</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_169"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We refer to the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_106" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Overview of Our Performance, Operating Environment, Strategy and Outlook</a><a href="#idfe6e72973fb4e83b28a5bb34d34299f_106" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">&#8212;Our Operating Environment</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_106" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">&#8212;The Global Economic Environment</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sections and the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_154" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Forward-Looking Information and Factors That May Affect Future Results</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A of this Form 10-Q and of our 2022 Form 10-K and to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2022 Form 10-K. We are including the following risk factors, which should be read in conjunction with the risk factors discussed in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2022 Form 10-K.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PENDING ACQUISITION OF SEAGEN</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be unable to complete the acquisition of Seagen within the anticipated timeframe or at all, which could prevent us from receiving the anticipated benefits from the acquisition in the anticipated timeframe or at all.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2023, we entered into a merger agreement with Seagen. The companies currently expect to complete the transaction in late 2023 or early 2024, subject to customary closing conditions, including the adoption of the merger agreement by the holders of a majority of the outstanding Seagen shares entitled to vote on such matter at a meeting of Seagen stockholders, the receipt of certain required government consents and approvals, and other customary conditions. As a result of such conditions, there is no assurance that the acquisition will be consummated in the anticipated timeframe or at all. In addition, Pfizer may be required to pay Seagen a reverse termination fee of approximately $2.22 billion, subject to certain limitations set forth in the merger agreement, if the merger agreement is terminated by either party as a result of certain antitrust and/or foreign direct investment law-related conditions. Any failure to consummate the acquisition in the anticipated timeframe or at all could prevent Pfizer from receiving the expected benefits from the acquisition. For additional information, see the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_106" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">O</a><a href="#idfe6e72973fb4e83b28a5bb34d34299f_106" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">verview of Our Performance, Operating Environment, Strategy and Outlook</a><a href="#idfe6e72973fb4e83b28a5bb34d34299f_106" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">&#8212;</a><a href="#idfe6e72973fb4e83b28a5bb34d34299f_106" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Our Business Development Initiatives</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_154" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Forward-Looking Information and Factors That May Affect Future Results</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sections within MD&amp;A.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We have expended and will continue to expend significant time and resources in connection with the acquisition of Seagen and expect to incur substantial indebtedness to fund the acquisition.  </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer has expended and will continue to expend significant management time and resources and expenses related to the acquisition of Seagen, many of which must be paid regardless of whether the acquisition is consummated. For example, such time, resources and expenses will be incurred in connection with seeking regulatory approvals for the transaction. We also expect to incur significant additional indebtedness to finance the acquisition, with approximately $31 billion of new, long-term debt plus additional short-term indebtedness to be issued prior to the acquisition, which indebtedness may limit our operating or financial flexibility relative to our current position.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes purchases of our common stock during the first quarter of 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:30.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Total Number of</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Shares Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Average Price</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Paid per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Approximate Value of Shares That May Yet Be Purchased Under the Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">January 1 through January 29, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">100,047&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">51.07&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,292,882,444&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">January 30 through February 26, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">8,347,800&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">42.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,292,882,444&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">February 27 through April&#160;2, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,406,317&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">40.94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,292,882,444&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">11,854,164&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">42.00&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Represents (i) 11,851,457 shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive programs and (ii) the open market purchase by the trustee of 2,707 shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who deferred receipt of performance share awards.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#idfe6e72973fb4e83b28a5bb34d34299f_148" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk&#8212;Capital Allocation Framework</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within MD&amp;A of this Form 10-Q and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our 2022 Form 10-K.</span></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_184"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000078003/000119312523068538/d408093d8k.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement and Plan of Merger, by and among Pfizer Inc., Aris Merger Sub, Inc. and Seagen Inc., dated as of March 12, 2023 is incorporated by reference from our Current Report on Form 8-K filed on March 13, 2023.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/0000078003/000162828023017196/pfe-exh101x04022023x10q.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 10.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Acknowledgment and Consent and Summary of Key Terms for Grants of RSUs, TSRUs, PPSs and PSAs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/0000078003/000162828023017196/pfe-exh311x04022023x10q.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/0000078003/000162828023017196/pfe-exh312x04022023x10q.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/0000078003/000162828023017196/pfe-exh321x04022023x10q.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 32.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/0000078003/000162828023017196/pfe-exh322x04022023x10q.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 32.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit 101:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EX-101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EX-101.SCH<br/>EX-101.CAL<br/>EX-101.LAB<br/>EX-101.PRE<br/>EX-101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema<br/>Inline XBRL Taxonomy Extension Calculation Linkbase<br/>Inline XBRL Taxonomy Extension Label Linkbase<br/>Inline XBRL Taxonomy Extension Presentation Linkbase<br/>Inline XBRL Taxonomy Extension Definition Document</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit 104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File&#8211;&#8211;the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div id="idfe6e72973fb4e83b28a5bb34d34299f_187"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jennifer B. Damico</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer B. Damico<br/>Senior Vice President and Controller<br/>(Principal Accounting Officer and<br/>Duly Authorized Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div></body></html>
